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Abstract 
Osteoarthritis (OA), depression and anxiety are common problems in 
primary care. OA coexisting with depressive and/or anxiety symptoms has 
detrimental consequences to the individual. To inform recognition and 
management of these important problems in primary care a better understanding 
of their coexistence is needed. 
A systematic review with meta-analysis was undertaken to determine the 
prevalence of depression and anxiety in adults with OA/joint pain in the 
community. Elevated anxiety symptoms were more common (45%) than 
depression symptoms (24%) in persons with OA/joint pain. Sources of between-
study variance include methods of ascertainment and geographical location. A 
review of measurement properties of several recommended patient-reported 
depression and anxiety measures found evidence to support properties in some 
populations, but some critical properties warrant investigation in adults with OA in 
the community.  
A secondary data analysis was conducted for older consecutive primary 
care patients with musculoskeletal pain recruited to a cohort (n=443) of the 
PROGnostic Research study. Latent Class Growth Analyses identified clusters of 
individuals who exhibited different trajectories of anxiety and depression 
symptoms over a 12-month period: three anxiety and two depression symptom 
trajectories. In total, 56% and 63% of participants experienced persistent anxiety 
and depression symptoms respectively for at least 12 months. Pain characteristics 
and coping strategies were the most prominent risk factors for persistent anxiety 
and depression symptoms. With the aim of identifying individuals with sub-
iii 
 
threshold persistent anxiety and depression symptoms, characteristics 
predisposing to symptoms persistence may be considered.  
A medical records review found that only half of all older musculoskeletal 
patients with persistent anxiety and depression symptoms have their mental health 
problems detected by their GP. Frequent consulters and those with more severe 
anxiety were more likely to be detected. This reinforces the need to recognise and 
manage OA coexisting with depression and/or anxiety by patients and health 
professionals alike. 
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“Did I know what it was? It was my pain, but I don’t think I would have 
called it depression. I think I would have called it my pain.”  
                                                                                         (Karp, p.13, 1994) 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Chapter one: Thesis outline, key concepts and operational 
frameworks 
 
1.1 INTRODUCTION 
Chapter one introduces key concepts to this thesis. Next, the reasons why it 
is important to investigate depression and anxiety coexisting with OA are 
discussed. The existing evidence for associations between OA and depression/ 
anxiety, underlying reasons for this potential association and the impacts on the 
individual are briefly considered. The approach taken by the National Institute for 
Health and Clinical Excellence (NICE) evidence-based clinical guidelines on 
depression and anxiety coexisting with OA is introduced and gaps in guidance (i.e. 
related evidence) are identified. These form the rationale for this thesis, with the 
chapter being concluded with the primary aim and objectives of the PhD. 
 
1.2 KEY CONCEPTS AND DEFINITIONS 
1.2.1   Osteoarthritis (OA) 
Osteoarthritis is the most common type of arthritis (Sacks et al., 2010). OA can 
develop in any synovial joint, but the knees, hips and small hand joints are most 
commonly affected (National Collaborating Centre for Chronic Conditions (NCC-CC), 2008). The 
development of a satisfactory definition of OA has presented substantial 
difficulties, with some authors even questioning the appropriateness of pursuing a 
‘definition of clinical osteoarthritis’ (Hurley et al., 2007). It has been described as a 
degenerative non-inflammatory disease that encompasses “failed repair of joint 
damage” and characterised by a linear progression (Lane et al., p. 479, 2011). There is, 
however, evidence indicating that inflammation can occur in OA (Ambramson, 2003, 
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Brooks, 2003 in Dieppe & Lohmander, 2005). The linear and fixed progression of osteoarthritis is 
not always the case, as demonstrated by evidence that OA is a metabolically 
active and dynamic disease involving the damage of cartilage, bone thickening 
and formation of new bone (Sahlstrӧm et al., 1997, Felson et al., 2000, Sharif et al., 2004). 
Subsequently, OA has been described as a multifactorial (Dieppe & Lohmander, 2005, NICE, 
2008) and heterogeneous group of disorders (Dieppe & Lohmander, 2005). Given this 
complexity, it is increasingly recognised that OA requires a multifaceted, stepwise, 
patient-specific and aetiology-related approach to management (Dieppe & Lohmander, 
2005, NICE, 2008, Lane et al., 2011). 
Structural features on plain radiography have been traditionally used to 
determine the presence of osteoarthritis (Felson et al., 1997), although the use of more 
sophisticated imaging (e.g. magnetic resonance imaging) offers the promise of 
new case definitions of OA (e.g. Hutton & Vennart, 1995, Tan et al., 2005). The value of a 
definition of OA based solely on radiographic changes is questionable, given the 
widely reported discordance between symptoms and radiographs (Hannan et al., 2000).  
Structural OA changes can be evident on radiographs without patients reporting 
pain; and joint pain can be present without X-ray evidence of OA changes to joints 
(McAlindon et al., 1996, Dieppe & Lohmander, 2005, NICE, 2008, Lane et al., 2011). Despite this discordance, 
there is nevertheless, a consistent association between symptoms and severity of 
radiographic features (Duncan et al., 2006, Zhang & Jordan, 2010). 
Traditionally, the American College of Rheumatology (ACR) clinical 
classification criteria (Altman et al., 1986, 1991) have been used for case definitions in 
research, although their validity in population studies has been questioned (Schouten 
& Valkenburg, 1995, Bierma-Zeinstra et al., 1999, Peat et al., 2006b) and there have been several recent 
attempts to provide evidence-based recommendations on the clinical diagnosis of 
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OA (e.g. Zhang et al., 2009, 2010). The Osteoarthritis Research Society International 
Disease State working group and the United States Food and Drug Administration, 
suggest that OA can be defined either as a clinical syndrome or a pathological 
disease (Lane et al., 2011). The clinical signs and symptoms of OA include use-related 
joint pain, joint stiffness and bony swelling associated with substantial functional 
limitation (NICE, 2008). In older adults osteoarthritis is the most common reason for 
joint pain (McCormick et al., 1995), and thus, diagnosing joint pain as osteoarthritis is 
increasingly valued in research (Peat et al., 2005) and a clinical syndrome definition is 
used in NICE OA clinical guidelines (NCC-CC, 2008, NICE, 2008).  
 
1.2.2   Depression  
The term depression is used to describe “a mood, a symptom and a 
syndrome” (Mendels, 1970). There is a lack of agreement on definition (Pilgrim & Bentall, 1999). 
In psychological theories it refers to emotional state (Lazarus, 2006), but for medical 
purposes has been defined as a syndrome with an underlying mood disorder that 
requires “the presence of several symptoms” (Montgomery, 1990).  
Depression is characterised by feelings of sadness (low/depressed mood) 
accompanied by hopelessness, loss of interest in previously enjoyable activities 
(anhedonia), sleep and appetite disturbances, feelings of worthlessness and, in 
some cases, thoughts of death (Feliciano & Arena, 2007). It has been argued that high 
levels of negative affect, for example, low mood, and low levels of positive affect, 
such as anhedonia, are key aspects of depression (Clark & Watson, 1991, Watson et al., 1995, 
Marshall et al., 2003, Cook et al, 2004). Affective symptoms are considered in combination with 
somatic and cognitive symptoms (Turk & Okifuji, 1994). Somatic symptoms of depression 
include: fatigue or loss of energy, significant weight loss/gain, sleep disturbances, 
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psychomotor agitation and social withdrawal. Cognitive symptoms of depression 
encompass: negative thinking about oneself or world or others, feelings of 
worthlessness, diminished ability to think or concentrate or make decisions, and 
suicidal thoughts (Feliciano & Arena, 2007). 
Categorical systems of mental disorder classification are surrounded with 
criticism related to the ambiguity of indicators of normality and the common 
comorbidity of disorders (Kendell, 1975, Widiger & Sankis, 2000, Widiger & Samuel, 2005), including 
often coexisting depression and anxiety (Cameron, 1985). A categorical approach is 
considered to be psychopathology-focused and is traced to Kraepelin (1917, cited 
in Pilgrim & Bentall, 1999), who as a medical naturalist, assumed an existence of 
“a real and invariant external world of natural disease entities” (Pilgrim & Bentall, p. 261, 
1999). Currently, a categorical approach is used and can be partially attributed to 
several factors including tradition, credibility, and endeavoured simplicity, utility 
and validity (for a summary see Widiger & Mullins-Sweatt, 2007).  
In 1948, the World Health Organization (WHO) revised the Manual of the 
International Statistical Classification of Diseases Injuries and Causes of Death 
(ICD-6) and added a mental disorder section (WHO, 1948). The Diagnostic and 
Statistical Manual of Mental Disorders, First Edition (DSM-I) was the first 
diagnostic system specific to mental disorders, developed in 1952 by the 
Committee on Nomenclature and Statistics of the American Psychiatric 
Association (APA, 1952). These two classifications remain the most commonly used 
systems, with the DSM-IV-TR (APA, 2000) and ICD-10 (WHO, 1992) versions currently 
available. The ICD-10 system of coding is officially used in clinical practice in the 
UK. Given evidence for diagnostic discordance (López-Ibor et al., 1994, Andrews et al., 1999, Slade 
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& Andrews, 2001, Andrews & Slade, 2002, López-Ibor, 2002, Vilalta-Franch et al., 2006, First, 2009), caution in 
comparing estimates, based on those two diagnostic classifications, is required. 
In the ICD-10 Classification of Mental and Behavioural Disorders (WHO, 1992), 
depression is classified as mood disorders including depressive episode, recurrent 
depressive episode and dysthymia. Mixed anxiety and depressive disorder 
belongs to a group of neurotic, stress-related and somatoform disorders (WHO, 1992). 
The DSM-IV-TR also classifies depression as mood disorders including: major 
depressive disorder, dysthymic disorder, depressive disorder not otherwise 
specified (APA, 1994). The DSM-IV-TR (APA, 2000) also includes adjustment disorders 
characterised by the presence of a more severe depressive mood than expected 
in a reaction to distress. In both classifications the presence and type of disorder is 
decided based on a number of symptoms, their duration and severity, and clinical 
significance, which encompasses the presence of distress and disability (Gruenberg et 
al., 2005). Both the DSM-IV-TR and ICD-10 provide psychotic and remission 
specifiers, but some course specifiers, such as a seasonal characteristic, are 
included in the DSM-IV-TR, but not in the ICD-10 (Gruenberg et al., 2005). 
 
1.2.3   Anxiety  
Similarly to depression, there are disparities about what constitute the 
definition of anxiety. Efforts have been made to build a consensus (Whitley, 1992, Bay & 
Algase, 1999). Anxiety can range from a temporary response to the maladaptive 
experience of prolonged and an intensive anxiety syndrome with an underlying 
anxiety disorder (Sarason & Sarason, 2004). The term anxiety has been used in animal 
models to describe an emotional state of heightened sense of apprehension and 
hypervigilance in response to an unrecognisable threatening stimulus (Blanchard & 
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Blanchard, 1989), with an underlying disassociation between the source and response 
(LeDoux, 1996). It has been hypothesised that information mismatch is translated into 
emotional, cognitive, behavioural, and somatic response including (Blanchard & 
Blanchard, 1989, Spielberger & Rickman, 1991, Seligman et al., 2001, Sarason & Sarason, 2004, Beesdo et al., 2009): 
 Emotional symptoms (excessive worries and a feeling of uncertainty) 
 Cognitive symptoms (sense of confusion, poor concentration, negative 
thoughts) 
 Behavioural symptoms (indecision, avoidance)  
 Physiological symptoms (muscular tension, tightness in the neck) 
 Hypervigilance symptoms (irritability, restlessness) 
Anxiety is believed to share with depression high levels of negative affect, 
but physiological hyperarousal is considered specific to anxiety (Clark & Watson, 1991). 
Cardiovascular excitation and apprehension is also a characteristic of fear (Whitley, 
1994), as both anxiety and fear involve activation of the sympathetic nervous system 
(Kalin, 1993, Neumann et al., 2011). Similarities and differences between fear and anxiety 
have been simultaneously delineated (Bay & Algase, 1999). Biologically, fear is a 
motivated defensive state that has been shown to originate from the amygdala 
(LeDoux, 1996, 2003). Consequently, fear has been defined as a temporary ‘flight or fight’ 
emotional response to a discrete actual stimulus identified and perceived as 
threatening (Blanchard & Blanchard, 1989).  
Anxiety is a heterogeneous condition, with anxiety symptoms being a 
primary feature (APA, 2000). The presence and type of disorder is decided based on a 
number of symptoms, their duration and severity, and the presence of distress and 
disability (Gruenberg et al., 2005). The ICD-10 classification includes organic anxiety 
disorders, which are not relevant to this thesis and non-organic anxiety disorders. 
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The latter are classified as neurotic, stress-related and somatoform disorders (APA, 
2000). Examples include, phobic anxiety disorders; agoraphobia with panic disorder, 
agoraphobia without panic disorder, social phobia, and specific phobia, obsessive-
compulsive disorder (OCD), other anxiety disorders; panic disorder, generalised 
anxiety disorder (GAD), mixed anxiety and depressive disorder, reaction to severe 
stress, and adjustment disorders; post-traumatic stress disorder (PTSD) and acute 
stress disorder (ASD) (WHO, 1992). 
The DSM-IV-TR classification of anxiety disorders includes generalised 
anxiety disorder, panic disorder with agoraphobia, panic disorder without 
agoraphobia, agoraphobia without history of panic disorder, specific phobia, social 
phobia, OCD, PTSD, ASD, anxiety disorder due to a general medical condition, 
anxiety disorder due to... [indicate the general medical condition] and anxiety 
disorder not otherwise specified (APA, 2000).  
 
1.2.4   Determining the presence of depression/anxiety symptoms and 
depressive/anxiety disorders 
A number of methods exist to determine the presence of anxiety and depression. 
These methods are considered below.  
 Self-report measures are designed to be compatible with diagnostic 
classifications of depressive/anxiety disorders (Feliciano & Arena, 2007), but are not 
diagnostic measures per se. Instead they allow clinicians/researchers to 
assess the severity and/or number of symptoms (Nease & Malouin, 2003).  Depression 
measures (e.g. the Nine-Item Patient Health Questionnaire (Spitzer et al., 2006)) and 
some self-report anxiety measures (e.g. the Beck Anxiety Inventory (Beck & Steer, 
1993)) assess more general levels of symptoms. Other anxiety measures (e.g. 
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the Generalised Anxiety Disorder Questionnaire (Newman et al., 2002)) are designed 
to assess symptoms of specific anxiety disorders. They differ in length and, 
based on time required to complete, can be divided into ultra-short (1 to 4 
items: <2 minutes), short (5 to 14 items: 2-5 minutes) and long/standard (15 or 
more: >5 minutes) (Mitchell & Coyne, 2007). Questionnaires also differ in psychometric 
and diagnostic properties (Williams et al., 2002). A self-report measure involves a 
patient indicating the degree to which one has experienced certain symptoms 
in a given time frame. The result is scored by a clinician/experimenter with the 
overall score reflecting the severity/numbers of depression/anxiety symptoms 
(Feliciano & Arena, 2007). The identification of symptoms with self-report measures is 
followed by a confirmation of the diagnosis with a more comprehensive 
assessment (Feliciano & Arena, 2007). 
 Diagnosis is reached upon attribution of a symptom manifestation to underlying 
causes perceived by the clinician (Andrews & Peters, 1998).  A structured diagnostic 
interview can be used for this purpose; a method valued for offering a deeper 
understanding of the mental health problem (Gibson, 1998). To ensure consistency 
and avoid misclassification, structured and semi-structured interviews are 
usually conducted (Sheehan et al., 1998).  
 
1.2.5   Definitions of screening, case identification, detection, diagnosis 
recognition 
The following section will define some of the key terms related to identification and 
assessment of depressive and anxiety symptoms used in this thesis: 
 Screening: Screening is “the presumptive identification of unrecognised 
disease or defect by the application of tests, examinations or other procedures 
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which can be applied rapidly. Screening tests sort out apparently well persons 
who probably have a disease from those who probably do not. A screening test 
is not intended to be diagnostic.” (Wilson & Junger, p. 11, 1968)  
 Targeted case identification: Kessler et al. (2005) have regarded the term 
targeted case-finding of depression in high-risk groups as more appropriate 
than screening. This distinction was made as according to Kessler et al. (2005) 
it appears that depression does not formally meet widely accepted criteria for a 
disease that is appropriate for screening. NICE (2009a, 2009b) depression 
guidelines refer to targeted case-finding as case identification (identification of 
a specific disease), hence this term will be used in the current thesis in the 
context of both depression and anxiety. 
 Detection: Clinical detection of a disease implies detection in a clinical setting 
among persons presenting to a clinician or using medical services (Porta, p.74, 
2008). Detection is not a synonym for diagnosis, therefore confirmation of the 
suspected diagnosis will require additional assessment (probably a formal 
diagnosis) (Porta, 2008).  In research detection appears to be used by academic 
general practitioners in the context of what has been defined as clinical 
detection (e.g. Dowrick & Buchan, 1995, Licht-Strunk et al., 2009a). For consistency within this 
thesis the term detection will be used in the context of primary care attendees 
considered to be possibly or definitely depressed (or anxious) by the general 
practitioner (GP) (Dowrick & Buchan, 1995). Similar to Licht-Strunk et al. (2009a), in the 
context of medical records review, this definition will be extended to evidence 
of initiation of treatment.  
 Diagnosis: Diagnosis is the process of “determining health status and the 
factors responsible for producing it; may be applied to an individual, family, 
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group, or community. The term is applied both to the process of determination 
and to its findings.” (Porta, p. 66, 2008) 
 Recognition: The term recognition does not appear to be clearly delineated in 
health literature and seems to be closely related to detection. In research it 
seems to be used in two contexts; recognition (identification) of symptoms (e.g. 
Baik et al., 2005) and recognition of a condition (evidenced by a formal 
diagnosis/definite problem (e.g. NICE, 2009b)), which typically implies meeting formal 
diagnostic criteria. 
 
1.3     WHY IS IT IMPORTANT TO INVESTIGATE DEPRESSION AND ANXIETY 
COEXISTING WITH OA IN PRIMARY CARE ADULTS?  
1.3.1   Prevalence of OA, depression and anxiety in primary care 
Osteoarthritis  
Osteoarthritis (OA) is a worldwide public health problem with an increasing 
prevalence related to the aging population (Felson et al., 2000, Kopec et al., 2008). It is one of 
the commonest chronic conditions managed in primary care (ARMA, 2004, ARC, 2002) 
accounting for an estimated 15% of musculoskeletal disease consultations in 
general practice (NCC-CC, 2008). As shown by the annual 2007 report for Weekly 
Returns Service of Royal College of General Practice ((RCGP) 2007), consulting 
prevalence rates for osteoarthritis are high. They ranged from 252 in 10,000 
registered adults aged 45-65 years to 923 per 10,000 registered adults aged 75 
years or over (RCGP, 2007). 
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Depression and anxiety in primary care 
Depressive and anxiety disorders are known to be the most common 
mental health diagnoses in primary care settings (Goldberg & Lecrubier, 1995, Sartorius et al., 
1996). According to the annual 2006 RCGP (2006) report, depression and anxiety 
states are common reasons for consultation in age groups also consulting for OA. 
Consulting prevalence rates of depression ranged from 70 per 10,000 registered 
males aged 65-74 years to 202 per 10,000 registered females aged 45-64 years 
(RCGP, 2006). In these age groups, person consulting prevalence rates of anxiety 
states were even higher, ranging from 111 per 10,000 registered males aged 65 - 
74 years to 320 per 10,000 registered females aged 45-64 years (RCGP, 2006).  
 
1.3.2   Coexistence of OA, depression and anxiety 
Empirical evidence of the coexistence 
The prevalence of OA is known to increase with age (Woolf & Pfleger, 2003, NCC-CC, 
2008) and multimorbidity, including psychopathologies, are common in older adults 
(Marengoni et al., 2011). Community-based and primary care studies have consistently 
shown that adults with chronic painful conditions are at an increased risk of 
developing depressive and anxiety symptoms (Sartorius et al., 1996, Gureje et al., 1998, Cole & 
Dendukuri, 2003, Katon et al., 2007, Moussavi et al., 2007). Based on a population of 5438 individuals 
across 15 primary care centres, the WHO has estimated that depressive disorders 
were six times more likely in patients with two or more chronic physical health 
problems (Sartorius et al., 1996). The same data indicated that patients with persistent 
pain might be four times more likely to have anxiety or depressive disorders than 
those without pain (Gureje et al., 1998). Through a systematic search of the MEDLINE 
electronic database, Katon et al. (2007) have investigated the association of 
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depression and anxiety with chronic medical illness. The review found that patients 
with arthritis have a high rate of affective disorders (20–40%) (Katon et al., 2007). 
Surprisingly, “[in contrast to rheumatoid arthritis] less research has been 
completed describing the link between OA and psychosocial variables” (Katon et al., 
p.152, 2007).  
 
Why OA, depression and anxiety coexist? 
Mechanisms underlying OA, depression and anxiety seem unclear and 
difficult to understand - given their relationships are likely to be bi-directional (Arola et 
al., 2010). Potentially useful information on related factors can be drawn from 
psychological models of adjustment to pain - based on or tested in populations 
with chronic pain (mainly or exclusively originating from musculoskeletal 
diseases). A shared view of these models is that clinically significant anxiety and 
depression symptoms coexisting with pain, are a result of difficulties with adjusting 
to pain.  
Under the framework of the fear-avoidance model a cognitive interpretation 
of pain as threatening (pain catastrophising) leads to pain-fear, which affects 
attention leading to avoidance behaviours, followed by hypervigilance of bodily 
sensations, disability, disuse, and depression, which then further fuel catastrophic 
thinking (Vlaeyen et al., 1995). This model has been supported in a large sample of 
patients with chronic pain, although older patients had lower levels of pain fear 
than middle-aged adults (Cook et al., 2006). Heuts et al. (2004) supported a significant 
association between pain severity, pain-fear and the level of daily functioning in 
OA. In the updated version of the model, an anxiety pathway was added between 
pain-fear and pain-avoidance (Asmundson et al., 2004). Fear-avoidance and anxiety were 
13 
 
found to be independently associated with poor functioning in people with OA, but 
depression was found to influence functioning only when anxiety was low (i.e. 
anxiety was concluded to be the main factor) (Scopaz et al., 2009). 
Pain catastrophising plays a key role also in the misdirected-problem 
solving model (Eccleston & Crombez, 2007). In this model, worries about pain and cognitive 
evaluation (e.g. pain catastrophising) are adaptive reactions that aim to solve 
problems, i.e. make sense of pain by searching possible causes, consequences of 
pain and possible actions. This process engages attention - exaggerating worries 
about negative consequences and produces hypervigilance to pain. This results in 
repeated efforts to solve the pain problems (Eccleston & Crombez, 2007). If pain is framed 
as solely a biomedical problem - it will inevitably lead to attempts to remove or 
reduce pain. Failed attempts to achieve it further reinforce worries and the person 
can become stuck in a “perseverance loop” of increasing worries, where the 
unsuccessful strategy gets repeated. Examination of a small sample of patients 
with spinal pain showed the link between catastrophising, problem framing, and 
problem-solving, where the way people viewed their pain problem set the stage for 
catastrophic worry - a direction more similar to that of the fear-anxiety-avoidance 
model (Flink et al., 2011). In line with the model, in patients with chronic pain worrying, 
but not problem solving, had a unique contribution in explaining depressive mood 
in people with chronic pain (De Vlieger et al., 2006).  
In the acceptance-commitment model depression and anxiety are also 
related to difficulties in adjustment, which stem from dysfunctional cognitive 
structures (Hayes et al., 1999). In this model anxiety and depression are a result of 
psychological inflexibility (caused by avoiding or controlling pain) instead of 
focusing on achievable goals (advocated also in the misdirected problem-solving 
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model) (Ciarrochi et al., 2010). Pain acceptance was found to moderate the relation 
between pain and negative affect in a small group of females with osteoarthritis 
(Kratz et al., 2007). These results were confirmed by McCracken et al.’s (1999) and 
Vowles and McCracken’s (2008) studies with tertiary care patients with chronic 
pain, where pain-related acceptance led to less anxiety and depression symptoms 
and higher physical functioning. 
All three models acknowledge the impact of predisposing factors. Indeed, in 
addition to cognitive-behavioural factors, psychological adjustment in people with 
chronic pain (including musculoskeletal origin) can be affected by a range of 
external and internal factors (Lee & Mercurio-Riley, 2009). Lee and Mercurio-Riley (2009) 
reviewed empirical evidence on contributing factors that affect the psychosocial 
adjustment (anxiety, depression and substance abuse) among individuals with 
chronic pain (mostly originated in musculoskeletal disease). Following adaptation 
of the Risk and Resistance Model of Adjustment (Wallander et al., 1989, cited in Lee & Mercurio-
Riley, 2009) the authors generated a conceptual framework with various risk and 
resistance factors, which can be moderated and/or mediated by the resistance 
factors (see Figure 1.1 overleaf). Variables from each concept were tested by Lee 
and Chan (2007) for associations with each other and with depression symptoms 
in people with musculoskeletal pain. Structural pathway modelling showed that life 
interference, catastrophising, social and family support and stress, directly 
predicted depression symptoms. Life interferences were found to be predicted by 
pain severity and coping strategies. Stress was predicted by pre-injury and 
psychopathology.  
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Figure 1.1 The conceptual framework of risks (grey denotes) and resistance 
(white denotes) factors in adjustment to chronic pain. 
 
 
Source: Lee and Mercurio-Riley, 2009 
Note: The rectangle denotes the specific variable which contributes to the concept; * -Typically depression, 
anxiety or alcohol abuse. 
 
1.3.3   The impact of depression and anxiety on OA 
Anxiety and depression symptoms are known to have adverse effects on 
well-being of patients with OA. Qualitative and quantitative results from a small UK 
study of primary care patients with OA, found that depressive and anxiety 
symptoms were listed as one of the most upsetting aspects of OA the experience 
(Tallon et al., 2000). There is ample evidence from a large community-based study 
(Arbabzadeh-Bouchez et al., 2002, Tylee et al., 1999) and a large medical outpatients study (Wells et 
al., 1989b), to suggest that depression symptoms are associated with increased 
disability in people with arthritis. In a large community-based study depressive 
episode coexisting with arthritis was found to reduce general health status, more 
than arthritis alone, depression alone, and any combination of chronic diseases 
* 
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without depression (Moussavi et al., 2007). A study of 621 patients with OA found that 
depression symptoms even increase the risk of developing symptomatic OA in 
patients with minimal to moderate severity of radiographic changes (Kim et al., 2011). 
The impact of anxiety on OA-related outcomes has been less researched, but a 
study with 182 institutional practice patients with OA found that anxiety symptoms, 
but not depression symptoms, were associated with diminished physical 
functioning in OA (Scopaz et al., 2009).  
Evidence suggests that both depression and anxiety symptoms may also 
exert long-term effects on people with OA. A prospective study of 2,558 older 
primary care patients with chronic physical illnesses (including arthritis) found that 
patients with elevated depression symptoms at baseline had significantly lower 
quality adjusted life years over the 4-year study period (Unützer et al., 2000). In a study of 
621 community-based older adults with joint pain, multivariate analyses showed 
that anxiety symptoms predicted poor functional outcomes at 18 months, but no 
significant effect was found for depression symptoms (Mallen et al., 2007). 
Consequently, a need for an increased attention to depression and anxiety 
coexisting with OA has been highlighted in numerous studies (Summers et al., 1988, Salaffi 
et al., 1991, Creamer et al., 2000, Memel et al., 2000, Lin et al., 2003, Mallen et al., 2007, 2008, Axford et al., 2010, Kim et 
al., 2011). The importance of recognising and managing depression and anxiety in 
patients with arthritis has been recently reiterated by the King’s Fund and Centre 
for Mental Health group (Naylor et al., 2012). A multifaceted approach involving the 
identification and management of modifiable factors, such as coexistence of 
depression symptoms and other life stresses have been recognised and 
incorporated in OA NICE guidelines (NCC-CC, 2008, NICE, 2008).  
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1.3.4   Evidence-based clinical guidelines for primary care management of 
depression and anxiety in OA and gaps in guidance 
OA guidelines  
Clinical guidelines are intended to be the first reference source of evidence-
informed clinical decision-making in UK primary care (Hunsley & Mash, 2010). The full 
version of NICE OA guideline cites eleven studies on the association between 
depression, anxiety and life satisfaction in patients with OA, and recommends a 
holistic health approach to the management of OA including the active recognition 
of depression (NCC-CC, 2008). The proposed method of recognition is to “screen for 
depression” in patients with OA (NCC-CC, p. 20, 2008). The guideline provides no details 
of the best way of screening for depression or the effectiveness of interventions to 
reduce such depression. Instead it refers to a general guideline for depression 
(NICE, 2004). Anxiety recognition or management are not mentioned in NICE OA 
guidelines.  
 
Depression guidelines 
Since the publication of NICE OA guidelines there has been a revision to 
the NICE depression guideline (NICE, 2009a) and the publication of new guidance on 
the management of depression in patients with physical health problems (NICE, 
2009b). While the recommendations in the updated NICE depression guideline are 
broadly comparable with those made in the previous version, the term case 
identification (screening in groups at risk) is now used instead of screening. For 
specific recommendations for patients with chronic physical health problems, the 
general depression guideline (NICE, 2009a) refers to the depression guideline specific 
to physical health problems (NICE, 2009b), including diabetes, heart disease, cancer, 
musculoskeletal disease and respiratory or neurological disorders. Both guidelines 
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recommend the stepped-care approach to depression care through recognition 
(awareness, screening and assessment) and management (intervention and 
monitoring) (Figure 1.2). Similar recommendations are offered by clinical 
guidelines of the Canadian Task Force on Preventive Health Care (MacMillan et al., 2005) 
and The US Preventive Services Task Force ((USPSTF), 2002, 2009). 
 
Figure 1.2 The stepped-care model of depression management. 
 
 
 
Source: NICE, Depression in adults with a chronic physical  
health problem: Treatment and management, p.17, 2009b 
 
 
The recognition of depression involves case identification using two 
questions, followed by a diagnostic assessment of depression and psychosocial 
factors, which can be informed using validated measures (NICE 2009a, 2009b). The 
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Quality and Outcomes Framework (QOF) component of General Medical Services 
Contract (BMA, GPC 2009) supports NICE’s (2009a) recommendations, considers 
empirical evidence and suggests specific depression measures suitable for using 
in general practice. It recommends routine depression case identification as part of 
annual diabetes or coronary heart disease reviews, but not an annual OA review 
(BMA, GPC 2009). The NICE guideline for depression, coexisting with chronic 
conditions, advocates asking three additional questions on feeling worthless, poor 
concentration and suicidal ideations (NICE, 2009b).  
Figure 1.2 on page 18 presents a brief summary of recommended 
interventions based on the focus of depression intervention. A type of intervention 
should be performed in a framework of the person-centred care (NICE, 2009a). It 
should also be decided based on patient preferences, the duration and progress of 
symptoms, previous responses to treatment and possible effectiveness of 
treatment (NICE, 2009a). According to the guideline for adults with depression and a 
chronic physical health problem, the collaborative care approach should be 
considered for patients with moderate or severe depression and coexisting 
physical health problems (NICE, 2009b). The collaborative care approach 
encompasses delivery of depression interventions by cooperation between a 
patient, a GP, a care manager and a psychiatrist to achieve the best approach to 
management (NICE, 2009b).  
 
Anxiety guidelines 
The NICE depression guideline recommends considering treatment of an 
anxiety disorder first, if the patient has anxiety disorder and coexisting depressive 
disorders or depression symptoms (NICE, 2009b). The list of relevant anxiety 
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guidelines includes the Obsessive Compulsive Disorder (OCD) (NICE, 2005), the Post 
Traumatic Stress disorder guidelines (PTSD) (NCC-MH, 2005) and the Generalised 
Anxiety Disorder (GAD) and panic disorder (with or without agoraphobia) (NICE, 2007). 
These three guidelines offer no information on recognition and management of 
anxiety disorders, relevant to primary care patients with OA. 
 
1.3.5   The importance of improving the understanding of recognition of 
depressive and anxiety symptoms in primary care patients with OA  
There appears to have been less specific advice offered on management of 
patients with OA and the problem of depression. Currently, advice on OA 
coexisting with the problem of anxiety seems to be lacking entirely. One cannot 
confidently assume that arguments and evidence developed in other conditions 
can be simply applied to OA, as they seem to differ in characteristic, aetiology, 
progress, impacts on the well-being and available treatments. These factors may 
affect adjustment processes and thus emotional regulation can be expected to 
differ across conditions.  
NICE depression guidance suggests that management of depression is a 
process, involving targeted case identification to recognise symptoms and 
assessment to recognise the problem of depression, with the nature of intervention 
dependant on the characteristic of depression problem (NICE, 2009b). Awareness of 
the scope of the additional problems caused by depression and anxiety in patients 
with OA is important to recognition of depression and anxiety problems, as it can 
indicate a need for targeted case identification and prevention efforts. 
Consequently, it helps to inform service provision (Anderson et al., 2001, Barnard et al., 2006). 
Identification of patients presenting with symptoms of depression or anxiety is 
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crucial to initiate diagnosis. According to Katon et al. (2007), optimising the 
management of somatic symptom burden in chronic medical illness is closely 
related to the accuracy of diagnosis coexisting anxiety and depressive disorders.  
A large randomised controlled trial (RCT) of older primary care patients with 
arthritis found that systematic depression care can reduce not only depression 
symptoms, but also pain severity, improves functional outcomes and quality of life 
(Lin et al., 2003, 2006). Similarly, a large RCT in primary care adults found that systematic 
anxiety care for patients with recognised anxiety disorders can reduce not only 
symptoms of anxiety, but also depression symptoms and improve functional status 
(Roy-Byrne et al., 2010). In contrast, an older RCT of primary care patients in the UK 
found that GPs’ awareness of depression symptoms is unlikely to improve 
prognosis of these patients at 12 months (Dowrick & Buchan, 1995). Primary care health 
professionals have expressed difficulties with recognition and management of 
depressive and anxiety disorders in older adults and with chronic physical illness 
(Burroughs et al., 2006, Murray et al., 2006, Van Rijswijk et al., 2009, Coventry et al., 2011). Previous studies 
showed that the complexity of recognition and subsequent management of 
clinically significant depression symptoms in older primary care attendees is 
reflected in older adults often being undetected (Licht-Strunk et al., 2009a) and untreated 
(Kendrick et al., 2009) by their GPs. 
 
1.4      SUMMARY 
Disagreements exist regarding what constitutes osteoarthritis, but in 
general practice diagnosis of OA is most often clinical (examination and 
information on history and other symptoms). Depression and anxiety are 
descriptive terms, used for two distinct emotional reactions/states, which can 
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develop into clinically significant symptoms, traditionally classified into 
heterogeneous disorders. A number and severity of symptoms of depression and 
anxiety can be recognised through assessment with self-report measures. 
Recognition of depression and anxiety disorders (a traditional approach) involves 
a formal diagnosis.  
OA is a common reason for consultation in people aged 45 and above, and 
depression and anxiety disorders are common reasons for consultation in the 
same age group. It seems well-established that physical chronic illnesses 
commonly coexist with depression and anxiety. Several modern psychological 
theories of chronic pain attribute this to difficulties with emotional adjustment to 
pain. Both depression and anxiety are known to have detrimental consequences 
for persons with OA. Nevertheless, there appears to be less specific investigations 
of depression, anxiety coexisting with OA specifically than in other conditions (e.g. 
cardiovascular disease and diabetes). Furthermore, if evidence on coexisting 
depression and OA appears to be relatively scarce, evidence for anxiety is even 
scarcer. Evidence is needed to offer specific clinical guidance on how to recognise 
primary care patients with OA who may benefit from an intervention for their 
problems of depression and anxiety. This seems essential because emerging 
evidence suggests that the potential benefit of managing depression and anxiety 
problems coexisting with OA is important in itself, but their management could 
even improve physical functioning, disability and overall quality of life of patients 
with OA. 
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1.5 THESIS AIMS AND OBJECTIVES 
The overall aim of this thesis is to advance understanding of coexisting 
anxiety and/or depression in patients with osteoarthritis. The specific aims and 
objectives addressed to achieve the overall goal of this thesis are summarised 
below.  
 
1) The first aim is to advance understanding of the prevalence of coexisting 
depressive and anxiety symptoms/disorders in patients with OA. 
 
Specific objectives are: 
 To summarise the scientific evidence of prevalence rates of depression/anxiety 
and depression/anxiety disorders coexisting with OA/joint pain, by systemically 
reviewing the existing prevalence studies in community-dwelling/primary care 
adults with OA/joint pain and coexisting depression and anxiety 
 To examine sources of between-study variance in reported prevalence rates 
 
2) The second aim is to understand the comparative strengths and weaknesses 
of recommended patient-reported, self-complete, condition-specific measures 
used in assessing anxiety and depression symptoms in patients presenting to 
primary care with osteoarthritis.  
 
Specific objective is: 
 To conduct a narrative synthesis of evidence on key measurement properties 
and characteristics and suitability of selected depression (BDI (BDI-II and BDI-
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PC versions), HADS-D, PHQ (2- and 9-item versions)) and anxiety (GAD (2- 
and 7-item versions), HADS-A) symptom measures 
 
3) The third aim is to advance understanding of persistence of depressive and 
anxiety symptoms in older primary care patients with OA. 
 
Specific objectives are: 
 To describe changes in the rate of HADS defined depressive and/or anxiety 
symptoms in older patients presenting to general practice with musculoskeletal 
pain  
 To identify discrete 12-month post-consultation trajectories of symptoms of 
anxiety and depression in older patients presenting to general practice with 
musculoskeletal pain  
 To explore patterns of coexisting trajectories of symptoms of anxiety and 
depression symptoms 
 To examine their unique relationships with baseline person-related 
characteristics  
 
4) The fourth aim of this thesis is to improve the understanding of the detection of 
depression and anxiety in older primary care patients with OA.  
 
Specific objectives are: 
 To estimate the detection rate of persistent depression or anxiety symptoms in 
older patients presenting to general practice with musculoskeletal pain 
 To establish factors associated with detection in this sub-population 
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Chapter two: Prevalence of depression and anxiety in adults with 
osteoarthritis/joint pain: a systematic review and meta-analyses 
 
2.1     INTRODUCTION 
The potential importance of coexisting anxiety and depression to the 
effective primary care management of osteoarthritis was introduced in chapter 
one. Chapter two is a systematic review of observational studies investigating the 
prevalence of depressive and anxiety disorders and questionnaire-assessed 
depression and anxiety symptoms in primary care patients and community-
dwelling adults with osteoarthritis. The chapter starts with introducing the method 
used and arguing why such a review is needed, before describing the primary 
objectives. Finally, the results of the synthesised evidence are presented and 
discussed, and conclusions drawn. 
 
2.2      BACKGROUND 
2.2.1   Systematic review and meta-analyses 
Literature reviews typically involve narrative summaries of evidence 
conducted in an informal and subjective manner (Pai et al., 2004). By contrast, a 
systematic review is “a review in which there is a comprehensive search for all 
relevant studies on a specific topic, and those identified are then appraised and 
synthesised according to a predetermined and explicit method” (Klassen et al., p. 700, 
1998). As depicted in Figure 2.1 overleaf, a systematic review can be followed by a 
meta-analysis; “defined as the statistical combination of at least two studies to 
produce a single estimate of the effect” (Klassen et al., p. 700, 1998). A meta-analysis can 
be considered accurate only when resulting from a systematic review (Egger et al., 
2001a).  
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Figure 2.1 Types of reviews. 
 
              Source: Pai et al., 2004 
 
A systematic approach is recommended to manage the diversity of 
available scientific evidence (Khan et al., 2001, Glasziou, 2001). The major advantage of this 
method is that by stating clear objectives, pre-determined explicit eligibility criteria 
and a search strategy, allows a more effective and objective identification, 
appraisal and summary of study findings in the subject of interest (Egger et al., 2001a). 
Overall, it has been argued that a systematic review reduces the possibility of 
information and selection bias, making conclusions more objective, accurate and 
reliable (Glasziou, 2001). In contrast, non-systematic review methods are regarded 
more predisposed to bias and errors (Egger et al., 2001a). Nevertheless, systematic 
reviews are time consuming and have the potential for bias if not rigorously 
designed and executed (Glasziou, 2001, Pai et al., 2004), the risk of which is believed to be 
minimised by following a general guideline such as the PRISMA statement 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) (Liberati et al., 
2009). See Table 2.1 overleaf for a summary of advantages and limitations of a 
systematic review. 
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Table 2.1 Advantages and disadvantages of a systematic review. 
 
Advantages: 
 clearly described objectives and eligibility criteria 
 a balanced picture ensured by inclusion of a broad range of studies  
 a thorough search 
 reduced possibility of selection bias (by a verifiable and replicable search strategy 
and multiple reviewers) 
 concise and readable format  
 assessment of methodological quality- indicative of sources of bias in individual 
studies 
Disadvantages: 
 oversimplification of differences between individual studies 
 required considerably more effort than traditional literature reviews 
 misidentification of relevant literature including unpublished citations 
 can be misleading by ignoring issues of quality in interpretation  
Note: Based on  Glasziou, 2001, Pai et al., 2004. 
 
A meta-analysis can be a useful addition to a systematic review, as an 
alternative to highly subjective narrative synthesis (Egger et al., 1998, Egger et al., 2001a, Pai et 
al., 2004). Meta-analysis of observational studies (including cross-sectional, 
longitudinal and case-controls) has become increasingly common in the past 4 
decades (Stroup et al., 1997, cited in Stroup et al., 2000). It can involve combining individual 
measures of the relationship between the frequency of the event in the 
intervention/exposure group and that in the control/reference group, where the 
parameter of interest is an odds ratio or risk/rate ratio (Deeks et al., 2001). Alternative to 
an occurrence relationship, a meta-analysis can focus on occurrence estimates, 
where the parameter of interest is a prevalence or incidence (Egger et al., 2001a). This 
type of meta-analysis does not involve calculating effect size, but aggregating an 
estimate weighted by its precision (Egger et al., 2001a).  
Amongst the general advantages of combining and weighting estimates 
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from several studies are: (a) enabling recognition of inconsistencies in reported 
estimates (Blettner et al., 1999), (b) generating more accurate estimates than those 
obtained from any one primary study (Rosenthal & DiMatteo, 2001) and (c) improving 
comparability to previous research (Rosenthal & DiMatteo, 2001). Nonetheless, a meta-
analysis of findings from observational studies, with different aims and methods, 
may be at a high risk of biased results (Shapiro, 1994, Lipsey & Wilson, 2001). As a result, 
ways of improving the reliability of meta-analysis of observational studies have 
been proposed, including: generating a study protocol, conducting a systematic 
review, acknowledging study quality and biases, and ensuring study replicability 
(Egger et al., 1998, Egger et al., 2001a, 2001b). Shapiro (1994) has highlighted that high 
heterogeneity of estimates are likely in meta-analyses of observational studies, 
which can undermine the accuracy of this method. High heterogeneity of 
prevalence rates of depression and anxiety have been consistently found across 
previous meta-analyses (e.g. Anderson et al., 2001, Rutledge et al., 2006, Luppa et al., 2010,  Mitchell et al., 
2011).  In response to this problem, Egger et al. (1998) have suggested that rather 
than elimination of heterogeneity in meta-analyses of observational studies, a 
careful examination of its sources is necessary. 
Overall, the task of managing meta-analyses of prevalence rates derived 
from observational studies seems challenging. General methodological issues 
raised in previous reviews include managing: non-normal distribution of data, 
heterogeneity and study quality, methodological differences in study design, 
incompleteness of data and missing information (Polanczyk et al., 2007, Uthman, 2008, Fazel et al., 
2008, Luppa et al., 2010, Mitchell et al., 2011). Examples of previously reported challenges 
specific to meta-analyses of prevalence rates of depression and anxiety include 
variability in depression and anxiety ascertainment methods and ways of defining 
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depression and anxiety cases (Grigsby et al., 2002, Gilchrist & Gunn, 2007, Mitchell et al., 2011).  
Explicit guidance for decision making around meta-analyses of 
observational studies of prevalence rates is currently lacking. General quality 
criteria for meta-analyses are available including: QUORUM (Quality of Reporting 
of Meta-analyses) (Clarke, 2000), MOOSE (Meta-analysis Of Observational Studies in 
Epidemiology) (Stroup et al., 2000) and PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses) (Liberati et al., 2009).  
 
2.3     RATIONALE OF THE STUDY 
This thesis contends that coexisting anxiety and depression are important to 
the effective primary care management of osteoarthritis, yet despite the availability 
of suitable assessment tools, depression and anxiety are often undetected in 
primary care (Kessler et al., 2002, Licht-Strunk et al., 2009a). Furthermore, in one study with 336 
UK primary care patients, 60% and 70% patients with depressive and anxiety 
disorders respectively had unmet need for care (Boardman et al.,2004). Lord Layard, a 
health economist, stated that 2.75 million people in England visiting general 
practices are eligible for psychological therapies, of which only 8% receive such 
therapy (Centre for Economic Performance’s Mental Health Policy Group, 2006).  
One of the first steps in epidemiological exploration is to examine the scope 
of the problem of interest and its distribution across sub-populations in which it 
occurs. This involves consideration of case definition, populations of interest, and 
obtaining accurate estimates of occurrence (Webb & Bain, 2011). In the context of 
anxiety and/or depression coexisting with osteoarthritis, such exploration may 
serve several purposes.  
This should help establish whether this is a common problem of general 
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importance or a relatively rare occurrence (Glass, 2000). Such evidence may raise 
awareness of the distribution of the problem of interest within the population of 
interest. This may help formulate hypotheses about its causes as well as 
identifying groups of individuals in whom most attention is required. Increased 
awareness may also be necessary for formulating health policy, particularly 
prevention efforts. A ‘sufficient prevalence’ of the disease in a target group is 
important for considering routine case identification (Grimes & Schultz, 2002, UK National 
Screening Committee Recommendations, 2009), which is one of the potential approaches to 
improving the timely recognition of depressive and anxiety disorders in people with 
OA.  
Prevalence rates of coexisting depression and anxiety were systematically 
searched and synthesised in other long-term conditions, such as diabetes (Anderson 
et al, 2001, Grigsby et al., 2002, Ali et al., 2006, Barnard et al., 2006) or cardiovascular disease (Rutledge et 
al., 2006, Yohannes et al., 2010). In these conditions, recognition of coexisting depression 
and anxiety is advocated by clinical guidelines (BMA, GPC, 2009, Scottish Intercollegiate Guidelines 
NHS (SIGN), 2010, NICE, 2010). In the field of osteoarthritis there are several studies that 
have shown that both depressive and anxiety symptoms are common amongst 
primary care patients presenting to their general practitioners with osteoarthritis 
(Memel et al., 2000, Rosemann et al., 2007, Mallen & Peat, 2008). Yet, in the absence of agreed case 
definitions as well as differences in sample frames and study populations, 
prevalence estimates may differ widely from one study to another (Jacobsen et al., 2006). 
This has been consistently demonstrated by systematic reviews in other chronic 
conditions (Anderson et al, 2001, Grigsby et al., 2002, Rutledge et al., 2006, Yohannes et al., 2010, Mitchell et al., 
2011). A systematic approach to identifying and summarising published prevalence 
rates of depression and anxiety coexisting with OA is currently lacking.  
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This chapter presents the results of a systematic review and meta-analyses 
conducted to ascertain the prevalence of comorbid depressive and anxiety 
disorders and questionnaire assessed anxiety and depression symptoms in 
community based adults with OA/ joint pain. Subgroup meta-analyses to explore 
prevalence variability across study characteristics are reported (i.e. definition of 
the condition of interest, geographical location and study setting sample size, 
mean age, gender distribution, method of ascertainment, study quality). Meta-
regression analyses to quantify the effect of these characteristics are reported.  
 
2.4    AIM AND OBJECTIVES 
The aim is to advance understanding of the prevalence of coexisting depressive 
and anxiety symptoms/disorders in patients with OA. 
 
Specific objectives are: 
 To summarise the scientific evidence of prevalence rates of depression/anxiety 
and depression/anxiety disorders coexisting with OA/ joint pain, by systemically 
reviewing the existing prevalence studies in community-dwelling/primary care 
adults with OA/ joint pain and coexisting depression and anxiety  
 To examine sources between-study variance in reported prevalence rates 
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2.5     METHOD 
The PRISMA guideline (Liberati et al., 2009) for systematic reviews with meta-analyses 
was followed and a systematic review protocol was formulated. 
 
2.5.1  Search strategy 
Databases 
Published literature was searched from inception to the end of August 2009 
using the following electronic databases: EMBASE, MEDLINE, PsycInfo, CINAHL, 
Web of Science and CSA illumina. Unpublished literature was searched from 
inception to the end of August 2009 using CSA illumina and Web of Science. 
References cited in identified articles were examined and citations were tracked. 
 
Search terms 
A broad search strategy using both text words and thesaurus terms was 
designed with a help of an information specialist. Key areas searched for included 
‘depression’, ‘anxiety’, ‘primary care’, ‘general population’, ‘joint pain’, 
‘osteoarthritis’, ‘prevalence’, ‘observational studies’. For the detailed search 
strategies please refer to Box B.1.1 (in Appendix B.1 on page 323).  
 
2.5.2   Eligibility Criteria 
The following inclusion criteria were used in the review: 
 Observational study design  
 Adult participants  
 Primary care or general population settings 
 Diagnosed osteoarthritis or symptoms of OA/ joint pain 
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 Multiple articles on the same cohort were treated as a single study 
Excluded from the review were: 
 Non-English language citations 
 Secondary care populations 
 Studies without primary data  
 Samples comprising exclusively of patients with inflammatory arthritis (e.g. 
rheumatoid arthritis), spondyloarthropathy (e.g. ankylosing spondylitis), 
crystal arthropathy (e.g. gout), or other non-OA musculoskeletal disorders 
(e.g. fibromyalgia) 
 
2.5.3   Study selection  
Titles and abstracts were examined by the first reviewer. The process of 
initial screening of full texts for eligibility and selection for further consideration 
involved consensus between two reviewers. Following this, data extracted from 
selected articles by the first investigator was checked and quality assessed by 
another reviewer. At this point further exclusions were made on the basis of: 
duplicate papers, studies for which required data could not be obtained from 
authors, data for mixed depression and anxiety, and studies in which definitions of 
OA did not clearly meet the eligibility criteria. Studies with reported mean scores 
for depression and anxiety, but no prevalence rates were excluded from the 
systematic review but retained for use in chapter three. All disagreements in the 
process of study selection were reconciled by consensus with an independent 
third reviewer. 
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2.5.4   Data extraction 
The following descriptive characteristics were extracted from each of the 
eligible articles: authors, year of publication, location of study (country, city), 
setting, study design, response rate, number of participants, assessment method 
of the musculoskeletal disease of interest, anatomical site, and additional 
comments (e.g. to record information on variables such as ethnicity of participants 
and key study findings). In addition, the following information was extracted: 
depression and anxiety definition and prevalence, psychological assessment tool, 
mean scores of depression/anxiety symptoms and measure of distribution of 
scores (depending on availability of data within the identified studies). A data 
extraction sheet was developed, including columns for the above variables and a 
column for additional comments on key findings utilised in the discussion. One 
reviewer extracted data from all included articles and the second reviewer checked 
the extracted data. Authors were contacted to obtain missing data or to clarify 
identified studies. Disagreements were resolved by consensus. 
 
2.5.5   Quality assessment 
Methodological quality was assessed to identify bias in individual studies. 
To ascertain the validity of eligible studies, six validated checklists (Loney & Stratford, 
1999, Dionne et al., 2006, Mallen et al., 2006a, Pincus et al., 2006, Van Dijk et al., 2006, Thombs et al., 2007) 
previously used in systematic reviews of musculoskeletal studies formed the 
foundations of a quality assessment checklist. Additional articles were sought if 
methodological details were provided in linked publications (e.g. protocol papers). 
Quality assessment criteria were rated using the ‘yes/no/unclear’ (or not 
applicable) method, according to the presence/absence/lack of clarity (Jüni et al., 1999) 
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(or applicability of each criterion). 
For the purpose of inclusion in meta-regression analyses each ‘yes’ 
received a score of one, ‘no’ or ‘unclear’ were assigned zero points allowing 
summary quality scores to be generated for each article. Quality ratings were 
assigned, in relation to the number of criteria that were met, using the following 
scale: poor (0-7), fair (8-10) and good (11-15). The cut-off points were devised 
based on previously used systems (Pincus et al., 2002, 2006, Cesario et al., 2006), and can be 
found displayed below in Table 2.2. 
 
 
 
 
 
 
 
 
           Two reviewers assessed the methodological quality of each study using the 
quality checklist. The results were discussed at a series of meetings between 
reviewers. Levels of agreement between the first reviewer and four other 
reviewers were estimated (Sheskin, 2007) and interpreted (Altman, 1991) using unweighted 
Cohen’s Kappa. 
 
2.5.6   Data presentation 
The result section includes: presentation of the selection process, 
methodological quality assessment, description of studies and narrative synthesis 
of prevalence rates for which meta-analyses were unfeasible. Following this, 
results of the meta-analyses are presented including questionnaire data for 
clinically important levels of anxiety and depression symptoms and clinical 
Table 2.2 Quality rating system. 
 
Percentage of criteria met Quality score Quality rating 
75%-100% 11-15 Good 
50%-74% 8-10 Fair 
≥ 49% 0-7 Poor 
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interview data for anxiety and depressive disorders. The result of meta-analyses 
section concludes with a summary of results. Supplementary analyses are then 
discussed, including sensitivity analyses conducted to assess impact of individual 
studies on pooled prevalence rates. 
 
2.5.7   Data analyses 
Data entry was completed using SPSS software (version 15). Meta-
analyses were conducted with STATA software (version 11.1). Analyses were 
conducted independently for anxiety and depressive disorders assessed with 
clinical interviews and anxiety and depression symptoms assessed with self-report 
questionnaires. Prevalence rates were meta-analysed and the general principles 
outlined by Sterne et al. (2003) were applied. A meta-analysis (Klassen et al., 1998) was 
conducted when at least two estimates were available for a specific type of 
depressive/anxiety disorder. Data not included in meta-analyses was reported in 
narrative synthesis.  
 
2.5.8   Classification of prevalence estimates 
All depressive and anxiety disorders defined by the DSM-IV-TR (APA, 2000) 
and the ICD-10 (WHO, 1992) diagnostic criteria were included, reported separately and 
analysed. Meta-analyses of self-report questionnaires were performed for all 
“clinically relevant” (qualify for an intervention) symptoms of depression and 
anxiety (typically mild to severe) (Anderson et al., 2001). Literature for specific 
questionnaires was searched to identify recommended cut-off scores. Self-report 
questionnaire data was divided into two categories: 1) possible depression/anxiety 
(mild symptoms or the minimum threshold of clinical relevance established for the 
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specific tool) 2) probable depression/anxiety (warranting treatment (NICE, 2009b)). The 
first group was referred to as ‘mild or worse’ symptoms and the second group was 
referred to as ‘moderate or worse’ symptoms. In cases of longitudinal studies and 
secondary data analyses, reported cross-sectional prevalence rates from the 
earliest wave of data collection were included.  
 
2.5.9   Overall and sub-grouped meta-analyses  
Given the anticipated large degree of heterogeneity, estimates were pooled 
and explored using a random effects approach (Eagger et al., 2001a). Normal distribution 
was required for pooling data, thus logit transformation was applied as outlined 
and adopted for pooling prevalence estimates by Uthman (2008) for effect size 
and standard error and weighted by inverse variance of logit transformed 
prevalence. Once generated, pooled logit estimates were back transformed to 
proportions (Uthman, 2008). 
The pooled estimates were calculated for each group (command metan), 
the precision (95% CI) was determined and heterogeneity assessed, using 
Cochran’s Q test (reported with chi2-value and p-value) and the I2 test. The latter 
provides a measure of the degree of heterogeneity, with low, moderate, and high 
values of 25%, 50%, and 75% (Higgins et al., 2003).  
Sub-group estimates were calculated (command metan, by (covariate)) for 
disorders and ‘mild or worse’ symptoms. Subgroup meta-analyses involved 
recommended (Stroup et al., 2000) or previously investigated (Fazel et al., 2008) study 
characteristics. Pre-defined factors across which pooled estimates and individual 
studies were compared (depending on the availability of information) included: 
method of defining OA/ joint pain cases, anxiety/depression assessment tool, 
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study setting, proportion of females (dichotomised by median), study quality 
(poor/fair vs. good), age (dichotomised by median), study geographical location 
and sample size (>200 vs. ≤200 (Fazel et al., 2008)). As prevalence rates for ‘moderate 
or worse’ symptoms severity were derived from samples for which ‘mild or worse’ 
symptoms were reported, it was regarded as sufficient to perform sub-group 
analyses for the latter only. Studies with no variability in covariates (e.g. studies of 
women only) were omitted from the relevant sub-group analysis as were those 
with more than 50% missing covariate data (Polanczyk et al., 2007). Between-group 
heterogeneity cannot be calculated if high within-group variance is present (Sterne et 
al., 2003). 
 
2.5.10 Meta-regression analyses 
To quantify the effects of between-study sources of heterogeneity a meta-
regression analysis was applied to prevalence estimates as outlined and 
operationalised by Harbord and Higgins (2008). Random-effect meta-regression 
analyses were performed (command metareg) with Knapp-Hartung modification 
for coefficients (including the calculation of standard errors, p-values, and 
conﬁdence intervals). Random-effects meta-regression estimates the between-
study variance followed by estimation of the coefficients (using weighted least 
squares) (Harbord & Higgins, 2008). Restricted maximum likelihood (REML) regression 
estimate is the default algorithm in metareg (Harbord & Higgins, 2008). All covariates 
included in sub-group analyses were considered. Studies with insufficient 
variability in covariates (≥70% sample with same value) were excluded. Initially, 
covariates were tested individually for their associations with prevalence rates (an 
unadjusted model). All covariates with p≤0.10 in unadjusted models were included 
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in adjusted (multivariable) models (Fazel et al., 2008), for which statistical significance 
was established at the level of p<0.05.  
 
2.5.11 Test for publication bias 
The presence of publication bias was investigated using Egger’s test 
(command metabias) as outlined by Harbord et al. (2009). Egger's test is for small-
study effects, and involves regressing the standard normal deviate of intervention 
effect estimate against its standard error (Harbord et al., 2009). Notably, whilst it is a test 
for publication bias, in practice the test indicates whether precision in estimating a 
pooled prevalence increases as the sample size of component studies increases. 
Therefore, results of this test should not be interpreted as indicative of bias in 
likelihood of being published per se. As such the test was considered here suitable 
for prevalence rates reported in the same publication (e.g. a multinational study), 
as long as estimates are derived from different samples.  
 
2.5.12 Sensitivity analyses 
To explore impact of individual estimates on the pooled effect, sensitivity 
analyses were conducted. To estimate the impact of inclusion of prevalence rates 
derived from samples with ‘arthritis’, they were omitted and pooled prevalence 
rates re-estimated.  
In addition to between study variance, heterogeneity can also be related to 
inclusion of specific, biased studies. Exploration of this problem can involve a non-
standardised method of investigating the influence of each individual study on the 
overall pooled estimate and 95% CI (Sterne et al., 2003). For this purpose metaninf 
command in STATA can be used, with the production of a numerical table (print 
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id), showing the pooled estimate omitting each study in turn. Graphs can also be 
generated to visually provide the same results in a plot. The non-standardised 
method of investigating impact of individual studies involves assessment of a 
relative difference between the omitted meta-analytic estimate and the combined 
analysis. Recently introduced methods of sensitivity analyses include equally 
effective, sequential and combinatorial analyses (Patsopoulous et al., 2008). A sequential 
algorithm involves omitting one estimate at each time (n-1). “The study that is 
responsible for the largest decrease in I2 is dropped and a new set of n-1 studies 
is created” (Patsopoulous et al., p. 1149, 2008) combinatorial algorithm involves omitting two 
studies at a time. The method has been criticised for being potentially misleading 
(Higgins, 2008). To explore the impact of individual studies, both the commonly used 
method and the sequential algorithm method, were implemented and compared. 
Numbers of estimates required to achieve ≤75% and ≤50% I2 using both methods 
are reported. 
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2.6    RESULTS 
2.6.1  Selection of studies 
 
Table 2.3 Numbers of papers identified at each stage of the search. 
 
 Hits After 
removing 
duplicates 
Abstracts 
read 
Initial 
screening 
of full text 
Text 
Further 
screened 
for 
eligibility 
Included 
in the 
review 
PsycInfo 361 343 37 17 5 0 
CINAHL 713 690 43 16 4 1 
Medline 1991 1980 180 84 40 9 
EMBASE 3058 2938 82 36 15 4 
CSA Illumina 1132 1109 94 48 21 11 
Web of 
Science 
3346 3223 310 96 34 11 
Total 10601 10283 746 297  
(+12 from 
citations) 
119 
(+8 from 
citations) 
36 
(+1 from 
citations) 
 
Table 2.3 gives details of papers identified through 6 databases, at each 
stage of the search process. The literature search identified 10601 articles (10283 
after removing duplicates), 9537 papers were excluded on title review and the 
remaining 746 abstracts were examined. Of these, 309 full text articles were 
assessed for eligibility and 127 of these were chosen for further eligibility and 
quality assessment. Included in the current review were 37 articles (36 studies) for 
which prevalence rates of depression and anxiety were reported or provided by 
authors upon request (2 cases). One study reported rates for self-report 
questionnaires and clinical interviews (Dunlop et al., 2004, 2005) and thus both articles 
were considered to be the same study. For flow of information through stages of 
the review see Figure 2.2 overleaf and for an overview of the included articles 
refer to Table B.2.1 (in Appendix B.2 on page 328).  
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Figure 2.2 Flow of information though the different phases of a systematic 
search. 
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2.6.2   Quality assessment 
Quality characteristics and total quality scores of each of all 127 articles that 
were assessed and underwent further screening for eligibility, are provided in 
Table B.3.1 (Appendix B.3, p. 338). An analysis of agreement on quality score 
(ranging from ‘poor’ to ‘very good’) between reviewers, supports the effectiveness 
of a checklist and clarity of its criteria are listed in Table 2.4. As shown levels of 
agreement on quality ratings of the 37 included studies were comparable to those 
yielded for all 127 potentially relevant studies. 
 
Table 2.4 Inter-rater agreement for all 127 full texts articles and the included 
37 articles. 
 
Reviewers 
initials 
Unweighted 
Cohen’s Kappa 
coefficient 
95% CI SE Level of agreement on 
quality rating* 
Anxiety and/or depressive data (all 127 full texts articles) 
BN/MR 0.49 0.42, 0.55 0.03 Moderate 
GMP/MR 0.63 0.55, 0.72  0.04 Good 
CM/MR 0.68 0.60, 0.75 0.04 Good 
KB/MR 0.89 0.85, 0.94 0.02 Very good 
Anxiety and/or depressive data (37 included articles) 
BN/MR 0.55 0.40, 0.69 0.07 Moderate 
GMP/MR 0.67 0.55, 0.79 0.06 Good 
CM/MR 0.70 0.59, 0.77 0.05 Good 
KB/MR 0.88 0.82, 0.94 0.03 Good 
Note: * - Interpretation: <0.20 - poor; 0.21-0.40 fair, 0.41-0.60 moderate, 0.61-0.80 good, 0.81-1.00 very good 
(Altman, 1991)
; BN - Barbara Nicholl, CM - Christian Mallen, GMP - George Peat, KB - Kay Benyon, MR - 
Magdalena Rzewuska.
 
 
A summary of issues around specific quality domains are presented for the 
included 37 articles. The quality of studies described in 2 articles was classed as 
‘poor’, 15 ‘fair’ and 20 ‘good’. Quality domains that were most frequently 
addressed in original articles were: the quality of data, analysis, results and data 
presentation (Table 2.5 overleaf). The quality assessment criteria that were less 
frequently reported in studies reporting anxiety/depression separately, included: 
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inclusion of a sample size calculation (reported in n=6); the description of non-
respondents (n=12); the description of eligibility criteria (n=13); and clear definition 
of OA (n=17). These should be regarded as possible sources of bias. 
 
Table 2.5 Quality of studies regarding depression/anxiety described in 37 articles. 
 
Item Quality Criteria Exemplar          No. of  articles* 
   + - ? 
 Study design:     
A Is study objective clearly defined? Mallen et al. (2006a)  35 2 0 
B Is the study design appropriate for the 
research question? 
Loney & 
Stratford(1999)  
Van Dijk et al. 
(2006a)  
34 1 2 
C Is the sample size calculation 
presented? 
Loney & 
Stratford(1999)  
Van Dijk et al. (2006)  
Thombs et al. (2007)  
6 31 0 
 
D Are the inclusion/exclusion criteria 
adequately described? 
Mallen et al.(2006)  13 19 5 
E Is definition of the physiological 
condition of interest (case) clear? 
Pincus et al. (2006)  
Van Dijk et al. (2006)  
17 16 4 
 Study population:     
F Are the study subjects obtained 
appropriately for a given study design? 
Loney & 
Stratford(1999)  
Pincus et al. (2006)  
Thombs et al. (2007)  
30 2 5 
G Is the setting described in detail? Loney & Stratford 
(1999)  
26 9 2 
 Non-respondents:     
H Is response rate  70%* 
 
Pincus et al. (2006)  
Thombs et al. (2007)  
23 9 4 
I Is information about non-respondents 
provided?* 
Van Dijk et al. (2006)  12 22 2 
 Quality of data:     
J Were all data collected directly from the 
subjects? 
Dionne et al. (2006)  35 2 0 
K Is standardised collection of data used? Mallen et al. (2006a)  30 2 5 
L Are objective and suitable criteria used 
for measurement of outcome? 
Loney & Stratford 
(1999)  
Thombs et al. (2007)  
Pincus et al. (2006)  
Dionne et al. (2006)  
34 3 0 
 Analysis, results and data 
presentation: 
    
M Are frequencies of the primary outcome 
measures given in detail? 
Loney & Stratford 
(1999)
  
Van Dijk et al. (2006)  
35 2 0 
N Are employed analysis techniques 
appropriate? 
Van Dijk et al. (2006)  33 0 4 
O Is description of study participants 
adequate? 
Thombs et al. (2007)  27 10 0 
Note: * - one case of N/A; + - yes; - no; ? - unclear. 
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2.6.3   Included studies  
Description of studies 
An overview of included studies can be found in Table B.2.1 (in Appendix 
B.2 on page 328). Thirty six studies (described in 37 articles) reported prevalence 
estimates of depressive and/or anxiety disorders and/or symptoms. 23 studies 
used cross-sectional design, 11 (described in 12 articles) prospective-cohort and 2 
nested case-control design. Nine studies were conducted in primary care and 27 
studies (described in 28 articles) in the general population. Sample sizes ranged 
from 81 (Nour et al., 2005) to 23405 (Fuller-Thompson et al., 2009). The mean age of participants 
with OA/joint pain ranged from 35.2 (He et al., 2008) to 83.8 (Jakobsson & Hallberg, 2006) years. 
The percentage of female participants ranged from 31.5% (Creamer et al., 1999b) to 
100% (Szoeke et al., 2008). Studies were conducted in the U.S.A (n=12, described in 13 
articles), France (n=1), the UK (n=8), Sweden (n=1), Netherlands (n=2), Canada 
(n=5), China (n=2), Germany (n=1), Australia (n=1), Nigeria (n=1), a multinational 
study (n=2).  
Definitions of OA could be grouped into the following categories: 
symptomatic OA (n=9), self-reported OA (n=4), medical records defined OA (n=2), 
the American College of Rheumatology (ACR) criteria defined OA (n=3), 
radiographic OA (n=1). Through agreement between reviewers involving careful 
consideration of characteristics of samples (e.g. age and comorbidities) included 
are also studies concerning ‘arthritis’ (n=7, described in 8 articles). Inclusion of 
studies involving samples with arthritis is based on the evidence suggesting that 
osteoarthritis is by far the most common type of arthritis (Sacks et al., 2010). There is 
also evidence that the term ‘arthritis’ is being used exchangeable to the term 
‘osteoarthritis’ by primary care patients (Peat et al., 2005). These studies will be referred 
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throughout as ‘arthritis’ and the difference in prevalence estimates between clearly 
defined OA and ‘arthritis’ was explored in a sensitivity analysis.  
 
Identified prevalence rates  
In total 24 eligible studies (described in 25 articles)  provided prevalence 
estimates of depressive disorders and/or symptoms (Barberger-Gateau et al., 1992, Dexter & 
Brandt, 1994, Woo et al., 1994, Creamer et al., 1999, Scudds & Robertson, 2000, Wilcox et al., 2000, Kramer et al., 2002, 
Dunlop et al., 2004, Fisher, 2004, Figaro et al., 2005, Dunlop et al., 2005, Nour et al., 2005, Polsky et al., 2005, Jakobsson 
& Hallberg, 2006, Kadam & Croft, 2007, Moussavi et al., 2007, Muus, 2007, Niti et al., 2007, Rosemann, 2007, Allen et al., 
2008, Gureje et al., 2008, Sale, 2008, Schram et al., 2008, Szoeke et al., 2008, Fuller-Thomson & Shaked, 2009). In 
addition, 11 eligible studies provided prevalence estimates of both depressive and 
anxiety disorders and/or symptoms (O’Reilly et al., 1998, Memel et al., 2000, Croft et al, 2005, Patten et 
al., 2006, Peat et al., 2006a, Hill, 2007, Leveille et al., 2007, Wilkie et al., 2007, He et al., 2008, Mallen & Peat, 2008, 
McWilliams et al., 2008) and one of anxiety disorders only (Wells et al., 1989a). Studies which 
had only one estimate or could not be classified into pre-defined categories are 
listed in Table 2.6 overleaf, along with reported prevalence rates and specific 
reasons for exclusion from meta-analyses. 
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Table 2.6 Prevalence rates excluded from meta-analyses. 
 
Study Geograp
hical 
location 
Definition of 
joint 
problem 
Reported 
prevalence 
Construct  Reason for 
exclusion from 
meta-analyses 
Depression:      
Dunlop, 2005 U.S.A Arthritis 40.3% Depression Unclear cut-off point 
Figaro,2005 U.S.A ACR criteria 22.0%  2 questions: 
mood and 
anhedonia 
Unclear classification 
of severity   
Fisher, 2004 U.S.A Arthritis 23.2% Depression Non-standardised 
tool 
Jakobsson, 
2006 
Sweden Self-reported 
OA 
36.3% Depression Non-standardised 
tool 
Kadam, 2007 UK Medical 
records 
define OA 
2.8% Depressive 
disorders 
Only one estimate 
Mallen, 2008 UK Symptomatic 
OA 
18.2% 
 
2 questions: 
mood and 
anhedonia 
Unclear classification 
of severity   
Moussavi, 2007 60 
countries 
Arthritis Average: 
10.7%  
Depressive 
episode 
Only one estimate  
Muus, 2007 U.S.A Arthritis 18.8% Self-
reported 
recall of 
doctor 
diagnosed 
depression 
Unclear classification 
of severity   
Polsky, 2005 U.S.A Arthritis 4.4% Depression Unclear classification 
of severity   
Szoeke, 2008 Australia Self-reported 
OA 
17.0% Depression Unclear cut-off point 
Anxiety:       
Leveille, 2007 U.S.A Symptomatic 
OA 
19.0% ‘Prevalent’ 
anxiety 
Unclear classification 
of severity   
McWilliams, 
2008 
U.S.A Arthritis 9.4% Simple 
phobia 
Only one estimate 
Wells, 1989a U.S.A Arthritis 11.9% Anxiety 
disorders 
Only one estimate 
 
 
Numbers of pooled estimates across pre-defined categories, and methods 
of ascertainment are displayed in Table 2.7 overleaf. Notably, prevalence rates of 
clinical interview defined depression and anxiety disorders are not only based on 
samples with ‘arthritis’, but the majority of prevalence rates have been derived 
from one publication (He et al., 2008). 
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Table 2.7 Numbers of pooled estimates and instruments used. 
 
Construct Number of 
prevalence 
estimates  
Assessment  instrument 
(number of prevalence rates estimated with the tool) 
Depressive disorders 
    Major depression 
    
 
23 
 
 
WMH WHO-CIDI (20)^, WMH WHO-CIDI-SF (2), 
AUDADIS (1) 
     Dysthymia 19 WMH WHO-CIDI (18)*, AUDADIS (1) 
Depression symptoms 
    ‘Mild or worse’ 
    ‘Moderate or worse’ 
 
18 
10 
 
CESD-20 (7), HADS-D (6), GDS-15 (3), PHQ-9 (1),  
GDS-30 (1) 
AIMS-D (2), HADS-D (6), CESD-20 (1), PHQ-9 (1) 
Anxiety disorders 
    GAD 
    Social phobia 
    Panic with agoraphobia 
    PTSD 
 
19 
19 
19 
18 
 
WMH WHO-CIDI (18)*, AUDADIS (1) 
WMH WHO-CIDI (18)†, AUDADIS (1) 
WMH WHO-CIDI (18)*, AUDADIS (1) 
WMH WHO-CIDI (18)* 
    Panic disorder 2 WMH WHO-CIDI (1),  AUDADIS (1) 
Anxiety symptoms 
    ‘Mild or worse’ 
    ‘Moderate or worse’ 
 
6 
5 
 
HADS-A (6) 
HADS-A (5) 
Note: AIMS-D - Arthritis Impact Measurement Scales-Depression; AUDADIS - Alcohol Use Disorders and 
Associated Disabilities Interview; CESD - Center for Epidemiologic Studies Depression Scale; GAD - 
generalised anxiety disorder; GDS - Geriatric Depression Scale; HADS-D, -A - Hospital Anxiety and Depression 
Scale-Depression and Anxiety subscale; PHQ - Patient Health Questionnaire; PTSD - post-traumatic stress 
disorder; WMH WHO-CIDI - World Mental Health (WMH) Survey Initiative version of the World Health 
Organization's Composite International Diagnostic Instrument; 
Numbers of estimates derived from a study by He et al. (2008):
 
* - all, ^ -18, † - 17. 
 
 
2.6.4 Meta-analyses of questionnaire data for clinically relevant symptoms of 
depression and anxiety coexisting with osteoarthritis 
2.6.4.1 Depression symptoms: questionnaire data 
‘Moderate or worse’ severity of depression symptoms 
Prevalence rates of ‘moderate or worse’ depression symptoms identified in 
individual studies ranged from 3.2% to 36.8%. A meta-analysis of ten prevalence 
estimates of ‘moderate or worse’ depression symptoms resulted in a pooled 
proportion of 14.6% (95% CI 9.9, 21.0) (Dexter & Brandt, 1994, Creamer et al., 1999, Memel et al., 
2000, Kramer et al., 2002, Croft et al., 2005, Nour et al., 2005, Peat, 2006a, Rosemann et al., 2007, Wilkie et al., 2007, 
Mallen & Peat, 2008), with a significant and high inconsistency between studies 
(chi2=387.4, p<0.0001, I2=97.7% (95% CI 96.8, 98.3)) being evident (Table B.4.1. 
in Appendix B.4 on page 343), but no evidence of publication bias (p=0.395; see 
Table B.5.1 in Appendix B.5 on page 349).  
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‘Mild or worse’ severity of depression symptoms 
 Prevalence rates of ‘mild or worse’ symptoms ranged from 9.6% to 54.0%. 
Eighteen prevalence estimates of ‘mild or worse’ depression symptoms were 
meta-analysed (Barberger-Gateau et al., 1992, Woo et al., 1994, O’Reilly et al., 1998, Memel et al., 2000, Scudds et 
al., 2000, Wilcox et al., 2000, Kramer et al., 2002, Nour et al., 2005, Peat et al., 2006a, Hill et al., 2007, Leville et al., 2007, 
Niti et al., 2007, Rosemann et al., 2007, Wilkie et al., 2007, Allen et al., 2008, Mallen & Peat, 2008, Sale et al., 2008, 
Schram et al., 2008). A pooled proportion was 23.8% (95% CI 20.6, 27.2; see Figure 2.3 
overleaf), with a significant and high level of heterogeneity (chi2=344.89, 
p<0.0001, I2=95.1% (95% CI 93.4, 96.3)) (Table B.4.2 in Appendix B.4 on page 
343) and no evidence of publication bias (p=0.730; see Table B.5.1 in Appendix 
B.5 on page 349). Removal of two prevalence estimates from samples with 
‘arthritis’ resulted in pooled prevalence of 24.2% (95% CI 20.8, 27.8), and still 
heterogeneity (chi2=331.41, p<0.0001, I2=95.5% (95% CI 93.9, 96.6)). This 
indicates unlikely impact on inclusion of samples defined as having ‘arthritis’ on 
pooled prevalence estimates. 
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Figure 2.3 Prevalence rates of ‘mild or worse’ depression symptoms in 
community-dwelling adults with osteoarthritis. 
 
 
 
Note: CESD - Center for Epidemiologic Studies Depression Scale; GDS - Geriatric Depression Scale; HADS - 
Hospital Anxiety and Depression Scale-Depression subscale; PHQ - Patient Health Questionnaire; 
Framed in black - primary care studies; Framed in red - two studies in adults with ‘arthritis’. 
 
 
 Pooled prevalence estimates by subgroups can be found in Table 2.8 
(overleaf). The majority of pooled estimates ranged from 21% to 28%, with two 
outliers identified for the ACR criteria defined and medical records defined OA. 
Prevalence rates the two commonest questionnaires used to assess depression 
(CESD-20 and HADS-D) are displayed in Figure 2.4 (on page 52). 
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Table 2.8 Summary of subgroups of pooled estimates of ‘mild or worse’ 
depression symptoms arranged by % weight. 
 
Grouping factor No. of 
ES 
ES. 
range 
Pooled 
prevalence 
95%CI I
2
 % 
weight 
Questionnaire to assess 
depression symptoms: 
      
CESD-20 [1, 2, 11, 17, 22, 24, 
26] 
7 13.3,54.0 21.5 17.1,26.6 94.1  39.51 
HADS-D [9, 13, 14,18, 19, 27] 6 19.0,35.5 26.7 23.7,30.0 84.1  34.24 
GDS-15 [16, 23, 28]  3 16.7,39.8 26.5 14.0,44.2 96.8  16.46 
PHQ-9 [21] 1 28.4 - 25.7,31.3 - 5.97 
GDS-30 [12]  1 9.6 - 5.7,15.8 - 3.83 
Definitions of OA:       
Symptomatic OA [2, 12, 13, 
19, 22, 24, 27, 28]  
8 9.6,39.8 24.4 19.8,29.6 96.6  45.46 
Self-reported OA [9, 11]  2 19.2,26.0 22.4 16.4,29.7 89.5  11.68 
Radiographic OA [1, 18] 2 13.3,19.0 22.9 14.2,34.8 81.7  11.51 
ACR criteria [21, 26]  2 17.9,28.4 15.8 11.0,22.1 94.2  11.05 
‘Arthritis’ [16, 23] 2 16.7,25.7 20.6 13.2,30.7 84.1  10.57 
Medical records defined OA 
[14, 17] 
2 29.2,54.0 40.8 19.8,65.7 93.0  9.73 
Study setting:       
General Population [1, 2, 11, 
12, 16, 17, 18, 22, 23, 24, 26, 
28] 
12 
 
9.6,54.0 21.6 17.2,26.7 
 
95.6  65.13 
Primary Care [9, 13, 14, 19, 
21, 27]  
6 24.6,35.5 28.0 25.5,30.6 79.0  34.87 
Geographical location:       
Europe [2, 9, 11, 13, 14, 18, 
19, 21, 23, 27] 
10 
 
15.8,35,5 24.5 21.2,28.2 93.8 57.18 
U.S.A, Canada [1, 12, 17, 22, 
24, 26] 
6 9.6,54.0 21.3 15.3,28.9 94.5 31.42 
China [16, 28]  2 16.7,39.8 26.8 10.2,54.1 98.3 11.40 
Sample size:       
>200 [1, 2, 9, 11, 13, 16, 18, 
19, 21, 22, 24, 26-28]   
14 15.8,39.8 23.8 19.7,24.5 95.6   81.39 
≤200 [12, 14, 17, 23]  4 9.6,54.0 27.1 14.6,44.6 93.3  18.61 
Age (years)* (range  61-79):       
>67 [2, 14, 17, 22, 24, 26]  6 15.8,54.0 25.1 19.2,32.1 94.5  33.07 
≤67 [13, 18, 19, 21, 27] 5 19.0,35.5 26.9 23.7,30.3 87.6  29.25 
Proportion of females*(52.4-75.6):      
>64 [13, 19, 24, 26, 27]  5 17.9,35.5 25.9 22.4,29.6 89.4 29.31 
≤64 [1, 11, 14, 18, 21, 22, 28]  7 13.3,39.8 23.4 17.8,30.3 96.2 39.96 
Study quality:       
≥Good [1, 9, 12, 13, 14, 16, 
17, 18, 19, 21, 22, 24, 26, 27] 
14 9.6,54.0 23.7 20.7,27.1 92.8  77.14 
Poor/fair [2, 11, 23, 28]  4 15.8,39.8 24.1 14.7,36.8 98.0  22.86 
Note: ACR - the American College of Rheumatology; CI - confidence intervals; CESD - Center for 
Epidemiologic Studies Depression Scale; ES -estimates; GDS - Geriatric Depression Scale; HADS - Hospital 
Anxiety and Depression Scale; OA - osteoarthritis; PHQ - Patient Health Questionnaire; 
[a number in square brackets] - represents a study ID number that can be found in Table B.2.1 (in Appendix 
B.2 on page 328); * - Data partially unavailable. 
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Figure 2.4 Prevalence of ‘mild or worse’ depression symptoms assessed 
with CESD-20 and HADS in community-dwelling adults with osteoarthritis. 
 
 
 
Note: CESD - Center for Epidemiologic Studies Depression Scale; HADS - Hospital Anxiety and Depression 
Scale.   
 
 
 
2.6.4.2 Anxiety symptoms: questionnaire data 
‘Moderate or worse’ levels of anxiety symptoms 
Prevalence rates of ‘moderate or worse’ symptoms ranged across individual 
studies from 17.0% to 24.4%. Five prevalence estimates were meta-analysed 
(Memel et al., 2000, Croft et al., 2005, Peat et al., 2006a, Wilkie et al., 2007, Mallen & Peat, 2008). A pooled 
estimate was 20.8% (95% CI 18.0, 23.8; see Table B.4.3 in Appendix B.4, p. 344), 
with high heterogeneity (chi2=23.91, p<0.0001, I2=83.3% (95% CI 62.0, 92.6) and 
no evidence of publication bias (p=0.281; Table B.5.1 in Appendix B.5, p. 349). 
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‘Mild or worse’ levels of anxiety symptoms 
 
Meta-analysed prevalence rates of ‘mild or worse’ symptoms of anxiety in 
patients with OA/ joint pain ranged from 39% to 50%. A pooled estimate was 
45.4% (95% CI 43.4, 47.5; see Figure 2.5) with low heterogeneity (chi2=10.12, 
p=0.072, I2=50.6% (95% CI 0.0, 80.4)) (Table B.4.4 in Appendix B.4, p. 344) and 
no evidence of publication bias (p=0.854; see Table B.5.1, p. 349 for details).  
 
Figure 2.5 Prevalence of ‘mild or worse’ anxiety symptoms in community-
dwelling adults with osteoarthritis.  
 
 
 
 
The low heterogeneity could be attributed to the consistency of the method 
of ascertainment, but also to the fact that five of the meta-analysed studies used a 
closely related sample-frame. Prevalence estimates for different sub-groups are 
presented in Table 2.9 overleaf. 
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Table 2.9 Summary of grouped estimates for ‘mild or worse’ symptoms of 
anxiety arranged by % weight. 
 
Grouping factor  No. 
of ES 
ES range Pooled 
prevalence 
95% CI I
2 
 % 
weight 
Definitions of OA:       
Symptomatic OA  
[13, 19, 27] 
3 44.4,46.0 45.4 44.1,46.6 0.0  70.13 
Self-reported OA [9] 1 50.0 - 46.0, 54.2 - 14.25 
Radiographic OA [18] 1 39.0 - 33.6, 44.6 - 9.21 
Medical records defined OA 
[14]  
1 46.0 - 39.0, 53.0 - 6.41 
Study setting:        
Primary care 
[9, 13, 14, 19, 27] 
5 44.4,50.0 45.9 44.4, 47.3 17.8  90.79 
General population [18] 1 39.0 - 33.6, 44.6 - 9.21 
Sample size:      
>200 [9, 13, 18, 19, 27] 5 39.0,50.0 45.4 43.2, 47.6 60.4 93.59 
≤200 [14] 1 46.0 - 38.9, 53.3 - 6.41 
Mean age (years)* (range 61-71):      
>65 [14, 19, 27] 3 45.0,46.0 45.4 44.1, 46.8 0.0 63.11 
≤65 [13, 18] 2 39.0,44.4 42.1 36.7, 47.8 59.6  22.63 
Proportion of females* (range 58-65):     
>60 [19, 27] 2 45.0,46.0 45.4 44.1, 46.6 0.0  56.71 
≤60 [13, 14, 18] 3 39.0,46.0 43.1 39.0, 47.2 37.2  29.04 
Unfeasible for sub-group analyses:     
Questionnaire to assess 
anxiety symptoms:                   consistent (HADS-A) 
Geographical location:              consistent (UK) 
Study quality:                           consistent (‘≥ good’) 
Note: CI - confidence intervals; ES - estimates;  
[a number in square brackets] - represents a study ID number that can be found in Table B.2.1 (in Appendix 
B.2 on page 328); * - Data partially unavailable. 
 
 
 
 
 
2.6.5    Meta-analyses of clinical interview data in people with arthritis 
2.6.5.1 Depressive disorders 
Major depression (MD)  
 
Prevalence rates of major depression reported in individual studies ranged 
from 1.4% to 19.2%. A meta-analysis was conducted for 23 12-month prevalence 
estimates of major depression (MD) in patients with OA/ joint pain (Dunlop et al., 2004, 
Patten et al., 2006, He et al., 2008, Gureje et al., 2008, McWilliams et al., 2008, Fuller-Thomson & Shaked, 2009). This 
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meta-analysis revealed a 7.3% (95% CI 6.3, 8.5; see Figure 2.6) pooled 
prevalence rate of major depression, high inconsistency between studies 
(chi2=342.54, p<0.0001, I2=93.6% (95% CI 91.6, 95.1)) (see Table B.4.5 in 
Appendix B.4, p. 345), and no evidence of publication bias (p=0.071; see Table 
B.5.2 in Appendix B.5, p. 350).  
 
 
Figure 2.6 Prevalence of major depression in community-dwelling adults 
with ‘arthritis’. 
 
 
 
Dysthymic disorder (dysthymia) 
Prevalence rates of dysthymia reported in individual studies (including 18 
from one multinational study) ranged from 0.0% to 10.6%. Nineteen 12-month 
prevalence estimates of dysthymia were meta-analysed (He et al., 2008, McWilliams et al., 
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2008). The pooled prevalence rate was 2.6 % (95% CI 2.0, 3.6; see Figure 2.7), with 
high heterogeneity (chi2=100.98, p<0.0001, I2=82.2% (95% CI 73.2, 88.1)) (see 
Table B.4.6 in Appendix B.4 on page 345), and no evidence of publication bias 
(p=0.155; see Table B.5.2 in Appendix B.5 on page 350 for details).  
 
Figure 2.7 Prevalence of dysthymia in community-dwelling adults with 
‘arthritis’. 
 
 
 
Sub-group analyses for major depression and dysthymia in community based 
adults with ‘arthritis’ 
Sub-group meta-analyses were feasible only for geographical location, 
sample size and assessment tool. The results for major depression and dysthymia 
are displayed in Table 2.10 overleaf. Details of variables unfeasible for sub-group 
analyses are also presented this table. 
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Table 2.10 Summary of subgroups of pooled estimates of major depression 
and dysthymia arranged by % weight. 
 
Grouping factor  No. of 
ES 
ES 
range  
 
Pooled  
prevalence 
95% CI I
2 
 % 
weight 
Major Depression (MD)     
Geographical location:        
U.S.A, Canada [29, 31, 33, 
35, 36] 
5 5.0,10.9 8.7 6.9,11.00 98.0 31.24 
West and South Europe [31] 6 3.8,6.8 5.7 4.8, 6.8 0.0  22.83 
Africa [30, 31] 3 2.2,7.9 5.6 3.2,9.5 88.0 14.22 
Colombia, Mexico [31] 2 9.3,10.2 9.8 7.3, 13.0 0.0 8.46 
East Asia [31] 3 2.2,5.7 4.2 2.4,7.1 0.0  5.91 
Middle East [31] 2 1.4,10.5 5.2 0.8, 28.6 71.0  5.85 
New Zealand [31]  1 6.2 - 5.0, 7.6 - 5.71 
Ukraine [31] 1 19.2 - 15.9, 23.0 - 5.70 
Sample size:      
> 200 [29, 30, 31, 33, 35, 36] 18 2.2,19.2 7.8 6.7,9.3 95.3 84.57 
≤ 200 [31] 7 1.4,9.2 4.9 3.3,7.4 41.3 15.43 
Assessment tool:       
WMH WHO-CIDI  
[30, 31, 36] 
20 1.4,19.2 6.5 5.2,8.1 90.9 81.03 
WMH WHO-CIDI-SF [29, 35] 2 9.9,10.9 10.3 9.4,11.2 71.9 12.65 
AUDADIS [33] 1 9.8 - 9.2,10.5 - 6.33 
Dysthymia:      
Geographical location:      
West and South Europe [31] 6 1.6,3.2 2.6 2.0, 3.4 0.0  36.21 
U.S.A [31, 33]  2 3.0,3.6 3.2 2.7, 3.8 36.6  18.81 
Colombia, Mexico [31] 2 1.6,2.0 2.0 1.0, 3.8 0.0  9.83 
Middle East [31] 2 1.1,3.9 3.8 2.3, 5.8 0.5  9.53 
Ukraine [31] 1 10.6 - 8.2, 13.7 - 9.05 
New Zealand [31] 1 2.4 - 1.8, 3.3 - 8.83 
Africa [31] 2 0.0,0.6 0.6 0.2, 2.0 0.0  4.29 
East Asia [31] 3 0.1,1.1 0.7 0.2, 3.2 0.0  3.45 
Sample size:       
 >200 [31, 33] 12 0.0,10.6 3.0 2.2,4.2 88.0 82.81 
 ≤200 [31] 7 0.1,2.2 1.5 0.8,2.7 0.0 17.19 
Assessment tool:       
WMH WHO-CIDI [31] 18 0.0,10.6 2.4 1.7,3.6 82.2 90.36 
AUDADIS [33] 1 3.0 - 2.6,3.4 - 9.64 
Unfeasible for sub-group analyses:  
Definition of OA: consistent (‘arthritis’) 
Study setting: consistent (general population) 
Proportion of females: >50% data unavailable 
Study quality: consistent (poor/fair) 
Mean age: >50% data unavailable 
Note: AUDADIS- Alcohol Use Disorders and Associated Disabilities Interview; CI- confidence intervals; ES- 
estimates; WMH WHO-CIDI (SF) - World Mental Health (WMH) Survey Initiative version of the World Health 
Organization's Composite International Diagnostic Instrument (short version).  
[a number in square brackets] - represents a study ID number that can be found in Table B.2.1 (in Appendix 
B.2 on page 328).  
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2.6.5.2 Anxiety disorders 
Generalised anxiety disorder (GAD) 
A meta-analysis of 19 prevalence rates (range 0.2% to 6.0%) (He et al., 2008, 
McWilliams et al., 2008) of 12-month prevalence of generalised anxiety disorder (GAD) 
produced a pooled estimate of 3.0% (95% CI 2.5, 3.9; see Figure 2.8), with 
moderate heterogeneity (chi2=69.91, p<0.0001, I2=74.3% (95% CI 59.6, 83.6)) 
(see Table B.4.7 in Appendix B.4, p. 346) and evidence of statistically significant 
publication bias (p=0.017; see Table B.5.2 in Appendix B.5, p. 350). This suggests 
that precision in estimating pooled prevalence of GAD increases as the sample 
size of component studies increases. 
 
Figure 2.8  Prevalence of GAD in community-dwelling adults with ‘arthritis’. 
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Social phobia 
A meta-analysis of 19 12-month prevalence rates (range 0.0% to 7.5%) of 
social phobia (He et al., 2008, McWilliams et al., 2008) revealed a 3.0% pooled prevalence 
estimate (95% CI 2.3, 3.9; see Figure 2.9), with no evidence of publication bias 
(p=0.198; see Table B.5.2 in Appendix B.5 on page 350) and a high level of 
heterogeneity (chi2=118.84, p<0.0001, I2=84.9% (95% CI 77.6, 89.7)) (see Table 
B.4.8 in Appendix B.4 on page 346).  
 
Figure 2.9  Prevalence of social phobia in community-dwelling adults with 
‘arthritis’. 
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Panic with agoraphobia 
A meta-analysis of 19 12-month prevalence rates (range 0.0% to 8.5%) of 
panic with agoraphobia (He et al., 2008, McWilliams et al., 2008) found a 2.2% pooled 
prevalence rate (95% CI 1.4, 3.4; see Figure 2.10), with no evidence of publication 
bias (p=0.409; see Table B.5.2 in Appendix B.5 on page 350) and high 
heterogeneity (chi2=199.35, p<0.0001, I2=91.0% (95% CI 87.4, 93.5)) (see Table 
B.4.9 in Appendix B.4 on page 347).  
 
Figure 2.10  Prevalence of panic disorder with agoraphobia in community- 
dwelling adults with ‘arthritis’. 
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Post-traumatic stress disorder (PTSD) 
Eighteen 12 month prevalence rates included in meta-analyses ranged from 
0.0% to 5.2% (He et al., 2008). A pooled estimate of prevalence PTSD was 1.8% (95% 
CI 1.2, 2.6, see Figure 2.11) with high heterogeneity (chi2=72.25, p<0.0001, 
I2=76.5% (95% CI 63.0, 85.0)) (see Table B.4.10 in Appendix B.4, p. 347). 
Statistically significant publication bias was found with the Egger’s test (p<0.0001; 
see Table B.5.2 in Appendix B.5, p. 350), what is likely to be due to 10 estimates 
being 0% or close to 0%. 
 
Figure 2.11 Prevalence of PTSD in community-dwelling adults with ‘arthritis’. 
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Panic disorder 
A meta-analysis of 2 (2.6% and 3.0%) 12 month prevalence rates (Patten et al., 
2006, McWilliams et al., 2008) of panic disorder resulted in a pooled estimate of 2.8% (95% 
CI 2.4, 3.2; see Table B.4.11 in Appendix B.4 on page 348), with high levels of 
heterogeneity detected (chi2=82.60, p<0.0001, I2=98.8% (95% CI 97.5, 99.4)). 
Whilst by definition two estimates were sufficient to perform meta-analysis, the 
STATA programme did not allow exploring a publication bias analysis for two 
estimates. 
 
Sub-group analyses for specific anxiety disorders 
Sub-group estimates were unattainable for panic disorder, as only 2 
prevalence rates were available. Data for other specific anxiety disorders was 
derived from three studies (Patten et al., 2006, He et al., 2008, McWilliams et al., 2008), and thus, 
there was a limited variability across the majority of pre-defined variables of 
interest. As the identified studies used cross-sectional study design and reported 
results for several countries with limited space for details about characteristics of 
sub-samples,  problems of consistency across studies or unavailable of data were 
common.  As a result, analyses could be performed for geographical location (see 
Table 2.11 overleaf) and sample size and assessment tool only (see Table 2.12 on 
page 64). Details of variables unfeasible for sub-group analyses are presented in 
Table 2.12. 
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Table 2.11 Summary of estimates grouped by geographical locations 
across anxiety disorders arranged by % weight. 
 
Geographical location  No. of 
ES 
ES. 
range 
Pooled 
prevalence 
95% CI I
2 
 % 
weight 
GAD:       
West and South Europe  
[31] 
6 0.2,3.2 1.7 1.0,2.8 46.0  24.99 
U.S.A [31, 33] 2 3.5,5.9 4.5 2.7,7.5 95.1 21.60 
East Asia [31] 3 2.6,3.6 2.9 1.6,5.4 0.0  10.70 
New Zealand [31] 1 3.9 - 3.0,5.0 - 10.07 
Ukraine [31] 1 6.0 - 4.2,8.5 - 9.04 
Africa [31] 2 0.2,3.5 1.0 0.0,14.3 86.7 9.20 
Middle East [31] 2 0.2,4.5 3.9 1.2,12.4 7.1  8.69 
Colombia, Mexico [31] 2 1.0,1.4 1.2 3.2,6.5 0.0  5.71 
Social phobia:       
U.S.A, Canada [31, 33, 36] 3 2.9,7.5 4.3 2.6,6.9 97.4  31.58 
West and South Europe 
[31] 
6 0.4,2.2 1.6 1.1,2.2 0.0  27.74 
Colombia, Mexico [31] 2 3.7,5.3 4.7 3.0,7.1 0.0  13.11 
New Zealand [31] 1 4.7 - 3.8,5.9 - 10.00 
Africa [31] 2 0.2,3.8 1.1 0.0,16.1 87.3  9.64 
Ukraine [31] 1 3.1
 - 
2.0,5.2 - 7.86 
Lebanon [31] 1 0.0 - 0.0,100.0 - 0.01 
East Asia [31] 3 0.0 0.0 0.0,80.0 0.0  0.07 
Panic with agoraphobia:      
West and South Europe 
[31] 
6 0.6,2.2 1.7 1.2,2.3 0.0  32.80 
U.S.A [31, 33] 2 0.8,5.0 2.1 0.0,11.5 99.2  14.77 
Africa [31] 2 1.1,8.5 3.2 0.0,21.0 95.0  13.18 
Colombia, Mexico [31] 2 2.9,3.2 3.0 1.8,5.2 0.0  12.28 
U.S.A [31] 1 5.2 - 4.2,6.5 - 11.57 
Middle East [31] 2 0.4,2.9 2.8 1.7,4.7 0.0  7.92 
New Zealand [31] 1 2.6 - 1.9,3.6 - 7.27 
Ukraine [31] 1 4.0 - 2.5,6.2 - 7.01 
East Asia [31] 3 0.0,0.9 0.7 0.0,3.4 0.0  4.77 
PTSD:       
West and South Europe 
[31] 
6 0.6,3.1 1.6 1.0,2.7 50.8  42.38 
U.S.A [31] 1 5.2 - 4.2,6.5 - 11.57 
New Zealand [31] 1 4.0 - 3.1,5.1 - 11.42 
Ukraine [31] 1 4.5 - 3.0,6.9 - 10.62 
Middle East [31] 2 0.7,1.1 1.0 0.4,2.2 0.0  9.35 
Colombia, Mexico [31] 2 0.3,0.6 0.4 0.0,1.9 0.0  5.77 
Africa [31] 2 0.0,0.5 0.4 0.0,1.6 0.0  5.33 
East Asia [31] 3 0.0,0.8 0.6 0.0,4.0 0.0  3.57 
Note: CI- confidence intervals; GAD- generalise anxiety disorder; ES-estimates; PTSD- post traumatic 
stress disorder; 
[a number in square brackets] - represents a study ID number that can be found in Table B.2.1 (in 
Appendix B.2 on page 328). 
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Table 2.12 Summary of estimates grouped by sample size and 
assessment tool across anxiety disorders. 
 
Grouping factor  
 
No. 
of 
ES 
ES. 
range 
Pooled 
   % 
95% CI I
2 
 % 
weight 
GAD:       
Sample size:       
>200 [31, 33] 12 0.2,6.0 3.2 2.4,4.1 81.7 83.84 
≤200 [31] 7 0.2,3.6 2.2 1.3,3.6 0.0 16.16 
Assessment tool:       
WMH WHO-CIDI [31] 18 0.2,6.0 2.7 2.1,3.7 74.1 88.93 
AUDADIS [33] 1 3.5 - 3.1,3.9 - 10.07 
Social phobia:     
Sample size:       
>200 [31, 33, 36]  12 0.2,7.5 3.1 2.3,4.1 90.2 89.39 
≤200 [31] 7 0.0,3.7 2.7 1.5,4.9 0.0 10.61 
Assessment tool:       
WMH WHO-CIDI [31, 36] 18 0.0,7.5 2.8 2.0,3.9 85.6 89.36 
AUDADIS [33] 1 3.6 - 3.6,4.0 - 10.64 
Panic with agoraphobia:      
Sample size:       
>200 (31, 33 ) 12 0.8,8.5 2.4 1.5,4.0 94.3 80.45 
≤200 (31) 7 0.0,3.2 1.9 0.9,3.4 0.0 19.35 
Assessment tool:       
WMH WHO-CIDI [31] 18 0.0,8.5 2.5 1.8,3.5 78.5 92.63 
AUDADIS [33] 1 0.8 - 0.6,1.0 - 7.37 
PTSD:       
Sample size:       
>200 [31] 11 0.0, 5.2 2.0 1.3, 3.1 83.3 81.49 
≤200 [31] 7 0.0, 3.1 1.4 0.7, 2.9 0.0 18.51 
Assessment tool: consistent (WMH WHO-CIDI)   
Unfeasible for sub-group analyses:    
Definition of OA:        consistent (‘arthritis’) 
Study setting:        consistent (general population) 
Proportion of 
females: 
        
       > 50% data unavailable 
Study quality:        consistent (poor/fair) 
Mean age:        > 50% data unavailable  
Note: AUDADIS- Alcohol Use Disorders and Associated Disabilities Interview; CI- confidence intervals; 
ES- estimates; WMH WHO-CIDI- World Mental Health (WMH) Survey Initiative version of the World 
Health Organization's Composite International Diagnostic Instrument; 
[a number in square brackets]- represents a study ID number that can be found in Table B.2.1 (in 
Appendix B.2 on page 328). 
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2.6.6 Meta-regression analyses of prevalence estimates of depressive/ 
anxiety disorders and symptoms 
Meta-regression analyses found that the 10% level required for adjusted 
analyses was achieved only for covariates associated with prevalence rates of 
major depression in an unadjusted model, but failed to reach the pre-defined level 
of statistical significance in an adjusted model. Details of unadjusted models 
estimates for questionnaire data, with specified reason for omitting are displayed 
in Table 2.13 overleaf. Results of unadjusted models of depressive and anxiety 
disorders and the adjusted model for major depression ascertain with clinical 
interview schedules and reasons for omitting specific covariates are listed in Table 
2.14 on page 67.  
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Table 2.13 Meta-regression analyses for prevalence estimates of questionnaire data, values show β, se (β), and the 
significance of β. 
 
                                                                                     Covariate 
 
 
 
Construct 
 
 
Model 
Age Sex Setting Geographical 
location 
Sample size  OA def. Tool Study 
quality 
 
Mean age Proportion 
of females 
General 
population 
vs. 
Primary 
care 
America vs. 
other 
<200 vs. 
≤200 
Robust vs. 
unclear 
CESD vs. 
other 
Fair/poor 
vs. 
good HADS vs. 
other 
Depression 
symptoms 
         
‘Mild or 
worse’ 
Unadj. 0.01 (0.03) 
p=0.704 
-0.22 (2.18) 
p=0.921 
0.36 (0.26) 
p=0.183 
0.21 (0.27) 
p=0.463 
0.24 (0.32) 
p=0.464 
0.24 (0.27) 
p=0.385 
0.18 (0.26) 
p=0.511 
Omitted 
(100% 
good) 
‘Moderate or 
worse’ 
Unadj. 0.03 (0.05) 
p=0.486 
-2.32 (1.69) 
p=0.208 
0.58 (0.47) 
p=0.257 
Omitted 
(70% 
 Europe) 
-0.19 (0.55) 
p=0.738 
Omitted 
(70% 
robust) 
0.69 (0.44) 
p=0.156 
Omitted 
(100% 
good) 
Anxiety 
symptoms 
         
‘Mild or  
worse’ 
Unadj.  0.03 (0.02) 
p=0.234 
-2.52 (1.98) 
p=0.209 
Omitted 
(83% primary 
care) 
Omitted 
(100% 
Europe) 
Omitted 
(83% ≤200) 
Omitted 
 (100% 
robust) 
Omitted  
(100% 
HADS) 
Omitted 
(100% 
good) 
‘Moderate or 
worse’ 
Unadj. Omitted  
(80% 65 
years) 
-0.39 (1.91) 
p=0.851 
Omitted 
(100% 
primary care) 
Omitted 
(100% 
Europe) 
Omitted 
(80% ≤200) 
Omitted 
 (100% 
robust) 
Omitted 
 (100% 
HADS) 
Omitted 
(100% 
good) 
Note: Omitted - for reasons described in result section concerning sub-group meta-analyses; OA – osteoarthritis; Unadj.- unadjusted. 
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Table 2.14 Meta-regression analyses for prevalence estimates of clinical interview data, values show β, se (β), and 
the significance of β. 
 
                                                                   Covariate 
 
Construct Model Geographical location Sample size Assessment  tool 
  America vs. other >200 vs. ≤ 200 WMH WHO-CIDI vs. other 
Depressive disorders     
Dysthymia Unadj. -0.07(0.39) p=0.859 0.76 (0.43) p=0.910 Omitted 
(95% assessed with WMH WHO-CIDI) 
Major depression Unadj. -0.41(0.22) p=0.081 0.51 (0.27) p=0.078 Omitted 
(87% assessed with WMH WHO-CIDI) 
 Adj. -0.35(0.22) p=0.122† 0.44 (0.27) p=0.117‡ - 
Specific anxiety 
disorders 
    
GAD Unadj. -0.17(0.42) p=0.694 0.42 (0.43) p=0.341 Omitted 
(95% assessed with WMH WHO-CIDI) 
Panic with agoraphobia Unadj. -0.12 (0.43) p=0.783 0.58 (0.51) p=0.273 Omitted 
(95% assessed with WMH WHO-CIDI) 
PTSD Unadj. -0.17(0.68) p=0.801 0.61 (0.61) p=0.339 Omitted 
(100% assessed with WMH WHO-CIDI) 
Social phobia Unadj. -0.72 (0.10) p<0.05 0.29 (0.54) p=0.569 Omitted 
(95% assessed with WMH WHO-CIDI) 
Note: Adj.- adjusted; Unadj.- unadjusted; GAD- generalised anxiety disorder; PTSD- Post Traumatic Stress Disorder; WMH WHO-CIDI- World Mental 
Health (WMH) Survey Initiative version of the World Health Organization's Composite International Diagnostic Instrument;  
†- adjusted for sample; ‡- adjusted for geographical location;  
Analyses for panic disorder and other covariates where omitted, for reasons described in result section concerning sub-group meta-analyses. 
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2.6.7   Supplementary analyses 
The impact of the individual studies on the heterogeneity of prevalence 
rates were explored using the non-standardised and sequential algorithm 
methods. Possibly due to the random-effects approach, the non-standardised 
method involving 95% CI was of limited effectiveness, as the majority of the 
estimates lay beyond the combined 95% CI. There was no clear superiority for the 
sequential algorithm method. Both methods resulted in high proportions of studies 
being removed and can be regarded of limited utility to meta-analyses of 
prevalence rates with a random effect approach (see Table B.6.1 in Appendix B.6 
on page 351 for a summary). 
 
2.6.8   Summary of findings for the prevalence of anxiety and depression 
Clinically relevant symptoms of depression and anxiety are common among 
people with OA. This systematic review and meta-analysis has found that 21.0% 
and 15.0% of people with OA have anxiety and depression symptoms classed as 
being ‘moderately severe or worse’ respectively. When mild symptoms are 
included, these estimates increase to 45.0% and 24.0% respectively. With the 
exception of major depression (7.3%), specific comorbid anxiety and depressive 
disorders in people with OA/ joint pain are comparatively rare (<5.0%). Between-
study heterogeneity of estimates was typically high ranging from 50.6% to 98.8%. 
In total, 13 studies prevalence estimates could not be included in meta-analyses 
due to lack of specification of the used cut-off points, unclear severity of symptoms 
or conceptualisation that could not be classified as any of the used constructs. A 
summary of details of pooled prevalence estimates, included estimates and meta-
regression analyses can be found displayed in Table 2.15 (on page 70). 
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Sub-group estimates suggest variation in prevalence of depression and 
anxiety in community-dwelling adults with OA across different sampling 
procedures, characteristic of sample and different methods of ascertainment. 
Marked differences appear, particularly for different geographical locations and for 
the method of determining anxiety and depression. Meta-regression analyses 
revealed the explored characteristics at the study level had small, inconsistent or 
statically non-significant effects of heterogeneity of pooled estimates.  
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Table 2.15 Summary of pooled prevalence estimates. 
 
Construct No. 
of 
ES 
Total 
combined 
study 
population 
Prevalen
ce % 
rates 
range  
Pooled 
% estimate  
(95% CI) 
I
2
  
(95% CI) 
Range of 
quality 
scores of 
analysed 
studies 
Public
ation 
bias 
Statistically   
significant 
sources of 
heterogeneity 
Questionnaire assessed symptoms:      
‘Moderate or worse’ 
depression symptoms  
10 9,005 3.2,36.8 14.6 
(9.9,21.0) 
97.7 
(96.8,98.3) 
10,14 
 
No No 
‘Mild or worse’ depression 
symptoms  
18 15,194 9.6,54.0 23.8 
(20.6,27.2) 
95.1 
(93.4,96.3) 
8, 15  No No 
‘Moderate or worse’ anxiety 
symptoms    
 
 
5 6,489 17.0,24.4 20.8 
(18.0,23.8) 
83.3 
(62.0,92.,6) 
11,13 
 
No No 
‘Mild or worse’ anxiety symptoms
 
 6 6,867 39.0,50.0 45.4 
(43.4,47.5) 
50.6 
(0.0,80.4) 
11,15 No No 
Clinical interviews defined disorders:      
Dysthymia  19 15,718 0.0,10.6 2.6 
(2.0,3.6) 
82.2 
(73.2,88.1) 
9,10  No No 
Generalised anxiety disorder  19 15,718 0.2,6.0 3.0 
(2.5,3.9) 
74.3 
(59.6,83.6) 
9,10  Yes No 
Major depression
 
 23 52,768 1.4,19.2 7.3  
(6.3,8.5) 
93.6 
(91.6,95.1) 
6,10 
 
No No 
Panic disorder   2 16,121 2.6,3.0 2.8 
(2.4,3.2) 
98.8 
(97.5,99.4) 
8,9    - No 
Panic with agoraphobia  19 15,718 0.0,8.5 2.2 
(1.4,3.4) 
91.0 
(87.4,93.5) 
9,10
 
 No No 
Post-traumatic stress disorder  18 7,842 0.0,5.2 1.8 
(1.2,2.6) 
76.5 
(63.0,85.0) 
10 Yes No 
Social Phobia  19 23,467 0.0,7.5 3.0 
(2.3,3.9) 
84.9 
(77.6,89.7) 
8,10 No Study location in 
America  
Note: ES – estimate; CI - confidence intervals. 
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2.7      DISCUSSION 
2.7.1   Summary of key findings 
This review suggests that symptoms of possible and probable depression 
and anxiety are common among community-dwelling adults with OA/joint pain. 
Analyses of samples of patients with an arthritis diagnosis, suggest that in total 
major depression (7%) and dysthymia (3%) can affect around 10% of people with 
osteoarthritis whilst specific anxiety disorders are rarely coexisting with 
osteoarthritis. Despite being more prevalent, symptoms of anxiety have received 
limited research attention in comparison to depression. In accordance with 
evidence derived from other populations of people with painful conditions (Routledge et 
al., 2006, Mitchell et al., 2011) and older adults (Luppa et al., 2010), heterogeneity of prevalence 
estimates was typically high. This appeared, in part, to be attributable to 
geographical location and methods of ascertaining anxiety and depression. 
Variance in pooled estimates could not be clearly accounted for between-study 
variance. Together, these observations suggest that depression and anxiety 
symptoms vary across different groups of people with osteoarthritis, and that this 
variability may be related to factors that could not be explored in this review, such 
as the severity of joint pain or the patients’ economic situation. 
 
2.7.2   Sources of possible bias in the reviewed evidence  
The following section will examine sources of publication, selection and 
information bias in the reviewed evidence. 
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Publication bias 
Publication bias can be defined as the tendency for articles containing 
‘positive or new findings’ being more likely to be published (Porta et al., 2008). To reduce 
the risk of this type of bias, unpublished literature was searched using Web of 
Science and CSI Illumina. Unfortunately, identified unpublished evidence included 
dissertations that were difficult to access or conference publications that failed to 
meet the full-text inclusion criterion. However, a search for full-text publications 
(based on potentially relevant retrieved dissertations or conference publications) 
was conducted. This method appeared to be of limited use, as only a couple of 
full-text articles could be retrieved, both of which had been already identified 
through the systematic search.  
Publication bias also refers to the tendency of authors to selectively report 
results that conform to their predefined notions (Porta et al., 2008). Indeed, ten studies 
could not be included, as the authors failed to report prevalence rates and refused 
or were unable to provide relevant estimates through personal communication. 
This could result in publication bias, but the exact impact of it is not ascertainable 
using any exiting methods. 
 
Selection bias 
Selection bias can be defined as a distortion in the estimate that results 
from procedures in which subjects are selected for the study (Porta et al., 2008). In 
cases of systematic reviews, it can be introduced by omitting studies that differ 
systematically from included studies. Eligibility criteria, based on judgement over 
adequacy of specific definitions, were considered arbitrary and have potential for 
selection bias. The risk of selection bias was reduced by using broad inclusion 
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criteria and a comprehensive search. In addition, all eligible prevalence estimates 
were included and further summarised through either narrative synthesis or meta-
analyses. To reduce the risk of selection bias, study quality served as an indicator 
of sources of bias, rather than an inclusion criterion. When possible, study quality 
was included in meta-regression analyses. As a result of these decisions the task 
of managing potential information bias posed substantial challenges. 
 
Information bias 
Information bias is considered to result from systematic differences 
between various study groups in the quality of data obtained on exposure, 
covariates or outcome or flow in estimates resulting from measurement error (Porta 
et al., 2008). Although the reviewed studies were of variable quality, quality 
assessment suggested that most studies were of fair or good quality. The most 
common sources of information bias included limited sample size, heterogeneous 
case definitions for OA and the use of a variety of definitions and measures of 
anxiety and depression. Attention to these features in future studies would 
potentially reduce bias and assist the synthesis and pooling of data – a point that 
has been made before in the context of systematic reviews of Anderson et al. 
(2001), Grigsby et al. (2002), Barnard et al. (2006) and Mitchell et al. (2011). 
Information bias could have impacted on the findings presented in this 
review. As suggested by the methodological quality assessment, the issue of 
sample size calculations could impact on included estimates of specific anxiety 
disorders. The Egger’s test supported large effects for GAD and PTSD prevalence 
estimates in smaller studies indicating prevalence of those anxiety disorders is 
likely to be overestimated in small samples. Similar observations emerged from 
74 
 
previous systematic reviews (e.g. Anderson et al., 2001, Mitchell et al., 2011). 
Different studies used varied definitions of OA/joint pain. This made 
comparisons across studies challenging. The clarity over the impact of this 
problem on pooled estimates could be clarified by comparing prevalence rates 
across groups with different severity of symptoms or anatomical site of pain. 
Unfortunately, as included studies were mostly cross-sectional, with limited 
availability of additional data, this was not possible.  
As with defining OA, there are inconsistencies in the definitions of 
depression and anxiety used by individual studies, which pose challenges when 
comparing the identified prevalence estimates. This problem has been previously 
recognised by Regier et al. (1998) in their epidemiological study on the prevalence 
of mental disorders, where the authors highlight the problem of heterogeneity of 
prevalence rates and decisions around which symptoms should be of interest. The 
only way to reconcile this issue of disparate definitions, involves arbitrary a priori 
decisions. This, however, generates the risk of selection bias. 
Whilst self-report questionnaires are based on similar reference standards 
(Williams et al., 2002) and use similar classifications for symptom severity, prevalence 
rates of anxiety and depression in people with OA vary across the different tools 
used. The process of grouping prevalence rates exposes the issue of a lack of 
consensus over applicability of specific tools in patients with osteoarthritis and 
compatibly of anxiety and depressive measures used in patients with OA. 
Consequently, in line with Grigsby et al. (2002), management of the variety of 
assessment tools and cut-off points was particularly challenging in this study. Sub-
group analyses indicated the impact of methods of ascertainment of estimates, but 
the heterogeneity within sub-group estimates indicated that heterogeneity is multi-
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factorial and could not be simply resolved by arbitrary inclusion to specific 
methods of ascertainment. 
Two general observations should be acknowledged regarding sources of 
anxiety questionnaire data. Anxiety in general was unlikely to be investigated on 
its own. Consequently, given that HADS includes two short depression and anxiety 
subscales, it seemed to be a practical choice of tool to use. Another issue is that 
studies reporting estimates of anxiety were derived from closely related sample 
frames, namely older people with OA/joint pain recruited from one area of England 
(North Staffordshire). Relatively low heterogeneity of anxiety estimates could be 
related to these two factors, but the exact impact of it on the generalisability of 
these findings is unclear. 
 
2.7.3   Comparison with other populations 
Adults with osteoarthritis vs. osteoarthritis-free adults 
It is difficult to interpret differences between pooled anxiety and depression 
prevalence estimates in adults with OA and the general population, due to 
confounding impacts of age, sex and presence of other co-morbidities. There is 
evidence from primary general population surveys which suggest that adults with 
OA might be at an increased risk of depression and anxiety compared to those 
without OA. A nested case-control study of adults aged 40-79 has shown that 300 
people with knee OA had significantly higher mean HADS depression and anxiety 
scores than 300 age and sex matched controls without OA (O’Reilly et al., 1998). The 
study has also shown significantly higher frequency of mild to severe depressive 
and anxiety symptoms (HADS score ≥8) in those with knee OA than their 
counterparts without OA (O’Reilly et al., 1998). A sample of community-dwelling adults 
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with joint disorders (including arthritis) compared with a pain free group; revealed 
that OA may be associated with higher odds of depressive disorders, panic attacks 
and GAD (McWilliams et al., 2004). 
 
Adults with osteoarthritis vs. with other musculoskeletal diseases 
To the author’s best knowledge, there are no published systematic reviews 
and meta-analyses of prevalence rates of depression and anxiety coexisting with 
other musculoskeletal disease. Evidence from primary studies suggests that 
prevalence rates of depressive disorders, panic disorder and GAD reported by 
adults with joint disorders (McWilliams et al., 2004, Munce & Stewart, 2007) are 1% to 3% lower 
than these coexisting with back problems. In Munce and Stewart’s study (2007) 
women with fibromyalgia reported a prevalence of depressive disorders of 23.7%, 
considerably higher than 11.0% prevalence of depressive disorders in women with 
arthritis/rheumatism. The same pattern, but less considerable was found for men. 
The discrepancy could be due to pain characteristics of these two conditions, but 
could also be affected by the lack of adjustment for age or a low prevalence (1%) 
of fibromyalgia in the investigated population. 
  
Adults with osteoarthritis vs. with cardiovascular problems and diabetes (i.e. long-
term conditions for which recognition is already advocated) 
Two reviews of prevalence rates of depression coexisting with chronic heart 
failure could be identified (Rutledge et al., 2006, Yohannes et al., 2010). Yohannes et al. (2010) 
also identified prevalence rates of anxiety coexisting with chronic heart failure. 
Rutledge et al. (2006) conducted a non-systematic review but descriptions of 
included studies were lacking, so results are not directly comparable to this study. 
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Pooled prevalence rates of depression assessed using higher and lower cut-off 
points were 14.0% and 38.0% (Rutledge, 2006). Yohannes et al. (2010) also used a 
non-systematic approach, failed to state eligibility criteria and only partially 
described the studies included. Prevalence rates of anxiety symptoms ranged from 
11.0% to 45.0% and 18.0% of clinically diagnosed anxiety disorders (Yohannes et al., 
2010). 
Three reviews of depression prevalence in Type 1 diabetes (Barnard et al., 2006), 
Type 2 diabetes (Ali et al., 2006) and both types combined (Anderson et al., 2001) were 
identified. A systematic review of prevalence rates of anxiety in both types of 
diabetes is also available (Grigsby et al., 2002). In reviews by Ali et al. (2006) and Barnard 
et al. (2006) questionnaires and clinical interview data were aggregated. Mixed 
settings study designs were included. As sub-group analyses were not provided in 
the above, a systematic review by Anderson et al. (2001), which did include sub-
group analyses, is arguably more useful. The authors reported 11.4% prevalence 
of depressive disorders assessed with diagnostic interview data (Anderson et al., 2001). 
This is comparable to the estimated prevalence rates of major depression and 
dysthymia in this thesis. Anderson et al. (2001) reported 31.0% pooled prevalence 
rate of depression symptoms, which is 8% higher than the estimate reported in this 
thesis (Anderson et al., 2001). Pooled prevalence estimates reported for community 
samples (20%) and mixed clinical settings (32%) suggest that the discrepancy 
between prevalence rates of depression symptoms could be due to the impact of 
spectrum bias (Anderson et al., 2001). Spectrum bias occurs when cases within a limited 
range of a disease spectrum are included, such as medical inpatients or 
participants from randomised controlled trials (Willis, 2008). 
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Comparison with the Grigsby et al.’s (2002) review is more challenging as 
the authors provided incomplete descriptions of included studies and did not 
perform meta-analyses and sub-group analyses by study settings. Grigsby et al. 
(2002) reported a pooled prevalence rate of panic disorder (1.3%) coexisting with 
diabetes that was lower than the estimate presented earlier in this chapter for 
patients with OA/joint; and a pooled prevalence rate of PTSD (1.2%) was 
comparable to that estimated for adults with OA/ joint pain (Grigsby et al., 2002). Pooled 
prevalence of GAD (13.5%) and social phobia (7.3%) were higher than those 
estimated in people with OA/ joint pain (Grigsby et al., 2002). Notably, 30% of pooled 
estimates of anxiety disorders were derived from studies with less than 100 
participants and 30% from studies with between 100 to 200 participants. A pooled 
prevalence of elevated anxiety symptoms coexisting with diabetes (39.6%) (Grigsby et 
al., 2002) was lower than that estimated for adults with OA. This may be due to the 
inclusion of various questionnaires and cut-off points in the current review. In 
general, comparing the current study with the reviews for patients with diabetes 
was challenging, due to discrepancies in the ways the meta-analyses were carried 
out. Prevalence rates of depressive disorders coexisting with OA and diabetes are 
likely to be comparable. Seemingly, once the impact of disease spectrum biases 
and used questionnaires are taken into account, prevalence rates of elevated 
depression symptoms coexisting with diabetes and OA may well be comparable. 
Prevalence rates of specific anxiety disorders coexisting with diabetes are likely to 
be distorted by sample size, and thus, should be interpreted with caution. 
 
2.7.4   Strengths and limitations 
Strengths in the current study were: the use of a systematic approach to the 
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identification and selection of studies; additional search of related articles and 
attempts to contact authors for missing information; independent data extraction 
and quality assessment; the use of a clear approach to standardised weighting for 
pooled prevalence estimates; and rigorous efforts to understand the sources of 
heterogeneity. On this latter point, comparing two suggested methods of exploring 
the impact of individual studies, demonstrated that both methods were of limited 
use, in this particular study at least. An acceptable heterogeneity level can be 
reached by omitting individual studies, but this method tends to selectively omit 
large studies. As previously noted (Song et al., 2001), the author of this thesis concludes 
that the conducted meta-regression analyses of prevalence rates require caution 
on interpretation. This is particularly due to limited variability or partial 
unavailability of data for studies entered in meta-regression analyses. 
Heavy reliance of clinical interview data on He et al.’s (2008) study should 
be acknowledged. The current review contributed to this study by providing 
valuable pooled estimates. Other potential criticism of this work which might arise 
pertains to the decisions around the selection and organisation of the data. 
Possible difficulties related to the decisions discussed in section 2.7.2 on page 71 
were dealt with by: reporting results with full transparency and highlighting 
limitations in interpretations, performing sensitivity analyses for the impact of 
broadly defined ‘arthritis’, taking a random effect approach, which assumes natural 
variability between estimates, providing sub-group estimates and quantifying 
effects of individual factors on heterogeneity.  
 
2.7.5  Implications for clinical practice  
Studying the frequency of a health phenomenon cannot be expected to 
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result in immediate changes to clinical practice without strong evidence from other 
forms of research (e.g. treatment effectiveness or diagnostic test accuracy). 
Nevertheless, the descriptive findings in this chapter arguably focus attention 
towards two important clinical implications. The higher frequency of anxiety 
symptoms over depression does not appear to be reflected in current 
management guidance where the emphasis has firmly been on targeted 
depression case identification and management in patients with physical 
conditions. The development and routine use of brief instruments for anxiety 
assessment such as the HADS-A (Zigmond & Snaith, 1983) or the GAD-7 (Spitzer et al., 2006) 
and ultra-brief instruments such as the GAD-2 (Kroenke et al., 2007) may redress this 
imbalance. 
On the basis of frequency alone, the case for recognition of coexisting 
anxiety and/or depression appears as strong in the case of OA as for other 
physical conditions specifically identified in the existing guidelines (e.g. diabetes 
and cardiovascular disease). The high prevalence of anxiety and depression 
symptoms together with the high consultation prevalence of OA suggests that a 
degree of targeting may be needed. One approach is to focus efforts on the 
recognition of rarer anxiety and depressive disorders. Evidence suggests this 
approach is useful for treatment decision making as all identified cases would 
arguably qualify for intervention - the assumption that cannot be made based on 
questionnaire assessment (Van Rijswijk et al., 2009). On the other hand, as mentioned in 
the context of recognition of schizophrenia, this approach can be argued to 
mitigate secondary prevention (Van Os & Delespaul, 2005). It may also require using 
clinical interview schedules arguably unfeasible for use in primary care (Hanel et al., 
2009). Another approach is to distinguish between relatively transient states of 
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anxiety and depression and more persistent symptoms and investigate the 
possibility of identifying in the latter cases that may benefit from an intervention. 
 
2.8     CONCLUSIONS 
This review provides estimates of the frequency with which anxiety and 
depression symptoms and disorders occur in adults with OA and joint pain in the 
community. The ‘best estimates’ are: major depression 7%; dysthymia 3%; ‘mild or 
worse’ depression symptoms 24% and ‘moderate or worse’ depression symptoms 
15%; generalised anxiety disorder 3%; social phobia 3%; panic disorder 3%; panic 
with agoraphobia 2%; post-traumatic stress disorder 2%; ‘mild or worse’ anxiety 
symptoms 45% and ‘moderate or worse’ anxiety symptoms 21%. The key sources 
of bias in the available evidence were missing data, the impact of sample size, and 
the lack of consistency in case definitions and measurement instruments. This 
might reflect the complexity of the conditions under investigation and the lack of 
consensus in this field. These are potential areas for improvement in future 
studies.  
Putting to one side the fact that there may be considerable heterogeneity in 
pooled estimates, this study draws attention to an important implication. Namely, 
in seeking to identify cases with depressive or anxiety disorders it can be 
anticipated that there will be as many as 4-15 times that number of individuals who 
report anxiety or depression symptoms of whom half will be reporting moderate or 
worse symptoms. The significance of these more common symptoms is clearly of 
interest for primary care management. In chapter five the extent to which these are 
likely to be transient or persistent states among a sample of older patients 
presenting with musculoskeletal pain to primary care will be investigated. 
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Chapter three: Self-report measures for depression and anxiety 
symptom screening and assessment in osteoarthritis: a narrative 
review of selected measurement properties 
 
3.1     INTRODUCTION 
The previous chapters have outlined the context for the recognition, 
measurement and classification of anxiety and depression symptom severity in 
general practice, and provided estimates of the frequency of these in adults with 
OA/joint pain. While the reference standards for diagnosis of anxiety and 
depressive disorders are generally well-established, greater choice and 
uncertainty exist around which of the many patient-reported self-complete 
instruments used to ascertain and quantify the severity of anxiety and depression 
symptoms are most suitable for use in this subpopulation. This chapter identifies 
the potentially suitable measures in this subpopulation and critically considers the 
evidence for their reliability, responsiveness, validity, and acceptability to patients 
and health care professionals. 
 
3.2      RATIONALE OF THE STUDY 
Diagnostic tests – those that help discriminate between patients with and 
without a disease or health condition of interest - are a critical part of health care 
(Leeflang et al., 2008). Health professionals may be interested in knowing which of the 
available depression and anxiety questionnaires should be used, how they should 
be interpreted, and whether the use of those tests has been demonstrated to 
improve patient outcomes (van Rijswijk et al., 2009). As discussed in chapter one, clinical 
guidelines suggest that in aiding the assessment of depressive and anxiety 
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symptoms, self-report instruments serve several purposes covering the recognition 
of symptoms and the measurement and classification of symptom severity. Their 
primary purpose is not the diagnosis of an anxiety and depressive disorder per se 
although they may contribute to this process, for example as a basis for initial case 
identification. The evaluation of self-report instruments for anxiety and depression 
symptoms must therefore extend beyond diagnostic accuracy to incorporate an 
evaluation of other properties, including aspects of reliability, validity and 
interpretability as well as practical considerations of acceptability and feasibility 
(Nunnally, 1978, Myers & Winters, 2002, Hunsley & Mash, 2010, Fava et al., 2012). 
It is known that some of these measurement properties vary across settings 
and the population in which they are assessed (Bot et al., 2004). The challenge of the 
current work was to consider evidence for general primary care adults before 
attempting to critically relate this to subpopulations of older adults and people with 
musculoskeletal problems, such as osteoarthritis. There are several reasons for 
believing that the variation in measurement properties noted by Bot et al. (2004) 
applies here. Firstly, there may be concern over spectrum bias (Furukawa & Guyatt, 2006, 
Willis, 2008) in so far as evidence of measurement properties derived from tertiary 
care patients may be particular to a selective part of the spectrum of symptoms 
(the more severe end or symptoms that are atypical). The same measures may 
perform differently in primary care patients, where a wider spectrum of symptoms 
can be expected. Secondly, the recognition and assessment of anxiety and 
depression symptoms in older age groups, where osteoarthritis becomes 
increasingly prevalent, is known to present particular challenges. For example, 
under-recognition of depression in older community-dwelling adults appears to be 
more prominent than in younger adults (Bowers et al., 1990, Iliffe et al., 1991). In addition, 
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diagnostic rates of major depression differ across age groups (Volkers et al., 2004) and 
specific psychological tests might perform differently across younger and older 
adults (Jeste et al., 2005). Thirdly, recognition of depressive disorders in primary care 
patients with musculoskeletal problems might be difficult because of overlap in the 
somatic aspects of depression and symptoms of musculoskeletal problems (e.g. 
sleep problems or psychomotor retardation) (Turner & Romano, 1984, Novy et al, 1995, Rosemann et 
al., 2006). Indeed, as shown in patients with musculoskeletal pain, using the DSM-IV 
criteria inclusive of somatic symptoms - regardless of presumed cause increased 
the prevalence rate of major depression by nearly half (Wilson et al., 2001). Since 
somatic-vegetative symptoms are core to anxiety (Blanchard & Blanchard, 1989, Spielberger & 
Rickman, 1991, Seligman et al., 2001, Sarason & Sarason, 2004, Beesdo et al., 2009), the problem of 
symptoms overlapping with musculoskeletal disease holds true for anxiety.  
In the previous chapter a total of 15 depression and 8 anxiety symptom 
measures had been used in population and primary care studies of the prevalence 
of coexisting depression and/or anxiety in adults with OA or joint pain. Table 3.1 
overleaf lists these together with the papers describing their use.  
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Table 3.1 Depression and anxiety symptom measures used in observational 
studies in OA/ joint pain.   
 
Depression symptom measures  
(a study in which was used) 
Anxiety symptom measures 
(a study in which was used) 
AIMS-D    (Creamer, 1999, Dexter, 1994) AIMS-A  (Creamer, 1999) 
BDI-13      (Viinamäki, 2002)  
BDI-21      (Williams, 2004)  
CESD- 7   (Tsai, 2005)  
CESD- 8   (Polsky, 2005)  
CESD-10  (Szoeke, 2008)  
CESD-20  (Barberger-Gateau,1992, Brandt, 
2000, Scudds, 2000, Wilcox, 2000, Kramer, 
2002, Baker, 2003, Nour, 2005, Ferreira, 
2006, Kalichman, 2007, Maly, 2007, Allen, 
2008, Sale, 2008) 
 
4 DSQ-D   (Reilingh, 2008) 4DSQ-A  (Reilingh, 2008) 
GADS-D   (Menz, 2006) GADS-A  (Menz, 2006) 
GDS-15    (Woo, 1994, Niti, 2007, Appelt, 
2007, Schram, 2008) 
 
GDS- 30   (Martin, 1996, Leveille, 2007)  
HADS-D   (O’Reilly, 1998, Badcock, 2002, 
Peat, 2006a, Hill, 2007, Spies-Dorgelo, 2007, 
Wood, 2007, Gignac, 2008, Mallen, 2008) 
HADS-A  (O’Reilly, 1998, Memel, 2000, 
Badcock, 2002, Peat, 2006a, Hill, 2007, 
Spies-Dorgelo, 2007, Mallen, 2008) 
IRGL-6 (Hopman-Rock, 1997) IRGL-A   (Hopman-Rock, 1997)  
Negative affect scale^  (Fisher, 2004)  
PHQ-2  (Figaro, 2005, Mallen, 2008)  
PHQ-9  (Rosemann, 2007)  
 POMS     (Hampson, 1996) 
 STAI-20  (Williams, 2004) 
 STAI-40  (Maly, 2007) 
Note: AIMS-A/D - Arthritis Impact Measurement Scales-anxiety/depression subscale; BDI - Beck Depression 
Inventory; CESD - Center for Epidemiologic Studies Depression Scale; 4DSQ-A/D - Four dimensional 
Symptoms Questionnaire-anxiety/depression subscale; GADS-A/D - Goldberg Anxiety and Depression Scale- 
anxiety/depression subscale; GDS -Geriatric Depression Scale; HADS-A/D - Hospital Anxiety and Depression 
Scale- /depression subscale; IRGL-A/D - Influence of Rheumatic Diseases on Health and Lifestyle- 
anxiety/depression subscale; PHQ - Patient Health Questionnaire; POMS - Profile of Mood States; STAI - 
State-Trait Anxiety Inventory; 
^ - the 7-item negative affect scale formulated from the CES-D. 
 
 
A comprehensive evaluation of the measurement properties, characteristics 
and performance within the target population of interest (older adults with 
osteoarthritis) for all the measures is beyond the scope of this thesis. Instead, this 
chapter will focus on comparing the measurement properties and characteristics of 
a selection of these and their suitability for use in older adults with joint pain. 
The three depression measures selected were the Beck Depression 
Inventory (BDI-II: Beck et al., 1996, BDI-PC: Beck & Steer, 1997), the Hospital 
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Anxiety and Depression Scale – Depression subscale (HADS-D: Zigmond & 
Snaith, 1983) and the Patient Health Questionnaire (PHQ-2, PHQ-9: Kroenke et 
al., 2001, Kroenke et al., 2003). The BDI-II, HADS and PHQ-9 are the measures 
currently recommended for use in UK primary care settings for assessment of 
severity of symptoms in general adults and in patients with other chronic physical 
health problems, i.e. coronary heart disease (BMA, GPC, 2009). The two-item 
depression screener, derived from the PHQ-9 (i.e. PHQ-2: Kroenke et al., 2003), 
was also recommended for screening in primary care patients at high-risk of 
depression (NICE, 2009a, 2009b). BDI-II, PHQ-9 and HADS together with CESD and 
GDS, were regarded by Smarr and Keefer (p. 454, 2011) as the “most relevant 
[measures] for the assessment of depression in the context of rheumatology 
clinical and/or research practice” although only the BDI-II has been recommended 
for outcome evaluation in chronic pain clinical trials (Dworkin et al., 2005). All four tools 
are available as clinical Read terms (i.e. Patient health questionnaire score (388f.), 
depression screening using questions (6896.), HAD scale: depression score 
(388P.), Beck depression inventory second edition score (388g.)), when searched 
with reference to the NHS Information Authority ((NHSIA) 2000) devised Clinical 
Terms Version 3. The BDI for Primary Care (BDI-PC), now known as Fast 
Screener (BDI-FS), was included for comparison with the PHQ-2. 
For anxiety symptom assessment, the selection is more difficult. There is a 
lack of agreed authoritative recommendations, reflecting the more limited research 
evidence in this field. Detailed recommendations are unavailable from either the 
Quality and Outcomes Framework contract (BMA, GPC, 2009) or NICE guidelines on 
generalised anxiety disorders, and panic with and without agoraphobia (NICE, 2007). 
Other NICE anxiety guidelines deal only with narrow disorders such as screening 
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for Post-Traumatic Stress Disorder (National Collaborating Centre for Mental health (NCC-MH), 2005) 
and Obsessive-Compulsive Disorder (NICE, 2005). A variety of approaches has been 
suggested in published research articles and opinion pieces. For screening and 
case identification these include using an anxiety subscale on the Symptoms 
Checklist-90-R combined with the SF-36 (Gilbody et al., 2001), or using broad screening 
tools (e.g. Primary Care Evaluation for Mental Disorders) and brief measures (e.g. 
General Health Questionnaire) to assess general distress and an anxiety subscale 
on the Brief Symptom Inventory-18 (Lang & Stein, 2002). For measuring anxiety in 
primary care they include using anxiety subscales (e.g. HADS-A) and general 
distress scales (e.g. Kessler Psychological Distress Scale, Somatic and 
Psychological Health Report) (Hickie et al., 2002). 
Recently, the HADS-A (Zigmond & Snaith, 1983) and the Generalised Anxiety 
Disorder Scale (GAD-7) (Spitzer et al., 2006) have been both reported as useful for 
assessment of anxiety disorders in primary care medically ill patients (Levenson et al., 
2010, Roy-Byrne et al. 2009) although only the HADS-A was included in the recent review of 
anxiety measures for rheumatologic populations by Julian (2011). The GAD-7 has 
been used in NHS mental health programmes such as Improving Access to 
Psychological Therapies (IAPT) (Department of Health, 2008 in Ross, 2010), which included 100 
UK Primary Care Trusts (Ross, 2010). IAPT was launched in year 2008 (Lester & Glasby, 
2010) following Lord Layard’s report, showing poor access to psychological 
therapies (Centre for Economic Performance’s Mental Health Policy Group, 2006). The apparent 
receptiveness to the recently developed GAD-7 (Spitzer et al., 2006) might be related to 
the fact that the GAD scale was derived from the PRIME-MD. Both the HADS-A 
and GAD-7 are available through NHS Read terms (NHSIA, 2000): Generalised anxiety 
disorder 7 item score (Read code: XaA5Z) and HAD scale: anxiety scale (Read 
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code: 388N). The GAD-2 (Kroenke et al., 2007) offers promising potential for quick, 
targeted case-identification of primary care patients at risk of possible/probable 
anxiety problems. It was decided that the current chapter would therefore focus on 
these two measures - the Hospital Anxiety and Depression Scale-Anxiety subscale 
(HADS-A) and the Generalised Anxiety Disorder tool (GAD-2, -7). 
 
3.3  AIM AND OBJECTIVES 
The overall aim of this chapter was to understand the comparative 
strengths and weaknesses of recommended patient-reported, self-complete, 
condition-specific measures for use in assessing anxiety and depression 
symptoms in patients presenting to primary care with osteoarthritis.  
In the context of the thesis, this would also provide the opportunity to 
evaluate the absolute and relative performance of the HADS – the measure used 
in empirical analyses presented in subsequent chapters of this thesis.  
 
Specific objective is: 
 To conduct a narrative synthesis of evidence on key measurement properties 
and characteristics and suitability of selected depression (BDI (BDI-II and BDI-
PC versions), HADS-D, PHQ (2- and 9-item versions)) and anxiety (GAD (2- 
and 7-item versions), HADS-A) symptom measures 
 
3.4      METHODS  
3.4.1   Evaluation framework 
In this study, the framework for evaluating self-report instruments for 
anxiety and depression symptoms was constructed from traditional psychometric 
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(e.g. Streiner, 2003) and recent clinimetric approaches (Mokkink et al., 2010). Four main 
clinimetric aspects of health related measures, agreed through a consensus of 43 
clinimetric experts, are: reliability (internal consistency, reliability and 
measurement error), validity (content validity, criterion validity and construct 
validity), responsiveness and interpretability (Mokkink et al., 2010). All of these properties 
are broadly comparable to psychometrics and some of them were considered in 
the current work, with the addition of acceptability. Acceptability was added as 
limited acceptability on assessment measures might have practical implications, 
such as avoidance of its use (Dowrick et al., 2009). Selection of indicative evidence was 
based on previous literature, with the choice of a method of quantifying concurrent 
validity being most challenging (see Table C.1.2 in Appendix C.1 on page 355 for 
a summary of possible methods). As a means of managing the variety of methods 
to quantify concurrent validity, evidence of rule-out and rule-in accuracy was 
desired, and thus, the review focused on likelihood ratios (Deeks & Altman, 2004) as they 
appear to be more commonly used and are considered to be prevalence 
independent (Deeks & Altman, 2004). Each of the measurement properties and 
characteristics covered in the used framework is briefly described in Table 3.2 
overleaf.  
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Table 3.2 Adapted evaluation framework. 
Dimension Definition Components Definition Indicative types of evidence 
Feasibility The quality of 
being practical 
and possible 
Administration burden 
(Bot et al., 2004)
 
- Ease of the scoring method (adequate: symptoms count/ 
severity or simple algorithms, inadequate: complex 
formulas) 
Interpretability 
(Bot et al., 2004)
 
 Interpretation of scores (adequate: underlying reasons for 
system classification and its relationship with classification 
defined by a gold standard) 
Accessibility  
(Julian, 2011) 
- Financial burden (adequate: free, inadequate: charges) 
Readability and 
comprehension 
(Bot et al., 2004)
 
 
- 
Required literacy level (adequate: easy or average, 
inadequate: difficult) 
Time to administer  
(Bot et al., 2004)
 
- Time taken to complete (adequate: less than 10 minutes) 
Reliability The extent to 
which the tool is 
free of 
measurement 
error, i.e. the 
difference 
between a 
measured value 
and its true value 
(Mokkink et al. 2010) 
Internal consistency  The extent to which items in 
a(sub) scale are interrelated, 
thus measuring the same 
construct 
 
(Terwee et al.,  p. 39, 2007)
 
 Cronbach’s alpha: alphas 0.70 to 0.80 adequate for 
research and ≥ 0.90 adequate for clinical purposes 
(Bland 
& Altman, 1997)
 
 Item-total correlation: correlations in the approximate 
range of 0.30–0.70 regarded adequate 
(Streiner & Norman, 
2008)
 
 Factor analyses: exploratory or confirmatory factor 
analysis tested 
(Porta et al., p. 92, 2008, Kline, 1994)
,
 
adequate if 
consistent across populations and no issues with item 
loading emerged 
Test-retest- reliability The measure’s stability over 
time 
(Bot et al., 2004)
, whilst no 
changes in depression or 
anxiety occurred  
 
 Intra-class correlation: ICC > 0.70 regarded 
adequate, if a time interval and 95% CI are reported 
(Boot et al., 2004)
  
 Correlations between presentations: correlations r ≥ 
0.80 repeated over one to two weeks and r ≥ 0.70 over 
one month are taken to represent evidence of adequate 
reliability 
(Meades & Ayers, 2010)
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Table 3.2 cont. Adapted evaluation framework. 
Dimension Definition Components 
 
Definition Indicative types of evidence 
Construct 
validity 
Construct validity 
concerns the degree 
of the 
measurement’s 
compatibility with 
theoretical concepts 
describing the 
construct under 
study 
(Porta et al., 2008)
 
Convergent 
validity 
The extent to which a scale 
correlates with other 
measures that assess the 
same construct 
(Porta et al., 2008)
 
Correlations with measures to assess the same construct. 
Cohen’s criteria used to evaluate effect size of r (r=0.1, 
small, r=0.3, medium, r=0.5, large 
(Meades & Ayers, 2010)
, with a 
large effect being adequate 
Compatibility with  
functional status  
(Kroenke et al., 
 
2001)
 
 
 
Interpretability of the results 
of assessment in a general 
context of well-being
 
 
Any correlations with general functioning measures 
considered to be adequate  
‘Somatic bias’† A systematic 
misclassification of pain and 
somatic symptoms of 
depression/anxiety  
Degree of somatic symptom variance on the measure, 
which is not necessarily related to depression/anxiety, but 
reflects somatic disease.  
Adequacy: no clear criteria available 
Criterion validity The degree of 
correlation between 
the results of an 
external criterion and 
the tool 
(Porta et al., 2008)
 
Concurrent 
validity 
 
 
The correlation between the 
measure of interest and an 
external reference standard 
at the same point in time 
 
(Porta et al., 2008)
 
Diagnostic accuracy expressed by the power of changing 
pre-test probability into the post-test probability 
(Ahrens & Pigeot, 
2005)
: positive likelihood ratio (LR+) and negative likelihood 
ratio (LR-), with LR+ above 10 and LR- below 0.10 
indicating a large change, i.e. strong evidence for adequate 
rule-in and rule-out accuracy respectively 
(Jaeschke et al., 1994, 
Stengel et al., 2003, Deeks & Altman, 2004)
  
Responsiveness 
to change 
An ability to capture 
changes in scores 
following intervention 
aiming for symptom 
reduction  
(Hays & Hadorn, 1992)
 
- - Distribution-based approaches (i.e. Effect size (ES) 
standardised response mean (SRM), responsiveness index 
(RI)) and anchor-based approaches (i.e. use of an external 
clinical or patient-based criterion to assign subjects into 
groups reflecting the scope of changes) 
(Revicki et al., 2008) 
Cohen ‘rule of thumb’ used for interpreting ES of change 
(<0.20: trivial, ≥0.20 and <0.50: small, ≥0.50 to <0.80: 
moderate, ≥0.80: large)
 (Revicki et al., 2008)
, with any change 
regarded adequate 
Acceptability† Adequacy of the 
practice of 
assessment to 
satisfy a need for use 
To patients - Quantitative/qualitative analyses of patients’ perception 
Adequacy: no clear criteria available 
To clinicians - Quantitative/qualitative analyses of clinicians’ perception 
Adequacy: no clear criteria available 
Note: †- given a lack of consensus on interpretation, adequacy could only be judged subjectively.  
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3.4.2      Literature search and narrative synthesis 
3.4.2.1  Search strategy 
Published English-language studies reporting primary data (i.e. primary 
studies or reviews) on one or more measurement property or characteristic were 
sought through searching 7 electronic databases - Cochrane library, PsycInfo, 
CINAHL, MEDLINE, EMBASE, CSA illumina and Web of Science - from inception 
to November 2011 using the following key groups of terms: 
1. data synthesis/ recommendations (e.g. review* OR recommend*) 
2. depression/ anxiety measures (e.g. depress* OR anxiet*) 
3. psychometric/clinimetric properties (e.g. diagnos* OR validity OR reliability) 
4. primary care adults (e.g. primary and care)  
5. community-dwelling/primary care elderly (e.g. ‘old*’ AND ‘comm* OR prim*’) 
6. musculoskeletal complaints (e.g. osteoarthrit* OR musculoskelet*)  
(Please refer to Box C.2.1 in Appendix C.2 on page 358 for the search 
strategy) 
In addition, the Centre for Review and Dissemination, Cochrane Library, 
MEDLINE and EMBASE electronic databases were searched for reviews and 
expert recommendations, from inception to November 2011. Relevant studies 
known to the authors of the review were also searched and evidence from these 
and the studies contained therein was extracted. 
 
3.4.2.2 Data extraction 
Data was extracted by one reviewer and included: study author, population, 
setting, sample size, depression and/or anxiety measure and the findings pertinent 
to the measurement properties and characteristics under investigation. 
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3.4.2.3 Data analyses and presentation  
All data was narratively synthesised and presented separately for 
depression measures and anxiety measures with the exception of data on 
acceptability which is presented in one combined section. Where studies provided 
the necessary figures, likelihood ratios were calculated in Excel, using the 
equation provided in Table C.1.2 (Appendix C.1, p. 355), to assist the evaluation of 
criterion validity. To explore relatively high or low likelihood ratios a possibility of 
bias was considered (Whiting et al., 2003) and 95% CI confidence intervals were 
estimated using a Diagnostic Test calculator (Schwarz, 2002). Wider 95% CI were 
attributed to small sample size and small numbers of observed frequencies in a 
2x2 diagnostic accuracy table (Table C.1.1 in Appendix C.1, p. 354), so it was not 
possible to conclude that any observed difference was not due to chance alone. 
Using the same system as Ahrens and Pigeot (2005) likelihood ratios were 
described as large (LR+>10.0, LR-<0.10), moderate (5 -10, 0.1-0.2), small (2-5, 
0.2-0.5) or negligible (1-2, 0.5-1.0). For ease of reference, these categories were 
colour-coded in the tabulated results. 
 
3.5       RESULTS 
3.5.1    Identified studies 
The BDI-II and -PC, HADS and PHQ-9 and -2 can be found compared in 
several reviews of measures used in primary care settings, including the UK, and 
systematic reviews including those focused on the impact of questionnaire 
assisted screening on depression recognition (Pignone et al., 2002), case identification 
abilities of depression tools in primary care (Williams et al., 2002) and in older primary 
care attendees specifically (Watson & Pignone, 2002, Snowden et al., 2009). One study 
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summarised reviews into the diagnostic utility of depression screening tools (Nease & 
Malouin, 2003). In total, 42 individual papers containing original data were identified 
and included for review in this chapter with criterion validity of depression and 
anxiety measures being the most common focus (see Table 3.3 overleaf). The 
following sections briefly summarise their findings.  
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Table 3.3 Included studies of measurement properties of selected depression and anxiety symptom measures. 
Measurement 
property 
Depression symptom measures Anxiety symptom measures 
Acceptability† Coventry, 2011, Dowrick, 2009, Wood, 2002, Simpson, 2008, Rosemann, 2006 Wood, 2002 
 BDI-II or -PC HADS-D PHQ-9 or -2 GAD-7 or -2 HADS-A 
Feasibility Beck et al., 1996, Pignone, 
2002, Williams, 2002, Nease, 
2003, Pearson Education, Inc. 
2012 
Zigmond, 1983, 
Williams, 2002, Nease, 
2003, GL Education 
Group, 2012 
Pignone, 2002, Williams, 
2002, Nease, 2003, 
Snowden, 2009, Pfizer, Inc., 
2012 
Williams, 2002, Spitzer, 
2006, Garcia-Campayo, 
2010, Pfizer, Inc., 2012 
Zigmond, 1983, 
Williams, 2002, 
Nease, 2003, GL 
Education Group, 
2012 
Chronbach’s 
alpha 
Beck, 1997, Arnau, 2001, Poole, 
2009a 
El-Rufaie, 1995, Pallant, 
2005, Bunevicius, 2007, 
Cameron, 2008, Terluin, 
2009 
Kroenke, 2001, Pinto-Meza, 
2005, Cameron, 2008, Han, 
2008 
Spitzer, 2006, Garcia-
Campayo, 2010 
Pallant, 2005, 
Bunevicius, 2007, 
Terluin, 2009 
Item-total 
correlation 
Beck, 1997, Arnau, 2001 Cameron, 2008 Cameron, 2008, Han, 2008, 
Yeung, 2008 
Garcia-Campayo, 2010 - 
Factor structure Arnau, 2001, Harris, 2008, 
Corbière, 2011 
Pallant, 2005, Cameron, 
2008 
Cameron, 2008 Spitzer, 2006, Garcia-
Campayo, 2010 
Pallant, 2005 
Test-retest 
reliability  
- Angst, 2008 Lowe, 2004b, Han, 2008, 
Kroenke, 2001 
Garcia-Campayo, 2010 Angst, 2008 
Convergent 
validity 
Corbière, 2011 Cameron, 2008 Cameron, 2008, Yeung, 
2008 
Spitzer, 2006, Garcia-
Campayo, 2010 
Garcia-Campayo, 
2010 
Correlation with 
functional status 
Krugh, 1997, Arnau, 2001 - Kroenke, 2001, Klapow, 
2002, Rosemann, 2007 
Spitzer, 2006, Kroenke, 
2007, Garcia-Campayo, 
2010, Ruiz, 2011 
- 
 
‘Somatic bias’ Harris, 2008, Corbière, 2011 Pincus, 1996 - - Pincus, 1996 
Criterion validity Beck, 1997, Poole, 2009b Wilkinson, 1988, El-
Rufaie, 1995, Lam, 
1995, Harter, 2001, 
Watt, 2002, Bunevicius, 
2007, Terluin, 2009, 
Axford, 2010 
Whooley, 1997,Spizter,1999, 
Kroenke, 2001, Arroll, 2003, 
Kroenke, 2003, Carpacioglu, 
2004, Henkel, 2004, Han, 
2008,Yeung, 2008, Arroll, 
2010, Phelan, 2010, Li 2007  
Kroenke, 2007, Garcia-
Campayo, 2010 
Lam, 1995, El-Rufaie, 
1995, Harter, 2001, 
Watts, 2002, 
Wetherell, 2007, 
Bunevicius, 2007, 
Terluin, 2009, Axford, 
2010 
Responsiveness Poole, 2009a Cameron, 2008, Angst, 
2008 
Lowe, 2004b, Cameron, 
2008 
- - 
Note: †- acceptability data considered jointly for any anxiety or depression measures, with the aim to seek an improved understanding of implementation of self-report 
measures in primary care. 
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3.5.2   Depression symptom measures 
3.5.2.1 Feasibility of BDI-II, HADS-D and PHQ-9  
The BDI-II is copyrighted by the author and available for purchase from 
Pearson Assessment (Pearson Education, Inc., 2012). The HADS is copyrighted and 
available for purchase from GL assessment (GL Education Group, 2012) and the PHQ-9 is 
freely available from Pfizer Inc. (2012) (see Appendix C.3, p. 360-363 for copies 
of the three measures). Table 3.4 overleaf shows characteristics, of the three 
questionnaires, extracted from Williams et al.’s (2002) and Nease and Malouin’s 
(2003) reviews and checked with the original papers with additional information 
extracted for the BDI-II (Beck et al., 1996) and the HADS-D (Zigmond & Snaith, 1983). 
The BDI-II, PHQ-9 and HADS-D require administration time shorter than 
consultation time in primary care. All three measures have severity 
classifications, but underlying reasons for these classifications appear to be 
either arbitrary or lacking. An advantage of the BDI-II is the easy literacy level 
required. Advantages of the PHQ-9 and the HADS are their brief forms. The 
PHQ-9 also allows for symptom counts offering a direct translation into the DSM-
IV-TR classification (Nease & Malouin, 2003). Based on this information and superior 
positive predictive value of the PHQ-9, Nease and Malouin (2003) regarded the 
PHQ-9 most optimal for primary care patients, but authors of other reviews have 
refrained from stating the superiority of any tool (Williams, et al., 2002, Pignone et al., 2002, 
Snowden et al., 2009).  
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Table 3.4  Feasibility of the BDI-II, HADS-D and PHQ-9. 
 
Instrument  
(abbreviation) 
Number of 
items 
(shorter 
versions)/ 
scale 
Possible score 
range: severity 
Admin. 
time 
Literacy 
level^ 
 
Original 
time frame 
of items 
Beck Depression 
Inventory-II 
(BDI-II) 
 
21 (13,7)/ 
0-3 
0-63: 
Minimal    (0-13) 
Mild          (14-19) 
Moderate (20-28)  
Severe     (29-63)  
2-5 min Easy 
 
 
 
Past two 
weeks  
Hospital Anxiety 
and Depression 
Scale-depression 
(HADS-D) 
7 (-)/  
0-3 
0-21: 
Non-cases (0 - 7) 
Doubtful†   (8 - 10) 
Definite      (≥11) 
≤ 2 min 
 
Difficult 
 
Past week 
Patient Health 
Questionnaire- 
depression 
(PHQ-9) 
9 (8,2)/ 
0-3 
0-27: 
None        (1-4) 
Mild          (5-9) 
Moderate (10-14) 
Moderately  
severe     (15-19) 
Severe    (20-27) 
Diagnostic 
algorithm‡ 
2-5 min Average 
 
Past two 
weeks 
Note: Admin. - Administration;  
^ Classified by Williams et al. (2002) using Fog Formula, into three grade reading levels: 3-5 (Easy), 6-9 
(Average), ≥9 (Difficult);  
† -  score range for doubtful and definite cases, are used as indicative of ‘mild’ and ‘moderate to severe’ 
severity respectively  (e.g. Kendrick et al., 2009);  
‡ - to establish provisional diagnoses for selected DSM-IV disorders (including symptom count, severity and 
impact).  
 
 
3.5.2.2 Reliability of BDI-II and -PC, HADS-D and PHQ-9  
The BDI-II exhibited Cronbach’s alphas adequate for clinical use, as shown 
in both patients in primary care (0.94) (Arnau et al., 2001) and with chronic pain (0.91) 
(Poole et al., 2009a). One of these studies, however, found item-total correlations (0.54 - 
0.74) suggesting possible item redundancy and two factors (Arnau et al., 2001), while 
three factors were found in people with musculoskeletal problems (Corbière et al., 2011, 
Harris et al., 2008). Overall, internal consistency of the BDI-II is unclear (Table 3.5, p. 
99). 
A direct comparison of Cronbach’s alphas of the HADS-D (0.84) and PHQ-9 
(0.83) in adult primary care patients showed similar internal consistency, but 
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adequate for research use only (Cameron et al., 2008). This was broadly comparable to 
results in musculoskeletal complaints (HADS-D: 0.84) and older adult (PHQ-9: 
0.86) subpopulations. Further head-to-head comparisons confirmed internal 
consistency, as shown by adequate item-total correlations of the HADS-D (0.47-
0.69) and PHQ-9 (0.42 - 0.65), and established factor structures (Cameron et al., 2008). 
Chinese version PHQ-9 showed possible item redundancy (0.52 - 0.85). 
Test-retest reliability was rarely studied in the relevant populations (Table 
3.5 overleaf), where the PHQ-9 showed adequate test-retest reliability over 48 
hours (Kroenke et al., 2001), one week (Lowe et al., 2004b) and three week (Han et al., 2008) 
intervals. Test-retest reliability of the HADS-D over a four week interval (Angst et al., 
2008) is unclear, given only one estimate is available and 95% confidence intervals 
were not reported. 
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Table 3.5 Reliability of the BDI-II and -PC, HADS-D and PHQ-9. 
 
 
Population/country Setting N Cronbach’s 
alpha 
Item-total 
correlation 
Factor 
structure 
ICC    
(95% CI)  
Test-retest 
correlation 
coefficient 
(r)    
BDI-II          
Arnau, 2001 Young adult/ U.S.A Primary care 340 0.94 0.54 - 0.74 2 - - 
Corbière, 2011 Chronic pain/ Canada Hospital 203 - - 3 - - 
Harris, 2008 Chronic pain/ Canada Tertiary care 481 - - 3 - - 
Poole, 2009a Chronic pain/ UK Tertiary care 584 0.91 - - - - 
BDI-PC         
Beck, 1997 Adults/ U.S.A Primary care 56 0.88 0.51 - 0.77 - - - 
Poole, 2009a Chronic pain/ UK Tertiary care 584 0.84 - - - - 
HADS-D         
Angst, 2008 MSK/ Switzerland Tertiary care 273 - - - 0.89 - 
Bunevicius,2007 Adult/ Lithuania Primary care 503 0.78 - - - - 
Cameron, 2008 Adult/ UK Primary care 1063 0.84 0.47 - 0.69 1 - - 
El-Rufaie,1995 Adult/ UAE Primary care 217 0.88 - - - - 
Pallant, 2005 MSK/ Australia Hospital 296 0.84 - 1 - - 
Terluin, 2009 Adult/ Netherlands Primary care 295 0.83 - - - - 
PHQ-9         
Cameron, 2008 Adult/ UK Primary care 1063 0.83 0.42 - 0.65 1 - - 
Han, 2008 Older adult/ South Korea Community 1060¥ 0.86 0.40 - - 0.79 
Kroenke, 2001 Adult/ U.S.A Primary care 3000 0.89 - - - 0.84π 
Lӧwe, 2004b Older adult/ U.S.A Primary care 123 - - - 0.81†; 0.96‡ - 
Pinto-Meza, 2005 Adult/ Spain Primary care 375 0.86^ - - - - 
Yeung, 2008 Adult/ U.S.A Primary care 1940 - 0.52 - 0.85 - - - 
Note: ICC - Intra-class correlation; MSK - with musculoskeletal complaints; UAE - United Arab Emirates; 
 ^ - 0.82 for telephone administered; ¥- of which n=56 used for test-retest reliability; † - the worst-case sample (n=41), i.e. change due to treatment and no control of prior 
depression; ‡ - the ‘best-case’ sample (n=82), i.e. the same number of DSM-IV depression symptoms at both assessments; π -
 
administered telephonically. 
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3.5.2.3 Construct validity of BDI-II and -PC, HADS-D and PHQ-9 and -2 
Evidence relating to convergent validity and correlation with functional status is 
summarised in Table 3.6.  
 
Table 3.6  Construct validity of the BDI-II and -PC, HADS-D and PHQ-9 and -2. 
 Population/ 
country 
Setting N Convergent 
validity 
Correlation with 
functional status 
BDI-II      
Arnau, 
2001 
Adult/ U.S.A Primary 
care 
340 - Negative correlation with 
functional status‡  
Corbière, 
2011 
Chronic pain/ 
Canada 
Hospital 206 With CESD 
(r=0.66-0.72) 
- 
Han, 2008 Older adult/ 
South Korea 
Community 1060 With PHQ-9 
(r=0.77) 
- 
Krugh, 
1997 
Adult/ U.S.A Primary 
care 
77 - Negative correlation with 
AIMS physical function 
score, general health 
perception and arthritis 
impact scores, but no 
correlation with 50-foot 
walk time and mean grip 
strength, AIMS pain and 
social scores 
HADS-D      
Axford, 
2010 
OA/ UK Tertiary 
care 
54 - Negative correlation with 
disability  assessed with 
the Western Ontario and 
McMaster Universities 
Osteoarthritis Index 
Function scale 
Cameron, 
2008 
Adult/ UK Primary 
care 
1063 With PHQ-9 
(r=0.68) 
- 
PHQ-9      
Cameron, 
2008 
Adult/ UK Primary 
care 
1063 With HADS-D 
(r=0.68) 
- 
Han, 2008 Older adult/ 
South Korea 
Community 1060 With GDS 
(r=0.74) 
With BDI-II 
(r=0.77) 
With CESD 
(r=0.67) 
- 
Klapow, 
2002 
Adult/ U.S.A Primary 
care 
2466 - Negative correlation with 
functional status‡  
 Older adult/ 
U.S.A 
Primary 
care 
534 - Negative correlation with 
functional status‡ 
Kroenke, 
2001 
Adult/ U.S.A Primary 
care 
3000 
 
- Negative correlation with 
functional status ‡  
Rosemann, 
2007 
OA/ Germany 
 
Primary 
care 
1021 - Negative correlation  with 
the AIMS2-SF  
PHQ-2      
Kroenke, 
2003 
Adult/ U.S.A Primary 
care 
3000 - Negative correlation with 
functional status‡ 
Li, 2007 Older adults/ 
U.S.A 
Community 8205 - Negative correlation with 
functional status‡ 
Note: AIMS (SF) - Arthritis Impact Measurement Scale (Short version); CESD - Center for Epidemiologic 
Studies Depression Scale; GDS - Geriatric Depression Scale;  
‡ - assessed with the Short Form Health Survey (12 or 20 items versions). 
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Convergent validity  
           There is evidence for convergent validity of the PHQ-9 and HADS-D, 
which correlated (r=0.68) in a large sample of adult primary care patients (Cameron 
et al., 2008) (Table 3.6, p. 100). The PHQ-9 and BDI-II were significantly correlated 
(r=0.77) in a large study of community-dwelling older adults (Han et al., 2008). The 
BDI-II and Center for Epidemiologic Studies Depression Scale were correlated 
(r=0.66-0.72) in a small group of hospital patients with musculoskeletal 
complaints (Corbière et al., 2011). Overall, given consistently large correlations found to 
across populations, adequate convergent validity of can be assumed. 
 
Correlation with functional status 
There is consistent evidence for significant association between increasing 
PHQ-9 and -2 scores and decreasing functional status of adults, older adults and 
primary care patients with OA (Table 3.6 on page 100). Significant correlations 
were also found between BDI-II scores and functional status of primary care adults 
(Krugh, 1997, Arnau et al., 2001). Likewise, HADS-D scores were significantly associated 
with functional status of tertiary care patients with OA (Axford et al., 2010). 
 
‘Somatic bias’  
The problem of ‘somatic bias’ was predominantly investigated for the BDI-II 
in North American populations (Callahan et al., 1991, Harris & D-Eon, 2008, Corbière et al., 2011), with 
an addition of one UK based study using the HADS-D (Pincus et al., 1996). No relevant 
data for the PHQ-9 could be identified. A brief summary of the identified studies is 
displayed in Table 3.7 overleaf. 
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Table 3.7 Summary of identified studies into somatic bias of BDI-II and 
HADS-D. 
 
 Population/ 
country 
Setting N Selected findings Relevant 
conclusions 
HADS-D      
Pincus, 
1996 
RA cases  
Matched 
controls/ 
UK 
Cases: 
Tertiary 
care 
Controls: 
? 
Cases:  
163  
Controls: 
115  
 A rheumatologist 
indicated  items 1
†
 
and 4
‡
, as closely 
related to RA 
status 
 Cases scored 
higher than 
controls on items 1 
to 6 
The elevation in 
depression scores 
are not an artefact 
of RA, i.e. the tool 
is relatively free of 
criterion 
contamination 
BDI-II      
Corbière, 
2011 
 
Chronic pain/ 
Canada 
Tertiary 
care 
206  3 factor
 
structure 
found, including 
somatic 
 Mean score of the 
somatic dimension 
was the highest of 
the three 
 Perceived reasons 
for experiencing 
each symptom 
varied across 3 
factors  
 High 
endorsement of 
somatic items 
greatly 
contributed to 
overall scores 
 A sub-question 
on cause of 
somatic 
symptoms is 
needed 
Harris,  
2008
 
 
 
Chronic pain/ 
Canada 
Tertiary 
care 
481  3 factor structure 
found, including 
somatic 
 Item-total 
correlations for 
somatic items 
ranged from 0.34 
to 0.58 
 Somatic items 
most likely to be 
endorsed  
 All dimensions 
were equally 
associated with 
subjective pain 
experience  
 Inflation of 
depression 
score is unlikely 
 A need for 
inclusion of 
somatic items 
can be 
assumed  
Note: RA - rheumatoid arthritis;  
†- item 1: “I enjoy things as much as I used to”; ‡ - item 4: “I feel as if I am slowed down”. 
 
Given an apparent lack of consensus on quantifying the degree of ‘somatic 
bias’ and its impact on the tool’s general utility, the identified evidence is not 
directly comparable. Overall, the limited number of studies that attempted to 
ascertain overlap between chronic pain and somatic symptoms of depression, 
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found some degree of somatic symptom variance on the HADS-D (Pincus et al., 1996) 
and BDI-II (Harris & D-Eon, 2008, Corbière, 2011), which is not necessarily related to 
depression, but may reflect somatic disease. Furthermore, two studies found that 
BDI-II somatic symptom variance would explain a large part of inflation in scores 
on this scale in patients with musculoskeletal problems (Harris & D-Eon, 2008, Corbière, 2011). 
However, the impact of removing BDI-II and HADS-D somatic items, on their 
ability to discriminate between patients with and without depression has not been 
investigated, i.e. the extent to which somatic symptoms on self-report measures 
can be informative of major depression is unclear.  
 
3.5.2.4 Criterion validity of BDI-II and -PC, HADS-D and PHQ-9 and -2 
Likelihood ratios for each of the depression measures and in all populations 
are listed in Table 3.8 (please refer to Table C.4.1 in Appendix C.4 on page 365 
for data extracted to estimate likelihood ratios). For ease of comparability across 
studies the findings have been grouped according to the specific depression 
measure and version (e.g. the BDI-II) and criterion (e.g. major depression) being 
investigated and then ordered by cut-point.  
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Table 3.8 Criterion validity of the BDI-II and -PC, HADS and PHQ-9 and -2. 
 Population/ 
country 
Setting N Criterion Reference standard Cut-off Likelihood ratios* 
LR+ LR- 
BDI-II         
Poole, 2009b Chronic Pain/ UK Tertiary care 36 Major depression + recurrent 
depressive disorder 
SCID (DSM-IV) 15 2.5 0.00 
Poole, 2009b Chronic Pain/ UK Tertiary care 36 Major depression + recurrent 
depressive disorder 
SCID (DSM-IV) 22O 8.9 0.12 
Poole, 2009b Chronic Pain/ UK Tertiary care 36 Major depression + recurrent 
depressive disorder 
 
SCID (DSM-IV) 25 100# 0.27 
BDI-PC         
Beck,1997 Adult/ U.S.A Primary care 56 Major depression 
 
PRIME-MD 
(DSM-III-R) 
6O 17.0# 0.18 
HADS         
Bunevicius, 
2007 
Adult/ Lithuania Primary care 503 Major depression MINI (DSM-IV-TR) 6O 2.6 0.29 
Harter, 2001 MSK/ Germany Tertiary care 206 Major depression + recurrent 
major depression +dysthymia 
M-CIDI (DSM-IV) 16R 2.7 0.31 
Terluin, 2009 Adult/ Netherlands Primary care 295 Moderate + severe major 
depressive disorder 
CIDI (DSM-IV) 8R 1.4 0.13 
Terluin, 2009 Adult/ Netherlands Primary care 295 Moderate + severe major 
depressive disorder 
CIDI (DSM-IV) 11O 1.8 0.34 
Terluin, 2009 Adult/ Netherlands Primary care 295 Moderate + severe major 
depressive disorder 
CIDI (DSM-IV) 12O 1.8 0.55 
Terluin, 2009 Adult/ Netherlands Primary care 295 Moderate + severe major 
depressive disorder 
CIDI (DSM-IV) 14 2.7 0.62 
Lam, 1995 Older adult/ UK Primary care 100 Depressive, anxiety, sleep 
disorders 
CIS (DSM-III) 6O 8.7 0.24 
Wilkinson,1988 Adult/ UK Primary care 100 Depressive and anxiety 
states 
SCID (DSM-III) 8RO 6.4 0.12 
El-Rufaie,1995 Adult/ UAE Primary care 217 Depression CIS (DSM-III) 7O 22.0# 0.35 
Axford, 2010 MSK/ UK Tertiary care 54 Depression Structured clinical 
interview (ICD-10) 
8R 3.5 0.55 
Watts, 2002 Older adult/ UK Primary care 268 Subclinical mood disorders GMSA (DSM-III) 8R 2.2 0.85 
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Table 3.8 cont. Criterion validity of the BDI-II and -PC, HADS and PHQ-9 and -2. 
 Population/ 
country 
Setting N Criterion Reference standard Cut-off Likelihood ratios* 
LR+ LR- 
PHQ-9 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Major depression SCID (DSM-IV) 8 3.6 0.16 
Arroll, 2010 Adult/ NZ Primary care 2642 Major depression C-CIDI (DSM-IV) 8 5.8 0.16 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Major depression SCID (DSM-IV) 9 4.4 0.16 
Gilbody, 2007 Adults/ UK Primary care 96 Major depression SCID (DSM-IV) 9 3.5 0.08 
Kroenke, 2001 Adult/ U.S.A Primary care 580 Major depression Overview of SCID-I 
(DSM-IIIR) + PRIME-
MD (DSM-IV) 
9 5.9 0.06 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Major depression SCID (DSM-IV) 10R 3.5 0.46 
         
Gilbody, 2007 Adults/ UK Primary care 96 Major depression SCID (DSM-IV) 10R 4.2 0.11 
Kroenke, 2001 Adult/ U.S.A Primary care 580 Major depression Overview of SCID-I 
(DSM-IIIR) + PRIME-
MD (DSM-IV) 
10R 7.3 0.14 
Arroll, 2010 Adult/ NZ Primary care 2642 Major depression C-CIDI (DSM-IV) 10R 8.4 0.28 
Yeung, 2008 Adult/ U.S.A Primary care 184 Major depression CB-SCIDI-I/P(DSM-IV) 15R 17.0 0.09 
Kroenke, 2001 Adult/ U.S.A Primary care 580 Major depression Overview of SCID-I 
(DSM-IIIR) + PRIME-
MD (DSM-IV) 
15 13.6 0.34 
Arroll, 2010 Adult/ NZ Primary care 2642 Major depression C-CIDI (DSM-IV) 15R 15.0 0.57 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Minor + major depressive 
disorder 
SCID (DSM-IV) 6 2.5 0.34 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Minor + major depressive 
disorder 
SCID (DSM-IV) 8O 4.4 0.28 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Minor + major depressive 
disorder 
SCID (DSM-IV) 10R 5.1 0.47 
Han, 2008 Older adult/ U.S.A Community 1060 Depressive disorder MINI (DSM-IV) 2 2.2 0.07 
Han, 2008 Older adult/ U.S.A Community 1060 Depressive disorder MINI (DSM-IV) 5O 3.6 0.26 
Han, 2008 Older adult/ U.S.A Community 1060 Depressive disorder MINI (DSM-IV) 10R 7.7 0.49 
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Table 3.8 cont. Criterion validity of the BDI-II and -PC, HADS and PHQ-9 and -2. 
 Population/ 
country 
Setting N Criterion Reference standard Cut-off Likelihood ratios* 
LR+ LR- 
PHQ-2 (scale) 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Major depression SCID (DSM-IV) 1 2.2 0.21 
Kroenke, 2003 Adult/ U.S.A Primary care 580 Major depression SCID (DSM-III) 1 2.4 0.04 
Arroll, 2010 Adult/ NZ Primary care 2642 Major depression C-CIDI (DSM-IV) 1 2.4 0.07 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Major depression SCID (DSM-IV) 3R 4.2 0.44 
Kroenke, 2003 Adult/ U.S.A Primary care 580 Major depression SCID (DSM-III) 3 8.3 0.19 
Arroll, 2010 Adult/ NZ Primary care 2642 Major depression C-CIDI (DSM-IV) 3R 7.6 0.42 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Major depression SCID (DSM-IV) 4 5.4  0.67 
Kroenke, 2003 Adult/ U.S.A Primary care 580 Major depression SCID (DSM-III) 4 17.0 0.48 
Arroll, 2010 Adult/ NZ Primary care 2642 Major depression C-CIDI (DSM-IV) 4 10.0 0.62 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Minor + major depressive 
disorder 
SCID (DSM-IV) 1 2.5 0.27 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Minor + major depressive 
disorder 
SCID (DSM-IV) 3R 5.3 0.52 
Phelan, 2010 Older adult/ U.S.A Primary care 71 Minor + major depressive 
disorder 
SCID (DSM-IV) 4 17.0 0.66 
Kroenke, 2003 Adult/ U.S.A Primary care 580 Any depressive disorder SCID (DSM-III) 1 2.5 0.14 
Kroenke, 2003 Adult/ U.S.A Primary care 580 Any depressive disorder SCID (DSM-III) 3 14.0 0.44 
PHQ-2
 
(binary response version) 
Whooley, 1997 Adult/ U.S.A Primary care 536 Major depression QDIS (DSM-IV) ‘yes’ to either R 2.2 0.07 
 Age 18-35/ U.S.A Primary care 51 Major depression QDIS (DSM-IV) ‘yes’ to either R 2.4 0.00 
 Age 35-64/ U.S.A Primary care 358 Major depression QDIS (DSM-IV) ‘yes’ to either R 2.0 0.10 
 Age 65+/ U.S.A Primary care 127 Major depression QDIS (DSM-IV) ‘yes’ to either R 3.2 0.00 
Arroll, 2003 Adult/ NZ Primary care 421 Major depression C-CIDI ‘yes’ to either R 2.9 0.05 
Arroll, 2003 Adult/ NZ Primary care 421 Major depression C-CIDI ‘yes’ to first 3.0 0.19 
Arroll, 2003 Adult/ NZ Primary care 421 Major depression C-CIDI ‘yes’ to second 3.9 0.22 
Li, 2007 Older adults/ 
U.S.A 
Community 8205 Minor + major depressive 
disorder 
AUDADIS-IV (DSM-IV) ‘yes’ to either R 4.4 0.00 
Li, 2007 Older adults/ 
U.S.A 
Community 8205 Minor + major depressive 
disorder 
AUDADIS-IV (DSM-IV) ‘yes’ to first 4.4 0.10 
Li, 2007 Older adults/ 
U.S.A 
Community 8205 Minor + major depressive 
disorder 
AUDADIS-IV (DSM-IV) ‘yes’ to second 5.7 0.18 
Li, 2007 Older adults/U.S.A Community 8205 Minor + major depressive AUDADIS-IV (DSM-IV) ‘yes’ to both 5.5 0.27 
107 
 
Table 3.8 cont. Criterion validity of the BDI-II and -PC, HADS and PHQ-9 and -2. 
 Population/ 
country 
Setting N Criterion Reference standard Cut-off Likelihood ratios* 
LR+ LR- 
PHQ-9 (algorithm)     
Henkel, 2004 Adult/ Germany Primary care 448 Dysthymia + major 
depression 
CIDI (DSM-IV) Algorithm 5.5 0.24 
Corapcioglu, 
2004 
Adult/ Turkey Primary care 1387 Major + minor depressive 
disorder 
Formal interview 
(DSM-IV) 
Algorithm 5.2 0.28 
Corapcioglu, 
2004 
Adult/ Turkey Primary care 1387 Major depression Formal interview 
(DSM-IV) 
Algorithm 8.8 0.31 
Spitzer, 1999 Adult/ U.S.A Primary care 585 Major depression Overview of SCIDI 
(DSM-IIIR) + PRIME-
MD (DSM-IV) 
Algorithm 36.0# 0.28 
Note: AUDADIS - Alcohol Use Disorder and Associated Disabilities Interview Schedule; CB-SCIDI-I/P - patient version of Chinese-bilingual Clinical Interview schedule for 
DSM-IVI; (C)CIDI- (computerised) Composite International Diagnostic Interview; CIS - semi-structured clinical interview schedule; DSM - Diagnostic and Statistical Manual of 
Mental Disorders; GMSA - short Geriatric Mental State Examination; LR- - negative likelihood ratio; LR+ - positive likelihood ratio; MINI - Mini-International Neuropsychiatric 
Interview;
 
MSK - musculoskeletal complaints; NZ - New Zealand; O - reported as optimal; QDIS- Quick Diagnostic Interview Schedule; PRIME-MD - Primary Care Evaluation 
of Mental Disorders; R - reported as recommended; SADS - Semi-structured review from the Schedule of Affective Disorders and schizophrenia; SCID - structured clinical 
interview for DSM disorders; UAE - United Arab Emirates. 
# - unusually high estimates. 
* The colour code used for adopted categories of changes in depressive disorders likelihood was: large - marked in green, moderate - orange, small - red, negligible - white. 
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The majority of studies (18 out of 26) were conducted for adults in primary 
care settings, with an additional six studies in older adults and three small studies 
in people with musculoskeletal complaints. Relative to major depressive disorder 
(16 studies), depressive disorders categorised for severity (e.g. moderate and 
severe major depressive disorder) and other types of depressive disorders (e.g. 
dysthymia), received limited research attention. In a wide range of reference 
standards used, however, diagnostic criteria used in UK primary care practice (i.e. 
the ICD-10) were rarely used.  
Many studies were small (five used sample sizes smaller than 100). Five 
studies reported unusually high estimates of LR+ (marked with # in Table 3.8 on 
page 104). In two of these studies the sample size was smaller than 100 (e.g. 
Poole et al., 2009b: LR+ 100 (95% CI (1.87, 451), Beck et al., 1997: LR+ 17 (95% 
CI 4.45, 62.0)). A relatively large estimate was reported by Spitzer et al. (1999), 
possibly reflecting a degree of incorporation bias, as the index test formed part of 
the reference test. The exact reason for the unusually high LR+ found by El-
Ruifaie and Absood (1995) is unclear. The authors attributed the difference to 
linguistic factors, but incorporation bias was also possible, as a reference standard 
was focused on the same constructs as the index test.  Overall, increasing cut-off 
points increased LRs+ at the expense of LRs-, with likelihood ratios typically small 
or moderate. 
Surprisingly few estimates were directly comparable (i.e. studies using the 
same questionnaire, criterion, reference standard and cut-off) across different 
populations. Phelan et al.’s (2010) small study in older adults showed consistently 
lower LR+ estimates on the PHQ-2 scale, than the larger adult primary care 
studies of Kroenke et al. (2003) and Arroll et al. (2010). In contrast, the nested 
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analysis in Whoolley et al. (1997) found a little difference in performance of the 
PHQ-2 (a binary response format) in the oldest participants (65 years or older) and 
all adults in the sample, and even better performance than in the age group 35-64 
years. 
There were few directly comparable estimates of diagnostic accuracy 
across different diagnostic criteria (i.e. based on the same study population, 
instrument and cut-off, and reference standard). Corapcioglu et al. (2004) found 
little difference for the PHQ-9 between major depressive disorder and a criterion 
inclusive of minor depressive disorder. In contrast, in older adults Phelan et al. 
(2010), found better ruling-out accuracy of PHQ-9 for major depression than for 
major depressive disorder and a criterion inclusive of minor depressive disorder.  
Rule-out (LRs-) and rule-in (LRs+) accuracy apparently differed across 
specific tools. Overall, the HADS-D and PHQ-2 (a binary response format), were 
more successful in ruling-out than ruling-in, and the opposite pattern emerged for 
the PHQ-2 and PHQ-9 scales. The BDI was comparable in both aspects. Two 
large studies directly compared measures (Whooley et al., 1997, Arrol et al., 2010). Whooley et 
al. (1997) have contrasted the PHQ-2 (a binary response format) and BDI-II, with 
unsatisfactory LRs+ of all the tools and superior rule-out accuracy of the PHQ-2. 
The study by Arroll et al. (2010) suggests that the PHQ-2 scale is a better at 
ruling-out than ruling-in and the PHQ-9 is a better in ruling-in than ruling-out major 
depression in adult primary care patients.  
 
3.5.2.5 Responsiveness of BDI-II and -PC, HADS-D and PHQ-9  
There was limited evidence suggesting adequate responsiveness of the 
PHQ-9 and the HADS-D, with a direct head-to-head comparison suggesting 
110 
 
similar large effect sizes in adult primary care patients (Cameron et al., 2008) (Table 3.9). 
A study by Poole et al. (2009a) found comparatively small effect sizes for the BDI-
II (0.28) and BDI-PC (0.23) in 584 chronic pain patients. Likewise a study by Angst 
et al. (2008) found a relatively small effect size (0.43) for the HADS-D in 273 
chronic pain patients. However, effect sizes appeared to be associated with 
duration and type of treatment, rather than the population per se. For example, 
increasing effect sizes were associated with longer periods of treatment (Poole et al., 
2009a vs. Angst et al., 2008) and the use of specialist mental health treatment, as opposed 
to psychology informed pain management programs (Cameron et al., 2008 vs. Angst et al., 
2008). 
 
Table 3.9 Responsiveness of the BDI-II and -PC, HADS-D and PHQ-9. 
 
 Population/ 
country 
Setting N Intervention Responsiven
ess 
BDI-II      
Poole, 
2009a 
Chronic 
pain/ UK 
Tertiary 
care 
584 A 16 days 
multidisciplinary pain 
management 
programme 
ES=0.28 
 
BDI-PC      
Poole, 
2009a 
Chronic 
pain/ UK 
Tertiary 
care 
584 A 16 days 
multidisciplinary pain 
management 
programme 
ES=0.23 
HADS-D      
Angst, 
2008 
Chronic 
pain/ 
Switzerland 
Tertiary 
care 
273 A four week in-
patient 
interdisciplinary pain 
program 
ES=0.43, 
SRM=0.53 
Cameron, 
2008 
Adult/ UK Primary 
care 
1063 Treatment provided 
by mental health 
workers* 
ES=1.00 
PHQ-9      
Cameron, 
2008 
Adult/ UK Primary 
care 
1063 Treatment provided 
by mental health 
workers* 
ES=0.99 
Lӧwe, 
2004b 
Older adult/ 
U.S.A 
Primary 
care 
434 Access for up to 12 
months to a 
depression clinical 
specialist 
ES=1.30 
Note: ES - effect size; MSK - musculoskeletal complaints; SRM - Standardised Response Mean;  
* - a time frame unreported. 
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3.5.3   Anxiety symptom measures 
3.5.3.1 Feasibility of GAD and HADS-A 
The GAD-7 is copyright and freely available from Pfizer Inc. (2012). The 
HADS is copyrighted and available from GL assessment (GL Education Group, 2012) (see 
Appendix C.3, p. 363-364 for copies of the two anxiety measures). Both tools have 
a clearly specified classification of severity (Zigmond & Snaith, 1983, Spitzer et al., 2006), but 
evidence of their compatibility with ‘gold standards’, across all anxiety disorders 
seem to be lacking. The required time to administer the GAD-7 (Garcia-Campayo, 2010) 
and HADS-A (Williams et al., 2002) is compatible with use in a routine GP consultation 
time slot (Table 3.10). The literacy level required for the HADS-A might pose 
difficulties for some patients.  
 
Table 3.10 Feasibility of the GAD and HADS-A. 
 
Instrument  
(abbreviation) 
Number of items 
(shorter versions)/ 
scale 
Possible score 
range: 
Severity 
Admin. 
time 
Literacy 
level^ 
 
Original 
time 
frame 
of items 
Generalised 
Anxiety Disorder 
scale (GAD-7) 
7 (2)/0-3 0-21: 
Minimal     (0-4) 
Mild           (5-9) 
Moderate  (10-14) 
Severe      (15-21) 
 2.5 min 
 
Average
† 
 
Past 2 
weeks 
Hospital Anxiety 
and Depression 
Scale -anxiety  
(HADS-A) 
7(-)/0-3 0-21: 
Non-cases (0-7) 
Doubtful     (8-10) 
Definite      (≥11) 
≤ 2 
minutes 
 
Difficult Past 
week 
Note: Admin. - Administration;  
^ Classified by Williams et al. (2002) using Fog Formula into three grade reading levels: 3-5 (Easy), 6-9 
(Average), ≥9 (Difficult);  
† - estimated for the original source of items, i.e. the self-reported version of the PRIME-MD (Williams et al, 
2002); ‡-  score range for doubtful and definite cases, are used as indicative of ‘mild’ and ‘moderate to severe’ 
severity respectively  (e.g. Kendrick et al., 2009). 
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3.5.3.2 Reliability of GAD-7 and HADS-A  
The internal consistency of the GAD-7 was found to be adequate for clinical 
use (Cronbach’s α=0.92-0.94) from two studies with a combined sample of 1187 
adult primary care patients (Spitzer et al., 2006, Garcia-Campayo et al., 2010) (Table 3.11 
overleaf). Although there were no direct head-to-head comparisons of the two 
measures within the same population the values for HADS-A were somewhat 
lower (0.78 - 0.83). Similar internal consistency was found for HADS-A in 296 
patients with musculoskeletal conditions in hospital setting as observed in adult 
primary care patients (Pallant & Bailey, 2005).  
Limited evidence on other aspects of reliability for either measure in 
relevant populations was found. In one study, a one-factor structure of the HADS-
A was confirmed (Pallant & Bailey, 2005), although one item failed to load adequately. A 
one-factor structure of the GAD-7 has been consistently supported in two studies 
with adult primary care patients (Spitzer et al., 2006, Garcia-Campayo et al., 2010), but item-total 
correlations above 0.68 indicate possible redundancy of some items. One of these 
studies (Garcia-Campayo et al., 2010) also reported test-retest reliability on the GAD-7 
(ICC=0.93) over an interval of one week, but 95% CI were not reported. 
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Table 3.11 Reliability of the GAD-7 and HADS-A. 
 
 Population/ 
country 
Setting N Cronbach’s 
alpha 
Item-total 
correlation 
Factor 
structure 
ICC 
(95% CI) 
Test-retest 
correlation 
coefficient  
       (r) 
GAD-7         
Garcia-Campayo, 2010 Adult/ Spain Primary care 222 0.94 >0.68 1 0.93 0.84 
Spitzer, 2006 Adult/ U.S.A Primary care 965 0.92 - 1 - - 
HADS-A         
Angst, 2008 Chronic pain/ Switzerland Tertiary care 273 - - - 0.81 - 
Bunevicius, 2007 Adult/ Lithuania Primary care 503 0.78 - - - - 
         
Pallant, 2005 MSK/ Australia 
 
Hospital 296 0.83 - 1 (item 7 
loaded 
poorly) 
- - 
Terluin, 2009 Adult/ Netherlands Primary care 295 0.83 - - - - 
Note: ICC - Intra-class correlation; MSK - musculoskeletal complaints.
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3.5.3.3 Construct validity of the GAD-7 and HADS-A 
Evidence relating to convergent validity and correlation with functional status is 
summarised in Table 3.12.  
 
Table 3.12 Construct validity of the GAD-7 and HADS-A. 
 
 Population/ 
country  
Setting N Convergent 
validity 
Correlation with 
functional status 
GAD-7      
Garcia-
Campayo, 
2010 
Adult/ Spain Primary care 222 With HADS-A 
(r=0.90) 
Negative correlation 
with functional 
status‡  
Kroenke, 2007 Adult/ U.S.A Primary care 965 - Negative correlation 
with functional 
status† 
Ruiz, 2011 Adult/ Spain Primary care 212 - Negative correlation 
with functional 
status‡ 
Spitzer, 2006 Adult/ U.S.A Primary care 965 With BDI       
(r=0.72) 
With HAM-A 
(r=0.74) 
- 
HADS-A      
Garcia-
Campayo, 
2010 
Adult/ Spain Primary care 222 With GAD-7 
 (r=0.90) 
- 
Note: HAM-A - Hamilton Anxiety rating scale;  
† - using the 20-Item Short Form Health Survey (SF-20); ‡ - using the World Health Organization Disability 
Assessment Schedule II (WHODAS II). 
 
 
Convergent validity 
There is evidence for adequate convergent validity of the GAD-7, which 
was significantly correlated with the Beck Anxiety Inventory (r=0.72) and the 
Hamilton Anxiety Scale (r=0.74) in a group of 965 adult patients recruited from 15 
primary care trusts (Spitzer et al., 2006). The HADS-A and GAD-7 were found to be 
highly correlated (r=0.90) in a small group of primary care adults (Garcia-Campayo et al., 
2010), with a large effect size supporting their convergent validity. 
 
Correlates with functional status 
Two studies, with a combined total of 1187 primary care adults, found that 
increasing GAD-7 scores have been associated with decreasing functioning, as 
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assessed with the SF-20 (Spitzer et al., 2006, Kroenke et al., 2007) and World Health 
Organization Disability Assessment Schedule II (Garcia-Campayo et al., 2010). The GAD-7 
severity scores have also been shown to predict disability assessed with the 
WHO-DAS II in 212 primary care adult patients (Ruiz et al., 2011).  
 
‘Somatic bias’ 
No eligible studies were found that presented original evidence on somatic 
item bias for the GAD-7. ‘Somatic bias’ was, however, examined for the HADS-A 
(Pincus et al., 1996). The anxiety scale showed a difference between cases (163 patients 
with rheumatoid arthritis from an outpatient clinic) and 115 matched controls on 
items 1 (“I feel tense or wound up”) and 4 (“I can relax and sit at ease”), where 
item 4 was indicated as a possible contaminator by the rheumatologist. Whilst the 
study authors are inconclusive about this finding, ‘somatic bias’ seems possible. 
 
3.5.3.4 Criterion validity of GAD-7 and -2 and HADS-A  
           Likelihood ratios for each of the anxiety measures and in all populations are 
listed in Table 3.13 overleaf (see Table C.4.2 in Appendix C.4 on page 370 for 
data extracted to estimate likelihood ratios). The majority of evidence comes from 
adult primary care patients in the U.S.A, with only two relatively small studies in 
older adults and two in musculoskeletal disease populations. 
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Table 3.13 Criterion validity of the GAD-7 and -2 and HADS. 
 
 Population/ 
Country 
 
Setting N Criterion Reference 
standard 
Cut-off Likelihood ratios* 
LR+ LR- 
GAD-2         
Kroenke, 2007 Adult/ U.S.A Primary care 965 GAD SCID (DSM-IV) 2 2.6  0.08 
Kroenke, 2007 Adult/ U.S.A Primary care 965 GAD SCID (DSM-IV) 3R 5.1   0.17 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Panic disorder SCID (DSM-IV) 2 2.5  0.14 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Panic disorder SCID (DSM-IV) 3R 4.1   0.30 
Kroenke, 2007 Adult/ U.S.A Primary care 965 PTSD SCID (DSM-IV) 2 2.4  0.22 
Kroenke, 2007 Adult/ U.S.A Primary care 965 PTSD SCID (DSM-IV) 3R 3.1   0.51 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Social phobia SCID (DSM-IV) 2 2.3  0.22 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Social phobia SCID (DSM-IV) 3R 3.6  0.35 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Any anxiety disorder SCID (DSM-IV) 2 2.9  0.20 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Any anxiety disorder SCID (DSM-IV) 3R 5.2  0.40 
GAD-7         
Kroenke, 2007 Adult/ U.S.A  Primary care 965 GAD SCID (DSM-IV) 5 2.2  0.05 
Garcia-Campayo, 
2010 
Adult/ Spain Primary care 212 GAD Clinically diagnosed       
(DSM-IV-TR) 
8 6.6 0.08 
Kroenke, 2007 Adult/ U.S.A Primary care 965 GAD SCID (DSM-IV) 10R 4.9   0.13 
Garcia-Campayo, 
2010 
Adult/ Spain  Primary care 212 GAD Clinically diagnosed       
(DSM-IV-TR) 
10R 13.0# 0.14 
Garcia-Campayo, 
2010 
Adult/ Spain Primary care 212 GAD Clinically diagnosed       
(DSM-IV-TR) 
14 99.9 0.38 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Panic disorder SCID (DSM-IV) 5 2.1 0.11 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Panic disorder SCID (DSM-IV) 10R 3.9   0.14 
Kroenke, 2007 Adult/ U.S.A Primary care 965 PTSD SCID (DSM-IV) 5 2.1  0.18 
Kroenke, 2007 Adult/ U.S.A Primary care 965 PTSD SCID (DSM-IV) 10R 3.5  0.37 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Social phobia SCID (DSM-IV) 5 2.4  0.22 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Social phobia SCID (DSM-IV) 10R 3.6  0.35 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Any anxiety disorder SCID (DSM-IV) 5 2.4  0.16 
Kroenke, 2007 Adult/ U.S.A Primary care 965 Any anxiety disorder SCID (DSM-IV) 10R 5.5  0.20 
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Table 3.13 cont. Criterion validity of the GAD-7 and HADS. 
 
 Population/ 
country 
Setting N Criterion Reference standard Cut-off Likelihood ratios* 
LR+ LR- 
 
HADS         
Wetherell, 2007 Older adult/ U.S.A Primary care 37 GAD ADIS-IV (DSM-IV) 8R 2.9 0.05 
Bunevicius, 2007 Adult/ Lithuania Primary care 503 GAD MINI (DSM-IV-TR) 9O 2.8  0.33 
Bunevicius, 2007 Adult/ Lithuania Primary care 503 Panic disorder MINI (DSM-IV-TR) 11O 4.4 0.00 
Bunevicius, 2007 Adult/ Lithuania Primary care 503 Social phobia MINI (DSM-IV-TR) 9O 2.6 0.08 
Bunevicius, 2007 Adult/ Lithuania Primary care 503 Social phobia, panic 
disorder, GAD 
MINI (DSM-IV-TR) 9O 3.1 0.31 
Terluin, 2009 Adult/ Netherlands 
 
Primary care 295 Panic disorder, 
agoraphobia, and social 
phobia 
CIDI (DSM-IV) 8R 1.3 0.07 
Terluin, 2009 Adult/ Netherlands 
 
Primary care 295 Panic disorder, 
agoraphobia, and social 
phobia 
CIDI (DSM-IV) 13O 1.9 0.49 
Lam, 1995 Adult/ Chinese Primary care 100 Depressive, anxiety, sleep 
disorders 
CIS (DSM-III) 3 3.9 0.40 
Terluin, 2009 Adult/ Netherlands Primary care 295 Any anxiety disorder CIDI (DSM-IV) 8R 1.3 0.07 
Terluin, 2009 Adult/ Netherlands Primary care 295 Any anxiety disorder CIDI (DSM-IV) 13O 2.2 0.50 
Harter, 2001 MSK/ Germany Tertiary care 206 Any anxiety disorder M-CIDI (DSM-IV) 17 2.7 0.35 
El-Rufaie, 1995 Adult/ UAE Primary care 217 Anxiety CIS (DSM-III) 8 5.4 0.34 
Axford, 2010 MSK/ UK Tertiary care 54 Anxiety Structured clinical 
interview (ICD-10) 
8R 4.6 0.15 
El-Rufaie, 1995 Adult/ UAE Primary care 217 Anxiety CIS (DSM-III) 9O 8.9 0.37 
Watts, 2002 Older adult/UK Primary care 268 Subclinical mood disorders GMSA (DSM-III) 8R 2.0 0.61 
Note: ADIS - Anxiety Disorders Interview Schedule for DSM-IV; CIS - semi-structured clinical interview schedule; CIDI - Composite International Diagnostic Interview; DSM - 
Diagnostic and Statistical Manual of Mental Disorders; GAD - Generalised Anxiety Disorders; GMSA - short Geriatric Mental State Examination; ICD - International 
Classification of Diseases; LR- - negative likelihood ratio; LR+ - positive likelihood ratio; M-CIDI - Munich-Composite International Diagnostic Interview; MINI - Mini-International 
Neuropsychiatric Interview; MSK - musculoskeletal complaints; O - according to authors of a study optimal cut-off point; R - recommended cut-off point; SCID - structured 
clinical interview for DSM disorders; UAE - United Arab Emirates. 
# - unusually high estimates. 
* Colour codes for adopted categories of changes in anxiety disorders likelihood: large - green, moderate - orange, small - red, negligible - white.
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The most commonly used criterion was any anxiety disorder (7 out of 11 
studies), followed by generalised anxiety disorder (4), with other types of anxiety 
disorders and sub-threshold symptomology, rarely being investigated. The majority 
of reference standards were DSM-IV criteria based, with an addition of one study 
that used the ICD-10 criteria, which are embraced in UK primary care practice.  
Positive likelihood ratios were typically small and negative likelihood ratios 
were typically small to moderate. Large LRs- were more common than large LRs+, 
for both the HADS and GAD, i.e. the two tools were more accurate in ruling-out 
than ruling-in. Three studies had relatively small sample size (from 37 to 100).  A 
validation study of Spanish version of PHQ-9 estimates resulted in an unusually 
high LR+ (Garcia-Campayo et al., 2010, LR+ 13 (95% CI 6.40, 27.0). Given that 
little information was provided about the execution of the reference test, a 
plausible reason for this discrepancy is unclear. 
There were no directly comparable estimates of diagnostic accuracy across 
different criteria (i.e. based on the same instrument, cut-off, and reference 
standard). There were apparent differences in performance across specific anxiety 
disorders, with direct head-to-head comparisons available from three studies in 
adult primary care attendees (Kroenke et al., 2007, Bunevicius et al., 2007, Terluin et al., 2009). In one 
of these studies, the GAD-7 and -2 were compared across GAD, any anxiety 
disorder, panic disorder, PTSD and social phobia, where any anxiety disorder had 
the highest LRs+ (i.e. ruling-in accuracy) and GAD the highest LRs- (i.e. ruling-out 
accuracy) (Kroenke et al., 2007). In contrast, the HADS-A had the highest LR+ and LRs- 
for panic disorder as opposed to GAD, social phobia and any anxiety disorder 
(Bunevicius et al., 2007). Partially in line with this study, Terluin et al. (2009) have found for 
the HADS-A a higher LR- in patients with panic disorder/ agoraphobia/ social 
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phobia, than in patients with any anxiety disorder, but LRs+ were the same in both 
groups. 
 
3.5.3.5 Responsiveness of GAD-7 and HADS-A 
No eligible studies were found that presented original evidence on 
responsiveness for the GAD-7 in relevant populations. In one study with 273 
patients with chronic pain recruited from a Swiss rehabilitation clinic, the HADS-A 
showed responsiveness (ES=0.35, SRM=0.45) to changes following four week in-
patient interdisciplinary pain program (Angst et al., 2008). 
 
3.5.4   Acceptability 
The acceptability of selected depressive and anxiety measures in primary 
care was rarely investigated (see Table 3.14 overleaf for a summary of studies). 
Of these studies, one identified study considered psychiatric case identification 
questionnaires in UK general practice, and thus applies to anxiety measures (Wood 
et al., 2002). However, no data specific to anxiety measures could be identified. 
General acceptability of self-report measures and their underlying concepts and 
purposes are briefly summarised in the following sections - for both patients and 
health professionals. 
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Table 3.14 Summary of identified studies into acceptability of the concept 
of depression measures. 
 
 Population
/Country 
N Method Condition of 
interest/ 
measure of 
interest 
Study Aim 
Coventry, 
2011 
Health 
professiona
ls†, service 
users with
 
diabetes 
and/or 
CHD, 
carers/UK 
Stage I: 
19 health 
professionals,  
7 service 
users, 
3 carers  
Stage II: 
6 health 
professionals,  
7 service 
users,  
1 carer 
Stage I: 
In-depth 
interview  
Stage II: 
Focus 
group  
Depression/  
any measures 
used in primary 
care 
Barriers in 
management of 
depression in 
patients with long 
term conditions 
 
Dowrick, 
2009 
GPs and 
patients/ 
UK 
34 GPs 
24 patients 
Open 
ended, in-
depth 
interviews 
Depression/ 
assessment 
measures 
recommended 
by the QOF 
Views on 
depression 
severity 
questionnaires 
incentivised in UK 
quality and 
outcomes 
framework 
Rosemann, 
2006 
GPs, 
practice 
nurses and 
patients 
with OA/ 
Germany 
20 GPs 
20 practice 
nurses 
20 patients 
with OA 
Semi-
structured 
interview 
with open-
ended 
questions 
Depression/ 
Depression 
questionnaires 
 e.g. PHQ-9) 
Problems and 
needs or 
improving primary 
care of 
osteoarthritis 
patients 
Simpson, 
2008 
Primary 
care 
patients/UK 
13 Semi-
structured 
interviews 
Depression/ 
PHQ-9 
Patients’ 
experiences of 
receiving 
collaborative care 
for depression 
Wood, 
2002 
Primary 
care 
patients/ 
UK 
127¥ 20 focus 
groups 
Psychiatric 
disorders/ 
an exemplar 
provided 
 (GHQ-12)  
Patients’ attitudes 
to questionnaires 
for common 
mental health 
disorders 
Note: GHQ - General Health questionnaire; GP - general practitioner; QOF - Quality and Outcomes 
Framework; 
† - predominantly from primary care; ¥ - the number of groups which discussed each of the themes: tools 
validity (n=14), tools usefulness (n=20), the issue of confidentiality (n=20), perceived stigma (n=18). 
 
 
 
 
 
121 
 
3.5.4.1 Patients 
Two qualitative studies detailed general attitudes of UK patients towards 
general self-report depression and self-report psychological measures (Wood et al., 
2002, Dowrick et al., 2009). Both studies concluded that the majority of patients were willing 
to complete questionnaires. The extent of equivocality differed across these two 
studies. 
Wood et al. (2002) found that (particularly older) patients were likely to be 
ambivalent about psychiatric case identification questionnaires. Two main areas of 
concern were data confidentiality and perceived stigma (e.g. intrusive questions, 
fear of being judged). The majority of doubts were expressed in relationship to the 
tool validity (e.g. influence of temporary factors), but these concerns were likely to 
be stimulated by the provision of an exemplar questionnaire. Relative to other 
aspects of questionnaires, patients were more likely to raise advantages of their 
use (e.g. legitimising emotional problems). 
In contrast, Dowrick et al. (2009) found that patients were in general less 
equivocal about self-report measures. They rarely raised the issue of their validity. 
Overall, they were likely to perceive questionnaires as more important than (or an 
important aide to) a clinician’s judgment, although a holistic approach to 
interpretation was preferred. Patients were likely to perceive questionnaires as 
useful for management of symptoms (e.g. monitoring symptoms, improved self-
awareness). This was confirmed by a small group of patients, receiving 
collaborative care for depression who found the PHQ-9 easy to understand and 
good at improving self-awareness (i.e. an acceptable way of monitoring progress 
of symptoms) (Simpson et al., 2008). Overall, views expressed by patients in a small 
122 
 
number of studies suggest that questionnaires may be acceptable for primary care 
patients but this may differ according to their individual preferences. 
 
3.5.4.2 Health care professionals 
Following semi-structured interviews with 40 primary care health 
professionals, Rosemann et al. (2006) concluded that depression questionnaires 
(e.g. PHQ-9) are not used ‘to reveal depression’, but further details on their 
usefulness were not reported. Two small qualitative studies considered the views 
of healthcare professionals on self-report depression measures used in UK 
general practice (Dowrick et al., 2009) and in patients with long term conditions (Coventry et 
al., 2011). In both studies health professionals expressed willingness to use 
questionnaires. They raised various advantages and disadvantages but overall 
they were likely to be equivocal. 
GPs typically reported that self-report measures serve as a confirmation of 
their clinical judgment and are thus more useful for GPs with limited clinical 
experience. They suggested that in a general sense the scores needed to be 
interpreted in the context of patient information (Dowrick et al., 2009). Likewise, a 
common view was that self-report measures may be inappropriate (i.e. reductionist 
or unsubtle) for patients with long term conditions, adding little to what can be 
offered by clinical judgment and continuity of care (Coventry et al., 2011). 
Aside from GPs’ valuing the questionnaires for their clinical judgement, a 
critical issue was surrounding the use of questionnaires in practice, i.e. 
acceptability. The difficulty was negotiating between a formal assessment 
according to the QOF and limited consultation time (Dowrick et al., 2009). Similarly, a 
further important issue identified for primary care patients with long term conditions 
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was that higher work load was associated with using instruments, and using the 
recommended questionnaires in patients with poor English (Coventry et al., 2011). 
Some GPs were positive about possible advantages of using depression 
questionnaires in practice (e.g. standardisation of care, matching intervention to 
severity) (Dowrick et al., 2009). Despite common resistance, formal assessment under the 
QOF recommendations was perceived by some health professionals as an 
improvement of management of depression in patients with long term conditions 
and a good experience for patients (Coventry et al., 2011). Overall, as health 
professionals were less likely to be positive about the purpose and usefulness of 
self-report measures of depression in UK primary care it seems that their 
acceptability may be limited. 
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3.6     DISCUSSION 
3.6.1   Summary of key findings 
For ease of comparison across properties and measures, a summary of findings is 
presented in Table 3.15.  
 
Table 3.15 Summary of availability of evidence for the adapted evaluation 
framework. 
 
 Depression symptom measures 
 
Anxiety symptom measures 
Measurement property BDI HADS-D PHQ GAD HADS-A 
 
Feasibility      
  - Administration burden +  +  +  +  +  
  - Interpretability ? ? ? ? ? 
  - Accessibility  ? ?  +  +  ?  
  - Readability and  
comprehension 
+  ?  +  +  ?  
  - Time to administer  +  +  +  +  +  
Reliability      
  - Cronbach’s Alpha + (a)  + (a, m)  + (a, o)  + (a) + (a, m) 
  - Item-total correlation ? (a)  ? (a)  ? (a, o)  ? (a) - 
  - Factor structure ? (a, m)  + (a, m)  + (a) + (a) ? (a) 
  - Intra-class correlation - + (m) + (o) + (a) -  
  - Test-retest correlation 
coefficient 
- - + (o, a) + (a) - 
Construct validity      
   - Convergent validity + (o, m)  + (a)  + (a, o)  + (a) + (a) 
   - Correlation with 
functional status 
+ (a)  + (m) + (m) + (a) - 
   - ‘Somatic bias’ + (m) + (m) - - + (m) 
Criterion validity      
   -  Ruling-out accuracy ? (m) ? (a, o, m) + (a, o) + (a) + (a); ?(o) 
   -  Ruling-in accuracy ? (m) ? (a, o, m) + (a);?(o) + (a) ? (a, o, m) 
Responsiveness + (m) + (a, m) + (a, o) - + (m) 
Acceptability  
  -  Patients ? (p) 
  -  Health professionals ? (p) 
Note: Identified evidence was classified as: + - supporting evidence; - - no data available; ? - doubtful (i.e. 
inadequate performance or weak evidence);  
Kinds of study populations used: (a)- adult primary care adults, (o) primary care/community base adults, (m) - 
people with musculoskeletal complaints/ chronic pain, (p) - general primary care;  
Marked in red - no UK data available. 
  
 
 
There is some supporting evidence for most measurement properties for 
each of the measures. While feasibility and reliability appear well-supported, there 
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was less evidence for acceptability and criterion validity.  
On the basis of this review it would be difficult to advocate the use of one 
particular measure over another. The key reasons for this are the lack of direct 
head-to-head comparisons within the same population, and the lack of large 
studies in the elderly and people with musculoskeletal complaints (or at least 
stratification within general adult primary care studies by age or presence of 
musculoskeletal conditions). A consequence of this paucity of evidence is the 
limited extent to which one can critically compare properties of each measure and 
concomitantly judge whether it is reasonable to assume that adequate 
performance in adult primary care will necessarily translate to older patients with 
OA. Assuming that data for primary care/community older adults is likely to reflect 
performance in older primary care attendees with OA, the PHQ-9 appears to 
perform relatively better than other measures. This echoes Nease and Malouin’s 
(2003) conclusions. Of the anxiety measures compared in this review, the GAD 
seems to be promising, but currently lacks evidence in older and musculoskeletal 
complaint populations.  
With specific reference to the HADS, this review suggests its adequacy as a 
research tool. It is short, easy to administer and has evidence for adequate 
internal-consistency and test-retest reliability. The HADS has adequate 
responsiveness to changes over time and thus is suitable for longitudinal data 
analyses. Being relatively free of ‘somatic bias’, it is unlikely to lead to score 
inflation or exaggeration of prevalence rates (therefore prevalence estimates 
based on HADS reported in chapter three, are least likely to be affected by OA or 
joint pain status). 
A critical issue to consider for studies that aim for clinical applicability is how 
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to use the HADS to inform clinical practice. In the process of reaching a formal 
diagnosis, self-report severity measures act as an adjunct to clinical judgement 
based on symptoms count and functional impairment (NICE, 2009b), and indeed, GPs 
seem to share this view (Dowrick et al., 2009). Nevertheless, the choice of intervention is 
closely related to the classification of symptoms severity (NICE, 2009b). In the previous 
chapter, an approach based on classification of symptoms severity formed the 
basis for estimation of prevalence rates. Consequently, in the context of the 
current thesis, further analyses will continue to be focused on HADS defined 
classification of severity of symptoms.  
 
Sources of bias in evidence  
Aspects of psychometric and clinimetric properties and specific populations 
have been selectively investigated in the identified papers. This often appeared to 
be related to practical issues such as the original purpose of a specific tool and the 
year of development. Studies concerning the PHQ-9 and GAD-7 appeared more 
focused on feasibility, associations with functional outcomes and diagnostic 
accuracy as these tools are intended  for diagnosing and monitoring primary care 
patients (Kroenke et al., 2001, Spitzer et al., 2006).  
Whilst no systematic method of quality assessment was employed in this 
review, it has been observed that investigating criterion validity is particularly 
challenging. This could be related not only to limited access to relevant patients, 
but also the time-consuming nature of implementing ‘gold’ reference standards 
(i.e. clinical interview schedules). It is clear that selection and observer bias are 
difficult to avoid entirely, as through analyses of unusually low or high LRs several 
types of bias became apparent. For example, partial verification bias (e.g. Yeung et al., 
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2008), disease progression bias (Axford et al., 2010), incorporation bias (e.g. Corapcioglu et al., 
2004) and the execution of reference test was not described (Beck et al., 1997). 
 
3.6.2   Strengths and limitations 
Three key methodological decisions warrant critical considerations. These 
include a targeted approach to the included measures, taking a non-systematic 
approach to this review and the ability to fully specify the basis for judging 
‘adequate’ performance. 
It could be argued that the most commonly used measures (i.e. those listed 
in this review as used in OA or joint pain observational studies in general 
population/primary care adults) should be comprehensively reviewed. However, 
this would result in omitting the BDI-II and -PC and GAD-7 and -2, yet the BDI-II is 
advised for use in both UK primary care and for patients with rheumatologic 
problems. The GAD, in contrast, appears to be increasingly popular in UK primary 
care practice, but to date has not been compared against other anxiety specific 
measures. Consequently, the included questionnaires which were approved for 
primary care use, are of most relevance to primary care patients with OA.  
The review was non-systematic, with one reviewer developing the search 
strategy, extracting data and judging the adequacy of the instruments 
performance. Furthermore there was no formal critical evaluation of the quality of 
the study designs. As discussed in the previous chapter, this suggests that this 
review is inevitably less robust and objective than a systematic review would be 
(i.e. it is potentially more predisposed to selection biases and errors). Nonetheless, 
the conducted search involved several approaches designed to identify all relevant 
studies, including searching systematically and including other data reviews and 
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their reference lists, followed by a broad search of electronic databases. By taking 
a non-systematic approach, it was possible to review a wider range of potentially 
relevant studies, and thus including evidence from primary care adults and older 
adults specifically, before seeking to critically compare this to patients with 
musculoskeletal disease.  
This review sought to cover only selected measurement properties, omitting 
two clinimetric properties (content validity and cross-cultural validity). No 
comprehensive and pre-defined checklist for the quality assessment, was 
followed, such as the one developed by Bot et al. (2004). However, several 
psychometric properties were addressed and the review moved beyond this with 
considerations of clinical utility. This approach can be found in previous reviews of 
assessment measures (e.g. Meades & Ayers, 2010). In addition, to evaluate selected 
properties, specific indicative evidence has been-predefined and reported, and an 
effort was made to provide clear interpretation of criteria for judging ‘adequate’ 
performance. 
 
3.6.3   Implications  
Implications for clinical practice 
Evidence of adequate measurement properties appears to be an 
expectation of any instrument to be used in clinical practice. The reviewed articles 
draw attention to the issues of reliability and validity of assessment measures 
being only part of the wider concern over the utility of self-report measures. This 
review touched on some important issues connected to utility such as 
acceptability, responsiveness, feasibility, and their usefulness of their application 
in practice. These require separate consideration in the context of improved 
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decision-making, patient outcome and cost-effectiveness, which were beyond the 
scope of this review. Overall, some gaps in performance of anxiety and depression 
questionnaires used in practice for older primary care attendees with OA are 
evident. 
None of anxiety and depression measures reviewed are without 
disadvantages. The next question is: Can inadequate performance in one or more 
measurement properties affect their applicability and interpretation in practice for 
older adults with OA? In practice, the extent to which inadequacy on any of 
measurement properties is likely to affect applicability and interpretation of the 
results seems related to the degree to which the health professional rely on the 
measure with his interpretation and have ‘adequate’ skills to be independent of it. 
In these terms, inadequacy of one or more measurement properties is more likely 
to lead to misinterpretation in hands of health professionals, with less accurate 
clinical judgment, and subsequently, to be less applicable to older people with OA. 
Given that some GPs perceive questionnaire as ‘more useful’ (Dowrick et al., 2009), for 
less experienced healthcare professionals, the risk of misinterpretation is possible. 
 
Research implications 
Since specific anxiety disorders are uncommon in people with OA, future 
research may contribute to the current classificatory system of anxiety disorders, 
by validating a new category - sub-threshold persistent anxiety disorder. This can 
be inspired by criteria used for dysthymia (persistent sub-threshold depression 
symptoms present for at least 2 years) (APA, 2000, WHO, 1992). 
The understanding of depression and anxiety symptoms in primary care 
populations with OA or joint pain is heavily reliant on the HADS data. 
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Consequently, it would be useful to investigate psychometric and clinimetric 
properties of the HADS and compare them with the BDI-II and -2, PHQ-9 and -2 
and GAD-7 and -2 in a large sample of primary care patients with musculoskeletal 
pain, including sub-threshold forms of depressive and anxiety disorders.  
 
3.7     CONCLUSIONS 
          The measurement properties of recommended depression and anxiety 
symptom measures have been reviewed. Although there is evidence to support 
some properties, a number of gaps in the evidence were identified. An 
understanding of how robust these measures are within the subpopulation of older 
primary care patients with OA is currently lacking, as are sufficient numbers of 
direct, head-to-head comparisons of measures within the same population. There 
are insufficient direct comparisons and studies within the subpopulations of 
interest to come to a confident recommendation for the most useful tool. However, 
the PHQ-9 – previously recommended by Nease and Malouin (2003) – has the 
potential to be a useful tool in older primary care attendees with OA.  
Adequacy of the HADS was considered for estimating the longitudinal 
course of depressive and anxiety symptoms and detection of these problems in 
general practice. In the context of the former analyses, there is evidence to 
support HADS’ stability whilst no changes in depressive and anxiety symptoms 
occur (as indicated by the adequate test-retest reliability) and responsiveness to 
occurring changes. Since the HADS does not include questions on aetiology of 
somatic symptoms of depression and anxiety, evidence to support this tool being 
relatively free from ‘somatic bias’ reduces a possibility of inflation of scores. The 
anxiety subscale seems to be more prone to this bias, than the depression 
131 
 
subscale. The critical issue for consideration in detection analyses is that the 
HADS is not a diagnostic tool and (as other reviewed measures) serves a 
relatively poor proxy for depressive and anxiety disorders. However, assuming that 
the HADS is suitable to assess the trajectories of symptoms and persistent 
symptoms are more easily identifiable over time than transient forms, valid 
conclusions can be drawn about detection of possible/definite anxiety and 
depression. 
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Chapter four: The course of anxiety and depression symptoms in 
older patients presenting to general practice with musculoskeletal 
pain 
 
Part 1: Source and suitability of the PROG-RES dataset  
 
4.1      INTRODUCTION 
The primary objective of this chapter is to describe the data source used in 
subsequent chapters. Following a brief overview of secondary data analyses, this 
chapter describes the study design and sampling procedures used in the 
PROGnostic RESearch (PROG-RES) study. A brief introduction of the data 
collected and the characteristics of the study participants are presented. Suitability 
of the dataset, for the purposes of this thesis, is explored based on 
recommendations for secondary data analyses and with particular reference to the 
potential impact on analyses reported in chapters five, six and seven. 
The purpose of chapters five, six and seven are to describe the course of 
anxiety and depression symptoms in older patients with osteoarthritis (associated 
person-related characteristics) and to assess detection of these coexisting 
psychological complaints in general practice. To achieve these goals, data from 
the PROG-RES study will be analysed.  
 
4.2     BRIEF OVERVIEW OF SECONDARY DATA ANALYSIS  
In the broadest sense, secondary data analyses can be defined as 
analyses conducted by a person not involved in either the study design or data 
collection (Boslaugh, 2007). According to Vartanian (p. 3, 2010) “[secondary data 
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analyses] include any data that are examined to answer a research question other 
than the question(s) for which the data were initially collected”.  
There is no single list of issues to consider whilst evaluating 
appropriateness of secondary datasets. Exploration of the source of data has been 
broadly regarded a major aspect of secondary data analyses (Boslaugh, 2007, Vartanian, 
2010). According to Boslaugh (2007) for this purpose the following issues can be 
considered: 
 The original purpose of the study: For instance, features of the targeted 
population or specific wording used might influence characteristics of data 
 Study design and sampling procedures: The impacts of issues relevant to 
primary data such as time of data collection, methods of ascertainment, 
sampling procedures, response rate, or characteristics of the sample, are of 
concern to secondary data analysis 
  Data handling procedures: This issue considers the practicality of data, 
including coding of missing data or specific variables 
 
Vartanian (p.18 - 22, 2010) suggests that suitability of data can be evaluated by 
considering such issues as: 
 Feasibility, including accessibility of data, required authorisations and 
knowledge needed for the statistical software to be used 
 Adequacy of the population from which data was drawn 
 Generalisability of sampling frame 
  Availability and characteristic of dependent and independent variables 
 Adequacy of identifiers for the target group and sample size of sub-groups 
 
134 
 
4.3      THE PROG-RESS COHORT: DESCRIPTIVE FEATURES  
4.3.1   Design and setting 
The PROG-RES study comprises a prospective cohort of consecutive, older 
people consulting their general practitioners about their musculoskeletal pain (Mallen 
et al., 2006b).  Adults aged 50 years and over consulting their general practitioner with 
a new or on-going episode of musculoskeletal pain were eligible for inclusion. The 
primary aim of the study was to evaluate the prognostic value of a brief 
assessment tool (Mallen et al., 2006b). Excluded were patients with evidence of: 
traumatic injury; an acute swollen, red or hot joint; inflammatory arthropathy; or 
patients considered by GP to be vulnerable due to cognitive impairments or severe 
physical health problems. Patients were recruited from five Central Cheshire 
General Practices between September 2006 and March 2007 (Mallen & Peat, 2008). 
Ethical approval was received for this study. 
I had no role in the design or conduct of the PROG-RES study. The dataset 
is held by the Arthritis Research UK Primary Care Centre and I requested data to 
answer specific questions relevant to this thesis. The following sections will 
provide a brief overview of the design and conduct of the study, with a summary of 
key demographic findings provided to allow an understanding of the dataset used.  
 
4.3.2   Data collection 
A pilot study was completed between May and July 2006 at Kingsbridge 
Medical practice in Newcastle-under-Lyme. Following the implementation of minor 
amendments the study was conducted. Eligible participants triggered a specially 
designed electronic pop-up template by entering a predefined Read code (Mallen et al., 
2006b). If general practitioners decided that exclusion criteria did not apply, they 
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were requested to perform a brief assessment including six domains ascertained 
with seven questions and the consultation record was electronically ‘stamped’ 
(Mallen, 2009).  
Following weekly electronic searches, stamped electronic records were 
identified and names and addresses of eligible patients were downloaded. Within 
one week of an electronically ‘stamped’ consultation (index), all eligible 
participants were sent a study pack including a letter from the general practice, an 
information hand-out, name and contact details of the principal investigator, a 
postal questionnaire and written consent for further contact and medical record 
examination. Non-respondents were sent a reminder postcard two weeks after the 
study pack. 
Follow-up questionnaires were sent to all baseline respondents who 
consented for follow-up. Questionnaires were sent at 3, 6, 12 months, 2 and 3 
years from the initial consultation date. Throughout the mailing process, weekly 
checks for patient deaths and departures from the general practices were 
conducted by the Research Network team. Details extracted from medical records 
included: date of index consultation, code assigned with a general practice and 
Read codes used in index consultation. Information was also extracted on 
prescriptions, comorbidities, referrals and other primary care use. Data entry, 
coding, cleaning and storage were detailed in the author thesis (Mallen, 2009) and the 
study protocol (Mallen et al., 2006b). 
 
4.3.3   Response at baseline and follow-up 
Information about participation rates from baseline to 6 months were 
extracted from the principal investigator’s thesis. Details on 12 months, 2 and 3 
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years have been obtained from the custodian of the PROG-RES data. Sections 
below focus on time-points used in this thesis: baseline, 3, 6, and 12 months1. 
 
Baseline 
Five practices participated in the study. Forty four GPs (Mallen, 2009) completed 
templates on 650 potential participants. Of the 646 eligible participants 502 
responded to a baseline questionnaire (adjusted2 response 77.7%) (Figure 4.1 
overleaf). 
 
Follow-up 
At the 3-month follow-up 443 participants were mailed a questionnaire, of 
which 389 returned completed questionnaires (adjusted response 89.8%). At the 
6-month follow-up a questionnaire was emailed to 446 participants. Of these 370 
completed their questionnaires (adjusted response 85.1%). The 12-month follow-
up questionnaire was posted to 430 participants, of which 329 completed their 
questionnaires (adjusted response 77.2%) (Figure 4.1). 
 
Consenters 
Of the 502 respondents at baseline, 443 (88.2%) consented for follow-up. 
Permissions for medical record review were provided by 428 participants (a 
consent rate of 85.3%). In total, 403 participants consented at baseline for both 
follow-up and for medical record review (a consent rate of 80.3%).  
 
                                                 
1
 At 2 years n=250 mailed (214 respondents) and at 3 years n=244 mailed (202 respondents). 
2
 An adjusted response rate refers to the response rate calculated with those who were excluded 
from the mailing process, due to death or died medical reasons or not living at the address to which 
the questionnaire was mailed. 
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Figure 4.1  Flowchart of 1-year follow-up responses to PROG-RES study. 
 
No consent for further contact, 
n=59 
Baseline consent rate for 
further contact 88.2% 
 
Eligible 3 month population, n=443 
Respondents at 3 months, n=398 
Adjusted response rate 89.8% 
 
Eligible 6 month population, n=435 
Respondents at 6 months, n=370 
Adjusted response rate 85.1% 
 
Respondents at 12 months (n=329) 
Adjusted response rate 77.2% 
Mailed 12 month population, n=430 
Respondents to baseline questionnaire, n=502 
Adjusted response rate 77.7% 
 
Non-respondents, n= 41 
(+Refusals, n=4) 
 
No consent for further contact, 
n=6  
(+Refusals, n=1) 
 
Non-respondents, n=61 
(+Refusals, n=4) 
 
Excluded, n=0 
Excluded, n=1 
No consent for further contact, 
n=5  
(+Refusals, n=0) 
 
Excluded, n=2 
Excluded, n=4 
 
Eligible 12 month population, n=426 
No consent for further contact, 
n=90  
(+Refusals, n=7) 
 
Original baseline population, n=650 
 
Excluded, n=4 
Eligible baseline population, n=646 
  
Refusals/ 
Non-respondents, n=144 
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4.3.4   Study participants 
Sixty per cent (60%) of the study population were female. The mean age of 
participants was 63.1 years (SD 10.6) (Mallen & Peat, 2008). 
 
4.4    THE PROG-RES COHORT: EVALUATION AS A SECONDARY DATA 
SOURCE FOR THIS THESIS  
4.4.1  Generalisability of the sampling frame  
Prevalence rates of ‘mild or worse’ anxiety symptoms (43.6%) and 
‘moderate or worse’ anxiety symptoms (20.5%) were determined using HADS for 
the 502 baseline respondents. These were consistent with the pooled prevalence 
rates reported in chapter two (45.4% and 20.8% respectively). Prevalence rates of 
‘mild or worse’ depression symptoms (27.9% vs. pooled 23.8%) and ‘moderate or 
worse’ depression symptoms (11.0% vs. pooled 14.6%) in the PROG-RES 
baseline respondents, were broadly comparable to the pooled estimates (chapter 
two). These findings support the generalisability of the cross-sectional 
characteristics of the main study outcomes. However, analyses of trajectories and 
detection rates could be affected by generalisability of the sample frame. 
Statistical comparisons between the local and national populations were not 
conducted. In general, populations from all practices were likely to be white and 
have a higher than the national average Quality and Outcomes Framework (QOF) 
score (Mallen, 2009). Consequently, ethnic minorities and practices with poorer quality 
of standards might be under-represented in the study. How this may impact on 
generalisability of the analyses of the trajectory of anxiety and depression in 
people with OA or joint pain is unclear. Both race and socio-economic status has 
been shown to affect a GP’s perception of patients, which can affect consultation 
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behaviour (van Ryn & Burke 2000). Assuming that quality of doctors’ care for patients is 
important to depression outcome (Croghan et al., 2006), detection rates of psychological 
problems can be expected to be positively associated with increasing QOF scores.  
The participants suffered severely disabling pain, more severe than 
reported in previous observational research (Mallen, 2009). This was unlikely to limit 
generalisability of the sample to UK primary care patients, as evidence suggests 
that UK primary care patients reporting joint pain are more likely to suffer severely 
disabling pain than mild or moderately disabling pain (Thorstensson et al., 2009). However, 
an obvious consequence of this observation is that, it can be expected that at the 
time of the study PROG-RES participants were already in the process of adjusting 
to pain. Subsequently, it is possible that many of them could have experienced 
symptoms of depression and anxiety prior the study. 
 
4.4.2   The risk of response bias and loss of precision due to attrition, non-
consent to follow-up and medical record review 
Response bias  
Non-response bias is a systematic difference in characteristics of those who 
responded when compared with those who did not respond, which can reduce the 
representativeness of the contacted sample (Jooste et al., 1990). High response rates 
are believed to reduce the chance of response bias (Singleton & Straits, 2005). According 
to Bowling (2002) response rates of 75.0% and above could be considered good, 
and thus the response rate of over 77.7% appears to reduce the chance of 
response bias. However, in the PROG-RES women appeared to be more likely to 
respond than men, but statistical significance was not tested for (Mallen, 2009). In 
accordance with previous research (Dunn et al., 2004), response was the highest in age 
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group 70-79 years and the lowest for younger men (50-59 years) and older women 
(80 years or older) (Mallen, 2009). The precise impact this could have on the 
trajectories and detection rates presented in subsequent chapters is unclear. 
 
Consent bias 
Participants in the oldest age group (80 years or above) were less likely to 
consent for follow-up (e.g. 80 years or above: 74.0% vs. 50-59 years: 91.5%). 
Women in the oldest group were less likely to be represented in medical records 
(e.g. females aged 80 years or above: 79.4% vs. males aged 70-79 years: 94.1%). 
As indicated by previous research, the decreased likelihood to consent for follow-
up in older age is a common problem (Dunn et al., 2004). This is most likely to be due to 
unwillingness to participate- a common reason for lack of consent in older medical 
patients (Bakke et al., 1990). Given that older people are less likely to consult their GPs 
for depressive and anxiety symptoms (RCGP, 2006), the results of medical record 
review analyses could be influenced by under-representation of the oldest adults. 
Comparisons of non-consenters and consenters for medical record review and 
further contact suggests that those consenting to the latter were more likely to be 
older, widowed, have poorer physical health and more depression symptoms. 
Statistical significance was not tested. Overall, there is some limited evidence for 
consent bias by age in the PROG-RES study (Mallen, 2009). Nevertheless, 
comparisons of baseline respondents and consenters for further contact and 
medical record review (conducted by the principal investigator of the PROG-RES 
study (Mallen, 2009)) demonstrated that consent for further contact at baseline was 
similar across age, gender, general health, psychological and pain characteristic. 
These suggest that any consent bias was unlikely to be substantial. 
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Attrition bias 
Attrition affects longitudinal investigations and occurs when participants are 
lost to follow-up (Porta, 2008). The effect of drop-out was further ascertained by the 
PROG-RES principal investigator using variables explored in consent analyses. As 
the current study looks at one year trajectories only, this time frame sufficed. 
Comparisons were made between baseline consenters for medical record review 
and further contact, respondents to the 6-month follow-up and non-respondents at 
six months. The observed pattern appears to be broadly comparable to that found 
for consenting, except for age. Although typically older adults are less likely to 
successfully be followed-up (Chatfield et al., 2005), in the PROG-RES study, participants 
aged 70 years or older were more likely to respond at follow-up. According to 
Mallen (2009) this could be due to interest in the study topic and short intervals 
between follow-ups. The exact impact of this possible attrition bias by age on the 
current study is unclear.  
  
4.4.3   Case definition for musculoskeletal pain 
The most common reasons for consultations reported on the baseline 
questionnaire included low back pain, followed by shoulder and knee pain (Mallen, 
2009). On the baseline manikin, the knee was the commonest pain location, 
followed by low back and shoulder pain. In total, of the 502 baseline participants 
454 (90.4%) had pain at more than one location (Mallen, 2009) (Table 4.1 overleaf). 
Although all participants were older adults and joint pain was frequently reported, 
clearly musculoskeletal pain cannot be assumed to be all related to OA.  
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A selective sample of patients with an OA diagnosis could be identified 
through reviewing medical records. However, this would lead to the loss of power 
of analyses due to a reduced sample size. Furthermore, the use all forms of 
musculoskeletal pain is supported with ample evidence suggesting that the 
specific diagnosis of OA can pose difficulties for GPs (Bedson et al., 2005, Bierma-Zeinstra et al., 
2000). Diagnostic labels for knee OA seem to be used with caution by primary care 
practitioners in the UK, as diagnosis of knee OA was found not to be an initial 
response to the presentation of knee symptoms (on average taking 10 years to be 
allocated a formal knee OA diagnosis) (Bedson et al., 2005). Likewise, a specific 
diagnosis was registered for only 32% of the 400 older general practice patients 
(20 per individual GP) with new hip problems in the Netherlands (Bierma-Zeinstra et al., 
2000). The number of patients who received a hip OA diagnosis varied from 5% to 
50% (Bierma-Zeinstra et al., 2000).  
Table 4.1 Pain location, by index consultation and manikin data. 
                        Pain location 
Anatomical site Consulting 
    n (%) 
Manikin 
   n (%) 
Ankle/foot 99   (19.7) 173 (34.5) 
Low back 148 (29.5) 232 (46.2) 
Elbow 31   (6.2) 102 (20.3) 
Hip 90   (17.9) 209 (41.6) 
Knee 127 (25.3) 250 (49.8) 
Neck 75   (14.9) 148 (29.4) 
Shoulder 133 (26.5) 211 (42.0) 
Wrist/hand 68   (13.5) 127 (25.3) 
Other 82   (16.3) - 
Note: Numbers not equal 502, because some patients consulted with and shaded pain at 
more than one anatomical site. 
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Diagnostic labels of OA may also be used inaccurately by GPs. For 
example, the diagnostic concordance between GP diagnosis of knee OA and ACR 
clinical classification was found to be fair (Kappa (k) =0.28, 95% CI -0.01, 0.56) in 
general practice attendees in the UK (Peat et al., 2005). Likewise, levels of agreement 
between rheumatologists and referring primary care practitioners in patients with 
musculoskeletal disease in Spain, were found to be moderate for peripheral OA 
(k=0.48, 95% CI 0.38, 0.57), knee pain (k=0.40, 95% CI 0.29, 0.59) and muscular 
pain diagnosis (k=0.15, 95% CI 0.10, 0.20) (Candelas et al., 2010). Difficulties with 
diagnosis can be partially related to the lack of valid standardisation of diagnosis 
(Bierma-Zeinstra et al., 2000). Since radiographs are infrequently used in initial diagnosis of 
a patient with probable OA (as recommended by NICE (2008)) and nearly half of 
patients with radiographic evidence of OA are asymptomatic, the diagnosis of OA 
is most often reliant on the GP’s clinical skills (Altman et al., 2009).  
Inclusion of patients with spinal problems seems justified on the basis of 
common coexistence of spinal pain and peripheral joint. For example, Suri et al. 
(2010) reported that over half of all patients with symptomatic tibiofemoral knee 
OA had pain in low back. Low back pain was found correlated with higher scores 
on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 
(Wolfe, 1999). It can be argued that this correlation may simply be a marker for 
individuals with a greater propensity to pain states (Natvig et al., 2001). Some 
researchers believe that low back pain is biomechanically linked to knee pain via 
the so-called ‘knee-spine syndrome’ (Tsuji et al., 2002). Indeed, Suri (2010) found that 
pain in low back and ipsilateral foot pain were significantly and independently 
associated with higher WOMAC knee pain scores, and concluded that join affects 
nearby joints both above and below in the kinetic chain. 
144 
 
Lumbar spinal facet joints are suggested to be a source of low back and 
lower extremity pain, with an on-going debate over this idea in the medical 
literature (Borenstein, 2004, Kalichman et al., 2008). No significant relationships were found 
between degenerative changes in the lumbar spine facet joints and symptomatic 
low back pain (Schwarzer et al., 1994, Kalichman et al., 2008). However, supporting evidence (for 
lumbar spinal facet joints being a source of low back pain) come predominantly 
from decreased back pain following intra-articular or peri-articular joint injections 
(Lewinnek & Warfield,
 
1986, Schwarzer et al., 1994). Furthermore, many of the therapies for 
osteoarthritis have generalised effects throughout the body, i.e. therapies found to 
be effective for the appendicular skeleton are also effective for axial skeletal 
disease (Dieppe & Brandt, 2003).  
 
4.4.4   Ascertainment of anxiety and depression symptoms  
Suitability of HADS as an instrument 
In the PROG-RES study, depressive and anxiety symptoms were 
ascertained with the HADS. The suitability of this questionnaire, in the context of 
this thesis, was considered in chapter three, where the absolute and relative 
performance of the HADS was evaluated. HADS is a standardised and feasible 
longitudinal research tool and widely used to assess severity of depressive and 
anxiety symptoms, but serves a poor proxy for depressive/anxiety disorders (see a 
summary on pages 125-126 and conclusions on page 130). A cut-off score ≥8, 
inclusive of mild to severe symptoms is of clinical relevance to primary care (NICE, 
2009b). Three recommended score range (Zigmond & Snaith, 1983) and their severity 
classification (Kendrick et al., 2009) include; 0-7; none, 8-10; mild symptoms, ≥11; 
moderate to severe. Previous analyses conducted for PROG-RES data, however, 
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also included cut-off score ≥15 being indicative of severe symptoms (Mallen & Peat, 
2008). 
 
Suitability of the time frame 
The PROG-RES study provides six repeated HADS measures. HADS 
scores collected at baseline, 3, 6 and 12 months were used in identification of the 
trajectories of depressive and anxiety symptoms in primary care attendees 
consulting their GPs about musculoskeletal pain. Two and three year follow-up 
HADS data was excluded from the analyses presented in this thesis due to the 
reduced numbers of respondents. The choice of the time frame and frequency of 
repeated measures still provided multiple repeated measures which according to 
Harris et al. (2006) can be useful to depict relapsing of symptoms.  
 
Coexistence of depressive and anxiety symptoms 
Table 4.2 overleaf shows that 47.0% PROG-RES respondents had no 
anxiety or depression symptoms. ‘Mild or worse’ depression symptoms without 
anxiety symptoms were present in 7.0% of patients. This pattern was broadly 
comparable across four time points. The statistical implication of this pattern for 
this thesis is a need to increase a sample size by independently focusing on 
anxiety and depression symptoms, regardless of coexisting depressive/anxiety 
symptoms. This decision is supported by clinical reasons as primary care patients 
frequently experience coexisting depressive and anxiety symptoms (Mitchell et al., 2011). 
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Table 4.2 Frequency of co-occurrence of mild or worse anxiety and/or 
depression symptoms (HADS score ≥8). 
 
 Baseline 
N=502 
Month 3 
N=398 
Month 6 
N=370 
Month 12 
N=329 
n (%) n (%) n (%) 
 
n (%) 
Neither 236 (47.0) 201 (50.5) 191 (51.6) 168 (51.1) 
Anxiety and depression 102 (20.3) 84   (21.1) 70   (18.9) 58   (17.6) 
Only anxiety  117 (23.3) 80   (20.1) 76   (20.5) 78   (23.7) 
Only depression  35   (7.0) 21   (5.3) 16    (4.3) 20   (6.1) 
Note: Percentage is not equal 100% due to missing scores. 
 
Distribution of HADS data 
Means, standard deviations and the result of tests for asymmetry are 
presented in Table 4.3. Together with visual examination, Kolmogorov-Smirnov 
and Shapiro-Wilk tests of normality (that yielded significant results at levels 
p<0.0001 for both anxiety and depression symptoms at each time point) suggest 
an asymmetry from the normal distribution of HADS data. A consequence of this 
non-normality is that it limits the use of parametric tests. 
 
Table 4.3 Asymmetry of HAD depression and anxiety scores at 4 time point. 
 
Time point n Mean  Standard  
deviation 
Skewness Kurtosis 
Statistic SE Statistic SE 
 
HADS depression score (0-21)     
Baseline 502 7.21 4.112 0.373 0.110 -0.178 0.220 
3 m 398 7.08 4.094 0.364 0.124 -0.249 0.247 
6m 370 6.82 4.295 0.338 0.129 -0.481 0.257 
12m 329 6.64 4.183 0.350 0.135 -0.416 0.270 
HADS anxiety score (0-21)     
Baseline 502 5.67 3.633 0.748 0.110  0.208 0.219 
3 m 398 5.47 3.654 0.588 0.123 -0.119 0.246 
6m 370 5.11 3.923 0.928 0.129  0.663 0.257 
12m 329 5.05 3.753 0.600 0.135 -0.281 0.270 
Note: HADS - Hospital Anxiety and Depression Scale; SE - standard error. 
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4.4.5   Availability of covariate data 
The PROG-RES study offers access to a range of baseline data including 
general demographics, physical health status, pain characteristics, psychological 
and social factors. Two basic demographic characteristics were included, namely 
age and gender. Lee and Mercurio-Riley’s (2009) conceptual framework of factors 
found to be associated with psychological adjustment to chronic pain (mainly 
originating in musculoskeletal pain) (see Figure 1.1 on page 15), was used to 
select covariate data. Selected factors were based on principles of: availability in 
the PROG-RES study; parsimony; and limited instability of a factor (to reduce a 
confounding impact of transient states). Data on intrapersonal factors (e.g. self-
efficacy, personality, readiness) and stress factors (psychopathologies, movement 
avoidance, and pain-related stressor) was not available from the PROG-RES 
questionnaire data. As the selected frameworks are operational this is not 
detrimental to the result of analyses. 
 
Demographic characteristics  
Age (“date of birth”) and gender (“male/female”) were assessed using 
standard, single questions. The method of grouping age was categorised as per 
the primary analyses of this dataset (50-59, 60-69 and 70 years or above) (Mallen et 
al., 2007). This way consistency was maintained, without compromising the size of 
age groups. 
 
Pain condition (Lee and Mercurio-Riley’s, 2009) 
The type of pain conditions included in the PROG-RES study were non-
inflammatory musculoskeletal pain, including OA. No further distinction was made 
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by diagnosis, but information on the pain location and severity was available. 
Anatomical pain location was assessed with a manikin. This method involves 
using diagrams of front and back views of a body manikin on which participants 
are asked to shade the location of their pain with reference to pain experience in 
the past four weeks. There is evidence for the tool’s inter-rater reliability (Lacey et al., 
2005), but the validity warrants further investigation. Shaded manikins can also be 
used to assess the extent of pain (Lacey et al., 2005), which can be determined by using 
established criteria such as separating a manikin into 44 mutually exclusive 
anatomical areas and counting the number of pain sites (Lewis et al., 2002). This method 
has been used in this thesis. 
Pain severity was assessed using the 7-item Chronic Pain Grade (CPG) 
scale. This measure is a composite of pain intensity, disability days and 
interference with activities, which using scoring rules grades pain severity into 4 
hierarchical classes (Von Korff et al., 1992). The measure has good reliability and 
convergent and construct validity (Smith et al., 1997). Only selected CPG items were 
included in the analyses and full details are described in the next section. 
 
Functional dependence (Lee and Mercurio-Riley’s, 2009) 
The PROG-RES study collected data on pain-related interference with 
social, work, and daily activities, assessed with three items on the Chronic Pain 
Grade (Von Korff et al., 1992). Each of these questions refers to the past three months 
and are graded 0 (“no interference”) to 10 (“unable to carry on any activities”). The 
idea of using questions on pain interference with everyday life activities 
independently as a proxy for pain interference with activities is not novel in 
musculoskeletal pain research, with these items being previously extracted from 
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general measures such as the MOS SF-12 (Thomas et al., 2004). Scores computed from 
these CPG pain-interference items have not yet been directly tested for validity 
and reliability in persons with OA. However, the CPG pain-interference score 
showed increasing correlation with mental health, general health, emotional 
problems, energy, physical functioning, physical problems, social functioning and 
pain subscales on SF-36, at baseline in UK general practice patients (Smith et al., 1997). 
The CPG, which incorporates these items, has shown increasing associations with 
unemployment rate, functional limitation, depression, self-rated health, use of 
opiates, and pain-related doctor visits at a 1-year follow-up in primary care patients 
with chronic pain, including back pain (Von Korff et al., 1992).  
 
Stress processing factors (Lee and Mercurio-Riley’s, 2009) 
Information on participant’s use of selected pain coping strategies was 
available in the PROG-RES from an abbreviated version of the 2-item version of 
the Coping Strategies Questionnaire (CSQ) (Jensen et al., 2003). The selected coping 
strategies were: catastrophising, increased behavioural activities; coping self-
statements, and ignoring pain. The frequency with which participants report using 
each coping strategy is assessed by two items (8 items in total in the PROG-RES 
survey instrument) with response options indicated on a 7-point numerical rating 
scale ranging from 0 (“never do”) through 3 (“sometimes do”) to 6 (“always do 
that”), without a specified time frame. For the purpose of analyses conducted in 
this thesis the highest tertiles were calculated for each of the four pain coping 
strategies and used as cut-off points. This was based on the assumption that 
people are likely to try several coping strategies, with those strategies which are 
used often more likely to persist over time (Craighead & Nemeroff, 2004). Highest tertile 
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points estimated for the PROG-RES dataset, ranged from 4 to 5 across individual 
coping strategies, and thus, overlapped with answer options – between 
“sometimes do that” and “always do that” – suggestive of strategies being used 
often. Internal reliability and validity have been confirmed for each coping strategy 
(Rosenstiel & Keefe, 1983, Jensen et al., 2003). 
 
Socio-ecological factors (Lee and Mercurio-Riley’s, 2009)  
Six socio-ecological factors were assessed in the PROG-RES: living 
arrangements; marital status; availability of emotional and instrumental support; 
occupation and employment status. Living arrangements were assessed by asking 
participants whether they were living alone (“yes/no”), a question that has been 
widely used in research (e.g. Thomas et al., 2004, Iliffe et al. 2009). Marital status was assessed 
using a single question (Thomas et al., 2004), with six answer options available (“married/ 
single/ divorced/ widowed/ separated/ cohabiting”). As in previous research (Mallen et 
al., 2007), for the purpose of analyses described in subsequent chapters, marital 
status was dichotomised into married/cohabiting vs. not married/cohabiting. The 
availability of instrumental and emotional support were each assessed using one 
question asking participants if they had anyone providing emotional support and 
extra help (“no/yes/no need”) (Krumholz et al., 1998). Responses were dichotomised into 
no vs. yes/no need.  
Two free text questions on current or most recent job titles were utilised to 
establish socio-economic classes. As in previous research (Jordan et al., 2008) the 
National Statistics Socio-Economic Classification (NSS-EC) (Office for National Statistics, 
2010) was used for this purpose, with socio-economic status divided into four 
classes (managerial or professional/ intermediate/ routine or manual/ other (e.g. 
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house wives and never employed)) (Office for National Statistics, 2010, Jordan et al., 2008). 
Responses were grouped into manual/routine vs. not manual/routine for the 
purpose on statistical analysis. Current employment status was assessed in the 
PROG-RES by asking participants to classify their employment status as one of 
the following: “Employed/ not working due to ill health/ retired/ housewife/ 
unemployed/other”. Employment status was excluded from analyses conducted in 
this thesis, due to a high proportion of participants being retired. 
 
4.4.6   Completeness of the key data 
The levels of missing data amongst scales and items used in this thesis can 
be found in Table 4.4 overleaf. Levels of missing main outcome data were low, 
with a small decrease at the 6-month follow up point. Low levels of missing data 
were found for all covariate data, except for coping strategies. High levels of 
missing CSQ data (17.9%) have been previously reported in a community-dwelling 
sample of older adults (Kovacs et al., 2008), which the authors attributed to using the 
length of the survey. In the PROG-RES study, the CSQ appeared after the HADS. 
This suggests that the content of the CSQ questions could be perceived by some 
participants as sensitive. This finding is interesting, as it might suggest that in 
general the investigated sample was receptive to reporting depressive and anxiety 
symptoms, but less acceptant of considering their role in management of pain. 
 
 
 
 
 
152 
 
Table 4.4 Levels of missing data amongst items and scales at baseline, 3-
month, 6-month and 12-month follow-ups. 
 
Measure: Variable PROG-RES 
at baseline 
(n=502) 
% 
PROGR-RES at 
3- month follow-
up (n=398) 
% 
PROG-RES at 
6-month 
follow-up 
(n=370) 
% 
PROG-RES at 
12-motnh 
follow-up  
(n=329) 
 % 
HADS-D: depression 
symptoms 
1.2 1.5 3.5 1.2 
HADS-A: anxiety 
symptoms 
2.2 2.3 3.2 1.5 
HADS*: depressive and 
anxiety symptoms 
2.4 3.2 4.6 1.6 
Pain manikin: number of 
pain sites  
0.0 N/A N/A N/A 
CPG: Interference with 
daily activities 
4.0 
 
N/A N/A N/A 
CPG: Interference with 
work 
3.8 N/A N/A N/A 
CPG: Interference with 
social activities 
3.8 N/A N/A N/A 
CSQ-2: Catastrophising 9.0 N/A N/A N/A 
CSQ-2:  Coping self-
statements 
8.0 N/A N/A N/A 
CSQ-2: Coping by 
ignoring pain 
10.4 N/A N/A N/A 
CSQ-2: Coping by   
increased behavioural 
activities 
9.4 N/A N/A N/A 
1 item: Living 
arrangement 
0.4 N/A N/A N/A 
1 item: Marital status 0.8 N/A N/A N/A 
1 item: Instrumental 
support 
0.6 N/A N/A N/A 
1 item: Emotional support 1.0 N/A N/A N/A 
Occupation: socio-
economic class 
2.0 N/A N/A N/A 
Note: CPG - Chronic Pain Grade; CSQ - Coping Strategies Questionnaire; HADS - Hospital Anxiety and 
Depression Scale; N/A - data not used in this thesis; 
 * - missing either or both scores. 
 
 
4.4.7   Size of cohort and statistical power for analyses 
The 443 participant’s consenting to follow-up formed the basis for the 
analyses described in chapters five, six and seven. There is no minimum sample 
size specified for analyses of trajectories or medical records data. Nandi et al. 
(2009) identified 29 studies that assessed heterogeneity in the trajectories of 
depression and anxiety, with sample sizes of the identified studies ranging from 
157 to 11559. There are examples of comparable sample sizes used in identifying 
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trajectories of depression and anxiety in other medical populations, for instance in 
475 patients after myocardial infarction (Kaptein et al., 2006) and 398 patients with breast 
cancer (Dunn et al., 2011). There is a study in which medical records of 2294 patients 
were used (Kendrick et al., 2009). However, accessing medical records data appears 
challenging, consequently it is not uncommon to use samples ranging between 
150 and 200 (Dowrick & Buchan, 1995, Cully et al., 2009) or even less than 100 (Licht-Strunk et al., 
2009a). 
Subsequently, the sample size of the PROG-RES appears relatively small, 
but not exceptional, and thus adequate for the planned analyses. This will 
however, have implications for statistical analyses, including: the number of 
included covariates and categorisation of responses; the choice of the minimum 
required sample size for trajectories; as well as the choice of statistical tests for 
analyses of detection (where the sample size is expected to further decrease). 
 
4.5     CONCLUSIONS  
The PROG-RES data appears applicable to UK primary care patients with 
symptomatic OA. This has been achieved by recruiting older consecutive primary 
care consulters with non-inflammatory musculoskeletal pain including OA. As a 
longitudinal data source it enables the current research to meet objectives set out 
for the next chapters. The available time frame and multiple repeated measures 
allow investigation of the relapsing nature of psychological distress symptoms 
without compromising the power of analyses. The combination of self-report and 
linked medical record data is an advantage. 
The dataset enables access to the outcome variable and relevant covariate 
data, including the HADS recommended for primary care. The methods of 
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ascertainment have been previously used in research and are mostly 
standardised. In general, response, consent and follow-up rates for the 
investigated time were good and the key data is well-completed, with unlikely 
substantial response, consent and attrition bias.  
It is unclear to what extent the PROG-RES data is generalisable to people 
from ethnic minorities, patients registered with practice with below average QOF 
scores, and with mildly to moderately disabling pain. Participants with non-OA 
musculoskeletal pain were included in analyses conduced for the purposes of this 
thesis. These issues are critical considerations, rather than limitation per se. The 
relatively small sample size is a limitation of the PROG-RES dataset. This will be 
considered in further methodological decisions. 
As the PROG-RES study was not designed to meet the purposes set out for 
this thesis, it is not free of issues inherent to secondary data analyses, such as the 
choice of measures and availability of covariates. As described in chapter three, 
the HADS diagnostic use is limited without support from clinical expertise. 
Investigating the support and relationships with significant others might also 
benefit from taking a qualitative rather than a quantitative approach. The dataset 
does not allow for investigating intrapersonal and stress factors. Clinical factors, 
such as the effect of depression or anxiety treatments, belief in powerful others 
(e.g. doctors and medical treatment), patient attitude to recognition of symptoms 
and diagnosis of depression and anxiety and perceived need for help cannot be 
explored. 
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Chapter five: The course of anxiety and depression symptoms in 
older patients presenting to general practice with musculoskeletal 
pain  
 
Part 2: A latent class growth analysis 
  
5.1     INTRODUCTION 
Chapter two identified that anxiety and depression symptoms commonly 
coexist with OA or joint pain in older people. To date, much of this information 
comes from cross sectional general population surveys with less being known 
about the course of anxiety and depression symptoms over time. This chapter 
considers the course of depression and anxiety symptoms (determined using the 
HADS questionnaire) over a 12-month period. 
 
5.2    METHODOLOGICAL BACKGROUND 
5.2.1  Variable-centred vs. person-centred methods for identifying  the 
course of symptoms  
Muthén and Muthén (2000) highlight the differences between person-
centred and variable-centred approaches. The latter approach uses methods such 
as prevalence rates, structural equation modelling, regression or factor analysis. 
These types of analyses aim to explore the relationships between variables by 
identifying predictors of outcome variables or relationships between dependent 
and independent variables.  
In contrast, person-centred approaches such as cluster analysis, latent 
class analysis, and finite mixture modelling, explore the relationships among 
people by classifying them into distinct groups or categories based on individual 
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response patterns. The objective of this approach is to extract information about 
inter-individual differences in intra-individual changes over time (Nesselroade, 1988). The 
analysis presented in this chapter will focus on person-centred longitudinal 
approaches for two main reasons: a) It can provide information about individual 
patient outcomes over time and b) It can separate the effect of changes 
experienced over multiple time points by an individual patient from between-
subject differences at baseline (cohort effect). Person-centred analyses will be 
complemented with cross-sectional analyses (i.e. changes in the rate of symptom 
reporting), to enhance comparability with previous research. 
 
5.2.2  Choice of a person-centred method of identifying symptom trajectories 
Three methods specifically tailored for modelling longitudinal data, which 
allow the use of a single outcome variable at multiple time points to define discrete 
subgroups were compared: latent class growth analyses (LCGA), growth mixture 
modelling (GMM) and longitudinal latent class analyses (LLCA). Critical 
considerations were made between these techniques, including the work of 
Croudace et al. (2003), Feldman et al. (2009) and Peng (2011). Table 5.1 overleaf 
shows a summary of key considerations made during comparisons. 
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Table 5.1 Key critical considerations made to choose the method of 
modelling longitudinal data. 
 
Critical considerations Longitudinal 
latent class 
analyses 
(LLCA) 
Latent class 
growth 
analyses 
(LCGA) 
Growth mixture 
modelling  
(GMM) 
What is modelled? Patterns of 
state across 
time 
Patterns of 
change over 
time on a 
given variable 
Patterns of change 
over time on a 
given variable 
Does it capture changes 
across multiple time 
points? 
 
Yes Yes Yes 
Is time order accounted? 
 
No Yes Yes 
Is within-class variation not 
allowed? 
 
Yes Yes No 
Is user-friendly statistical 
software available? 
 
Yes Yes No 
Are standardised methods 
of assessing goodness of 
fit of the model available? 
 
Yes Yes Yes 
Other critical 
considerations? 
Comparable 
trajectories to 
LCGA with 
covariates. 
 
An increased 
risk of violation 
of local 
independence. 
 
Data is 
required to be 
normally 
distributed. 
Serves as a 
good starting 
point for 
conducting 
GMM.  
 
Data is 
required to be 
normally 
distributed. 
 
Difficult to interpret. 
 
Data is required to 
be normally 
distributed. 
 
Exploration for 
within-class 
predictors is 
enabled. 
 
 
Longitudinal class growth analysis (LCGA) was selected for the following 
key methodological reasons: a) it defines distinct groups of individuals who share 
patterns of progress b) it can be used for multiple re-measurement points and c) 
time order is allowed. LCGA also appeared to be feasible due to its relatively easy 
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interpretation, as variation within a cluster is not allowed and user-friendly 
statistical software is accessible (Latent GOLD).  
 
Statistical justification for performing LCGA 
The process of estimating symptoms over time, using group based 
modelling, has been described as “cumbersome” (Delucchi et al., 2004). In addition to 
clinical benefits, the need for using a person-centred method of analyses is 
considered justified, if progress of symptoms is expected to vary (Laursen & Hoff, 2006). 
In the investigated sample this could be judged by establishing a number of 
observed individual patterns of symptoms with a frequency of occurrence ≥1% 
(Peng , 2011). 
 
Details of the LCGA model for binary data  
LCGA, referred to as a group based modelling (Nagin, 2005), allows for 
grouping of individual differences in longitudinal trajectories into a finite number of 
latent clusters. It is a semi-parametric method (Nagin, 2005), with parameters 
describing individual level trajectories that are assumed to be distributed according 
to a multivariate normal distribution (Titterington et al., 1985). If this criterion is met, each 
cluster can be an estimate of true population parameters. If the data is not 
normally distributed, it should be accommodated by non-distribution based 
methods of model estimation, including categorical data (Bauer & Curran, 2003).  
  For binary data LCGA  assumes that variance in a sequence of a repeated 
binary observed variable C (in this case depression or anxiety) measured at t time 
points for a person i, can be explained by a latent categorical variable X (latent 
clusters) with j clusters and j=1,2,...J. The probability of having depression/anxiety 
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(        at each time point t=1,2,....T is estimated for each cluster. The estimation 
of having depression/anxiety (       , given being in cluster j, is made using the 
binary logit distribution (Nagin, p. 35, 2005). The model implemented in this study is 
embodied in the following equation: 
 
 (     |     
  
    
 
     
 
  
 
    
    
 
     
 
  
 
 
 
Where      represents depression/anxiety for a patient i at t time points (t =1,2,3,4), 
X is a latent binary variable with J categories (X=j, j=1,2,...J). For each cluster j, 
LCGA estimate the mean growth curve which is a function of time and contains 
growth factors such as intercept (  ) and linear slope (  
 
) and quadratic slope (  
 
) 
parameters; and    is the factor loading of time with specified time order of 
observed variables. In addition to the time-order effect, LCGA assumes that the 
variance and covariance estimates for the growth factors with each cluster are 
fixed and equal zero (Nagin, 2005). In other words growth factors of each individual i 
are equal to the mean growth factor for all individuals in cluster j (Peng, 2011).  
 
Classification of cluster membership  
A commonly used method for assessing cluster membership is the posterior 
membership probability derived from Baye’s theorem (see Peng, p. 41, 2011). Allocation 
of anxiety/depressive outcome to cluster j is based on maximum posterior 
probability with the sum of all posterior probabilities for each individual equal 1. In 
other words, following this assignment depressive/anxiety outcome is allocated to 
j-cluster where posterior probability is the highest.  
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Choosing the optimal model: judging goodness of fit   
There is not one single criterion for judging model fit. Instead, several indices of 
goodness of fit are available, the ones used in this study included: 
 Log-likelihood (LL) test was conducted with Latent GOLD to assess the 
differences in the log-likelihood between neighbouring LCGA models (Peng, 2011). 
The LL difference is denoted as log-likelihood ratio (LR) and is defined 
as  (      (     , where     refers to the log value of the maximised 
likelihood of the j-cluster model and   (     is the log value for the j-1 cluster’s 
maximised likelihood (Nylund et al., 2007). The change in the log-likelihood statistics 
from (j-1) to j-cluster model can be explored using a graphic representation, 
with a flattened pattern being indicative of little improvement in model fit by 
adding j+1 cluster.  
 Bayesian Information Criterion (BIC) was also used (Schwarz, 1978, Kass & Raftery, 
1995). The BIC for the log-likelihood for the model with j-cluster (   ), and is 
denoted as -2        (     , where Npar is the number of free parameters 
in the j-cluster model and n is the sample size. The number of clusters is 
increased until BIC minimum is found. With the lowest value of BIC indicating 
the optimal number of clusters (Nylund et al., 2007). 
 To obtain an additional indicator of improvement of fit by adding a class (j+1), a 
bootstrap estimate of the p-value related to the difference in log-likelihood 
value (-2LL-difference) between two models with j and j-1 clusters was 
implemented. The test is referred to as a Bootstrap likelihood ratio test 
(BLRT) (McLachlan & Peel, 2000). “Replication samples are generated from the 
probability distribution defined by the maximum likelihood estimates under H0 
(j-1-model)” (Vermunt & Magidson, p. 54, 2005). The p-value reflects the proportion of 
161 
 
samples with a larger BLRT statistic than the original one. P-value less than 
0.05 indicate a benefit of additional cluster for the model fit (McLachlan & Peel, 2000).  
 
Choosing the optimal model: practical evaluation 
It has been argued that in addition to judging goodness of fit, choosing the 
optimal model should encompass practical assessment of the data (Vermunt & Magidson, 
2002, Magidson & Vermunt 2004, Peng, 2011). Overall, the criteria for pragmatic evaluation as 
summarised by Peng (2011) were followed, including: 
 The optimal model is judged as optimal if had a large (near to 1) average 
posterior probability across clusters (e.g. 0.80, 0.10, 0.10), with no comparable 
average posterior probabilities for two or more clusters (e.g. 0.30, 0.30, 0.40). 
 Clusters in the optimal model are expected to have distinct characteristics.  
 There is no consensus on the minimum cluster size. The adequate size of a 
cluster depends on the aims and the sample size (Croudace et al., 2003, Clark et al., 2006, 
Nylund et al., 2007). In depression symptoms literature can be found examples of 
cluster size as small as 1.3% (Olino et al., 2010). Peng (2011) also adopted 1.0% 
minimum prevalence of class membership. The minimum cluster size for a 
dataset can be practically evaluated by observing of changes in models’ 
stability (Peng, 2011).  
 
Latent GOLD statistical software  
For the purpose of model estimation, Latent GOLD relies on the mean of 
the maximum likelihood (ML) estimator of item conditional probabilities (Vermunt & 
Magidson, 2005). Latent GOLD generates the expectation-maximisation (EM) algorithm 
with random start values. EM is argued to be stable, and thus, a good estimator for 
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obtaining a converged solution (Vermunt & Magidson, 2005), defined as models having no 
difficulties in optimising the likelihood function across random start values (Peng, 
2011). One of the possible problems with this method is the possibility that a 
converged solution might not be a global optimal solution (Vermut & Magidson, 2005), 
which is indicated by the number of times the largest log-likelihood is replicated 
(Peng, 2011). There are inconsistencies in numbers of replications indicating a local 
optimal solution (Múthen & Múthen, 2009, Hipp & Bauer, 2006). One recommended method of 
avoiding this problem is the use of multiple sets of starting values (Vermut & Magidson, 
2005), with the disagreement of the optimal number required (Múthen & Múthen, 2005, Hipp & 
Bauer, 2006). Based on previous investigations (e.g. Kreuter & Múthen, 2008, Croudace et al, 2003) 
Peng (2011) has recommended 1000 starting values in running through 100 
iterations. 
 
5.3      BACKGROUND 
5.3.1   Depression and anxiety symptoms over time: previous research in 
older adults and tertiary care patients with musculoskeletal problems 
No studies investigating symptoms change over time for anxiety and 
depression symptoms in older people with musculoskeletal pain could be 
identified. However, potentially informative evidence was identified from studies 
that used predominately variable-centred methods to investigate the course of 
depressive and anxiety symptoms in older adults and adults with pain in the 
community. Also of use are the results of a person-centred analysis of the course 
of depressive and anxiety symptoms in tertiary care patients with chronic pain 
(including musculoskeletal origin) and rheumatoid arthritis. 
There is robust evidence to suggest that the course of depression 
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symptoms in depressed older in the community is heterogeneous, and that 
symptoms often persist (Cole, 1999, Licht-Strunk et al., 2007).  A systematic review found that 
in adults aged 60-65 years with depressive disorders, 32.7% had clinically 
significant symptoms of depression at 24 months (Cole et al., 1999). Cole et al. (1999) 
conclude that depression in population and primary care older adults has a poor 
prognosis and is likely to be chronic and/or, relapsing. Estimated rates of 
depression at follow-up in older adults who were depressed at baseline are high, 
for example: 63.2% at one year (Prince et al., 1998), 61.2% at two years (Harris et al., 2006) 
and 50.4% (Beekman et al., 2001) and 51.7% (Schoevers et al., 2003) at three years. Licht-Strunk 
et al. (2009a, 2009b) have demonstrated that the recovery rates of major 
depressive disorder in primary care older adults are low, but that they do increase 
with time; from 20.5% at 6 months to 35% at 1 year, 60% within 2 years and 68% 
in 3 years. The authors estimated that the median duration of a major depressive 
episode in older adults was 18 months (Licht-Strunk et al., 2009b). In a separate set of 
analyses Licht-Stunk investigated trajectories of depression symptoms over 3 
years, in 296 older general practice attendees with major depressive disorder or 
sub-threshold depression assessed through at least four interviews (Licht-Strunk, 2008). 
The 4-cluster solution was chosen with 42% of patients having no depression 
symptoms from 6 months onwards (so-called Recovery cluster). The remaining 
three clusters include people who continued experiencing symptoms of depression 
for three years (Clusters: Persistent mild symptoms (35%), Chronic symptoms 
(18%), Chronic severe symptoms (5%)) (Licht-Strunk, 2008). 
Anxiety data in older adults is scarce, but one large study indicates that 
anxiety symptoms might also have heterogeneous outcomes and a tendency to 
persist over time (De Beurs et al., 2000, Schuurmans et al., 2005). Overall, 26% of participants 
164 
 
had HADS defined elevated anxiety symptoms at baseline. Of these 17.9% were 
found to be chronically anxious over a 3-year period. Of those without anxiety 
symptoms at baseline, 10.8% were found to become anxious by a 3-year follow-up 
(De Beurs et al., 2000). Based on the same sample, Schuurmans et al. (2005) have 
estimated that 23% of the participants with anxiety disorders at baseline had 
persistent anxiety at a 6-year follow-up, with 47% having sub-syndromal 
symptoms and 31% in full recovery. 
It is unclear if having OA or joint pain increases the risk of an adverse 
course of depressive and anxiety symptoms. Chronic physical illness (including 
OA) did not predict poor anxiety outcome in a large sample of older adults (De Beurs 
et al., 2000, Schuurmans et al., 2005). Cole et al.’s (1999) review concluded an inconsistent 
impact of physical illness on the course of depression. Supporting evidence is 
provided by a large study of adults with depressive and/or anxiety disorders and 
coexisting pain, recruited from community, general practice, and secondary mental 
health care settings (Gerrits et al., 2012). Overall, 61.5% of people with anxiety or 
depressive disorders at baseline still suffered from clinically significant symptoms 
depressive or anxiety at a 2-year follow-up (Gerrits et al., 2012). In addition, 43.5% had a 
chronic course with at least mild depression symptoms over the entire follow-up 
period. Pain location, high number of pain sites, ≥90 days of pain, using pain 
medication daily and a higher CPG score were significant predictors of depression 
symptoms at the 2-year follow-up (Gerrits et al., 2012). Pain for 90 days and a higher 
CPG were associated with having a chronic course, but after adjustment for the 
severity of depression/anxiety none of these factors were associated with ‘chronic 
course’ of depression symptoms. However, a large study of adults with early 
rheumatoid arthritis, recruited from rheumatology clinics, found that depressive or 
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anxiety symptoms can persist for over 10 years (Norton et al., 2011). A latent general 
mixture modelling identified four distinct trajectories of ‘psychological distress’, i.e. 
HADS defined depressive and/or anxiety symptoms, over 10 years including: low-
stable HADS score (68%), high-stable HADS score (12%), high-decreasing HADS 
score (9%) and low-increasing HADS score (11%) (Norton et al., 2011). People with high-
stable HADS symptoms had poor pain profile at baseline (i.e. more tender joints, 
higher pain intensity, early morning stiffness and higher disability) (Norton et al., 2011), 
but correlations between variables and their relative importance remains unclear 
as regression analyses were not performed. 
 
5.3.2   The importance of examining symptom change over time 
The clinical importance of examining symptom changes over time has been 
acknowledged in the field of mental health research (Solomon et al., 1997). For example, 
Lucassen et al. (2008) advocate a stepped model for the diagnosis of depression 
in primary care, including problem formulation by a patient, supporting the patient 
in problem solving, followed by a period of ‘active monitoring’ and re-assessment 
before deciding on the medical diagnosis and treatment. The understanding of the 
development of anxiety and depression over time and the associated factors is 
important for clinical decision making (NICE, 2009a). Clinicians have been found to 
experience difficulties in distinguishing between clinically significant cases and 
psychological problems of a transient nature (Barley et al., 2011, van Rijswijk et al., 2009). 
Consequently, it can help to estimate how many patients that due to the severity 
and persistence of their symptoms, might require medical intervention (Pedersen et al. 
2008). A further important aspect of investigating heterogeneity of trajectories of 
symptoms is the value of this information for the patient, including increased 
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awareness of prognosis, i.e. how it can influence their life and what interventions 
might be received (Dunn et al., 2006). 
 
5.4     RATIONALE OF THE STUDY 
Clinical guidelines recommend that the management of depression 
symptoms should include consideration for symptom trajectories (NICE, 2009a), yet to 
date limited information is available to support clinicians managing patients with 
OA in the community. Qualitative data on primary care practitioners’ views on the 
management of anxiety and depression in primary care (van Rijswijk et al., 2009) suggests 
that a limited understanding of the natural history of progress of depressive and 
anxiety symptoms acts as a barrier to their effective recognition and management.  
The analysis presented in this chapter will investigate the course of anxiety and 
depression symptoms in older people with musculoskeletal pain in primary care. 
 
5.5     AIM AND OBJECTIVES 
The overall aim of this study is to advance understanding of the persistence of 
depressive and anxiety symptoms in older primary care patients with OA. 
 
Specific objectives are: 
 To describe changes in the rate of HADS defined depressive and/or anxiety 
symptoms in older patients presenting to general practice with musculoskeletal 
pain 
 To identify discrete 12-month post-consultation trajectories of symptoms of 
anxiety and depression in older patients presenting to general practice with 
musculoskeletal pain 
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 To explore patterns of coexisting trajectories of symptoms of anxiety and 
depression 
 
5.6      METHOD 
5.6.1   Sample 
For consistency, descriptions of changes in the rate of symptom anxiety 
and depression symptoms reporting were based on the same samples used to 
choose the optimal models of depressive and anxiety trajectories. The choice of 
anxiety and depression models was based on participants who provided complete 
HADS anxiety and depression data (scores at all 4 time points). This way, 
individual HADS anxiety and depression values could be explored in each 
identified cluster. This would not be possible if a sample with missing values had 
been used, as the Latent GOLD software does not impute missing values.  
 
5.6.2   Statistical analyses: sampling frame effects on the main outcomes 
and person-related characteristics 
As a loss of the sample can raise concerns about the validity of the results 
(He, 2010) the possibility of selection bias was explored. The severity of anxiety and 
depression symptoms and baseline covariates included in subsequent chapters 
were described (using PASW version 18.0) for all baseline participants who 
consented to follow-up (n=443) and compared with individuals who provided 
complete HADS anxiety and depression data. The median was used for 
descriptive purposes of three baseline variables, due to non-normal distribution of 
scores (see Appendix D.1 on pages 374-376 for distribution of scores). 
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The effect of participants with complete data on the main outcome over time 
was further explored. The frequency of depressive and anxiety symptom severity 
were described for people who provided complete anxiety and depression data, 
and then compared against all participants (i.e. HADS anxiety and depression 
scores at 0-4 time points). To avoid multiple testing, statistical significance 
(established at the level of p<0.05) of differences between selected frequencies, 
was verified for the most apparent discrepancies (followed by testing all 
differences only if the most apparent differences were found to be statistically 
significant). For this purpose the Chi2 test or the Fisher’s exact test (when 
expected cell frequencies were less than 5) was used. Data analyses were 
performed using PASW version 18.0. 
 
5.6.3   Statistical analyses: analyses to describe changes in the rate of HADS 
defined depressive and anxiety symptoms 
The course of the rate of depressive and anxiety symptoms was explored in 
participants with complete depressive and anxiety data by describing changes in 
the frequencies of symptom reporting. Data was grouped by severity of symptoms 
at baseline and proportions of different severity of depression and anxiety over 
time 0-4 were described. Analyses were conducted in PASW version 18.0. 
 
5.6.4   Statistical analyses: discrete trajectories of depressive and/or anxiety 
symptoms 
One of the assumptions of LCGA is a multivariate normal distribution of 
parameters describing individual level trajectories (Titterington et al., 1985). As this 
assumption was not met in the investigated sample (Table 4.3. on page 146) a 
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non-distribution based method of model estimation was chosen – as suggested by 
Bauer and Curran (2003). It involved dichotomising data (HADS scores 0-7 vs. 
≥8). A practical reason for this decision was a relatively small sample size, 
examples of previous research (e.g. Licht-Strunk, 2008) allowed expecting that analyses 
based on continuous data were likely to result in a number of small clusters 
(increasing the risk of model instability). This decision is supported with clinical 
reasons, at least for depression, any elevated symptoms are of clinical relevance 
to UK primary care (NICE, 2009b). 
Individual patterns of binary depression and anxiety outcomes at 4 time 
points were generated (using PASW version 18.0). LCGA models were then 
estimated using Latent GOLD, using the mean of the maximum likelihood (ML) 
estimator of item conditional probabilities (Vermunt & Magidson, 2005). To generate the 
expectation-maximization (EM) algorithm, 1000 starting values running through 
100 iterations were used for LCGA models (Croudace et al, 2003, Kreuter & Muthén, 2008, Peng, 
2011). Three indicators of goodness of fit were generated with the Latent GOLD 
including: log-likelihood (LL), Bayesian Information Criterion (BIC) and Bootstrap 
likelihood ratio test (BLRT) (with statistical significance established at the level of 
p<0.05). The posterior membership probabilities derived from Baye’s theorem 
were then used to classify cluster membership (Peng, p. 41, 2011). Average posterior 
probabilities were then calculated for each cluster using PASW version 18.0. 
Sensitivity analyses, involving multiple repetitions of the above procedure, 
revealed that clusters of less than 5.0 % prevalence tended to be unstable, and so 
a minimum of ≥5.0% of cluster prevalence was decided for evolution of practical 
utility of a LCGA model. To investigate associations between the selected models 
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of depressive and anxiety trajectories, prevalence rates of the depression 
trajectories nested in the anxiety model were estimated. 
 
5.7      RESULTS 
5.7.1   Sample size 
Of the 443 baseline consenters for follow up, 293 (66% of the consenters) 
and 298 (67%) participants had HADS anxiety scores and HADS depressive 
scores respectively, available at all four time points.  
 
5.7.2   Sampling frame effects on the main outcomes and the covariates 
The possibility of bias resulting from omitting participants was explored. 
Outcome variables at baseline, and baseline covariates, were compared across 
the original sample of consenters for follow-up (n=443), samples used for choosing 
the optimal anxiety and depression models (n=298 and n=293 respectively). Table 
5.2 overleaf shows that differences were marginal indicating that substantial 
selection bias was unlikely. 
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Table 5.2 Baseline characteristics for consenters for follow-up and selected samples used in chapter six. 
 
  Anxiety symptoms Depression symptoms 
Factors Consented for follow-up 
n=443 
n (%) 
Complete data over time 
n=293 
n (%) 
Complete data over time 
n=298 
n (%) 
Main outcome:    
HADS-D    
    None (0 - 7) 315 (72.1) 215 (73.6) 219 (73.5) 
    Mild (8 - 10) 69 (15.8) 47 (16.1) 47 (15.8) 
    Moderate (11 - 14) 43 (9.8) 27 (9.2) 29 (9.7) 
    Severe (15 - 21) 10 (2.3) 3 (1.0) 3 (1.0) 
 
HADS-A 
   
     None (0 - 7) 234 (53.8) 151 (51.5) 149 (50.5) 
     Mild (8 - 10) 106 (24.4) 80  (27.3) 79 (26.8) 
     Moderate (11 - 14) 77 (17.7) 51(17.4) 19 (19.0) 
     Severe (15 - 21) 18 (4.1) 11 (3.8) 11 (3.7) 
     Missing 
 
8  - 3 
Pain characteristic: median (IQR)    
Number of pain sites (0-44) 
 
7 (9) 7 (9) 7 (9) 
Interference with daily activities (0-10) 6 (5) 5(4) 5 (10) 
Missing 
 
18 9 11 
Interference with work (0-10) 5 (5) 5 (4) 5 (5) 
Missing 
 
16 7 9 
Interference with social activities (0-10) 6 (5) 5 (5) 5 (5) 
Missing 
 
15 6 8 
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Table 5.2 cont. Baseline characteristics for consenters for follow-up and selected samples used in chapter 
six. 
  Anxiety symptoms Depression symptoms 
Factors Consented for  follow-up 
n=443 
n (%) 
Complete data over time 
n=293 
n (%) 
Complete data over time 
n=298 
n (%) 
Socio-ecological:    
Living alone:    
     No 361 (81.5) 244 (83.3) 244 (81.9) 
     Yes 80 (18.1) 49 (16.7) 54 (18.1) 
     Missing 2  - - 
Marital status:    
     Married 317(72.2) 217 (74.6) 217 (73.3) 
     Separated 6 (1.4) 4 (1.4) 4 (1.4) 
     Divorced 25 (5.7) 11(3.8) 12 (4.1) 
     Widowed 65 (14.7) 41 (14.1) 45 (15.2) 
     Cohabiting 16 (3.6) 11 (3.8) 11 (3.7) 
     Single 10 (2.3) 7 (2.4) 7 (3.7) 
     Missing 4  2 2 
Instrumental support:    
     Yes 348 (78.9) 225 (76.8) 229 (76.8) 
     No 35 (7.9) 25 (8.5) 27 (9.1) 
     No need 58 (13.2) 43 (14.7) 42 (14.1) 
     Missing 2  - - 
Emotional support:    
     Yes 385 (87.9) 255 (87.6) 260 (87.8) 
     No 21 (4.7) 11 (3.8) 11 (3.7) 
     No need 32 (7.3) 25 (8.6) 25 (8.4) 
     Missing 5  2 2 
Socio-economic status:    
     Managerial/professional 126 (28.4) 86 (29.4) 88 (29.5) 
     Intermediate 92 (20.8) 72 (24.6) 73 (24.5) 
     Routine/manual 162 (36.6) 103 (35.2) 103 (34.6) 
     Other 
 
63 (14.2) 32(10.9) 34 (11.4) 
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Table 5.2 cont. Baseline characteristics for consenters for follow-up and selected samples used in chapter 
six. 
   Anxiety symptoms Depression symptoms 
Factors Consented for follow-up 
n=443 
n (%) 
Complete data over time 
n=293 
n (%) 
Complete data over time 
n=298 
n (%) 
Demographic characteristics:    
Age    
 50-59 years 162 (36.6) 96  (32.8) 96 (32.2) 
 60-69 years 146 (33.0) 110 (37.5) 112 (37.6) 
 70-79 years   98  (22.1) 70  (23.9) 69 (23.2) 
 80+ years                  37  (8.3) 17 (5.8) 21 (7.0) 
 
Gender 
   
 Female gender 271 (61.2) 177(60.4) 182 (61.1) 
Coping^:    
  Catastrophising (0-6)    
    <(4) highest tertile  282 (69.1) 194 (70.8) 197 (71.1) 
    Missing 35  19 21 
    
Self-statements (0-6) 
   
     <(4.5) highest tertile  227 (55.5) 152 (54.5) 156 (55.1) 
     Missing 34  14 15 
 
Ignoring pain (0-6) 
   
     <(4) highest tertile  288 (71.8) 199 (73.7) 202 (73.7) 
     Missing 42  23 24 
 
Increased behavioural activities (0-6) 
   
     <(5) highest tertile  192 (47.2) 129 (47.3) 133 (47.8) 
     Missing 36  20 20 
Note: ^ - highest tertiles for coping are based on n=502; HADS - Hospital Anxiety and Depression Scale; IQR- inter quartile range. 
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The severity of anxiety symptoms at each time point for the 293 participants 
who provided complete anxiety data (i.e. HADS anxiety score at all 4 time points) 
were described and then compared against all participants (i.e. HADS anxiety 
score at 0-4 time points). Results are reported in Figure 5.1 and the associated 
table. The most apparent difference was found for the baseline proportions of 
people without anxiety symptoms (54.2% vs. 51.5%), yet this difference was 
statistically not significant (chi2= 1.04, p=0.308). This indicates that using complete 
anxiety data was unlikely to result in substantial selection bias. 
 
Figure 5.1 Prevalence of none, mild, moderate and severe anxiety symptoms over 
time, for all patients (a) and with complete anxiety data at 4 time points (b). 
 
 Severity of anxiety symptoms (HADS-A score) 
None (0-7) Mild (8-10) Moderate (11-14) Severe(15-21) Total 
sample  n (%) n (%) n (%) n (%) 
(a)  All participants^     
Baseline 272 (54.2) 117 (23.3) 83 (16.5) 20 (4.0) 502 
Month 3 225 (56.5) 86   (21.6) 62 (15.6) 16 (4.0) 398 
Month 6 210 (56.8) 76   (20.5) 57 (15.4) 15 (4.1) 370 
Month 12 188 (57.1) 78   (23.7) 45 (13.7) 13 (4.0) 329 
(b) Participants with complete anxiety data    
Baseline 151 (51.5) 80 (27.3) 51 (17.4) 11 (3.8) 293 
Month 3 169 (57.7) 65 (22.2) 49 (16.7) 10 (3.4) 293 
Month 6 171 (58.4) 60 (20.5) 52 (17.7) 10 (3.4) 293 
Month 12 175 (59.7) 65 (22.2) 42 (14.3) 11 (3.8) 293 
Note: ^- numbers do not add up to 100% due to missing data. 
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The severity of depression symptoms at each time point in the 298 
participants who provided complete depression data (i.e. HADS-D score at all 4 
time points) were described and compared against all participants (i.e. HADS-D 
score at 0-4 time points) (Figure 5.2 and the assistant table). The most apparent  
differences were in the proportions of severely depressed patients between the 
two groups, with Fisher’s exact tests indicating statistically non-significant 
differences at baseline (p=0.272), 3 (p=0.250), 6 (p=0.360) and 12 (p=0.508) 
months. 
 
Figure 5.2 Prevalence of none, mild, moderate and severe depression symptoms over 
time, for all patients (a) and with complete depression data all time points (b). 
 
Severity of depression symptoms (HADS-D score) 
 None (0-7) Mild (8-10) Moderate (11-14) Severe (15-21) Total 
sample  n (%) n (%) n (%) n (%) 
(a) All participants^    
Baseline 356 (70.9) 85 (16.9) 44 (8.8) 11(2.2) 502 
Month 3 283 (71.1) 72 (18.1) 31 (7.8) 6  (1.5) 398 
Month 6 270 (73.0) 49 (13.2) 31 (8.4) 7  (1.9) 370 
Month 12 246 (74.8) 47 (14.3) 26 (7.9) 6  (1.8) 329 
(b) Participants with complete depression data   
Baseline 219 (73.5) 47 (15.8) 29 (9.7) 3 (1.0) 298 
Month 3 222 (74.5) 52 (17.4) 23 (7.8) 1 (0.3) 298 
Month 6 227 (76.2) 44 (14.8) 24 (8.0) 3 (1.0) 298 
Month 12 229 (76.8) 39 (13.1) 27 (9.1) 3 (1.0) 298 
Note: ^- numbers do not add up to 100% due to missing data. 
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5.7.3   Changes in the rate of depression symptoms over time 
Changes in the frequencies of none, mild, moderate and severe symptoms 
of depression were calculated for patients with complete depression data (n=298) 
at four time points. This was done separately for those without depression at 
baseline (n=219), those with mild symptoms at baseline (n=47) and those with 
moderate or severe symptoms (n=32). Results can be found displayed in Figure 
5.3. 
 
Figure 5.3 Frequencies of symptoms severity at 0-4 time points for patients 
without depression at baseline. 
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5.7.4   Changes in the rate of anxiety symptoms over time 
Patients with complete anxiety data at four time points (n=293) were split 
into three groups by severity of symptoms at baseline, including none (n=151), 
mild (n=80) and moderate or severe symptoms (n=62). Frequencies of none, mild, 
moderate and severe symptoms were then calculated for each group at 3, 6 and 
12 months. Results can be found displayed in Figure 5.4. 
 
Figure 5.4 Frequencies of symptom severity at 0-4 time points for patients 
without anxiety at baseline.  
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5.7.5   Trajectories of depression symptoms 
Description of the identified individual patterns of depression symptoms 
Exemplars of the observed individual patterns of HADS-anxiety or -
depressive scores are displayed in Appendix D.2 (on page 376). Patterns of binary 
depression data were examined for the 298 participants with complete data (Table 
5.3), with 16 patterns revealed, including 12 patterns that occurred ≥1.0% of 
participants. The most prevalent was a pattern of no depression at four time points 
(58.4%), followed by the pattern of depression at all four time points (12.4%). 
Some other common patterns such as ‘1000’ (6.0%) and ‘0100’ (3.6%) represent 
participants who at baseline and 3 months reported depression symptoms and the 
symptoms resolved by the 12-month follow-up.  
 
Table 5.3 The observed patterns of numbers of participants with (1) and 
without (0) elevated symptoms of depression across the four time points 
(n=298). 
 
Pattern* N % 
0000 174 58.4 
1111 37 12.4 
1000 18 6.0 
0100 12 4.0 
0001 10 3.6 
0010 7 2.3 
0111 7 2.3 
1110 7 2.3 
1100 6 2.0 
1011 5 1.7 
1001 4 1.3 
0110 4 1.3 
0011 3 1.0 
0101 2 0.8 
1010 1 0.3 
1101 1 0.3 
Total 298 100% 
Note: *- A pattern is a combination of binary grouping of HADS-D scores 
(0= scores <8, 1= scores ≥ 8) with an order of baseline, 3 month, 6 month, 
12 month; These patterns comprise 67.3% of baseline respondents who 
consented for follow-up. 
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LCGA depression models 
1,2...5-cluster LCGA were fitted to binary depression data. The results are 
presented in Table 5.4. BIC was the lowest for the 2-cluster model solution. The 
bootstrap likelihood ratio test showed statistical significance between the 1 cluster 
and 2-cluster model (p<0.0001). This indicates the benefit of adding a cluster to a 
one cluster solution. Statistically non-significant effects were observed by 
comparing the 2- and 3-cluster models, 3- and 4-cluster models and 4-and 5-
cluster models. 
 
Table 5.4 Optimal number of clusters: goodness of fit statistics for LCGA 
models using 4 time points and complete binary depression data (n=298). 
 
Cluster LL Par. BIC(LL) BLRT (p-value) 
1 -666.4341 3 1349.9594 NA  
2 -492.9665 7 1025.8126 346.9352  (<0.0001) 
3 -488.7824 11 1040.2329 8.3680  (0.0680) 
4 -486.3759 15 1058.2081 4.8132  (0.1880) 
5 -486.2550 19 1080.7547 0.2418  (0.4400) 
Note: LL- Log-likelihood; Par.- no. of parameters; BIC- Bayesian Information Criterion; BLRT=bootstrap 
parametric likelihood ratio test: k- cluster model vs. (k-1) cluster (BLRT values are not available for single 
group models (NA)). 
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Figure 5.5 Log-Likelihood (LL) for 1-5 clusters depression LCGA models. 
 
 
 
Figure 5.5 shows that the log-likelihood (LL) flattened after the 2-cluster 
model, suggesting that the 2-cluster solution was optimal. Overall, assessment 
statistics for the LCGA model of binary depression outcome among eligible 
participants consistently suggest that the 2-cluster depression model is optimal. 
Following the results of the goodness of fit index, the 2-cluster depression 
model was explored by assessing the proportion of individuals in each cluster and 
the distinctiveness of clusters, using average posterior probability. The smallest 
cluster consisted of more than 5.0% of the total sample, and so had an adequate 
sample size. Both clusters had high average posterior probabilities (0.9779, 
0.9579) for belonging to the assigned cluster and average posterior probability of 
belonging to the other cluster were low (Table 5.5 overleaf). This indicates a good 
separation of cluster 1 from cluster 2. It was therefore decided that the 2-cluster 
model was the optimal LCGA model. 
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Table 5.5 Average assignment probabilities based on maximum posterior 
probability for 2 clusters LCGA model for complete depression data. 
 
Assigned  
Cluster 
n % Average posterior probabilities 
for each cluster 
1 2 
1 232 77.8 0.9779 0.0221 
2 66 22.2 0.0421 0.9579 
 
 
The proportions of observed patterns of depression symptoms in each 
cluster are listed in Table 5.6 overleaf. Cluster one (Figure 5.6 on page 183), 
referred to as the no depression symptom trajectory, comprised the majority of the 
sample (77.8%) and predominantly included people without depression symptoms 
or with transient depression symptoms over time. Cluster two (Figure 5.7 on page 
184), referred to here as the persistent depression symptom trajectory, included 
patients with persistent depression symptoms (22.2%). An individual with a 
reported ‘1’ or ‘0’ at three time points was likely to be classified to the same cluster 
as a person with the same outcome at all 4 time points. When ‘1’ or ‘0’ were 
recorded twice, a classification was associated with a sequence of occurrence, so 
that, when depression symptoms emerged at 3, 6 or 12 months a person was 
likely to be classified as persistently depressed. It can be argued that those 
patterns can form a separate, small group, but this was not subsequently 
supported by the goodness of fit statistics. 
 
 
 
 
182 
 
Table 5.6 Patterns* observed in clusters 1 and 2 of the 
2-cluster LCGA depression model. 
 
Cluster 1 
n=222 
(no depression) 
Cluster 2  
n=66 
(persistent depression 
symptoms) 
Pattern n      (%) Pattern n    (%) 
0000 174 (75.0) 1111 37 (56.0) 
1000 18   (7.8) 1110 7   (10.6) 
0100 12   (5.2) 0111 7   (10.6) 
0001 10   (4.3) 1011 5   (7.6) 
0010 7     (3.0) 0110 4   (6.1) 
1100 6     (2.6) 0011 3   (4.5) 
1001 4     (1.7) 0101 2   (3.0) 
1010 1     (0.4) 1101 1   (1.5) 
Note: *- A pattern is a combination of binary grouping of HADS-A scores with 
an order of baseline, 3, 6 and 12 month follow-ups. 
 
Figure 5.6 overleaf shows the proportion of patients in the no depression 
symptom trajectory, with different classifications of symptom severity across four 
time points being displayed. Amongst the 232 patients in this cluster, twenty nine 
had ‘mild or worse’ symptoms at baseline. This number has gradually decreased 
from 18 to 8 cases at 6 months, followed by remission of 6 individuals into mild 
symptom severity at 12 months (see Figure D.3.1 in Appendix D.3 on page 379 for 
observed trajectories in the no depression symptom trajectory).   
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Figure 5.6 2-cluster LCGA depression model: no depression symptom 
trajectory (n=232). 
 
 
 
Figure 5.7 overleaf shows the proportion of patients in the persistent 
depression symptom trajectory, with different classifications of symptom severity 
across four time point. No depression symptoms were reported by 16, 8, 3 and 11 
individuals at baseline, 3, 6 and 12 months respectively. Mild symptoms were 
reported by 27 (baseline), 35 (3 months), 38 (6 months) and 27 (12 months) 
patients. Moderate or severe symptoms were presented by 23, 23, 25 and 28 
patients at baseline and three follow-ups respectively (see Figure D.3.2 in 
Appendix D.3 on page 379 for observed trajectories in the persistent depression 
symptom trajectory). Overall this cluster is characterised by increasing severity of 
symptoms from baseline to 6 months, with a decrease at 12 months. More 
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specifically, from 38 with mild symptoms at 6 months, 8 people showed a 
decrease of symptoms to no symptoms at 12 months and 2 developed into 
moderate symptoms at 12 months. 
 
Figure 5.7 2-cluster LCGA depression model: persistent depression 
symptom trajectory (n=66). 
 
 
 
5.7.6   Trajectories of anxiety symptoms 
Description of the identified individual patterns of anxiety symptoms 
Patterns of binary anxiety data were examined in the 293 participants with 
complete data, with 16 patterns revealed, of which 15 had frequency of occurrence 
equal or greater than 1.0% (Table 5.7 overleaf). The most prevalent pattern was of 
no anxiety at four time points (37.5%), followed by the pattern of persistent anxiety 
symptoms at all four time points (24.9%). Some other common patterns include 
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participants who initially reported symptoms 1000 (6.5%) and the symptoms 
resolved by 6 months and also participants with consistent anxiety at all but at 6 
months (3.8%). 
 
Table 5.7 Observed patterns of numbers of participants with (1) and without 
(0) elevated symptoms of anxiety across the four time points (n=293). 
 
Pattern* n % 
0000 110 37.5 
1111 73 24.9 
1000 19 6.5 
1101 11 3.8 
0010 10 3.4 
1001 9 3.1 
1100 9 3.1 
0111 8 2.7 
0100 8 2.7 
0110 7 2.4 
1011 7 2.4 
1110 7 2.4 
1010 6 2.0 
0001 4 1.4 
0011 4 1.4 
0101 1 0.3 
Total 293 100% 
Note: *- A pattern is a combination of binary grouping of HADS-D 
scores (0= scores <8, 1= scores ≥8) with an order of baseline, 3 
month, 6 month, 12 month; 
These patterns comprise 66.1% of baseline respondents who 
consented for follow-up. 
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LCGA anxiety models 
1-,2-,...6-cluster LCGA models were fitted to binary anxiety data and the 
results of assessment statistics are listed in Table 5.8. The log-likelihood values 
flattened out after the 2-cluster model (Figure 5.8). The same 2-cluster anxiety 
model was supported by BIC.  
 
Table 5.8 Optimal number of clusters: assessment statistics for LCGA 
models using 4 time points and complete binary anxiety data (n=293). 
 
Cluster LL Par. BIC(LL) BLRT (p-value) 
1 -799.1747 3 1615.3900 NA  
2 -609.7106 7 1259.1825 378.9282 (<0.0001) 
3 -599.9943 11 1262.4704 19.4328 (<0.0001) 
4 -595.9153 15 1277.0332 8.1579 (0.0260) 
5 -595.8863 19 1299.6959 0.0580 (0.4800) 
6 -595.8683 23 1322.3805 0.0361 (0.7500) 
Note: LL- Log-likelihood, Par.- no. of parameters, BIC-Bayesian Information Criterion; BLRT= 
bootstrap parametric likelihood ratio test: k-cluster model vs. (k-1) cluster (BLRT values are not 
available for single group models (NA)). 
 
 
Figure 5.8  Log-Likelihood (LL) for 1-5 clusters anxiety LCGA models. 
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The bootstrap likelihood test (BLRT) suggested a statistically significant 
difference between 1- and 2-cluster models, 2- and 3-cluster models, and also 
between 3- and 4- cluster solutions (Table 5.8 on the previous page). This 
indicates the benefit of adding a cluster to a 1- cluster, 2-cluster and 3-cluster 
solutions, but BLRT has modest significance for step up from 3 to 4. Therefore, the 
average posterior probabilities and the proportion of people within each cluster, 
across 2-, 3- and 4-cluster models were investigated. 
The results of comparisons for the three clusters are presented in Table 5.9 
overleaf, with average posterior probability marked in bold. In each model the 
smallest cluster was greater than 5.0% suggesting adequate cluster size. Each 
cluster in the 2-cluster anxiety model had a high average posterior probability 
(0.9247, 0.9641), which suggest good classification distinctiveness. Similarly, the 
3-cluster model was characterised by high average posterior probability across all 
the clusters (0.8656, 0.9312, 0.8461). Clusters in the 4-cluster model had high 
posterior probability across three clusters (0.9528, 0.9048, 0.7847, 0.6392). 
Cluster-4 in the 4-cluster model had the lowest average posterior probability 
(0.6392), but average posterior probabilities for belonging to the other clusters 
were low (0.1721, 0.1260, 0.0628). Average posterior probabilities suggested that 
all three models were therefore considered acceptable. The results of the 
goodness of fit statistics together with average posterior probabilities, suggested 
that either the 3-cluster and 4-cluster anxiety models may be a more optimal 
solution than the 2-cluster anxiety model. Consequently, the decision was made to 
investigate characteristics of these two models. 
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3-cluster LCGA model 
 
 
4-cluster LCGA model 
 
 
Table 5.10 overleaf shows patterns observed in clusters 1-3 in the 3-cluster 
solution. The most prevalent pattern in the 3-cluster model was cluster one 
(40.6%), which included individuals without elevated anxiety symptoms over time, 
referred to as the no anxiety symptom trajectory (Figure 5.9 on page 191). Cluster 
two (29.4%) included people of whom the majority experienced elevated 
symptoms at one or two time points, referred to as the transient anxiety symptom 
trajectory (Figure 5.10 on page 192). Comparable in size cluster three (30.0%) 
consisted of people with persistent anxiety symptoms (i.e. at three or more time 
points), hence called the persistent anxiety symptom trajectory (Figure 5.11 on 
page 193). 
Table 5.9 Average assignment probabilities based on maximum posterior 
probability for LCGA models for complete binary anxiety data (n=293). 
 
2-cluster LCGA model 
 
Assigned 
 cluster 
n % Average posterior probabilities for each 
cluster 
1 2 
1 159 54.3 0.9641 0.0359 
2 134 45.7 0.0753 0.9247 
Assigned  
cluster 
n % Average posterior probabilities for each 
cluster 
1 2 3 
1 119 40.6 0.8656 0.1342 0.0002 
2 86 29.4 0.0272 0.8461 0.1267 
3 88 30.0 0.0000 0.0688 0.9312 
Assigned 
cluster 
n % Average posterior probabilities for each cluster 
1 2 3 4 
1 121 41.3 0.9528 0.0002 0.0381 0.0089 
2 87 29.7 0.0002 0.9048 0.0948 0.0001 
3 56 19.1 0.1196 0.0920 0.7847 0.0037 
4 29 9.9 0.1721 0.1260 0.0628 0.6392 
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Table 5.10 Patterns* observed in clusters 1-3 of the 3-cluster LCGA anxiety 
model. 
Cluster 1 
n=119 
(no symptoms) 
Cluster 2 
n=86 
(transient anxiety 
symptoms) 
Cluster 3 
n=88 
(persistent anxiety 
symptoms) 
Pattern n (%) Pattern n (%) Pattern n (%) 
0000 109 (91.6) 1000  19  (22.1) 1111 73 (83.0) 
0010 10   (8.4) 1101  11  (12.8) 0111 8   (9.1) 
  1001  10  (11.6) 1011 7   (8.0) 
  1100  9   (10.5)   
  0100    8   (9.3)   
  0110 7   (8.1)   
  1110 7   (8.1)   
  1010 6   (7.0)   
  0001 4   (4.7)   
  0011 4   (4.7)   
  0101 1   (1.2)   
Note: * A pattern is a combination of binary grouping of HADS-A scores with an order of baseline, 3, 6 and 
12 month follow-ups. 
 
 
Patterns observed in clusters 1-4 in the 4-cluster solution are displayed in 
Table 5.10 (alternatively see Figure D.4.4 in Appendix D.4 on page 381). The 
three most prevalent clusters in the 4-cluster model were the 3 clusters nested in 
the 3-cluster model. The fourth cluster in the 4-cluster anxiety model, included 10 
individuals previously allocated to cluster one in the 3-cluster model (pattern: 
0010), 11 from cluster two in the 3-cluster model (7 with pattern: 0110; 4 with 
pattern: 0011) and 8 from cluster three in the 3-cluster model (pattern: 0111). The 
4th cluster in the 4-cluster model appeared to have no distinct trajectory of anxiety 
symptoms, so the 3-cluster model was considered the optimal solution. 
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Table 5.11 Patterns* observed in clusters 1-4 of the 4-cluster LCGA anxiety 
model. 
Cluster 1 
n=121 
(no symptoms) 
Cluster 2 
n=87 
(persistent anxiety 
symptoms) 
Cluster 3 
n=56 
(transient anxiety 
symptoms) 
Cluster 4 
n=29 
(?) 
Pattern n (%) Pattern n (%) Pattern n (%) Pattern n (%) 
0000 109 (90.1) 1111 73 (84.0) 1000 19 (33.9) 0010 10 (34.5) 
0100 8   (6.6) 1110 7  (8.0) 1101 11 (19.6) 0111 8   (27.6) 
0001 4   (3.3) 1011 7  (8.0) 1001 10 (17.9) 0110 7   (24.1) 
    1100 9   (16.1) 0011 4   (13.8) 
    1010 6   (10.7)   
    0101   1    (1.8)   
Note: * - A pattern is a combination of binary grouping of HADS-A scores with an order of baseline, 3, 6 and 12 
month follow-ups. 
 
Figure 5.9 overleaf shows the proportions of patients with the no anxiety 
symptom trajectory and different classifications of symptoms over time. Anxiety 
symptoms were absent over time, except for 10 participants with anxiety 
symptoms at 6 months follow-up respectively. For individual patterns of HADS-
anxiety scores over time see Figure D.5.1 in Appendix D.5 (on page 382). 
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Figure 5.9 3-cluster LCGA anxiety model: no anxiety symptom trajectory 
(n=119). 
 
 
 
Figure 5.10 overleaf shows the proportions of patients with the transient 
anxiety symptom trajectory and different classifications of symptoms over time. 
Numbers of patients without anxiety symptoms increased from 26 individuals at 
baseline to 43 at 3 months and 62 at 6 months, this was followed by a decrease to 
56 patients not anxious at 12 months. When elevated, symptoms of anxiety were 
predominantly mild (see Figure D.5.2 in Appendix D.5 on page 382 for individual 
patterns of HADS-anxiety scores over time). 
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Figure 5.10 3-cluster LCGA anxiety model: transient anxiety symptom 
trajectory (n=86). 
 
 
 
Figure 5.11 on the next page shows the frequencies of persons with the 
persistent anxiety symptom trajectory with different classifications of symptom 
severity across four time points. ‘Mild or worse’ anxiety symptoms were reported in 
all but 8 persons at baseline and 7 persons at 3 months. Approximately half of 
patients with anxiety had moderate or severe symptom at baseline (n=47), 3 
months (n=50), 6 months (n=52) and 12 months (n=46). Figure D.5.3 (in Appendix 
D.5 on page 383) presents individual HADS-anxiety scores over time for 
participants in this cluster. 
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Figure 5.11 3-cluster LCGA anxiety model: persistent anxiety symptom 
trajectory (n=88).  
 
 
 
 
 
5.7.7   Observed patterns of associations between anxiety and depression   
symptom trajectories 
 In total, 91.6% of those with the no anxiety symptom trajectory and 80.2% 
of those with the transient anxiety symptom trajectory respectively, had the no 
depression symptom trajectory. Of those in the persistent anxiety symptom 
trajectory 46.6% also were classified to the persistent depression symptom 
trajectory. Together, participants with persistent anxiety symptoms were more 
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likely to have persistent depression symptoms than individuals with either of two 
other anxiety trajectories. Table 5.12 shows the frequencies of the no depression 
symptom trajectory and the persistent depression symptom trajectory across 
persons with the three anxiety trajectories. 
 
Table 5.12 Frequencies of the two depression trajectories across the three 
trajectories nested in the 3-cluster LCGA anxiety model. 
 
 3-cluster LCGA anxiety model 
2-cluster LCGA 
depression model 
 
No anxiety 
symptoms            
n=119  
 n (%) 
Transient anxiety 
symptoms 
 n=86   
 n (%) 
Persistent anxiety 
symptoms  
 n=88 
   n (%) 
No depression 
symptoms 
n=232 
 
10 (91.6) 69 (80.2) 46 (52.3) 
Persistent depression   
symptoms 
n=66 
8    (6.7) 14 (16.3) 41 (46.6) 
Note: Due to missing data: 6 participants from the LCGA anxiety model had no depression trajectory 
assigned, 11 participants from the LCGA depression model had no anxiety trajectory assigned. 
  
 
 
 
5.8    DISCUSSION 
5.8.1  Summary of key findings 
Depression course in older primary care patients consulting with musculoskeletal 
pain 
Overall, 10% of people without depression symptoms (i.e. HADS score 0-7) 
at baseline reported having elevated depression symptoms at the 1-year follow-up. 
In total, more than half of participants with elevated depression symptoms at 
baseline still had depression symptoms at the 1-year follow-up. An analysis of 
discrete person-centred trajectories of depression symptoms showed that 63% of 
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older patients with musculoskeletal pain, who were depressed at baseline, had 
persistent depression symptoms for at least one year. In total, two distinct 
longitudinal trajectories were identified; 77.8% of patients were classified as 
having the no depression symptom trajectory and 22.2% had the persistent 
depression symptom trajectory. Across four time points, between 35% and 42% of 
patients with the persistent depression symptom trajectory, reported ‘moderate or 
worse’ depression symptoms (HADS-D score ≥11). 
 
Anxiety course in older primary care patients consulting with musculoskeletal pain 
Only 11% of people without anxiety symptoms (HADS-A score 0-7) at 
baseline reported elevated anxiety symptoms at the 1-year follow-up. In total, over 
half of participants with elevated anxiety symptoms at baseline still had symptoms 
at the 1-year follow-up. In contrast with depression symptom trajectories, finding 
the optimal model of anxiety symptom trajectories posed some challenges. The 
LCGA anxiety model with three distinct trajectories was selected as being the best 
model. This model, included: no anxiety symptom (41%), transient anxiety 
symptoms (29%) persistent anxiety symptom (30%) trajectories. Overall, 56% of 
older patients with musculoskeletal pain, who were anxious at baseline, had 
persistent anxiety symptoms for at least one year. At each time point half of the 
participants with in the persistent anxiety symptom trajectory reported ‘moderate or 
worse’ anxiety symptoms. Participants with transient anxiety symptoms had 
typically mild anxiety symptoms at baseline, followed by a symptom decrease or 
fluctuation at follow-ups. Persons with persistent anxiety symptoms were more 
likely to have coexisting persistent depression symptoms. 
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5.8.2  Comparison with previous research 
Course of depressive and anxiety symptoms   
Comparison with previous research is challenging as the majority of 
reported estimates of symptom persistence are based on two repeated measures 
and use variable-centred methods of analyses. In anticipation of this problem, 
latent class growth analyses were complemented with analyses of changes in the 
rate of HADS-anxiety and HADS-depression symptoms over time. 
Fifty nine percent of older primary care attendees with musculoskeletal pain 
and coexisting ‘mild or worse’ depression symptoms at baseline still had 
depression at the 1-year follow-up. This proportion is broadly comparable to the 
estimates previously reported for older adults in the community. For older adults 
depressed at baseline, prevalence rates of those continuing depressed at 1 year 
was 63.2% (Prince et al.,1998), at 2 years was 61.2% (Harris et al., 2006) and at 3 years were 
51.7% (Schoevers et al., 2003) and 50.4% (Beekman et al., 2001). In one study, 35% of older 
primary care patients recovered from major depression at 1 year (Licht-Strunk et al., 
2009a). This prevalence rate was comparable to recovery rate from ‘moderate or 
worse’ depression symptoms (34.4%) found in the current study. 
Likewise, observed changes in the rate of anxiety symptoms over time are 
broadly comparable to results of previous relevant studies in older adults in the 
community. In the current study, 71% of patients with elevated anxiety symptoms 
at baseline remained anxious at 1 year, and 11% of participants who were not 
anxious at baseline had elevated anxiety symptoms at 1 year. These estimates 
are comparable with those reported for older community-dwelling adults (De Beurs et 
al., 2000). More specifically, 69% of participants found to have persistent anxiety 
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symptoms at a 3-year and 14.5% of participants who were not anxious at baseline 
found to have elevated anxiety symptoms at 3 years (De Beurs et al., 2000).  
Due to a lack of research, comparisons for anxiety trajectories were not 
possible. However, the results of latent class growth analyses of depression 
symptoms can be compared with Licht-Strunk’s (2008) study in older general 
practice attendees. They used a comparable methodology to LCGA -longitudinal 
latent class analyses (LLCA). In contrast to the current study, it consisted 
exclusively of patients with depressive disorders at baseline and LLCA analyses 
were based on raw depression symptoms scores. A recovering group (42%), 
without elevated symptoms after 6 months follow-up was identified. In addition, 
three groups of patients with continuous elevated depression symptoms, of 
different severity mean scores (mild (35%), moderate (18%), severe (5%)). Putting 
on one side differences between the two studies, arguably they both identified two 
fairly stable groups of trajectories (characterised by elevated symptoms presence 
or their lack). Based on baseline depressive score, 63% of older primary care 
attendees with musculoskeletal pain had elevated depression symptoms over 
time. A similar frequency (60%) of persistent elevated depression symptoms over 
time was found in older primary care attendees by Licht-Strunk’s (2008). Licht-
Strunk (2008) found through univariable multinomial logistic regression analyses 
that the presence of a chronic somatic illness increases the risk of moderate or 
severe chronic symptoms, but no differences between the presence of one or 
more somatic co-morbidity emerged. The impact of the existence of one somatic 
comorbidity was found to be no longer significant when entered into a multivariable 
multinomial logistic regression. However, this could be partially affected by 
inclusion of as many as 11 factors in comparison of relatively small groups (125, 
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104 and 67 participants). Consequently, the impact of OA presence on depressive 
and anxiety symptoms persistence in older adults still warrants clarification. 
 
5.8.3  Strengths and limitations 
Strengths 
This investigation has two major strengths that go beyond the strength of 
the data source used here (i.e. PROG-RES study that was delineated in chapter 
four). A key strength is the relevance to primary care. This study offered the 
specific attention to anxiety symptoms, which to date has been under-research 
and overlooked in primary care guidance. Analyses focused on symptom severity, 
as in UK primary care, depression symptom severity plays an important part in the 
choice of intervention (NICE, 2009b). Furthermore, anxiety and depression symptoms 
were ascertained with the HADS, which is a standardised questionnaire 
recommended for primary care usage (discussed in chapter three).  
The research method is also a major strength of this study. The analyses of 
depressive and anxiety symptoms over time went beyond the usual description of 
the course of prevalence rates by presenting an in-depth exploration of 
trajectories. The identification of trajectories involved the use of a standardised 
person-centred method that is tailored to longitudinal data analyses and relatively 
easy to interpret.  
 
Limitations  
As highlighted by Shuurmans et al. (2005) in the context of the course of 
anxiety disorder in older adults, dichotomisation of the main outcome can lead to 
the loss of information. Nevertheless, the dichotomisation can be argued to make 
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data summarisation more efficient, and allows for simple interpretation of results. 
In the current study dichotomisation of HADS depression and anxiety scores 
simplified the task of grouping and describing observed trajectories, in each 
discrete trajectory. It can be argued that dichotomisation is appropriate only when 
a threshold effect value is meaningful (Abdollel et al., 2002). To date, biomarkers for 
clinically significant depressive and anxiety symptoms are lacking and diagnostic 
accuracy of all depressive and anxiety questionnaires is widely criticised. 
Consequently, it seems that meaningfulness of cut-off points on any depression 
and anxiety questionnaires is unlikely to represent ‘truly’ existing thresholds. 
However, given that NICE depression guidance for patients with a chronic physical 
health problem refers to mild depression symptoms (NICE, 2009b), using HADS score 
≥8 was a justified choice.  
 
5.8.4   Research Implications  
There are several research implications arising from this study. Validation 
analyses would be beneficial, particularly for the anxiety model, using a larger 
sample size and software such as MPlus 3, which is less user-friendly than the 
Latent GOLD software, but promises some useful improvements in the estimation 
of LCGA models (Nagin & Tremblay, 2001).  
 As demonstrated in chapter four, the sample included in this analysis is 
comprised of patients with a range of symptoms, with those with mild levels of 
disability and those with new episodes of depressive and anxiety symptoms 
underrepresented. As a result, the prevalence rates of individuals with emerging 
symptom trajectories could be underestimated. Future research would benefit from 
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performing analyses stratified by the length of endured pain with balanced 
proportions of new episodes and recurring musculoskeletal pain.   
GMM, LLCA and LCGA allow for the prediction of cluster membership by 
adding covariates to the model. Whilst this can add information, entering 
covariates to the model can substantially change the parameters of the trajectories 
of the outcome variable (Feldman et al, 2009).  Nylund and Masyn (2008) (cited in Feldman et al., 
2009) suggest that the number of clusters should be determined using an 
unconditional model (without covariates). Feldman et al. (2009) suggest that 
entering covariates should be based on a strong theoretical basis, with careful 
consideration of the interpretability and parsimony of the model. As such, a limited 
number of covariates should be entered, yet no specific number has been 
suggested. Consequently, including covariates was deemed unsuitable for the aim 
of this study, which intended to explore patterns of anxiety and depression. The 
next logical step in analyses of trajectories identification of person-related 
characteristics associated with different trajectories (e.g. Croudce et al., 2003, Licht-Strunk, 2008, 
Olino et al., 2010). This type of study has a potential to inform mechanisms underlying 
coexistence of OA and problems of depression and anxiety. Identified 
characteristics may also inform future research in targeting patients at risk of poor 
anxiety depression prognosis.  
 
5.9     CONCLUSIONS 
The current study is the first exploration of the course of depressive and 
anxiety symptoms in older patients consulting primary with musculoskeletal pain. 
Two discrete trajectories of depression symptoms over the 12-month period were 
identified, namely no depression symptom (78%) and persistent depression 
201 
 
symptom (22%) trajectories. Three anxiety trajectories were identified, including no 
anxiety symptom (41%), transient anxiety symptom (29%) and persistent anxiety 
symptom (30%) trajectories. With the aim of identifying cases with persistent 
depressive or anxiety problems in people who have mild to severe depressive and 
anxiety symptoms at the initial presentation, it can be anticipated that 63% and 
56% of these individual will have persistent depressive and anxiety symptoms 
respectively over the 12-month period. 
Older people with musculoskeletal pain experiencing persistent symptoms 
of anxiety and depression are most likely to be suffering adverse effects of 
depressive and anxiety symptomology. This highlights the importance of enquiring 
about addressing these problems in persons with OA. Further research is needed 
to understand factors associated with trajectories of anxiety and depression 
symptoms.  
 
 
 
 
 
 
 
 
 
 
202 
 
Chapter six: The course of anxiety and depression symptoms in 
older patients presenting to general practice with musculoskeletal 
pain  
 
Part 3: Factors associated with the course of anxiety and 
depression symptoms 
  
6.1      INTRODUCTION 
Chapter five described the course of depression and anxiety symptoms. 
This was determined based on the HADS questionnaire over the 12-month period 
in older patients presenting to general practice with musculoskeletal pain. Three 
anxiety and two depression symptom trajectories were identified. As described in 
research applications of the previous chapter (p. 199), this chapter includes the 
next logical step following identification of these trajectories. The identified growth 
trajectories are analysed for associations with person-related characteristics, using 
the baseline covariate data described in section 4.4.5 (p. 147). 
 
6.2     RATIONALE OF THE STUDY 
In addition to the fear-anxiety avoidance (Asmundson et al., 2004), misdirected-
problem solving (Eccleston & Crombez, 2007) and the acceptance-commitment (Hayes et al., 
1999) models, this thesis contends that coexisting anxiety and depression might 
reflect the multifactorial process of adjustment to OA symptoms. Empirical 
application of these theoretical concepts in subpopulations of people with 
musculoskeletal pain or OA specifically highlight the importance of pain severity, 
pain impact on daily functioning and coping strategies (Hayes et al., 1999, De Vlieger et al., 
2006, Kratz et al., 2007, Scopaz et al., 2009, Flink et al., 2011). Lee and Mercurio-Riley’s (2009) review 
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of the contributing factors in psychosocial adjustment to chronic pain of 
musculoskeletal origin, identified as many as six groups of associated factors. 
Factors included pain conditions, functional dependence, stress, stress 
processing, intrapersonal factors and socio-ecological factors (see Figure 1.1 on 
page 15 for more specific examples). Less is known about which of these factors 
can predict poor depressive and anxiety prognosis in depressed/anxious adults 
with musculoskeletal pain. Cole et al.’s (1999) review suggests that a number of 
factors have been analysed for their association with poor prognosis of depression 
at 24 months in elderly community, where no factors appeared to be 
predominately associated with poor depression outcome. Licht-Strunk et al. (2007) 
concluded in a comprehensive systematic review (including assessment of the 
strength of association) found that general practice evidence provides no strong 
support for any predictors of a poor depression outcome. “In community studies 
strong evidence [i.e. defined as significant associations with poor outcome in at 
least two high-quality cohorts] was found for older age, the presence of chronic 
somatic diseases, the presence of functional limitations, higher baseline 
depression level and an external locus of control” (Licht-Strunk et al., p. 172, 2007). To the 
best knowledge of the author of this thesis, there is no review of predictors of the 
curse of anxiety in elderly community or primary care.  
The previous chapter described the first exploration of the course of 
depressive and anxiety symptoms in older primary care patients with 
musculoskeletal pain. Inclusion of patient-related characteristics in developed 
models was deemed methodologically unsuitable for the aim of that study. The 
next logical step, however, is a need to identify person-related characteristics 
associated with different trajectories, particularly with persistent depressive and 
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anxiety symptoms. This type of study has two important implications. Firstly, it has 
the potential to inform mechanisms underlying the coexistence of OA and 
depression and anxiety responses. This might be used to inform the usefulness of 
psychological interventions that target mechanisms underlying adjustment to pain. 
The second important implication is that identified characteristics may also inform 
future research in targeting patients at risk of poor anxiety depression prognosis. 
For example, according to Licht-Strunk et al. (2009a), identifying patients at a high 
risk of persistent depressive and anxiety symptoms may improve their 
management and subsequent prognosis. This is also supported by clinical 
guidelines for depression that recommend for the recognition of patients with a 
chronic physical health problem a need of depression management to be based 
on contextual factors (NICE, 2009b). To date limited information is available to support 
recognition of the problem of depression in the community-dwelling patients with 
OA and improving the situation for anxiety seems even more demanding. The 
analysis presented in this chapter will investigate person-related characteristics 
associated with the course of anxiety and depression symptoms in older people 
with musculoskeletal pain in primary care. 
 
6.3     AIM AND OBJECTIVE 
The overall aim of this study is to advance understanding of the persistence of 
depressive and anxiety symptoms in older primary care patients with OA. 
 
Specific objective is: 
 To examine their unique relationships of the course of anxiety and depression 
symptoms with baseline person-related characteristics 
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6.4      METHOD 
6.4.1   Sample 
Analyses of factors associated with the identified trajectories were based on 
samples with at least three HADS depression scores and anxiety scores (i.e. at 3 
time points). This decision was grounded in statistical reasoning, that is, to 
improve the statistical power of regression analyses by increasing sample sizes. 
Selected were only participants with at least three HADS scores to avoid potential 
misclassifications of cluster membership, as minimum three repeated measures 
are required for conducting LCGA (Nagin, 2005, Vermunt & Magidson, 2005, Peng, 2011). 
 
6.4.2   Statistical analyses 
Each participant was assigned a cluster membership by re-estimating the 
selected optimal models (i.e. the 2-cluster LCGA depression model and the 3-
cluster LCGA anxiety model). The Latent GOLD handled missing data in the 
likelihood fashion, i.e. models were estimated using full-information maximum 
likelihood, which uses all available data and assumes that data are missing at 
random (Vermunt & Magdison, 2005). Characteristics of the trajectories of depressive and 
anxiety symptoms were then compared with the reference models.  
To explore factors associated with trajectories, in line with previous studies 
(e.g. Olino et al., 2010), descriptive statistics and logistic regression was used to compare 
the baseline characteristics of participants with different anxiety and depression 
trajectories. The baseline characteristics of interest were discussed in details in 
chapter four (section 4.4.5 on page 147). A brief summary is provided in Table 6.1 
overleaf.  
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Table 6.1 Baseline variables of interest. 
 
Variables  Measure Time 
frame 
Type Format used in 
logistic regression 
analyses  
Age Date of birth ≥ 50 
years 
ordinal 1=50-59 years 
2=60-69 years 
3=70+ years 
Availability of 
support: 
Emotional 
Instrumental 
1 item (yes/no/no 
need) 
not 
specified 
categorical 0=yes/no need 
1=no 
Coping strategies: 
Catastrophising 
Increased 
behavioural 
activities 
Coping self-
statements 
Ignoring pains 
sensations 
II-items version of 
the CSQ  
(the average of 2 
items) 
never-
always 
categorical below vs. above the 
highest tertile  
0=score <4 
1=score ≥4 
0=score < 5 
1=score ≥5 
0=score <4.5 
1=score ≥4.5 
0=score <4 
1=score ≥4 
Gender Female/male N/A categorical 0=male 
1=female 
Living 
arrangement 
Living alone (yes/no) currently categorical 0=not living alone 
1=living alone 
     
NS-SEC 
classification 
Job title  current 
or most 
resent 
categorical 0=managerial and  
professional/ 
intermediate/other  
1=routine and 
manual   
Number of pain 
sites 
Manikin past 4 
weeks 
count  0-44 pain sites 
Pain interference 
with: 
a) daily activities 
b) work/housework 
c) social and 
family      
          activities 
1 item each on 
Chronic pain Grade 
past 3 
months 
continuous 0-10 NRS 
Marital status Married/ single/ 
divorced/ widowed/ 
separated/ 
cohabiting 
currently categorical 0=married/cohabiting 
1=divorced/widowed/ 
separated/single 
Note: CSQ- Coping Strategies Questionnaire; NRS- numerical rating scale; NS-SEC- National Statistics-
Socioeconomic Class 2010 classification. 
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Where the LCGA analysis suggested a 2-cluster solution was the best fit 
(i.e. the 2-cluster depression model), binary logistic regression (r≤2 categories) 
was used to compare participants in each of the two trajectories. Where the LCGA 
solution included more than 2 clusters (i.e. the 3-cluster anxiety model), 
multinomial logistic regression was used, which can handle polytomous responses 
(r>2 categories). STATA version 11.1 was used for both logistic regression 
(command logit) and multinomial logistic regression (command mlogit, rrr). 
Regression analyses commenced with the preliminary identification of a 
potential problem of multicollinearity between analysed covariates (i.e. a highly 
correlated predictors that provide redundant information about the response). This 
involved conducting a variance inflation factor (VIF) analysis in STATA (command 
vif). For each factor tolerance and VIF estimates were estimated, where a 
tolerance of less than 0.10 and a VIF more than 10 (or ≤0.20 and ≥5.0 
respectively) indicated a possibility of multicollinearity (O’Brien et al., 2007). A univariate 
regression analysis was then conducted and variables with apparently wide 95% 
CI were identified and excluded. Following this, univariate regression analyses 
were conducted with and without a variable suspected of causing multicollinearity 
and changes in odds ratios and 95% CI of the remaining covariates were 
examined. If multicollinearity was confirmed the variable was excluded from further 
regression analyses. 
In order to preserve a model’s parsimony (Nagin, 2005) for the remaining 
covariates a method a backward elimination regression analyses were used with 
0.10 entry probability based on the Wald test. Statistical significance (for variables 
that met the entry probability) was established at the level of p<0.05. Backward 
elimination logistic regression analyses were used for the 2-cluster LCGA 
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depression model, with the no depression symptom trajectory as a reference 
group. The 3-cluster LCGA anxiety model was analysed using backward 
elimination multinomial logistic regression. Analyses commenced with the no 
anxiety symptom trajectory acting as a reference group, then the model was re-run 
using the persistent anxiety symptom trajectory as a reference category. To 
maintain consistency, odds ratios for both logistic and multinomial logistic 
regression were reported. As STATA allows for calculating relative risk ratios 
(RRRs) but not ORs, STATA technical guideline (Gould, 2000) was searched for 
solutions and e-mail communication with STATA support team was made. Both 
suggested that RRRs can be used as ORs. To confirm it multinomial logistic 
regressions in PASW version 18.0 were conducted, which provides estimates of 
ORs for multinomial logistic regression. Similar estimates were produced by sets 
of statistical software.  
 
6.5      RESULTS 
6.5.1   Sample size 
In total, 368 participants (83% of consenters for follow-up) had at least three 
HADS depression and anxiety scores recorded. Average posterior probabilities 
and cluster characteristics of the 2-cluster LCGA depression and the 3-cluster 
LCGA anxiety models are reported in Appendices E.3 (on page 387) and E.4 (on 
page 388) respectively. 
 
6.5.2   The issue of multicollinearity in regression analyses 
The result of the VIF test for multicollinearity suggests possible co-linearity 
with one of the factors. The ‘pain interference with daily activities’ variable resulted 
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in a VIF of 5.19 (see Table E.1.1 in Appendix E.1 on page 384), suggesting a need 
for further exploration of the impact of this variable on the models. A problem of 
multicollinearity was detected for the pain interference with daily activities variable, 
as indicated by changes in ORs after excluding this variable from saturated logistic 
regression and multinomial logistic regression analyses. Furthermore, the lack of 
emotional support variable had wide confidence intervals (95% CI 0.51, 29.7 and 
1.27, 27.38) (see Tables E.2.1 and E.2.2 in Appendix E.2 on pages 385-386), 
related to a small number of people who reported a lack of emotional support 
(n=16). Therefore, although both variables were included in descriptive analyses, 
they were excluded from backward elimination logistic regression and backward 
elimination multinomial logistic regression analyses. 
 
6.5.3   Baseline factors associated with the depression symptom trajectories  
Descriptive statistics 
Demographic and clinical characteristics at baseline for the 368 patients 
with at least three HADS-D scores, split by the no depression symptom trajectory 
(n=272) and the persistent depression symptom trajectory (n=96) are shown in 
Table 6.2 overleaf. Participants with persistent depression symptoms appear to 
have more widespread pain and pain interference with work, social activities and 
daily activities, when compared to participants in the no depression symptom 
trajectory. The persistent depression symptom trajectory included higher 
proportions of participants: with perceived lack of emotional and instrumental 
supports, coping by catastrophising, females, the oldest adults, people without a 
partner, living alone, performing routine or manual work. Participants in the no 
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depression symptom trajectory had higher frequency of people coping by self-
statements, ignoring sensations and increased behavioural activities. 
 
Table 6.2 Individual characteristics across people with no depression 
symptoms and persistent depression symptoms (n= 368). 
 
Baseline covariates No depression 
symptoms 
n= 272, n (%) 
Persistent depression 
symptoms 
n= 96, n (%) 
Age:  50-59 102 (37.5)  25 (26.0) 
         60-69 101 (37.1) 26 (27.1) 
         70+ 69   (25.4) 45 (46.9) 
Gender:   
        Females 163 (59.9) 63 (65.6) 
        Males 109 (40.1) 33 (34.4) 
Lack of partner   
        Married/cohabiting 215 (79.0) 68 (70.8) 
        Single/divorced/widowed/separated 55   (20.2) 27 (28.1) 
Number of pain sites Median (IQR) 6.0     (8) 10.5 (14) 
Pain interference with activities: Median (IQR)   
        Social and family activities 5.0     (5) 8.0   (3) 
        Daily activities 5.0     (4) 8.0   (2) 
        Work  4.0     (4) 8.0   (3) 
Living alone   
        Yes 
        No 
41   (15.1) 
230 (84.6) 
21 (21.9) 
75 (78.1) 
Catastrophising†    
         Not high  
 
196 (72.1) 
 
42 (43.8) 
         High 60   (22.1) 45 (46.9) 
Coping by increased behavioural activities†  
         Not high    
         High       
 
114 (41.9) 
147 (54.0) 
 
45 (46.9) 
38 (39.6) 
Coping by ignoring pain sensations† 
        Not high    
        High 
 
187(68.8) 
71  (26.1) 
 
57 (59.4) 
24 (25.0) 
Coping by using self-statement† 
        Not high 
        High 
 
137 (50.4) 
126 (46.3) 
 
53 (55.2) 
33 (34.4) 
Availability of emotional support 
        Yes/no need 
         No 
 
265 (97.4) 
4.0     (1.5) 
 
84 (87.5) 
12.0 (12.5) 
Availability of instrumental support 
        Yes/no need 
         No 
 
255 (93.8) 
16   (5.9) 
 
78 (81.3) 
18 (18.8) 
Manual/ routine work 
         No 
         Yes  
 
175 (64.3) 
97   (35.7) 
 
59 (61.5) 
37 (38.5) 
Note: IQR- inter quartile range;  
Percentage does not always add up to 100% due to missing data;  
†- Subscales from 2-item Coping strategy Questionnaires (Jensen et al., 2003). Cut-offs represent heights 
tertile in the current sample (see p. 206). 
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Logistic regression analyses 
Fourteen covariates were entered into the backward elimination model with 
a total number of 314 participants included in the analysis. Among the variables 
that failed to meet p<0.10 entry probability were: living alone (p=0.819), gender 
(p=0.742), coping by using self-statements (p=0.753) and ignoring pain sensations 
(p=0.762), the manual/routine work class (p=0.479), pain interference with work 
(p=0.461), a lack of partner (p=0.379), age 60-69 (p=0.291).  
Variables that met the entry probability threshold are listed in Table 6.3 
overleaf. Relative to the no depression symptoms trajectory, for every unit 
increase in pain interference with social activities the risk of having the persistent 
depression trajectory increased by 30.0%. With pain in one additional anatomical 
site, the risk of having persistent depression symptoms increased by 8.0%. 
Patients age 70 years or above demonstrated 3 times the risk of having the 
persistent depression symptom trajectory, as opposed to the no depression 
symptom trajectory. Pain coping with increased behavioural activities was 
protective of persistent depression symptoms (OR: 0.51). Participants with a lack 
of instrumental support had 4 times the risk of being in the persistent depression 
symptom trajectory, but wide confidence intervals indicate that the impact should 
be interpreted with caution. 
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Table 6.3 Backward elimination logistic regression analysis of baseline covariates: no depression symptom^ vs. 
persistent depression symptom trajectories. 
 
Baseline covariates Odds Ratio SE p 95% CI 
Age 70 years or older 3.03 1.01 0.001 1.57 5.84 
Interference with social activities (0-10) 1.30 0.09 <0.0001 1.14 1.48 
Lack of instrumental support 3.63 1.87 0.013 1.32 9.98 
Number of pain sites (0-44) 1.08 0.02 <0.0001 1.04 1.13 
Catastrophising 1.85 0.62 0.066 0.96 3.55 
Coping by increased behavioural activities 0.51 0.16 0.037 0.27 0.96 
Note: CI- confidence intervals; SE- standard error; ^- the reference group; 
The model was statistically significant (LL= -127.77, LR chi
2 
(6) = 85.00, Prob > chi p<0.001, Pseudo R
2
= 0.25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
213 
 
6.5.4   Baseline factors associated with the anxiety symptom trajectories  
Descriptive statistics  
Table 6.4 Individual characteristics across three anxiety trajectories (n= 368). 
 
Baseline covariates No anxiety 
symptoms 
n=142 
n (%) 
Persistent anxiety 
symptoms 
n=123 
n (%) 
Transient anxiety 
symptoms 
n=103 
n (%) 
Age: 50-59 45 (31.7) 53 (43.1) 31 (30.1) 
        60-69 58 (40.8) 30 (24.4) 38 (36.9) 
        70+ 39 (27.5) 40 (32.5) 34 (33.0) 
Gender:    
        Males 64  (45.1) 39 (31.7) 38 (36.9) 
        Females 78  (54.9) 84 (68.3) 65 (63.1) 
Lack of partner    
        Married/cohabiting 113 (79.6) 92 (74.8) 79 (76.7) 
        Single/divorced/widowed/ 
        separated 
28   (19.7) 30 (24.4) 23 (22.3) 
Number of pain sites Median (IQR) 5.5 (6.0) 9.0 (12.0) 8.0 (10.0) 
Pain interference with activities: 
Median (IQR) 
   
         Social and family activities 4.0 (5.0) 7.0 (4.0) 6.0 (5.0) 
         Daily activities 4.0 (5.0) 7.0 (3.0) 6.0 (4.0) 
         Work  3.0 (5.0) 6.0 (4.0) 6.0 (4.0) 
Living alone    
          Yes 
          No 
21   (14.8) 
120 (84.5) 
23   (18.7) 
100 (81.3) 
16 (15.5) 
87 (84.5) 
Catastrophising†    
           Not high  
 
119 (83.8) 
 
55 (44.7) 
 
63 (61.2) 
           High   14 (9.9) 56 (45.5) 36 (35.0) 
Coping by increased behavioural 
activities†  
           Not high 
           High 
 
 
53 (37.3) 
80 (56.3) 
 
 
60 (48.8) 
50 (40.7) 
 
 
49 (47.6) 
51 (49.5) 
Coping by ignoring pain sensations† 
           Not high 
           High 
 
99  (69.7) 
34  (23.9) 
 
76 (61.8) 
31 (25.2) 
 
69 (67.0) 
28 (27.2) 
Coping by using self-statement†                      
           Not high 
           High 
 
70  (49.3) 
66  (46.5) 
 
67 (54.4) 
45 (36.6) 
 
54 (52.4) 
45 (43.7) 
Availability of emotional support 
           Yes/no need 
           No 
 
139 (97.9) 
1     (0.7) 
 
110 (89.4) 
12   (9.8) 
 
100 (97.1) 
3     (2.9) 
Availability of instrumental support 
           Yes/no need 
           No 
 
137 (96.5) 
4     (2.8) 
 
102 (82.9) 
21   (17.1) 
 
95  (92.2) 
8    (7.8) 
Manual/ routine work: 
           No 
           Yes 
 
100 (70.4)  
42   (29.6) 
 
78  (63.4) 
45  (36.6) 
 
54  (52.4) 
49  (47.6) 
Note: IQR- inter quartile range;  
Percentage does not always add up to 100% due to missing data;  
†- Subscales from 2-item Coping strategy Questionnaires (Jensen et al., 2003). Cut-offs represent heights 
tertile in the current sample (see p. 206). 
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Table 6.4 on the previous page shows characteristics at baseline for the 
368 patients with at least three HADS-A scores, stratified by people with no 
anxiety symptoms (n=142), persistent anxiety symptoms (n=123), transient anxiety 
symptoms (n=103). 
By comparison with other trajectories, patients with the no anxiety symptom 
trajectory had: a lower number of pain sites, lower levels of pain interferences with 
activities, lower frequency of coping by catastrophising, higher frequency of coping 
with increased behavioural activities and a lower proportion of people performing 
manual/routine work. Individuals within the no anxiety symptom trajectory had 
lower proportions of the youngest patients and those without support than people 
with persistent anxiety symptoms. The no anxiety symptom trajectory was 
characterised by a higher proportion of males than the persistent anxiety symptom 
trajectory. 
Contrasting the transient anxiety symptom trajectory with the persistent 
anxiety symptom trajectory, suggest that participants with the latter: more often 
were in the youngest and the oldest age groups, were more often females, had a 
higher number of pain sites, higher levels of pain interference with daily and social 
activities, more often lived alone, more often coped by catastrophising, less 
frequently coped by increased behavioural activities and self-statements, had less 
perceived support and less frequently performed manual/routine work. 
 
Multinomial logistic regression analyses 
Fourteen covariates were entered into a backward elimination multinomial 
regression model, where the no anxiety symptom trajectory served as a reference 
group. A total number of 316 persons were included in the analysis. Variables that 
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did not meet the 0.10 entry probability included: living alone (p=0.997), coping with 
self-statements (p=0.886), a lack of a partner (p=0.847), pain interference with 
social activities (p=0.832), age 70 years or above (p=0.541), gender (p=0.387), 
ignoring pain sensations (p=0.223), and age 60-69 (p=0.113).  
Table 6.5 overleaf shows the results of a comparison between persons with 
no anxiety symptoms and persistent anxiety symptoms. Catastrophising and pain 
interference with work were the most prominent covariates. Catastrophising 
increased the risk of the persistent anxiety symptom trajectory (OR: 4.14). For 
every unit increase in the pain interference with work variable the odds of having 
the persistent anxiety symptom trajectory increased by 21%. With pain in one 
additional anatomical site, the odds of having the persistent anxiety symptom 
trajectory increased by 8%. Pain coping with increased behavioural activities 
decreased the risk of having persistent anxiety symptoms (as indicated by an odds 
ratio 0.40). Individuals reporting a lack of instrumental support had seven times the 
risk of having persistent anxiety symptoms, but a wide confidence interval 
indicates that more data needs to be collected to confirm the impact of this 
covariate. 
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Table 6.5 Backward elimination multinomial logistic regression analysis of 
baseline covariates: no anxiety symptom^ vs. persistent anxiety symptom 
trajectories. 
 
Baseline covariates Odds Ratio SE p 95% CI 
Catastrophising 4.14 1.61 <0.0001 1.93 8.87 
Coping by increased behavioural 
activities 
0.40 0.13 0.004 0.22 0.75 
Lack of instrumental support 6.99 4.93 0.006 1.75 27.85 
Manual/routine work 1.33 0.44 0.387 0.70 2.54 
Number of pain sites (0-44) 1.08 0.03 0.001 1.03 1.14 
Pain interference with work (0-10) 1.21 0.07 0.001 1.08 1.36 
Note: CI- confidence intervals; SE- standard error; ^- the reference group;  
The model was statistically significant (LL=-342.39, LR chi
2 
(18) = 106.42, Prob > chi p<0.001, Pseudo 
R
2
=0.13). 
 
 
 
         Table 6.6 overleaf shows the results of a comparison between participants 
with no anxiety symptoms and transient anxiety symptoms. For every unit increase 
in the pain interference with work variable the odds of having the transient anxiety 
symptom trajectory increased by 19%. Catastrophising increased the likelihood of 
the transient anxiety symptom trajectory, being reflected in an odds ratio 2.79. 
Performing manual/routine work is a prominent factor, increasing the likelihood of 
having transient anxiety symptoms (as reflected in an odds ratio 2.39, 95% CI 
1.31, 7.60, p=0.005). With pain in one additional anatomical site, the odds of 
having the persistent anxiety symptom trajectory increased by 6%. Pain coping 
with increased behavioural activities had a borderline effect on cluster 
membership. 
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Table 6.6 Backward elimination multinomial logistic regression analysis of 
baseline covariates: no anxiety symptom^ vs. transient anxiety symptom 
trajectories. 
 
Baseline covariates Odds Ratio SE p 95% CI 
Catastrophising 2.79 1.08 0.008 1.30 6.00 
Coping by increased behavioural 
activities 
0.55 0.17 0.050 0.31 1.00 
Lack of instrumental support 1.54 1.25 0.598 0.31 7.60 
Manual/routine work       2.39 0.74 0.005 1.31 4.37 
Number of pain sites (0-44) 1.06 0.03 0.013 1.01 1.11 
Pain interference with work (0-10) 1.19 0.07 0.002 1.06 1.33 
Note: The model was statistically significant (LL=-342.39, LR chi
2 
(18) = 106.42, Prob > chi p<0.001, Pseudo 
R
2
=0.13); ^- the reference group’; SE- standard error; CI- confidence intervals. 
 
 
As described in section 6.4.2 (on page 205), backward elimination 
multinomial regression analyses were repeated using the same variables, with the 
persistent anxiety symptom trajectory serving as a reference category. Table 6.7 
presents the results of comparisons with the transient anxiety symptom trajectory. 
No significant differences were found between the two groups. Preforming 
manual/routine activities had a borderline effect on cluster membership, with odds 
ratio suggesting a possibility of manual/routine increasing the likelihood of 
transient anxiety symptoms.  
 
Table 6.7 Backward elimination multinomial logistic regression analysis of 
baseline covariates: persistent anxiety symptom^ vs. transient anxiety 
symptom trajectories. 
 
Baseline covariates Odds 
Ratio 
SE p 95% CI 
Catastrophising  0.67 0.22 0.281 0.77 2.43 
Coping by increased behavioural 
activities 
1.37 0.40 0.698 0.59 2.21 
Lack of instrumental support 0.49 0.24 0.144 0.18 1.28 
Manual/routine work 1.80 0.54   0.051 1.00 3.24 
Number of pain sites (0-44) 0.98 0.02 0.273 0.94 1.02 
Pain interference with work (0-10) 0.98 0.06 0.758 0.88 1.10 
Note: CI- confidence intervals; SE- standard error; ^- the reference group;  
The model was statistically significant (LL=-342.39, LR chi
2 
(18) = 106.42, Prob > chi p<0.001, Pseudo 
R
2
=0.13). 
 
218 
 
6.6     DISCUSSION 
6.6.1   Summary of key findings 
In comparison with individuals with the no depression symptom trajectory, 
persons with persistent depression symptoms were more likely to be older, report 
more widespread pain, have more severe pain interference with social activities, 
less often cope with their pain through increased behavioural activities and more 
frequently perceive a lack of instrumental support.  
When compared to individuals with the no anxiety symptom trajectory, 
participants with persistent anxiety symptoms were more likely to catastrophise, 
report more widespread pain and more severe pain interference with work, and 
less often cope with their pain through increased behavioural activities. They also 
appeared to perceive a lack of instrumental support, but more data is needed to 
confirm the impact of this variable. In comparison with individuals with the no 
anxiety symptom trajectory, those with transient anxiety symptoms were more 
likely to catastrophise, be members of manual or routine occupational class, report 
more widespread pain and more severe pain interference with work. Persons with 
persistent anxiety symptoms and transient anxiety symptoms did not significantly 
differ across any of the explored variables. 
 
6.6.2   Comparison with previous research 
No direct causal inferences can be made with regards to the models of 
adjustment to pain - three of which were introduced in section 1.3.2 (p. 12). 
Nevertheless, this study is potentially informative for understanding the elements 
involved in the process of adjustment to musculoskeletal pain in older people.  
In the fear-anxiety-avoidance model (Asmundson et al., 2004), pain characteristics 
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play an important role in the adjustment to pain. This is especially true for initial 
pain severity and disability, where the latter is preceded by anxiety responses and 
followed by depressive responses. Indeed, having a higher number of pain sites 
and higher pain interference with activities are associated with a poorer 
adjustment to musculoskeletal pain in older adults which is reflected in persistent 
anxiety and depression symptoms. The current study expands the understanding 
of the role of specific aspects of disability and depressive and anxiety responses. It 
suggests that the level of interference with social activities is associated with 
persistent depression symptoms and levels of interferences with work with 
persistent anxiety symptoms. The importance of pain characteristics on depressive 
and anxiety symptoms over time has also been highlighted in the studies by 
Gerrits et al. (2012) and Norton et al. (2011). 
Fear-anxiety-avoidance (Asmundson et al., 2004), misdirected-problem solving 
(Eccleston & Crombez, 2007)  and acceptance-commitment (Hayes et al., 1999) models suggest 
that coping strategies play a key role in the process of adjustment to pain. In the 
fear-anxiety-avoidance model having catastrophic thoughts reflects the appraisal 
of a painful stimulus as a threat, which is likely to result in anxiety and then 
depressive responses (Asmundson et al., 2004). The current study found that 
catastrophising is indeed associated with persistent anxiety symptoms, though 
less strongly associated with persistent depression symptoms. Interestingly, a 
protective role of increased behavioural activities offers an important insight into 
difficulties with adjustment to musculoskeletal pain in older adults with 
musculoskeletal pain, which is reflected by persistent depressive and anxiety 
symptoms. Misdirected-problems solving (Eccleston & Crombez, 2007) and acceptance-
commitment (Hayes et al., 1999) models suggest that people with pain who direct their 
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efforts to continuing to engage in meaningful life activities (as opposed to focusing 
on a reduction of pain) are likely to better adjust to pain. It can be argued that older 
people with musculoskeletal pain who adjusted to pain by focusing on achievable 
goals (i.e. increased activities), showed better adjustment to pain which is 
reflected in a decreased chance of persistent anxiety and depression symptoms.  
In modern psychological models of pain adjustment (Hayes et al., 1999, Asmundson et 
al., 2004, Eccleston & Crombez, 2007), socio-ecological aspects seem to be viewed as 
contextual factors, but their exact roles are unspecified. The impact of socio-
ecological factors was limited in older people with musculoskeletal pain, as 
instrumental support was only found to be weakly associated with persistent 
anxiety depressive and anxiety symptoms. Emotional support, marital status, living 
alone and socio-economic status were found to have no significant impact on 
persistent depression and anxiety trajectories. Interestingly, performing 
manual/routine work was associated with transient anxiety symptoms. Arguably 
the risk of symptoms persistence can be expected to be greater for those with 
lowest employment status. However, evidence suggests that the risk of anxiety is 
associated with the level of control at work that was found to be unevenly 
distributed across types of occupations (Griffin et al., 2002). Unfortunately, no information 
on levels of control in the sample investigated in this thesis is available. However, 
older people with musculoskeletal pain and transient anxiety symptoms did not 
significantly differ in coping by increased behavioural activities form individuals 
without anxiety symptoms over time (albeit the difference was borderline). 
Previous research found a positive, moderate and significant association between 
levels of coping by increased behavioural activities and perceived pain control 
(Haythonthwaite et al., 1998). It could be then argued that a sense of control over pain may 
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differentiate between transience and persistence of anxiety symptoms, but this 
hypothesis warrant further investigation.  
Older age may serve as a predisposing factor to poor adjustment to pain 
and there are several plausible explanations for its association with persistent 
depression symptoms. One possible explanation is that a risk of multimorbidity 
increases with age (Marengoni et al., 2011). Another possibility is that older people appear 
to be less likely to consult their GPs for depressive and anxiety problems and 
therefore have limited access to relevant treatment (RCGP, 2006). The exact reason 
for the observed association between older age and the persistence of depression 
symptoms in primary care patients with musculoskeletal pain remains unclear. 
 
6.6.3   Strengths and limitations 
Strengths 
One strength of this study is a careful selection of variables. Considered 
were person-related characteristics, which are of potential use to identification of 
patients with OA and the problem of anxiety or depression. Most of the variables 
were selected on the basis of being listed in the conceptual framework of risks or 
resistance factors in adjustment to chronic pain. All of the variables have been 
considered in modern psychological theorises for their role in adjustment to pain 
(described in section 1.3.2 on page 12). When feasible, included variables were 
categorised, to provide clear interpretation of their impacts. The issue of 
multicoollinearity was addressed. Overall, both implications for primary care 
practice and statistical parsimony of models and were considered. 
In estimating the impact of these variables, this study went beyond purely 
descriptive approach by using regression analyses. This type of analyses allows 
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for probabilistic interpretation of the relationship between the likelihood of an event 
occurring and a set of conditions (Rindskopf, 2004).  
 
Limitations  
This study does not allow for making inferences about the impact of intra-
personal factors and clinical factors on the trajectories of depressive and anxiety 
symptoms. Furthermore, only limited conclusions can also be drawn about socio-
ecological factors. Examples of intrapersonal factors previously found to be 
associated with the course of depressive and anxiety disorder symptoms 
respectively include locus of control (Beekman et al., 2001, Harris et al., 2006) and neuroticism 
(De Beurs et al., 2000, Schuurmans et al., 2005). Concerning clinical factors, the PROG-RES 
study was not designed to make inferences about treatment effectiveness. 
Subsequently, the current study excluded on-going depression and anxiety 
treatment information, to prevent making false conclusions about treatment 
effectiveness. A lack of effect of treatment on the subsequent course of depressive 
and anxiety symptoms in primary care patients has been previously shown (Penninx et 
al., 2011, Licht-Strunk et al., 2009b).  As argued by Beekman et al. (2001) in many studies 
depression treatment data is available, but unused, due to the majority of older 
patients being untreated for this problem. The PROG-RES study did not include 
information on wider social network or the quality of interaction yet these variables 
may be important exploratory factors. In previous research, general social 
participation (Prince et al., 1998) and a large social network size (De Beurs et al., 2000) were 
significant predictors of a decreased likelihood of depressive disorders and anxiety 
symptoms respectively at follow-up in older adults.  
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6.6.4   Implications  
Implications for clinical practice 
The findings in chapter five and in this chapter focus attention towards three 
important clinical implications. One of the key finding reported in the previous 
chapter was establishing that people who consult primary with musculoskeletal 
pain who also have mild to severe depressive and anxiety symptoms at the initial 
presentation, 63% and 56% respectively, will have persistent symptoms over a 12-
month period. Approximately 65% and 50% of individuals in these two groups had 
mild depressive and anxiety symptoms respectively, at each time point. Together 
with analyses of factors associated with cluster membership, this highlights the 
importance of enquiring about depressive and anxiety symptoms over time, 
including persistent mild forms that can also be associated with detrimental 
consequences for well-being.  
Clearly a better understanding the course of depressive or anxiety 
symptoms in older people with musculoskeletal pain cannot be expected to result 
in immediate changes to clinical practice without strong evidence from other forms 
of research, including a need to improve current clinical practice. Nevertheless, 
assuming that the NHS would be interested in the recognition and management of 
persistent anxiety or depression symptoms in people with OA, this study draws 
attentions to the subject of how to identify patients with these problems. One 
possibility is annual evaluation of anxiety and depression symptoms severity, 
particularly among those older patients with more widespread pain, severe pain 
related disability, catastrophising or showing little interest in continuing meaningful 
activities regardless of OA. 
To date, recognition and management of anxiety symptoms persistence 
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seems to be overlooked in health literature. Guidance for management of mixed 
anxiety and depression symptoms is also lacking- this has been regarded one of 
the main shortcomings of the current NICE depression guidance (Kendrick & Peveler, 
2010). However, recent NICE depression guidance considered management of ‘sub-
threshold persistent depression symptoms’, which is an important step towards the 
model of care reflecting cases typically seen in primary care. NICE (2009b) 
depression guidance considers persistent sub-threshold depression symptoms, 
defined as present for a considerable time, typically several months, despite 
‘active monitoring’ or low- intensity treatment (for the DSM-IV and ICD-10 criteria 
of dysthymia, symptoms should be present for least 2 years) (Figure 1.2 on 
page18). Similar work is much needed for anxiety.  
The following issue is what constitutes ‘active monitoring’. It is currently 
undetailed in NICE guidance, but an interesting proposal for what it could be has 
been made by an academic general practitioner Lucassen et al. (2008). They 
outlined a stepped approach to diagnosing depression problem in general 
practice. This theoretical model implies that upon hearing the patient’s story, the 
GP and the patient should agree on the name of the combination of symptoms and 
agree on the relative importance of the problem. Next, the role of a GP is to 
restore patient’s beliefs in his/her own healing capacities. If despite of the forgoing 
activities the problem persists (there is no improvement in health), the use of 
medical diagnosis and treatment should be considered. Unfortunately this model 
remains only theoretical. Nevertheless, a recent systematic review of patient views 
on depression coexisting with a chronic physical illness (Alderson et al., 2012) seems to 
support this personalised approach to diagnostic labels, negotiating their meaning 
and management. The study found that patients hold different beliefs about 
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depression labels, its consequences, associated stigma, blame and responsibility 
and relevance of treatment, and patients’ personal preferences may be important 
to how they engage in recognition of depression problem (Alderson et al., 2012). Whilst 
the study did not consider anxiety separately, one of the findings suggests that 
participants associated depression emotionally with anxiety (Alderson et al., 2012). 
Another clinical implication of this study is an insight into factors potentially 
involved in adjustment to musculoskeletal pain, in the context of modern 
psychological theories. Interestingly, increased engagement in behavioural 
activities was found to have a positive effect on the course of depressive and 
anxiety symptoms. This finding supports a need for continuing enjoyable life 
activities by people experiencing musculoskeletal pain, a view advocated by the 
misdirected-problem solving and acceptance-commitment models. This stresses 
the importance of psychological interventions, which can modify unsuccessful 
coping strategies (e.g. catastrophising) and encourage more useful methods (e.g. 
increasing activities). Nevertheless, the persistence of anxiety and depression 
symptoms in older adults with musculoskeletal pain was found associated with a 
number of factors, including pain characteristics. Consequently, as advocated by 
NICE (2008) OA guidelines, successful adjustment to OA is likely to involve a 
multifaceted approach.  
 
Research implications 
Future research may consider modelling the dual trajectory of anxiety and 
depression symptoms inclusive of a limited number of time-varying covariates (e.g. 
number of pain sites or coping by increased behavioural activities), as this could 
result in additional clinical utility. It is also needed to assess contribution of factors 
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associated with the persistence of anxiety and depression symptoms coexisting 
with OA to an improved identification of these groups of primary care patients. This 
was previously advocated in the context of primary care patients in general (van den 
Brink et al., 2002). 
Identification of primary care patients with musculoskeletal pain coexisting 
with persistent anxiety and depression symptoms is important, as they may benefit 
from specific anxiety and depression treatment. Research has demonstrated 
existence of potentially effective models of depression and anxiety care (Lin et al., 2003, 
2006, Roy-Byrne et al., 2010). In practice, however, effective depression and anxiety care in 
older adults with musculoskeletal pain may be problematic. This issue is evident in 
the concerns raised by health professionals (Van Rijswijk et al., 2009, Barley et al., 2011). As 
such older primary care adults with depression are often undetected by their GPs 
(Licht-Strunk et al., 2009a) and older patients and patients with physical health problems 
often have their depression problem untreated (Kendrick et al., 2009). To date, little is 
known about this problem in older adults consulting primarily with musculoskeletal 
pain. 
 
6.7     CONCLUSIONS 
The study found that pain characteristics and coping strategies are the most 
prominent factors associated with the persistence of anxiety and depression 
symptoms in older people with musculoskeletal pain. Further research into the 
factors that may help to guide targeted identification of groups of individuals that 
would benefit most from depression or anxiety treatment is needed. In particular, 
future research may consider modelling the dual trajectory of anxiety and 
depression symptoms inclusive of a limited number of time-varying covariates, as 
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this could result in additional clinical utility. Understanding of factors associated 
with poor prognosis for depressive and anxiety symptoms have the potential to 
inform targeted case identification of patients with OA and coexisting depression 
or anxiety problems. However, to recognise a need for improvement, research is 
needed to understand the success of strategies implemented by GPs in primary 
care practice, to detect patients with possible or definite depression and anxiety 
problems. 
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Chapter seven: Documented detection of depression and anxiety in 
older adults consulting with musculoskeletal pain: analyses of 
medical record data 
 
7.1      INTRODUCTION 
Chapters three and five found that whilst formal depressive and anxiety 
disorders are relatively rare in people with OA/joint pain, persistent anxiety and 
depression symptoms are common in older adults consulting with musculoskeletal 
pain. The recognition, diagnosis and subsequent management of depressive and 
anxiety disorders in older patients and in particular those with chronic physical 
conditions, is challenging and consequently these conditions are likely to be 
undetected by general practitioners. To date, the detection of persistent anxiety 
and depression symptoms in older people with musculoskeletal pain is under-
researched. This chapter considers the detection of depression or anxiety 
problems in general practice among older patients with musculoskeletal pain and 
coexisting persistent depression or anxiety symptoms (as identified by the LCGA 
anxiety and depression models). Patient medical records are reviewed to estimate 
the detection rate and factors associated with this rate are established. 
 
7.2      BACKGROUND 
7.2.1   Primary care challenges in detecting depression and anxiety 
A critical challenge to detection of depression and anxiety in primary care 
practice is patient role in help-seeking. Typically it takes more than one 
consultation for the GP to detect mental health problems (Mitchell et al., 2009), with the 
low overall frequency of visits (combined with physical or pain presentation) 
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contributing to the further risk for the non-detection of depression in primary care 
adults (Menchetti et al., 2009). Underlying reasons for not seeking-help may be partially 
related to patient perception of the problem and the perceived need for health care 
(van Beljouw et al., 2010). A large study of primary care patients, with a confirmed 
diagnosis of depression and anxiety disorders, identified three distinct groups of 
patients who did not consult a health professional about their mental health 
problems. These three groups included patient’s with no self-perceived problem; 
patient’s with self-perceived problem but perceived no need for care and patient’s 
with self-perceived problem and perceived unmet need for care (van Beljouw et al., 2010). 
The group with an unmet need for care had a comparably poor prognosis to those 
who consulted a health professional about depression or anxiety (van Beljouw et al., 2010). 
Some reasons underlying the unmet need for care were identified in a small 
qualitative study of primary care patients with depression or anxiety (Kadam et al., 2001). 
Some patients suggested that limited consultation time and apprehension to the 
use of pharmacological treatment (perceived to be the most commonly offered) 
prevent them from disclosing depression and anxiety (Kadam et al., 2001). Alternatively, 
patients may seek to meet their needs for depression and anxiety care outside of 
conventional health care (Kadam et al., 2001). 
 Identification of possible or definite depression and anxiety problems is 
important for formal diagnosis and subsequently the nature of intervention. Broadly 
speaking, general practitioners are suggested by clinical guidance to diagnose 
depression and anxiety, and tell their patients that they have a disease (NICE, 2005, 
NCC-MH, 2005, NICE, 2007, NICE, 2009b). Lucassen et al. (p.161, 2008) have controversially 
argued, that this way “depression resembles appendicitis”. Primary care 
professionals report difficulties with the diagnosis of depression and anxiety in 
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older adults (Burroughs et al., 2006, Murray et al., 2006, Van Rijswijk et al., 2009) and in patients with 
chronic physical conditions (Van Rijswijk et al., 2009, Coventry et al., 2011). In particular, they find 
problems when distinguishing ‘true’ cases from transient forms (Oladinni, 2002, Murray et 
al., 2006, Van Rijswijk et al., 2009, Coventry et al., 2011). Recent research findings confirm this, with 
data from 32 sites participating in the Increasing Access to Psychological 
Therapies (IAPT) programme (Glover et al., 2010) showing that older patients (aged 65 
and over) had fewer anxiety and depression diagnoses than those under 65. 
Some authors attribute this difficulty to somatisation that is common in older age 
and in people with chronic physical conditions (Tylee & Walters, 2007). Furthermore, 
patients were often diagnosed with ‘mixed anxiety and depressive disorders’, 
highlighting the diagnostic problems arising from the frequent coexistence of these 
two conditions and the complex position of ‘subclinical’ conditions in the current 
classificatory systems (Glover et al., 2010). Van Beljouw et al.’s (2010) study found that 
in a group of participants with a confirmed diagnosis of depressive or anxiety 
disorders and no record of contacts with a health care professional, those without 
self-perceived problems had the ‘best course’ for their depressive and anxiety 
symptoms (i.e. they recovered from anxiety and depression symptoms). This 
evidence supports the view that recognition may be less about categorising 
patients using the current classificatory systems, and more about detecting 
patients with self-perceived (potentially unexpressed) problems of depressive or 
anxiety symptoms and supporting them in making an informed decision about 
management (Lucassen et al., 2008, van Beljouw et al., 2010). Although, clearly this view may be 
difficult to apply to patients who potentially fail to acknowledge their 
depression/anxiety problems, due to underlying psychological reasons, such as 
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fear of stigma - a problem commonly highlighted for depression by patients 
themselves (Alderson et al., 2012).  
Small qualitative studies suggest that the availability of access to relevant 
interventions may affect primary care professional willingness to identify mental 
health problems (Burroughs et al., 2006) and for patient willingness to disclose them (Kadam 
et al., 2001). Studies consistently show that treatments for depression and anxiety are 
under-utilised in older adults. For example, a large dataset of medical records of 
UK primary care patients with depression symptoms found that older patients and 
patients with chronic physical problems were less likely to be treated for 
depression (Kendrick et al., 2009). Similarly, in a large randomised controlled trial of older 
primary care patients with major depression or dysthymia (of whom approximately 
half had arthritis (Lin et al., 2003, 2006)) only 65% reported any lifetime depression 
treatment (Unützer et al., 2003). A systematic review of anxiety in older adults suggests 
that anxiety treatment utilisation may also be lower in older adults than in younger 
adults (Wolitzky-Taylor et al., 2010). Prescribing pharmacological treatment is a core 
professional skill of GPs yet this type of treatment may be poorly utilised in older 
patients with musculoskeletal pain, as these patients are known to be highly 
vulnerable to the adverse effects of psychotropic medications (Bulat et al., 2005), for 
example, benzodiazepines have been shown to increase the risk for falls and 
skeletal fractures (Bulat et al., 2008). Non-pharmacological treatment may also be poorly 
utilised in older patients with musculoskeletal pain, as primary care practitioners 
consistently expressed a sense of poor provision or problems with access to 
specialist mental health, volunteer or social services (Rogers et al., 2001, Telford et al., 2002, 
Pollock & Grime, 2003, Burroughs et al., 2006).  
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7.2.2   Is it important to detect depression and anxiety in older people with 
musculoskeletal pain?  
Regardless of the difficulty associated with detecting older primary care 
patients with musculoskeletal pain and coexisting problems of depression and 
anxiety, there are reasons to strive for detection, which goes beyond simply 
reducing the unpleasant symptoms associated with depression and anxiety. As 
discussed in chapter one, there is robust evidence to suggest the adverse effects 
of anxiety and depression symptoms can result in poorer OA-related outcomes. 
The Improving Mood-Promoting Access to Collaborative Treatment (IMPACT) trial 
offers promising potential improving OA-related outcomes through detection of 
possible or definite depression. This study included 1001 older primary care 
attendees with self-reported arthritis (mostly OA) and clinically diagnosed major 
depression and/or dysthymia and compared usual care (i.e. primary care 
treatment and potential referral to specialty mental health care) with a collaborative 
care approach (i.e. a case manager collaborating with a patient and primary care 
providers). The latter was not only associated with fewer depression symptoms, 
but importantly also improved OA-related outcomes, such as pain, functional 
outcomes and improved quality of life (Lin et al., 2003, 2006). The inclusion of patients 
with dysthymia, suggest that the result can be generalised to patients with 
persistent, subclinical symptoms of depression.  
A large RCT that was modelled on the IMPACT trial offers preliminary 
insight into the impact of detection of anxiety disorders in general primary care 
patients (Roy-Byrne et al., 2010). The study excluded milder forms of anxiety disorders 
and unstable medical conditions. Nevertheless, relative to usual care, collaborative 
care led to a greater reduction of in anxiety and depression symptoms and 
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improved functional status. An understanding of how successful this model is in 
people with OA warrants a similar trial in this sub-population of primary care 
patients. 
Clearly, it can be argued that collaborative depression and anxiety care 
may be unnecessary, if there is ample evidence to demonstrate that OA treatment 
can lead to clinically significant improvements in concurrent depression and/or 
anxiety. However, systematic reviews of the main modalities of OA pain control, 
including exercise (Fransen et al., 2009, Brosseu et al., 2010), paracetamol (Towheed et al., 2009), anti-
inflammatory medication (Watson et al., 2006, Derry et al., 2012), opioids (Nüesch et al., 2010) seldom 
summarise the effects on coexistent depression and/or anxiety. For example, 
conclusions of a systematic review of exercise, including two studies (in this one 
review of five studies) were limited to a statement that participants reported 
“decreased depression and anxiety” (Brosseu et al., 2010). 
 
7.3      RATIONALE OF THE STUDY 
Despite effective treatment options for anxiety (Wolitzky-Taylor et al., 2010) and 
depression (Yohannes & Caton, 2010), detection of these conditions in primary care is 
challenging. According to Timonen and Liukkonen (2008), cross-sectional studies 
suggest that between 50% and 70% of patients with depression in primary care 
settings are undetected. Based on a 3-year follow-up period, 37% of primary care 
patients with depression or anxiety were not detected (Kessler et al., 2002). A much 
higher rate - 67% - was reported for older primary care patients with depressive 
disorders followed-up for one year (Licht-Strunk et al., 2009a). Exact estimates of detection 
rates may be affected by the methodology used (i.e. symptoms persistence (Licht-
Strunk et al., 2009a), period of detection (Kendrick, 2008), definition of detection (Joling et al., 2011)). 
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A primary care study of 250 adult patients found that the odds of non-detection of 
depression were higher for patients presenting with physical symptoms (OR: 2.3; 
95% CI 1.1, 5.3) and specifically with pain (OR: 4.1; 95% CI 1.6, 9.9) (Menchetti et al., 
2009). Overall, older adults with coexisting musculoskeletal pain and clinically 
significant depression symptoms seem to be at a high risk of being under-detected 
in primary care. Much less is known about anxiety, but given that anxiety in 
general, received limited research attention in people with musculoskeletal pain; 
detection of anxiety is also likely to be poor. 
 
7.4      AIM AND OBJECTIVES 
The aim of this study is to describe the detection of depression and anxiety in 
older primary care patients with OA.  
 
Specific objectives are: 
 To determine the detection rate of persistent depression or anxiety symptoms 
in older patients presenting to general practice with musculoskeletal pain 
 To establish the factors associated with detection in this sub-population 
 
7.5      METHOD 
7.5.1   Selection of sample 
PROG-RES participants were eligible for this analysis if they consented for 
medical record review and were classified in the refined LCGA models (see 
section 6.4.2 on page 205) as having persistent anxiety symptom or depression 
symptom trajectories. A practical decision of focusing on patients with either 
depression or anxiety was made to increase the statistical power of analyses and 
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to account for an overlap in range of treatments used to manage depression and 
anxiety in the community. Focusing on persistent symptoms was grounded in a 
suggestion that relative to cross-sectional estimates, focusing on persistent 
symptoms might be more relevant for patient care by identifying more enduring 
and potentially more clinically relevant symptoms (Licht-Strunk et al., 2009a, Luccasen et al., 
2008).  
 
7.5.2   Data selection 
Evidence of detection 
Data indicative of the documented detection of depression and anxiety were 
selected for extraction from the medical records. This involved using a definition 
similar to those that have been used in previous studies (e.g. Licht-Strunk et al., 2009a, Joling 
et al., 2011, Cully et al., 2009).  
The first group of indicators included a Read-coded diagnosis of depression 
and/or anxiety symptoms (Licht-Strunk et al., 2009a, Joling et al., 2011, Cully et al., 2009). Henceforth 
this group of indicative medical records will be called documented 
diagnosis/problem codes.  
However, reliance only on recorded diagnosis is likely to result in an 
underestimation of detection rates for depression and anxiety (Joling et al., 2011). 
Records of antidepressant prescription were found to be the best single predictor 
of GP’s detection of depression, assessed with the Composite International 
Diagnostic Interview (CIDI) (Joling et al., 2011). As a result, and in line with previous 
research (Kendrick et al., 2009, Licht-Strunk et al., 2009a, Cully et al., 2009),  evidence of the provision 
of treatment for mental health problems was also extracted. This included 
receiving antidepressants and anxiolytic drug prescriptions in addition to referral to 
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mental health or appropriate social services. This group will be referred to as 
documented interventions. In summary, for the purpose of the analysis presented 
in this chapter documented detection encompasses evidence from the electronic 
medical record (EMR) of documented anxiety- and depression-related 
diagnosis/problem codes or interventions. 
Anxiety and depression-related Read-codes were identified using a list of 
clinical search terms and Read codes (5-byte, Version 2). These were generated 
using the NHS Information Authority ((NHSIA), 2000) Clinical Terms Version 3. A 
provisional list of search terms was enhanced by comparison with lists of search 
terms previously reported in studies into the diagnosis of depression (Rait et al., 2009) 
and antidepressants use (Coupland et al., 2011). Whilst medical records data for anxiety 
diagnosis and intervention has also been reported (Goodman & Tyer-Viola, 2010, Stein et al., 
2004), lists of search terms used in the identified studies were unavailable. The 
provisional list of search terms was discussed with an academic general 
practitioner (CM). For the agreed list of search terms see Appendix F.1 (p. 391).  
Records reflecting the diagnosis of depression and anxiety included broad 
(feeling stressed, emotional upset, low mood, anxiousness) and narrow terms (e.g. 
[X] Depressive episode, [X] Anxiety state). A term postnatal depression was 
excluded, as this condition was unlikely to be related to older general practice 
attendees.  
Medication used to identify treated cases of depression and anxiety 
included following classes of antidepressants and anxiolytic drugs (as described in 
the British National Formulary (BNF) 61 (Joint Formulary Committee,  2011): depression-
specific medication (e.g. tricyclic and related antidepressants, monoamine oxidase 
inhibitors, other antidepressants, compound antidepressants); anxiety-specific 
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medication (e.g. benzodiazepine or its derivative drugs and propranolol) and drugs 
that are indicated for both depression and anxiety (e.g. selective serotonin 
reuptake inhibitors, selective-norepinephrine reuptake inhibitors). Medical records 
were examined in detail, to ensure that medications were actually prescribed for 
depression and anxiety. Following a study in patients with heart failure, inclusion of 
trazodone and amitriptyline, was determined by excluding possibility of their use 
for other health problem, such as sleep and pain (Cully et al., 2009). The BNF 61 (Joint 
Formulary Committee, 2011) was used as a reference point. Although in general the BNF 
does not recommend amitriptyline for depression, 30 mg - 75 mg is suggested for 
depression, if needed gradually increasing to 150 mg - 200 mg. For neuropathic 
pain/migraine prophylaxis, the BNF suggests 10 mg, if necessary followed by a 
gradual increase to 75 mg (Joint Formulary Committee, 2011). The BNF recommends 75 mg 
to 300 mg trazodone for depression/anxiety (Joint Formulary Committee, 2011). Exclusions 
were informed by discussions with an academic general practitioner (CM). 
Psychological interventions were identified using methods described in the 
existing literature (Kendrick et al., 2009) (e.g. referral to counselors, psychologists, mental 
health or social workers, psychiatry services and occupational therapists). Any 
mental health encounters or clinic visits (Cully et al., 2009) or psycho-education or 
management plan (e.g. advice and crisis plans) were included. 
 
Time frame for extracting data 
As per previous research (Licht-Strunk et al., 2009a, Cully et al., 2009) analyses focused 
on a one year period following the index consultation, as the anxiety and 
depression trajectories were based on HADS data collected in that time period. In 
addition, the period of medical record review was extended one year either side of 
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the period of observation. A timeline of medical record reviews conducted for the 
selected sample can be seen displayed in Figure 7.1. 
 
 
Figure 7.1  Timeline of data extracted from medical records of PROG-RES 
participants eligible for the current study. 
 
 
 
In addition to exploring changes in the frequencies of detection over time, 
the choice of the three year period was done for two main reasons. Firstly, the 
analyses aimed to acknowledge the ‘real’ circumstances of making a clinical 
diagnosis. The likelihood of identification of psychological problems in primary care 
patients increases with the number of consultations (Roy-Byrne et al., 2000, Mitchell et al., 2009). 
This could be related to an increasing number of opportunities to prompt 
recognition or implementation of ‘watchful waiting’ by GPs (Simon & Von Korff, 1995), a 
method advocated by NICE (2009a, 2009b). Secondly, it was unlikely that the 
onset of anxiety and depression symptoms always coincided with the start of the 
study. As reported in chapter four, participants were likely to have disabling pain at 
the index consultation, and thus, the process of emotional adjustment to pain had 
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been initiated before the study commenced. In addition, numbers of new episodes 
of depression and anxiety at follow-up were low, as indicated by HADS scores. 
 
Data extraction procedures 
Data on all recorded consultations was extracted from the electronic 
medical records (EMR) for all patients consenting to review (n=428) by a data 
custodian. The data custodian provided dates of the index consultation and based 
on the pre-defined list of Read terms and Read codes extracted relevant 
consultations, referrals and prescription information from the EMR for the 428 
participants. During data extraction, both the data custodian and the principal 
investigator (MR) were blinded to the anxiety and depression trajectories of 
participants. Raw data were presented in the PASW long format. The index 
consultation dates were presented along with participants’ anonymised IDs. Raw 
data for consultations, referrals and prescriptions were provided separately and 
included: participants’ IDs, corresponding Read terms and dates of recording. 
Consultation and referral data also included specific Read codes and prescription 
data included relevant BNF chapters.  
 
7.5.3   Statistical analyses 
Rates of detection 
PASW Statistics version 20 was used for analyses of detection rates. 
Simple frequencies of occurrence of each depression- and/or anxiety- Read terms 
grouped as diagnosis/problem codes or interventions, were estimated using the 
entire 3-year period of record review. In cases when the same Read term was 
used more than once for the same patient it was counted as one record. The same 
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medications with different dose or in different forms were regarded to be the same 
Read term. 
The overall proportion of eligible participants with any documented 
evidence of diagnosis/problem codes and interventions were calculated separately 
and were not mutually exclusive. The overall frequency of all eligible participants 
with either Read coded diagnosis/problem codes or interventions, was calculated 
to form a basic estimate of the rate of detection of anxiety or depression over the 
3-year period of medical records review. The total number of times a relevant 
evidence of detection (i.e. diagnosis/problem codes or interventions) was also 
recorded in each 6-month interval. 
 
Factors associated with detection 
The numbers of all consultations were recorded for eligible participants by 
estimating time between the index consultation and identified anxiety- or 
depression-related Read codes. Average anxiety and depressive scores for 
baseline, 3-, 6- and 12-month follow-up scores were calculated. For consistency 
with the analyses described in chapter five, the following baseline covariates were 
also included: age (50-59, 60-69, 70 years or more); gender (male/female); living 
alone (yes/no); lack of partner (yes/no); manual/routine occupational class 
(yes/no); emotional and instrumental support (yes/no); coping (split by the highest 
tertile) by catastrophising, ignoring pain, coping-self statements, and increased 
behavioural activities; widespread pain (number of pain sites). Due to the issue of 
multicoolinerity reported in section 6.5.2 (p. 208) for variable ‘pain interference with 
daily activities’, the average of pain interference (0-10 NRS) with daily, social and 
work activities was taken. This was justified as these are typically combined in the 
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Chronic Pain Grade (see section 4.4.5, p. 148). The median was used to describe 
all continuous variables, due to non-normal distribution of scores (see Table 4.3 
(p. 146) for HADS scores, Appendix D.1 (p. 374-376) for pain interference with 
activities scores and the numbers of pain sites, Appendix F.2 (p. 395) for the 
numbers of all consultations). 
Statistical analyses were conducted in three parts, using PASW statistics 
version 20 in the first two parts and the STATA software (version 11.1) in the last 
part. In the first part, the differences between detected and undetected patients 
were determined across the selected factors. Due to non-normal distribution of 
scores, the differences across average anxiety and depressive HADS scores, 
widespread pain and interference with activities were determined using the Mann-
Whitney U test. This test was selected as data failed to meet the assumptions 
required for parametric tests. Differences in categorical data were compared using 
the Chi2 test or for expected cell sizes of less than 5, the Fisher’s exact test, for 
which statistical significance was established at the level of p<0.05. 
In the second part of the analyses, due to non-normal distribution of scores, 
median numbers of consultations were estimated across categorical data and 
correlations between continuous data and numbers of all consultations were 
estimated using the Spearman Rank Correlation test. This aimed to assess 
interactions between the frequency of consulting and other factors assessed for 
their associations with detection of depression or anxiety. 
In the third part, a multivariable logistic regression analysis was conducted 
for variables that yielded p<0.10 in the first part of analyses. Borderline variables 
were then included and the model was re-estimated, to assess changes in 
statistical significance (established at the level of p<0.05). 
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7.6     RESULTS 
7.6.1  Sample size 
In total, 143 participants were eligible for this analysis, as they consented for 
medical record review and were classified in the refined LCGA models (section 
6.5.1) as having persistent anxiety or depression symptoms. 
 
7.6.2   General descriptive findings 
 Read terms of diagnosis/problem codes and interventions that were 
identified in the medical records of PROG-RES participants with persistent 
depression or anxiety trajectories are displayed in Tables 7.1 overleaf and 7.2 on 
page 244 respectively. Overall frequencies were not provided, as multiple 
consultation terms were used for some participants. Read terms anxiety with 
depression and the medication diazepam were the most commonly used 
diagnosis/problem codes and interventions Read terms respectively. 
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Table 7.1 Diagnosis/problem codes Read terms and frequency 
of their occurrence for the 143 eligible participants. 
 
Read terms Frequency of 
occurrence‡ (%) 
 
Anxiety with depression 11 (7.7) 
Low mood 7 (4.9) 
Depressed 5 (3.5) 
Depression 4 (2.8) 
Stress related problem 4 (2.8) 
[X]Depressive episode 3 (2.1) 
Panic attack 3 (2.1) 
[X]Anxiety NOS 2 (1.4) 
[X]Anxiety reaction 2 (1.4) 
[X]Depression NOS 2 (1.4) 
Recurrent depression 2 (1.4) 
[X]Mild depressive episode 1 (0.7) 
[X]Recurrent depressive disorder 1 (0.7) 
Acute reaction to stress 1 (0.7) 
Anxiety states 1 (0.7) 
Chronic anxiety 1 (0.7) 
Emotional upset 1 (0.7) 
Panic disorder 1 (0.7) 
Pt health quest (PHQ-9) score 1 (0.7) 
Reactive Depression 1 (0.7) 
Note: NOS- not otherwise specified; [X] - ICD-10 criteria based; 
 ‡- If the code was used more than once for the same person, it was counted as used 
once. 
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Table 7.2 Interventions Read terms and frequency of their occurrence for 
the 143 eligible participants. 
 
Read terms Frequency of 
occurrence ‡ 
(%) 
Diazepam        (tablets 2 mg, 5 mg) 25 (17.5) 
Citalopram       (hydrobromide tablets 10 mg, 20 mg, 40 mg) 20 (14.0) 
Sertraline         (hydrochloride tablets 50 mg, 100 mg) 8 (5.6) 
Escitalopram   (tablets 5 mg, 10 mg, 20 mg) 7 (4.9) 
Dosulepin        (capsules 25mg, tablets 75 mg) 5 (3.5) 
Venlafaxine     (hydrochloride m/r capsules (75 mg, 150 mg),   5 (3.5) 
                        hydrochloride tablets 37.5 mg)   
Paroxetine       (hydrochloride tablets (20 mg, 30 mg),  4 (2.8) 
                        tablet 20 mg)   
Refer to counsellor 4 (2.8) 
Propranolol      (hydrochloride tablets 40 mg, 3 (2.1) 
                         hydrochloride m/r capsules 80 mg)   
Fluoxetine        (hydrochloride capsules 20 mg) 2 (1.4) 
Mirtazapine      (orodispersible tablets (15 mg, 30 mg),  2 (1.4) 
                         tablets 15 mg)   
Lofepramine     (tablets 70 mg)  1 (0.7) 
Lorazepam       (tablets 1 mg) 1 (0.7) 
Lormetazepam (tablets mg) 1 (0.7) 
Nortriptyline      (tablets 10 mg) 1 (0.7) 
Refer to occupational therapist 1 (0.7) 
Seen in psychiatric unit 1 (0.7) 
Trimipramine    (tablets 25 mg) 1 (0.7) 
Note: ‡- If the same medication (regardless of dose) was used more than once for the same person, it 
was counted as used once. 
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7.6.3   Documented depression and anxiety related detection 
 
Table 7.3 Frequencies of documented detection (i.e. diagnosis/problem codes or interventions) in older primary 
care patients with musculoskeletal pain†. 
 
                                     Persistent anxiety/depression symptom trajectories 
 
 Anxiety or 
depression 
combined 
Overlapping groups Mutually exclusive groups ‡ 
 
 Anxiety Depression Anxiety 
only 
Depression 
only 
Anxiety and 
depression 
 (n = 143) (n =113) (n = 87) (n = 55) (n = 27) (n = 57) 
 
Detection                 n (%) 61 (42.7) 51 (46.0) 37 (42.5) 23 (41.8)      8  (29.6) 28 (49.1) 
Diagnosis/problem   
codes                        n (%) 
 
37 (25.9) 
 
34 (30.1) 
 
24 (27.6) 
 
13 (23.6) 
 
3  (11.1) 
 
21 (36.8) 
Interventions             n (%) 57 (39.9) 48 (42.8) 36 (41.4) 20 (36.4) 8  (29.6) 27 (47.4) 
Note: †- frequencies of detection are not equal to the total number of diagnosis/problem codes or interventions as some participants were identified by more than 
one method; ‡- in four cases depression or anxiety trajectories only were available, and so mutual exclusiveness could not be judged.
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Table 7.3 (on the previous page) shows that having persistent HADS 
defined depression symptoms only was associated with a lowered rate of 
detection (29.6%). Of the 143 patients with persistent anxiety or depression 
symptoms over the 12-month period of observation, 42 (29.4%) had evidence of 
detection from the general practice medical record during the same 12-month 
period of having their depressive and anxiety symptoms assessed with the HADS. 
The above figure, however, may under-estimate the true rate of detection since 
extending the period of medical record review one year either side of the period of 
observation identified a further 19 detected cases giving a total estimated 
detection rate of 42.7% over 3 years (Table 7.4). In fact, the majority (n=35) of 
detected cases had already been identified before the index consultation (Table 
7.4). Evidence of detection came primarily from documented interventions, with 
just 4 out of 61 cases being detected on the basis of diagnosis/problem codes 
alone (Table 7.4). 
 
Table 7.4 Frequencies of documented depression- or anxiety-related 
diagnosis/ problem codes, interventions and overall detection over time for 
the 143 eligible participants. 
 
Time 
point 
        Diagnosis/ 
problem codes     
      Interventions 
         
 
         Detection 
            
 
N (%) 
 
N (cum %) N (%) N (cum %) N (%) N (cum %) 
- 12m 11 (7.7) 11 (7.7) 25 (17.5) 25 (17.5) 30 (21.0) 30 (21.0) 
-  6m 7   (4.9) 14 (9.8) 27 (18.9) 32 (22.4) 28 (19.6) 35 (24.5) 
   6m 9   (6.3) 19 (13.3) 29 (20.3) 41 (28.7) 31 (21.7) 45 (31.5) 
  12m 17 (11.9) 28 (19.6) 31 (21.7) 50 (35.0) 35 (24.5) 53 (37.1) 
+ 6m 14 (9.8) 32 (23.4) 31 (21.7) 54 (37.8) 35 (24.5) 57 (39.9) 
+12m 13 (9.1) 37 (25.9) 34 (23.8) 57 (39.9) 36 (25.2) 61 (42.7) 
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7.6.4   Patient characteristics associated with documented detection of 
depression or anxiety 
Table 7.5 overleaf presents the results of the characteristics of patients with 
detected vs. undetected anxiety and depression symptoms during the three year 
data extraction period. The result of the Mann-Whitney U test suggests that the 
total number of consultations was most strongly associated with detection. In other 
words, the 61 detected patients had significantly more opportunities for 
identification of their mental health symptoms than the 82 undetected patients as 
they consulted their doctor more frequently. The result of the Mann-Whitney U test 
indicates that the detected patients had significantly higher aggregated HADS-
anxiety scores, with the effect less robust than for numbers of consultations. 
According to the Man-Whitney U tests (found in Table 7.5 overleaf), patients who 
had their depression detected by the general practitioner had significantly higher 
pain interference with activities (daily activities, social activities and work 
activities). Women were more likely to have their depression or anxiety detected 
than men, with a 26% (95% CI 11.3, 41.2) difference in the proportion of females 
across the two groups. Table 7.6 on page 250 shows that higher levels of 
detection in women and in people with higher pain interference with different 
activities could be associated with these individuals being more likely to consult in 
general. Patients with more severe depression symptoms appeared also to have 
higher rates of detection although this finding was of borderline statistical 
significance. A multivariable logistic regression analysis (for variables that met the 
entry probability p<0.10 for observed significance level) was conducted. 
Decreasing number of consultations (OR: 0.98 (95% CI 0.96, 0.99), p<0.0001) and 
average HADS-anxiety score (OR: 0.82 (95% CI 0.70, 0.96), p=0.012) were found 
to be significantly associated with the risk of being undetected (Table 7.5 overleaf).  
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Table 7.5 Characteristics of older primary care patients with musculoskeletal pain, detected vs. undetected by the GP 
during the three year data extraction period. 
 
Variable  Detected 
(n=61) 
n (%) 
Undetected 
(n=82) 
n (%) 
Observed significance level 
 
Multivariable logistic¥ 
regression with entry 
probability p<0.10 
Number of                      Med. (IQR) 
consultations 
78    (61.0) 46   (32.5) MED 31.0 (95% CI 19.0, 43.0),  
p<0.0001 
OR 0.98 (95% CI 0.96, 0.99), 
p<0.0001 
Averaged  HADS-A†      Med. (IQR) 10.7 (3.8) 9.5  (3.3) MED 1.25 (95% CI 0.50, 2.25),  
p= 0.003 
OR 0.82 (95% CI 0.70, 0.96), 
p=0.012 
Averaged  HADS-D†      Med. (IQR) 8.3   (4.4) 7.8  (4.0) MED 0.92 (95% CI -0.25, 2.00),  
p=0.115* 
- 
Age          50-59 23    (37.7) 31   (37.8) p=0.598 - 
                 60-69 19    (31.1) 20   (24.4)   
                 70+ 19    (31.1) 31   (37.8)   
Gender     Males  
                 Females 
13    (21.3) 
48    (78.7) 
39   (47.6)  
43   (52.4) 
p=0.001 OR 0.49 (95% CI 0.21, 1.15), 
p=0.103 
Manual/ routine work     
                 No 39    (63.9) 50   (61.0) p=0.718 - 
                 Yes 22    (36.1) 32   (39.0)   
Living alone           
                 No 48    (78.7) 65   (79.3) p=0.933 - 
                 Yes 13    (21.3) 17   (20.7)   
Partner     No 17    (27.9) 20   (24.4) p=0.597 - 
                 Yes 43    (70.5) 62   (75.6)   
Emotional support     
                 No 7      (11.5) 4     (4.9) p=0.203 - 
                 Yes/no need 51    (86.9) 78   (95.1)   
Instrumental support     
                 No 11    (18.0) 8     (9.8) p=0.149 - 
                 Yes/no need 50    (82.0) 74   (90.2)   
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Table 7.5 cont. Characteristics of older primary care patients with musculoskeletal pain, detected vs. undetected by the 
GP during the three year data extraction period. 
 
Variable  Detected 
(n=61) 
n (%) 
Undetected 
(n=82) 
n (%) 
Observed significance level 
 
Multivariable logistic¥ 
regression with entry 
probability p<0.10 
Catastrophising     
                  No 
                  Yes 
25    (41.0)  
30    (49.2) 
45   (54.9)  
30   (36.6) 
p=0.100* - 
Ignoring pain     
                  No 40    (65.6) 51   (62.2) p=0.165 - 
                  Yes 11    (18.0) 25   (30.5)   
Coping-self statements     
                  No 34    (55.7) 44   (53.7) p=0.590 - 
                  Yes 21    (34.4) 33   (40.2)   
Increased behavioural activities     
                  No 27    (44.3) 41   (50.0) p=0.737 - 
                  Yes 26    (42.6) 35   (42.7)   
Number of pain sites       Med. (IQR) 11    (17.0) 9.0  (11.0) MED 2.0 (95% CI -1.0, 5.0), 
p=0.146 
- 
 
Interference with activities 
Med. (IQR) 
 
7.3   (4.0) 
 
6.0  (3.3) 
 
MED 1.0 (95% CI 0.0, 2.0),  
p=0.024 
 
OR 0.93 (95%CI 0.78, 1.10), 
p=0.413 
Note: IQR- inter quartile range; Med.- median; MED- median difference; 
Some proportions are not equal 100% due to missing values; 
†- averaged baseline 3, 6 and 12 months scores; 
¥- The model was statistically significant (LL= -73.19, LR chi
2
= 37.48, Prob > chi p<0.001, Pseudo R
2
= 0.21); 
* - The impacts of borderline variables ‘average HADS-D score’ and ‘catastrophising’ were investigated, with ‘number of consultations’ and ‘averaged HADS-A’ remaining 
to be the only statistically significant variables. 
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Table 7.6 Number of consultations across different characteristics 
of the 143 older primary care patients with musculoskeletal pain. 
 
Variable  Median numbers of 
consultations  (IQR) 
Averaged   HADS-A† Spearman rho   0.047, p= 0.577 
Averaged   HADS-D† Spearman rho      0.157, p= 0.061 
Age  
                    50-59 45.5 (41.5) 
                    60-69 66.0 (50.0) 
                    70+ 65.5 (53.0) 
Gender         
                    Males 44.5 (38.5) 
                    Females 65.0 (55.0) 
Manual/routine work  
                    No 58.0 (51.5) 
                    Yes 57.5 (52.5) 
Living alone        
                    No 54.0 (50.0) 
                    Yes 65.5 (58.0) 
Partner  
                    No 73.0 (51.5) 
                    Yes 54.0 (44.0) 
Emotional support  
                    No 57.0 (72.0) 
                    Yes/no need 58.0 (51.0) 
Instrumental support  
                    No 58.0 (52.0) 
                    Yes/no need 58.0 (53.0) 
Catastrophising  
                    No 51.0 (45.8) 
                    Yes 63.0 (63.5) 
Ignoring pain  
                    No 58.0 (50.0) 
                    Yes 50.5 (50.5) 
Coping-self statements  
                    No 61.5 (49.0) 
                    Yes 53.0 (53.8) 
Increased behavioural activities  
                    No 57.5 (40.0) 
                    Yes 56.0 (58.5) 
Number of pain sites  Spearman rho 0.066, p=0.431 
Interference with:       Spearman rho    
                   Daily activities  0.217, p=0.012 
                   Social activities  0.176, p=0.040 
                   With work  0.237, p=0.005 
Note: IQR- inter quartile range; †- averaged baseline, 3, 6 and 12 months scores. 
 
 
7.7      DISCUSSION 
7.7.1   Summary of main findings 
This study suggests that among older patients consulting general practice 
with musculoskeletal pain who also have coexisting persistent anxiety or 
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depression symptoms, just under half will have documented evidence that their 
mental health problems have been detected by the GP. The highest detection rate 
was found in patients with both persistent depressive and anxiety symptoms 
(49%). Patients with a higher numbers of consultations and those with more 
severe anxiety symptoms (adjusted for gender and pain inference with activities) 
were significantly more likely to be detected. Females and those with higher levels 
of pain that interfered with activities appeared more likely to have their coexisting 
depressive or anxiety symptoms identified (although these patients were, in 
general, more likely to have consulted their GPs). Patients with more severe 
depression symptoms and often catastrophising appeared in unadjusted analyses 
to have higher rates of detection, but this association was of borderline statistical 
significance. 
 
7.7.2   Comparison with previous findings 
Direct comparisons between this study and other studies, reporting 
detection of anxiety and depression in general practice are problematic for three 
main reasons. Assessing true differences is challenging in the light of varying 
methodologies, especially the period of observation, and the extracted evidence or 
independent consideration of depressive and anxiety symptoms. Identifying 
diagnosed depressive or anxiety disorders in primary care patients in general (the 
focus of many previous studies) may not represent a comparable challenge to 
detecting persistent, but largely mild to moderate symptoms among older patients 
with musculoskeletal pain. Analyses of factors associated with anxiety and 
depression symptom detection often have limited statistical power as they are 
often based on small samples – a problem acknowledged in the context of 
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depression detection by Licht-Strunk et al. (2009a). Nevertheless, with attention to 
these challenges, several comparisons are possible. 
 
Detection rates 
In Kessler et al.’s (2002) study, 88 primary care patients with clinically 
diagnosed depressive and anxiety disorders were followed for three years. In total, 
56 (67%) patients had medical record evidence indicative of detection (i.e. 
psychological diagnoses, treatments, and referrals). Given the methodological 
comparability to this thesis, 67% detection rate in general primary care patients, 
seemed greater than 43% found in the study population investigated in this thesis. 
In contrast, after taking into consideration methodological differences, 43% 
appeared broadly comparable with 33% (Licht-Strunk et al., 2009a) and 52% (Volkers et al., 2004) 
detection rates, reported for older primary care patients with depressive disorders. 
Overall, it is likely that older primary care consulters with musculoskeletal pain are 
at a high risk of non-detection of their depression or anxiety problem. 
 
Factors associated with detection 
The factors associated with detection are similar to those reported in 
previous studies. As originally reported by Menchetti et al. (2011), this study also 
found that the number of consultations are positively associated with detection 
rates. As consultation rates in England in 2007/2008 tended to be higher for 
females than for males (Hippisley-Cox & Jumbo, 2008), in this thesis women were found to 
have higher consultation rates and as such were more likely to have their anxiety 
and depression problems detected.  
As reported by other studies, patients with more severe anxiety symptoms 
were found to be more likely to receive mental health treatment (Weisberg et al., 2007, van 
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Beljouw et al., 2010, Licht-Strunk et al., 2009a). However, in contrast with previous research, the 
severity of depression symptoms was not significantly associated with detection 
(Dowrick & Buchan, 1995, van Beljouw et al., 2010, Licht-Strunk et al., 2009a). In the current sample having 
depression symptoms only was much less frequent (7% of 502 respondents to 
baseline questionnaire) than anxiety symptoms only (23%) (see Table 4.2 on page 
147). This could contribute to the observed lack of significant effect of depression 
symptoms severity on the likelihood of being detected. 
 
7.7.3   Strength and critical considerations 
Strength 
This study has two major strengths. It addresses some methodological 
issues previously identified as important to investigations of detection rates. 
Namely, numbers of opportunities for detection (Roy-Byrne et al. 2000, Mitchell et al., 2009), the 
longitudinal nature of clinical decision making (Dowrick & Buchan, 1995, Licht-Strunk et al., 2009a) 
and the choice of a variety of indicators when determining whether comorbid 
symptoms have been identified (Joling et al., 2011). This was achieved by using three 
years of medical record data and by selecting records of both diagnosis/problem 
codes (formal Read code in the medical records) and interventions (a range of 
treatments and referrals) for depression and anxiety.  
To the best of the author’s knowledge, this is the first study focussing on 
patients with persistent mental health symptoms. Given that mild to moderate 
depressive and anxiety symptoms are more common than formally diagnosed 
depressive and anxiety disorders in people with OA (chapter two), the use of 
repeated measures to assess anxiety and depression symptoms is a major 
strength when looking at the wider issue of persistent depressive and anxiety 
symptoms.  
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Critical considerations  
Factors that could influence the behaviour of GPs participating in the 
PROG-RES study require critical considerations. PROG-RES procedures involved 
GPs screening for depression symptoms at the index consultation with two 
questions. It could be argued that this could inflate the estimated detection rate. A 
comparison of HADS scores and the results of GP-administered screening, with a 
large number of patients with depression symptoms being missed, suggests that 
screening was unlikely to improve identification of depression symptoms in PROG-
RES participants (Mallen & Peat, 2008). Still, the results of screening could be influenced 
by the GP’s awareness of the participant’s medical history. Nevertheless, as found 
in this study, the majority of cases were detected before the index consultation and 
no marked increase in numbers of detected patients could be observed within six 
months from the index consultation (see Table 7.4 on page 246).  
Another factor that could impact GPs’ behaviour is the availability of clinical 
recommendations during the reviewed period of data extraction. From April 2006 
the UK general practice contract has incentivised general practitioners to 
systematically assess for the presence of depression in patients with heart disease 
and diabetes using standardised assessment tools. National clinical guidelines for 
depression and anxiety were introduced in 2004 and 2007 respectively, guidance 
for depression in chronic illness in 2009. PROG-RES participants were recruited 
between September 2006 and March 2007, and thus, the current study included 
records documented between September 2005 and March 2009. It is unclear if the 
national guidance affected decision making of GPs participating in the PROG-
RES. Assuming that guidance for depression in a chronic physical illness in 2009 
might affect recognition and management of this problem in OA, studies based on 
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medical records reviewed after year 2009 could result in a higher estimate than in 
the current study. 
A further factor that could influence the results of this study relates to the 
individual practices for GPs coding of consultations. The actual detection rate 
could be higher if GPs are failing to code consultations, rather than representing a 
lack of awareness (Ani et al., 2008, Joling et al., 2011). It is not possible to estimate the exact 
scope of non-recording in the current study. However, a prospective uncontrolled 
intervention study was conducted in the Keele General Practice Research 
Partnership research network, with coding found to be variable across practices, 
but repeated assessments, feedback, and training appeared to improve data 
quality of coding (Porcheret et al., 2004). Practices used in the PROG-RES are a part of 
the Keele General Practice Research Partnership, which conduct regular audits of 
their coding practices, so they are of high quality Read coding (Porcheret et al., 2004). 
This thesis excluded free-text recording in the electronic medical records, 
which include additional information (e.g. from diagnostic tests, operatives’ reports 
and consultation letters (Tu et al., 2010)). Tu et al. (2010) have argued that manual 
tagging of free-text data is heavily reliant upon personal judgment, which can lead 
to misinterpretations (Tu et al., 2010). Joling et al. (2011), in their study of detection 
rates of depression in general practice, used not only medical records of 
psychological diagnosis (including both depression and anxiety), treatment and 
referrals, but also added free-text records. They reported 69% of the overall 
detection rate - a number that appears broadly comparable to 63% reported by 
Kessler et al. (2002) for depression and anxiety (obtained without searching free-
text). Together there are no strong reasons to believe that detection rates would 
be altered if free-text search had been undertaken in the current study. 
Additionally, the estimates provided in this study can be regarded reliable, as a 
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comprehensive list of indicators of detection was used, which are comparable to 
indicators used in previous research (Kessler et al., 2002, Kendrick et al., 2009, Licht-Strunk et al., 
2009a, Cully et al., 2009). 
 
7.7.4   Implications 
Implications for clinical practice 
Assuming that the detection of depressive and anxiety problems in people 
with OA is of interest to the NHS, targeted case identification (using screening 
tools) has been proposed as a method of early detection. This method has been 
suggested in the context of managing the low levels of detection of depression in 
older patients who are at high risk (Licht-Strunk et al., 2009a) and in patients with painful 
conditions (Menchetti et al., 2009) and adults with anxiety in primary care (Stein et al., 2005). 
Yet, three systematic reviews in adult primary care attendees found that when 
used in isolation, routinely administered stand-alone screening questionnaires to 
assess anxiety or depression have little impact not only on detection, but also 
intervention used and clinical outcome (Pignone et al., 2002, Gilbody et al., 2005, 2008). 
Whilst the efforts of care providers to implement high quality mental health 
care should not be underestimated (Stein et al., 2005), Cully et al. (2009) highlight that 
the identification of patients in need of depression care may require additional 
attention to improving skills of care providers. A new line of evidence indicates that 
a GPs emotional readiness for discussing patients' emotions might be important 
for the detection of depression (Baik et al., 2005). A systematic review suggests that 
combined with guidelines implementation, provider training offers promising results 
for new-onset depression patient samples (Sikorski et al., 2012).  
Targeted case identification (Pignone et al., 2002, Gilbody et al., 2005, 2008) and adequate 
clinical skills in the recognition of patients at who may benefit from treatment (Sikorski 
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et al., 2012), have been argued to be of limited use if access to treatment is poor. Poor 
utilisation of psychological therapies in older people with arthritis and coexisting 
depressive disorders has previously been found in the IMPACT trial where 46% 
patients received any antidepressant treatment and 8% received psychological 
therapy in three months prior to the study (Unützer et al., 2003). A similar pattern of 
treatment utilisation emerged in the current study; out of 57 (39.9%) treated 
patients only 6 (4.2% of the whole sample, 10.5% of the treated group) patients 
were referred to specialist mental health professionals. When IMPACT participants 
were asked about preferences for depression treatment 51% reported that they 
would prefer counselling or psychotherapy clearly demonstrating the need for this 
treatment modality. Consequently, clinicians should be aware that a large 
proportion of patients may have a preference for psychological intervention. To 
address this need, GPs may use the Improving Access to Psychological Therapies 
programme supporting the frontline NHS scheme for implementing NICE 
depression and anxiety guidelines (NHS, IAPT, 2012).    
As delineated in section 7.2.1 on page 228 the identification of depressive 
and anxiety disorders and subsequent management in chronic physical illnesses 
seems to pose challenges for some GPs. Given the evidence of successful 
implementation of collaborative depression care in OA (Lin et al., 2003, 2006) and the 
NICE (2009b) depression guidance for chronic physical illnesses, this model of 
depression care may be beneficial for patients with OA. Collaborative anxiety care 
in patients with OA and is still to be investigated and as yet NICE does not 
recommend this approach. Successful implementation of collaborative anxiety 
care in the CALM trial (Roy-Byrne et al., 2010), however, suggests that this model may 
work in patients with OA, and thus may warrant further investigation. Nevertheless, 
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the GP and the patient with OA may decide that the collaborative anxiety care 
approach would be potentially beneficial for management of anxiety symptoms. 
 
Research implications 
There are three main research implications that go beyond a need of 
replication of this small study in selected primary care practices. Future research 
would benefit from using other approaches to supplement the medical record in 
attempt to gauge detection. For a deeper understanding, interviews with patients 
and GPs may be considered. This approach may help with estimating non-
documented detection, for example due to refusal to be treated or limited access 
to a preferred treatment modality. The role of other health professionals in the 
detection of depression and anxiety in older patients with OA is also still unclear. A 
care pathway analysis can be used in future research to gain a better 
understanding of their role in detection of depression and anxiety. 
There is still much to do to gain a deeper understanding of why some 
patients with OA and depressive and/or anxiety problems are detected and not 
others. It seems that this issue is likely to be more complex, than easily 
measurable person characteristics. The effects of individual differences across 
primary care professionals (e.g. skills, attitude, beliefs) and patients (e.g. 
perception on the problem, need for care, reasons for unmet care) - on the 
detection of depressive or anxiety symptoms coexisting in older primary care 
consulters with musculoskeletal pain remain unclear. Underlying purposes of 
studying this problem is to gain clarity over factors associated with ‘unmet’ needs 
for depression and anxiety management and constituting merits of ‘adequate’ core 
professional skills (including diagnostic skills and personality-related factors, such 
as emotional readiness (Baik, 2005)). 
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Little is known about the consequences of non-detection. Future research 
may follow detected and undetected patients, to compare recovery from 
depressive/anxiety symptoms, mortality rates and OA-related outcomes. Research 
may benefit from a deeper understanding of factors associated with poor 
prognosis at follow-up, in particular contribution of clinical factors such as a 
treatment modality. This type of study may be needed to confidently recommend a 
need for improved identification of depressed or anxious patients. 
 
7.8     CONCLUSIONS 
Only half of all older musculoskeletal patients with persistent anxiety or 
depression symptoms have their mental health problems detected by their GP, 
despite using a definition of detection that includes not only Read coded 
consultations, but also evidence of treatment including referral and prescription. 
Patients frequently consulting their GPs and experiencing more severe anxiety 
symptoms are most likely to be detected. This study re-iterates a problem of 
implementing effective detection strategies for patients with painful conditions 
(Menchetti et al., 2009). This investigation highlights the importance of patients’ 
awareness in their role in recognition and management of depression and anxiety 
problems (i.e. acknowledging the problem and self-managing it). It also highlights 
the need for GPs to be aware of their role in supporting patients in recognising 
these problems and making informed decisions about management (including the 
use of NHS resources). A deeper understanding of reasons underlying under-
detection and effects of non-detection to patient outcomes in patients with OA still 
warrants further investigation.  
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Chapter eight: Discussion, conclusions and recommendations  
 
8.1    INTRODUCTION 
This thesis arose from a need to advance our understanding of coexisting 
anxiety and/or depression in patients with osteoarthritis (Katon et al., 2007, Scopaz et al. 2009). 
Previous studies found that depression/anxiety (RCGP, 2006) and OA are common in 
primary care settings (RCGP, 2007) and that they are likely to coexist (e.g. Sartorius et al., 1996, 
Gureje et al., 1998, Katon et al., 2007). Depressive and anxiety symptoms are known to have 
adverse effects on well-being of people with OA, including functioning, general 
health and disability (e.g. Moussavi et al., 2007, Mallen et al., 2007, Scopaz et al., 2009). According to 
modern psychological models of adjustment to pain (section 1.3.2 on page 12), 
bio-psycho-social factors are likely to be involved in the bi-directional relationship 
between depressive and anxiety responses to OA-related pain. Previous studies 
suggest that the management of depression and anxiety symptoms is challenging 
in older people and with chronic physical illness (Burroughs et al., 2006, Kendrick et al., 2009, Licht-
Strunk et al., 2009a, Van Rijswijk et al., 2009, Coventry et al., 2011). However, effective models of 
depression and anxiety care exist, and can be beneficial not only for mental health 
care, but also for functioning, general health and disability (Lin et al., 2003, 2006, Roy-Byrne et 
al., 2010). The importance of the recognition and management of both depressive 
and anxiety symptoms coexisting with OA has been raised by many researchers 
and has been recently highlighted by the King’s Fund and Centre for Mental 
Health Group (Naylor et al., 2012). This chapter presents a discussion of the work 
undertaken in this thesis and the contribution of this work to knowledge in this 
field. It starts with a summary of the main findings and is followed by a critical 
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reflection on the key decisions made. It ends with a consideration of the 
implications of this thesis for future research and clinical practice. 
 
8.2     SUMMARY OF THE MAIN FINDINGS  
The thesis started with a fundamental question about the epidemiology of 
depression and anxiety coexisting with OA in community-dwelling adults. For this 
purpose a large systematic review with meta-analyses was conducted. The 
findings from 36 unique original prevalence studies were synthesised, providing 
‘best estimates’ (although based on highly heterogeneous estimates from 
individual studies) of frequency of a range of anxiety and depressive disorders and 
symptoms in people with OA. See Table 8.1 for a list of pooled ‘best estimates’. 
These estimates of depression and anxiety concurrent with OA highlight the 
importance of anxiety and depression problems. Heterogeneity of these estimates 
reflects issues surrounding definitions, methods of ascertainment and between-
study variance. 
 
Table 8.1 Summary of pooled ‘best estimates’ of frequency of occurrence in 
people with OA. 
 
 ‘Best estimate’ of frequency 
of occurrence in people with 
OA (%) 
Anxiety:  
     Anxiety symptoms: mild or worse 
     Anxiety symptoms: moderate or worse 
     Generalised anxiety disorder 
     Social phobia 
     Panic disorder 
     Panic with agoraphobia 
     Post-traumatic stress disorder 
45% 
21% 
3% 
3% 
3% 
2% 
2% 
Depression:  
     Depression symptoms: mild or worse 
     Depression symptoms: moderate or worse 
     Major depressive disorder 
     Dysthymia 
24% 
15% 
7% 
3% 
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Various self-report anxiety and depression measures are used in both UK 
primary care and OA research. A non-systematic review of measurement 
properties of several recommended patient-reported measures of depression 
symptoms (BDI-II and -Primary Care versions; HADS-D, PHQ-2- and -9 item 
versions) and anxiety (GAD-2 and -7 item versions; HADS-A) was conducted. In 
total, 42 articles were included. There is evidence to support some properties in 
some populations, but some critical properties warrant investigation, particularly in 
older people with OA/joint pain in the community. The feasibility and reliability of 
the reviewed questionnaires appears well-supported, but there is less evidence for 
acceptability and criterion validity. With specific reference to the HADS - a 
questionnaire used later in the thesis - it was concluded to perform adequately as 
a measure for assessing the course of depressive and anxiety symptoms (albeit 
the possibility of criterion contamination in the anxiety subscale). Likewise other 
reviewed questionnaires, point estimates based on HADS serve poor proxy for 
depressive and anxiety disorders, but multiple assessments can be expected to 
more reliably indicate anxiety and depressive problems. 
Following critical consideration of the strengths and weaknesses of the 
secondary data source, the persistence of depressive and anxiety symptoms in a 
group of consecutive, older people consulting their GPs about their 
musculoskeletal pain was investigated. Latent class growth analysis (a person-
centred method tailored for longitudinal data analysis) was used. Discrete 12-
month post-consultation trajectories (also called clusters) of symptoms of anxiety 
and depression based on HADS anxiety and depression scores (dichotomised 
using a cut-off point score ≥8) were identified. These analyses were based on 
participants who provided complete anxiety and depression data, where no 
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evidence of substantial selection was found. Identified anxiety and depression 
symptoms trajectories are presented in Table 8.2. Persistent depression 
symptoms more commonly co-occurred with persistent anxiety symptoms (47%), 
than transient anxiety (16%) and no anxiety symptoms (7%). At baseline 48.5% 
and 26.5% of older patients consulting with musculoskeletal pain reported ‘mild or 
worse’ (score ≥8) anxiety and depression symptoms respectively. Persistent 
anxiety (30%) and depressive (22%) symptoms were common. With the aim to 
identify persons with persistent depressive and anxiety problems, it can be 
expected that 56% and 63% patients with ‘mild or worse’ anxiety and depression 
symptoms respectively at the initial presentation will have persistent anxiety and 
depression symptoms. 
 
Table 8.2 Discrete trajectories of anxiety and depression symptoms nested 
in LCGA anxiety and depression models. 
 
Anxiety symptoms 
 
Depression symptoms 
Identified trajectories 
 
n     (%) Identified trajectories 
 
n      (%) 
 
No anxiety symptoms 119 (40.6%) 
 
No depression symptoms 232 (77.8%) 
Persistent anxiety 
symptoms 
88   (30.0%) 
 
Persistent depression 
symptoms 
66   (22.2%) 
Transient anxiety 
symptoms  
86   (29.4%) 
 
  
Total: 293 (100%)  298 (100%) 
 
Following careful selection of baseline variables, a group of person-
characteristics were examined for associations with trajectories, using backward 
elimination logistic regression (for the 2-cluster LCGA depression model) and 
backward elimination multinomial logistic regression (for the 3-cluster LCGA 
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anxiety model). To improve statistical power of these analyses, sample sizes were 
increased. Analyses were based on samples with HADS depression scores 
(n=368) and anxiety scores (n=368) reported at minimum 3 time points, where 
each participant was assigned a cluster membership by re-estimating the selected 
optimal models. Pain characteristics and coping strategies were the most 
prominently associated with persistent depression symptoms and persistent 
anxiety symptoms (see Table 8.3 for a brief summary of the results of regression 
analyses). The identified factors have the potential to inform identification of 
persisting symptoms of anxiety or depression.  
 
Table 8.3 Backward elimination multinomial logistic and logistic regression 
analyses of baseline covariates and trajectories of anxiety and depression 
symptoms respectively.  
 
 Anxiety  
trajectories 
Depression 
trajectories 
Baseline covariates No anxiety 
symptoms† vs. 
Persistent anxiety 
symptoms  
No anxiety 
symptoms† vs. 
Transient 
anxiety 
symptoms  
No depression 
symptoms† vs. 
Persistent 
depression 
symptoms  
 Adj. OR (95%CI) Adj. OR (95%CI) Adj. OR (95%CI) 
Age 70 years or older - - 3.03 (1.57, 5.84) 
Catastrophising 4.14 (1.93, 8.87) 2.79 (1.30, 6.00) 1.85 (0.96, 3.55) 
Coping by increased 
behavioural activities 
0.40 (0.22, 0.75) 0.55 (0.31, 1.00) 0.51 (0.27, 0.96) 
Lack of instrumental 
support 
6.99 (1.75, 27.85) 1.54 (0.31, 7.60) 3.63 (1.32, 9.98) 
Manual/routine work 1.33 (0.70, 2.54) 2.39 (1.31, 4.37) - 
Number of pain sites  
(0-44) 
1.08 (1.0, 1.14) 1.06 (0.01, 1.11) 1.08 (1.04, 1.13) 
Pain interference with 
social activities (0-10) 
- - 1.30 (1.14, 1.48) 
Pain interference with 
work (0-10) 
1.21 (1.08, 1.36) 1.19 (0.006, 1.33) - 
Note: † - a reference category. 
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Finally, 143 individuals identified from previous analysis as experiencing 
persistent anxiety and/or depression symptoms were used to investigate how often 
there was evidence that these problems had been detected in primary care. Data 
indicative of the documented detection of depression and anxiety was selected for 
extraction from the medical records, including diagnosis/problem codes and 
interventions. Analyses focused on a one year period following the index 
consultation (the main period of observation) found that 29% of patients were 
detected. However, as many as 25% patients had their depression and or anxiety 
problems detected within the year before first HADS data was collected. After the 
period of medical record review was extended one year either side of the main 
period of observation, 43% of all older musculoskeletal patients with persistent 
anxiety and depression symptoms had their mental health problems detected by 
their GP. In this sub-population of patients (as found using multivariable logistic 
regression analyses) those who consult more frequently (OR: 0.98, 95% CI 0.96, 
0.99) and have more severe anxiety symptoms (OR: 0.82, 95%CI 0.70, 0.98) will 
be significantly less likely to have their depression and/or anxiety problem 
undetected by their GP. Figure 8.1 overleaf presents a diagram summarising the 
key findings of this thesis. 
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Figure 8.1  Diagram summarising the key finding of this thesis. 
 
 
 
 
 
 
 
  
 
 
 
 
   
 
 
 
 
 
 In total, 43% of people with persistent depressive or anxiety 
symptoms were detected by their GPs over the 3-year period 
 25% participants had their problems detected within the year 
before the first HADS data collection 
 29% participants  had their problem detected during the time 
period of HADS data collection, based on which the anxiety and 
depression trajectories were estimated 
 Patients with higher numbers of consultations and more severe 
anxiety symptoms are more likely to have their depression and/or 
anxiety problems detected 
 
 
 
 
 Pooled estimate of ‘mild or worse’ symptoms of depression is 24% 
and anxiety is 45%  
 Pooled estimate of ‘moderately severe or worse’ symptoms of 
depression is 15% and anxiety is 21%  
 With the exception of major depression (7.3%), specific comorbid 
anxiety and depressive disorders are rare (<5.0%)   
 Large discrepancies in reported prevalence rates of depression and 
anxiety are apparently related to study geographical location and 
methods of ascertainment, but effects of explored factors were 
small and statistically non-significant 
 Anxiety is under-researched  
 
 
 
 
 
 
 Three anxiety symptom and two depression symptom trajectories 
identified over the 12-month period 
 20% and 30% participants had persistent depressive and anxiety 
symptoms respectively  
 63% of depressed and 56% of anxious people at baseline had 
persistent symptoms for at least 12 months 
 Persistent anxiety and depression symptoms frequently co-occur 
 Persons with persistent depression symptoms are likely to be 
older, report more widespread pain, more severe pain interference 
with social activities, less often cope with pain through increased 
behavioural activities and perceive a lack of instrumental support 
 Persons with persistent anxiety symptoms are likely to 
catastrophise, report more widespread pain, more severe pain 
interference with work, perceive a lack of instrumental support and 
less often cope with pain by increased behavioural activities 
Prevalence of depression and anxiety in adults with osteoarthritis/joint 
pain: a systematic review and meta-analyses 
 
 
 
 There is evidence to support some measurement properties in 
specific populations, but several critical properties are not evident  
 Direct, head-to-head comparisons of anxiety and depression 
measures within the subpopulation of older primary care patients with 
OA may be needed to confirmation of their adequate performance  
 HADS can adequately assess symptoms over time, with ‘somatic 
bias’ being more likely for the anxiety subscale. The tool very limited 
in the ability to accurately diagnose depressive and anxiety 
disorders. 
The course of anxiety and depression symptoms in older patients 
presenting to general practice with musculoskeletal pain 
Self-report measures for depression and anxiety symptom screening and 
assessment in osteoarthritis: a narrative review of selected measurement 
properties 
Documented detection of depression and anxiety in older adults 
consulting with musculoskeletal pain: analyses of medical record data 
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8.3 KEY DECISIONS AND THEIR IMPLICATIONS FOR THE  
INTERPRETATION OF THIS THESIS 
In this section some of the critical overarching issues that affect the thesis and the 
interpretation of the findings will be discussed. 
 
8.3.1  Definition of OA 
A key issue impacting on the interpretation of the findings in thesis is the 
definition of osteoarthritis used. The development of a satisfactory definition of OA 
has presented substantial difficulties (Hurley et al., 2007). This issue also became 
apparent in analyses of prevalence rates conduced in chapter two. Traditional 
methods of defining OA, such as examination of radiographic changes or the 
American College of Rheumatology (Altman et al., 1986, 1990) clinical classification criteria 
are commonly criticised (Schouten & Valkenburg, 1995, Bierma-Zeinstra et al., 1999, Peat et al., 2006b). 
Evidence suggests that ‘formal’ diagnosis may pose a challenge to many GPs 
(Bierma-Zeinstra et al., 2000,  Bedson et al., 2005, Peat et al., 2005). NICE (2008) uses a clinical 
syndrome definition, using the clinical signs and symptoms associated with OA 
which include use-related joint pain, joint stiffness and bony swelling associated 
with substantial functional limitation. In general practice, the diagnosis is typically 
driven by clinical judgment and is reached upon elimination of other possible 
causes (Altman et al., 2009). The majority of studies summarised in the systematic 
review included patients with joint pain, where the prevalence of depression 
symptoms was comparable to other definitions (with the exception of medical 
record based definitions). The PROG-RES participants had musculoskeletal pain 
that included a mixture of both OA-related and OA non-related pain reflecting the 
range of conditions typically encountered in primary care. Whilst many of these 
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patients have no ‘formal ACR’ diagnosis of OA, they are generalisable to the wider 
population of older people with musculoskeletal pain, many of whom will meet the 
clinical definition of osteoarthritis. 
  
8.3.2  Using secondary data analyses  
The use of repeated data collection over a one year period, linked to 
medical record data makes the PROG-RES study a good data source to answer 
the questions set out in this thesis. The sample itself is of limited 
representativeness to ethnic minority patients and for practices scoring lower than 
the national average Quality and Outcomes Framework score. The possibility of 
attrition bias was identified and the subsequent reduction in the prevalence of 
anxiety and depression symptoms was found. Preliminary data analyses 
conducted in chapter four suggested a small and statistically insignificant decrease 
in prevalence rates over time.  
One limitation of this study is the lack of inclusion of variables that may be 
important in determining the relationship between OA and mental health problems. 
These include patient intrapersonal factors (e.g. attitudes, personality), stress 
factors (e.g. psychopathologies), clinical factors (e.g. effects of treatment) and 
qualitative aspects of socio-ecological factors on the progress of symptoms. This 
kind of limitation is a common problem in secondary data analyses (Boslough, 2007, 
Vartanian, 2010). 
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8.4        IMPLICATIONS 
8.4.1    Implications for clinical practice 
       There are several direct implications of this thesis for primary care practice 
that will be discussed in the following section. Primary care professionals should 
be vigilant to the depressive/anxiety symptoms that frequently coexist in patients 
with OA/joint pain. Clinicians need to be prepared to face the challenge of 
recognising these symptoms, and formulate appropriate care plans in conjunction 
with their patients. Whilst the routine screening of patients with OA is currently not 
feasible, active case identification of those most at risk is a realistic option to 
identify those most in need of intervention. Focusing on persistent, rather than 
transient, symptoms is likely to have a greater impact on improving outcomes for 
those at risk of a poor outcome, although the impact of mild and moderate 
symptoms upon older people should not be underestimated. Healthcare 
professionals reported making efforts to distinguish between these two (van Rijswijk et 
al., 2009, Barley et al., 2011). 
In UK primary care practice, as shown by Kendrick et al. (2009) self-report 
depression measures are likely to assist the process of identification. As shown in 
chapters three and five, diagnosis based on a single HADS assessment, could 
lead to misclassification of transient forms of anxiety and depression symptoms. 
Adequate measurement properties are important for assisting recognition of 
people who have the persistent anxiety and/or depression problem, and thus, are 
likely to most benefit from treatment. Chapter three was unable to confidently 
identify the most appropriate measure to assess anxiety and depression 
symptoms in older adults with OA. As the persistence of symptoms is a common 
characteristic, adequate responsiveness to changes in people with OA seems a 
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particularly important measurement property to consider (in combination with 
feasibility, acceptability, reliability and validity). Awareness of person-related 
characteristics associated with the progress of symptoms, may assist the process 
of identifying patients with persistent symptoms of depression and anxiety. 
Advantageously, primary healthcare professionals are likely to be already 
acknowledging the importance of a wider patient context in the diagnosis and 
management of the problem of depression (Dowrick et al., 2009, Barely et al. 2011). The work 
undertaken in this thesis supports focusing on pain-related aspects (i.e. pain 
extent and functional disability) and psychological factors (coping by 
catastrophising and increased behavioural activities).  
An annual review may offer an opportunity to assess depression symptoms 
persistence as defined by NICE (2009b) depression guidance for chronic physical 
illnesses (present for a considerable time despite ‘active monitoring’ or low- 
intensity treatment). Whilst clinical guidance for anxiety in chronic physical illness 
is currently lacking, in seeking to recognise persistent anxiety problems GPs may 
choose to use the same approach as for persistent depression symptoms. ‘Active 
monitoring’, may involve the stepped approach to diagnosing depression problems 
in general practice, as delineated by an academic GP Lucassen et al.  (2008). This 
theoretical model makes use of the benefit that GPs have “over other healthcare 
workers because of personal continuity in a longstanding relation with the patient” 
(Lucassen et al., p.164, 2008). It also emphasises the importance of hearing the patient’s 
story, agreeing with the patient on the name of the combination of symptoms and 
agree on the relative importance of the problem. This view is echoed in findings of 
the systematic review of study of how patients understand depression with chronic 
physical diseases (Alderson et al., 2012). This study found a range of beliefs about 
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diagnostic labels, the origins of the problem and appropriateness of medication, 
suggesting a need for developing approaches to recognition and management, 
which are sensitive to a range of these beliefs (Alderson et al., 2012). As patients often 
view emotional representations for depression and anxiety as related (Alderson et al., 
2012) they should be considered jointly, with equal attention paid to both. Healthcare 
professionals are likely to already have this perspective on depression and anxiety 
(Coventry et al., 2011, Van Rijswijk et al., 2009). Perhaps, their efforts should focus on recognising 
in older patients with OA those with self-perceived problems of depression and/or 
anxiety and a need for managing these problems. This is important as these 
patients are at risk of the worst course of anxiety and depression symptoms- as 
shown by van Beljouw et al.’s (2010) study with primary care patients. Primary care 
health professionals should be prepared to discuss treatment options and facilitate 
access to relevant health professionals. Given an apparent problem of the limited 
consultation time, GPs may need to collaborate with trained practice nurses or 
other healthcare professionals. One systematic review (Barley et al., 2011) suggested 
that GPs may often view practice nurses’ role in recognition and management of 
late-life depressive disorders as limited (Burroughs et al., 2006). This approach may need 
to be challenged as practice nurses seem to view themselves as being in a better 
position to do these tasks, due to more time available and operating in a more 
holistic context (Murray et al., 2006). Since the recognition and treatment of late-life 
anxiety disorders is not supported by the QOF component of general practice 
contract, practice nurses’ role in management of this problem may be even more 
limited, though this requires more investigation. 
Whilst keeping in mind these important implications, the findings of this 
thesis should not be used to promote a predominant focus on OA-related 
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depression and anxiety symptoms. OA-related anxiety and depression symptoms 
are indicative of difficulties with adjustment to OA, and thus, should trigger co-
interventions to minimise psychological and physiological symptoms and optimise 
functioning. There is still much to be done to improve the management of OA 
(Dziedzic et al., 2009). However, a good starting point may be helping patients to 
understand OA (including identity, impact, prognosis and current management 
options) and the impact of coexisting depressive/anxiety symptoms. This may be 
important as illness perception is known to influence coping strategies in patients 
in medical patients (Hagger & Orbell, 2003) and health outcomes in people with OA (Hill et al., 
2007). Evidence suggests that the greatest impact of the disease lies in the effect it 
has on their ability to continue with a ‘normal’ daily life (Hill et al., 2007). To date, there 
is no treatment that can preserve this ability, although new promising treatments 
(i.e. anti-nerve growth factor (Lane et al., 2010) and strontium (Cooper et al., 2012)) have been 
developed. In contrast, shifting patients’ perception of illness through acceptance 
of pain and value-based action (using acceptance-commitment therapy) (Hayes et al, 
1999) was found to improve pain, depression, pain-related anxiety, disability, 
medical visits, work status, and physical performance (Vowles & McCracken, 2008).  
One of the many challenges faced by NICE is to address a need for 
feasible and explicit guidance in managing psychological and physiological 
symptoms of OA. The challenge for policy makers is the adequate provision of 
required resources, including access to depression and anxiety interventions – 
such as acceptance-commitment therapy (Hayes et al., 1999) (offering a promising 
potential for reduction of both psychological and OA-related symptoms). This is 
essential as management of persistent depression and anxiety symptoms is 
unlikely to be successful without relevant interventions (Gilbody et al., 2005, 2008).  
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8.4.2   Implications for patients 
It is perhaps true that some primary care health professionals lack 
knowledge and skills to recognise and manage coexisting depressive and anxiety 
disorders in patients with OA. Consequently their attitude reinforces patient 
normalising or deprioritising of depressive/anxiety symptoms. Nevertheless, it is 
also the role of the patient to be active in the recognition and management of their 
depressive and anxiety symptoms. Huber et al. (2011) recently challenged the 
WHO definition of health as focused on the absence of disease. The authors 
suggested a need for a shift towards supporting “the ability to adapt and self-
mange in the face of social, physical and emotional challenges” (Huber et al., p.1, 2011). 
Although from the perspective of some GPs it is reasonable not to dismiss the 
WHO definition entirely (Tallini, 2011, Lewis, 2011), patient awareness of their role in 
management may be critical for improving the long-term prognosis. 
There is ample evidence to suggest that some patients with chronic 
physical illnesses may find it difficult to acknowledge the need for depression help 
(Alderson et al., 2012). This seems to be related to a range of personal beliefs about 
diagnostic labels, causes, relevance and acceptability of treatment modalities 
social stigma, the course of symptoms or negative views about consequences of 
the disease (Alderson et al., 2012). Many of these patients view the GP as the right 
person to approach, given favourable circumstances (e.g. the patient’s awareness 
of the problem and wish to disclose it and the GP’s skills and beliefs) (Alderson et al., 
2012). Evidence suggests that primary care health professionals are willing to 
recognise and manage the problem of depression and anxiety, despite associated 
difficulties (Van Rijswijk et al., 2009, Barley et al., 2011, Coventry et al., 2011). Therefore, GPs may have 
a unique opportunity to overcome patients’ personal barriers. Nevertheless, 
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evidence suggests that perhaps practical issues may serve an additional obstacle 
for a patient to disclose the problem of depression, including limited consultation 
time or availability of access to preferred treatment modality (Kadam et al., 2001). Since 
the NHS aspires to implement the principles of person-centred care, patients can 
assume their right to negotiate their concerns over limited consultation time and 
availability of access to relevant treatment. Seeking advice from a GP is one of a 
patient’s rights, but given the organisational limitations of the NHS, it may be that a 
patient may need to opt for additional help from alternative sources. For example, 
the Arthritis Care (Arthritis Care, 2013) and the UK Expert Patients Programme (Expert 
Patients Programme Community Interest Company, 2012) provide and deliver free information on 
self-management of emotional responses to OA on a daily basis. Still, currently 
research cannot inform patients on acceptability and impacts of this type of 
support on psychological well-being and their use is likely to be depending on a 
patient’s awareness of their existence. 
 
8.4.3   Implications for future research 
A large study with community–based adults with OA (including primary care 
consulters and non-consulters) is needed to compare psychometric and clinimetric 
properties of the HADS, BDI, PHQ and GAD. Investigated measurement 
properties, should include properties relevant to usefulness in identifying persistent 
symptoms over time (e.g. test-retest reliability, responses to changes, minimal 
clinically significant change and associations with OA-related outcomes). This kind 
of study may be designed to serve the purpose of validating discrete trajectories of 
anxiety and depression symptoms. Analyses should include a period of 2 years, as 
NICE definitions of persistent symptoms refer to this period of time, and involve 
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comparison of trajectories based on the HADS, PHQ, BDI and GAD measures. 
The most appropriate measure for primary care use should be recommended 
based on measurement properties and upon the evaluation of criterion validity of 
persistent symptoms based on this questionnaire. Analyses of factors associated 
with cluster membership, should include factors found to be significant in this 
thesis and consider some of the modifiable outcomes that were omitted in this 
work. These factors may be related to the GP (e.g. attitude to depression and 
anxiety care, emotional readiness, relevant professional skills and experience) and 
the patient (e.g. locus of control, attitude to mental health treatment, perceived 
problem and need for care). Other factors worth consideration are availability of 
relevant intervention, effects on OA, depression and anxiety treatments and 
qualitative aspects of socio-ecological factors. Next, dual anxiety and depression 
symptoms modeling should be conducted, including time-varying covariance with 
a few most prominent predictors of cluster membership or stratified by type (e.g. 
pain characteristics, intrapersonal factors, coping or treatment effects). Finally, this 
cohort may be used to evaluate contribution of factors associated with the 
persistence of symptoms on improved identification and impact of health 
outcomes. 
Collaborative anxiety care warrants investigation in people with OA, using 
pragmatic a randomised controlled trial as opposed to an exploratory RCT. 
Importantly, in future studies the precise impact of issues surrounding 
management of depressive and anxiety symptoms need to be estimated. A study 
design similar to that used by van Beljouw et al. (2010) can be used to identify 
patients with met and un-met depression and anxiety care needs. These two 
groups could be then compared across potential obstacles to management (e.g. 
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GP-related and patient-related factors discussed in the paragraph above, 
availability of mental health support resources) and followed by care pathway 
analyses. This kind of study would help to identify the main obstacles to successful 
management of depression and anxiety problems in people with OA and 
subsequently help to optimise health care resources.  
 
277 
 
References 
Abdollel M, Leblanc M, Stephensen D, Harrison RV. Binary partitioning for 
continuous longitudinal data: categorizing a prognostic variable. Statistics in 
Medicine 2002; 21(22): 3395-409. 
Ahrens W, Pigeot I. Handbook of epidemiology. Berlin or Heidelberg: Springer; 
2005.  
Alderson SL, Foy R, Glidewell L, McLintock KL, House AO. How patients 
understand depression associated with chronic physical disease-a systematic 
review. BMC Family Practice 2012; 13(1): 41.  
Ali S, Stone M, Peters J, Davies M, Khunti K. The prevalence of co‐morbid 
depression in adults with Type 2 diabetes: a systematic review and meta‐analysis. 
Diabetic Medicine 2006; 23(11): 1165-1173.  
Allen KD, Renner JB, Devellis B, Helmick CG, Jordan JM. Osteoarthritis and 
sleep: the Johnston county osteoarthritis project. Journal of Rheumatology 2008; 
35(6): 1102-1107. 
Altman RD, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke 
TD, Greenwald R, Hochberg M, Kaplan D, Koopman W, Longley S III, Mankin H, 
McShane DJ, Medsger T Jr, Meenan R, Mikkelsen W, Moskowitz R, Murphy W, 
Rothschild B, Segal M, Sokoloff L, Wolfe F. Development of criteria for the 
classification and reporting of osteoarthritis: classification of osteoarthritis of the 
knee. Arthritis and Rheumatism 1986; 29(8): 1039-1049.  
Altman D. Practical statistics for medical research. London: Chapman and Hall; 
1991.  
Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, Brown C, 
Cooke TD, Daniel W, Feldman D, Greenwald R, Hochberg M, Howeli D, Ike R, 
Kapila P, Kaplan D, Koopman W, Marino C, Mcdonald E, Mcshane DJ, Medsger 
T, Michel b, Murphy WA, Osial T, Ramsey-Goldman R, Rothschild B, Wolfe F. The 
American College of Rheumatology criteria for the classification and reporting of 
osteoarthritis of the hip. Arthritis and Rheumatism 1991; 34(5): 505-514.  
Altman RD, Kuritzky L, Ruoff G. Improving long-term management of 
osteoarthritis: Strategies for primary care physicians. Journal of Family Practice 
2009; 58(2 Suppl): S17-S24. 
American Psychiatric Association (APA). Diagnostic and Statistical Manual: Mental 
Disorders. Washington, DC: American Psychiatric Association; 1952.  
American Psychiatric Association (APA). Diagnostic and Statistical Manual of 
Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 
1994.  
 
278 
 
American Psychiatric Association (APA). Diagnostic and Statistical Manual of 
Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric 
Association; 2000. 
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid 
depression in adults with diabetes. Diabetes Care 2001; 24(6): 1069-1078.  
Andrews G, Peters L. The psychometric properties of the composite international 
diagnostic interview. Social Psychiatry and Psychiatric Epidemiology 1998; 33(2): 
80-88.  
Andrews G, Slade T. The classification of anxiety disorders in ICD-10 and DSM-
IV: a concordance analysis. Psychopathology 2002; 35(2-3): 100-106.  
Andrews G, Slade T, Peters L. Classification in psychiatry: ICD-10 versus DSM-IV. 
British Journal of Psychiatry 1999; 174: 3-5.  
Angst F, Verra ML, Lehmann S, Aeschlimann A. Responsiveness of five condition-
specific and generic outcome assessment instruments for chronic pain. BMC 
Medical Research Methodology 2008; 8: 26. 
Ani C, Bazargan M, Hindman D, Bell D, Farooq MA, Akhanjee L, Yemofio F, Baker 
R, Rodriguez M. Depression symptomatology and diagnosis: discordance between 
patients and physicians in primary care settings. BMC family practice 2008; 9(1): 
1.  
Appelt CJ, Burant CJ, Siminoff LA, Kwoh CK, Ibrahim SA. Arthritis-specific health 
beliefs related to aging among older male patients with knee and/or hip 
osteoarthritis. Journals of Gerontology Series A: Biological Sciences and Medical 
Sciences 2007; 62(2): 184-190.  
Arbabzadeh-Bouchez S, Tylee A, Lepine JP. A European perspective on 
depression in the community: the DEPRES study. CNS spectrums 2002; 7: 120-
128.  
Arnau RC, Meagher MW, Norris MP, Bramson R. Psychometric evaluation of the 
Beck Depression Inventory-II with primary care medical patients. Health 
Psychology 2001; 20(2): 112.  
Arola H, Nicholls E, Mallen C, Thomas E. Self-reported pain interference and 
symptoms of anxiety and depression in community-dwelling older adults: Can a 
temporal relationship be determined? European Journal of Pain 2010; 14(9): 966-
971.  
Aroll B, Khin N, Kerse N. Screening for depression in primary care with two 
verbally asked questions: cross-sectional study. BMJ 2003; 327: 1144-1146. 
Arroll B, Goodyear-Smith F, Crengle S, Gunn J, Kerse N, Fishman T, Falloon K, 
Hatcher S.Validation of PHQ-2 and PHQ-9 to screen for major depression in the 
primary care population. Annals of Family Medicine 2010; 8(4): 348-353.  
279 
 
Arthritis Care. Understanding your feelings. 2011; Available at: 
http://www.arthritiscare.org.uk/LivingwithArthritis/Self-
management/Understandingyourfeelings. Accessed 13/02/2013. 
Arthritis and Musculoskeletal Alliance (ARMA). Standards of Care for People with 
Osteoarthritis. 2004; Available at: http://www.arma.uk.net/care.html. Accessed 
02/11/2011.  
Arthritis Research Campaign (ARC). Arthritis: the Big Picture. 2002; Available at: 
http://www.ipsos-mori.com/Assets/Docs/Archive/Polls/arthritis.pdf. Accessed 
11/12/2010.  
Asmundson GJG, Norton PJ, Vlaeyen JWS. Fear-avoidance models of chronic 
pain: an overview. In: Asmundson GJG, Vlaeyen JWS, Crombez G, editors. 
Understanding and treating fear of pain Oxford, UK: Oxford University Press; 
2004. p. 3-24.  
Axford J, Butt A, Heron C, Hammond J, Morgan J, Alavi A, Bolton J, Bland M. 
Prevalence of anxiety and depression in osteoarthritis: use of the Hospital Anxiety 
and Depression Scale as a screening tool. Clinical Rheumatology 2010; 29(11): 
1277-1283.  
Badcock L, Lewis M, Hay E, McCarney R, Croft P. Chronic shoulder pain in the 
community: a syndrome of disability or distress? Annals of the Rheumatic 
Diseases 2002; 61(2): 128-131.  
Baik SY, Bowers BJ, Oakley LD, Susman JL. The recognition of depression: the 
primary care clinician’s perspective. Annals of Family Medicine 2005; 3(1): 31-37.  
Baker TA. Arthritis symptoms as indicators of pain in older African Americans. 
Ethnicity & Disease 2003 Fall; 13(4): 513-520.  
Bakke P, Gulsvik A, Lilleng P, Overå O, Hanoa R, Eide GE. Postal survey on 
airborne occupational exposure and respiratory disorders in Norway: causes and 
consequences of non-response. Journal of Epidemiology and Community Health. 
1990; 44(4): 316-320.  
Barberger-Gateau P, Chaslerie A, Dartigues JF, Commenges D, Gagnon M, 
Salamon R. Health measures correlates in a French elderly community population: 
the PAQUID study. Journal of Gerontology 1992; 47(2):88-95.  
Barley EA, Murray J, Walters P, Tylee A. Managing depression in primary care: A 
meta-synthesis of qualitative and quantitative research from the UK to identify 
barriers and facilitators. BMC family practice 2011; 12(1): 47.  
Barnard KD, Skinner TC, Peveler R. The prevalence of co-morbid depression in 
adults with Type 1 diabetes: systematic literature review. Diabetic Med 2006; 23: 
445-448.  
 
280 
 
Bauer DJ, Curran PJ. Overextraction of Latent Trajectory Classes: Much Ado 
About Nothing? Reply to Rindskopf (2003), Múthen (2003), and Cudeck and Henly 
(2003); Psychological Methods 2003; 8: 384-393. 
Bay EJ, Algase DL. Fear and anxiety: a simultaneous concept analysis. 
International Journal of Nursing Knowledge 1999; 10(3): 103-111.  
Beck AT, Steer RA. Manual for the Revised Beck Depression Inventory. San 
Antonio, TX: Psychological Corporation; 1993.  
Beck AT, Steer RA, Ball R, Ciervo CA, Kabat M. Use of the Beck Anxiety and 
Depression Inventories for primary care with medical outpatients. Assessment; 4: 
1997.  
Beck A, Steer R, Brown G. Manual for beck depression inventory II (BDI-II). San 
Antonio, TX: Psychology Corporation; 1996.  
Bedson J, Jordan K, Croft P. The prevalence and history of knee osteoarthritis in 
general practice: a case–control study. Family Practice 2005; 22(1): 103-108. 
Beekman A, Deeg D, Geerlings S, Schoevers R, Smit J, Van Tilburg W. 
Emergence and persistence of late life depression: a 3-year follow-up of the 
Longitudinal Aging Study Amsterdam. Journal of Affective Disorders 2001; 65(2): 
131-138.  
Beesdo K, Hoyer J, Jacobi F, Low NCP, Höfler M, Wittchen HU. Association 
between generalized anxiety levels and pain in a community sample: evidence for 
diagnostic specificity. Journal of Anxiety Disorders 2009; 23(5): 684-693. 
Bierma-Zeinstra S, Bohnen A, Ginai A, Prins A, Verhaar J. Validity of ACR criteria 
for diagnosing hip osteoarthritis in primary care research. Journal of 
Rheumatology 1999; 26: 1129-1133.  
Bierma-Zeinstra SM, Lipschart S, Njoo KH, Bernsen R, Verhaar J, Prins A, 
Bohnen AM. How do general practitioners manage hip problems in adults? 
Scandinavian Journal of Primary Health Care 2000; 18(3): 159-164. 
Blanchard RJ, Blanchard DC. Attack and defense in rodents as ethoexperimental 
models for the study of emotion. Progress in Neuro-Psychopharmacology & 
Biological Psychiatry 1989; 13: S3-S14.  
Bland JM, Altman DG. Statistics notes: Cronbach’s alpha. BMJ 1997; 314 (7080): 
572. 
Blettner M, Sauerbrei W, Schlehofer B, Scheuchenpflug T, Friedenreich C. 
Traditional reviews, meta-analyses and pooled analyses in epidemiology. 
International Journal of Epidemiology 1999; 28(1): 1-9. 
 
281 
 
BMA (British Medical Association), GPC (General Practitioners Committee). 
Employers National Health Service (NHS). Quality and Outcomes Framework 
guidance for GMS contract 2009/10. 2009; Available at: 
www.nhsemployers.org/Aboutus/Publications/Documents/ 
QOF_Guidance_2009_final.pdf. Accessed 21/07/2010.  
Boardman J, Henshaw C, Willmott S. Needs for mental health treatment among 
general practice attenders. The British Journal of Psychiatry 2004; 185(4): 318-
327.  
Borenstein D. Does osteoarthritis of the lumbar spine cause chronic low back 
pain? Current Rheumatology Reports 2004; 6(1): 14-19. 
Boslaugh S. Secondary data sources for public health: a practical guide. 
Cambridge: Cambridge University Press; 2007.  
Bot S, Terwee C, Van der Windt D, Bouter L, Dekker J, De Vet H. Clinimetric 
evaluation of shoulder disability questionnaires: a systematic review of the 
literature. Annals of the Rheumatic Diseases 2004; 63(4): 335-341.  
Bowers J, Jorm A, Henderson S, Harris P. General practitioners' detection of 
depression and dementia in elderly patients. Medical Journal of Australia 1990; 
153(4):192.  
Bowling A. research methods in health. Investigating health and health services. 
2nd ed. Buckingham: Open University Press; 2002.  
Brandt KD, Heilman DK, Slemenda C, Katz BP, Mazzuca S, Braunstein EM, Byrd 
D. A comparison of lower extremity muscle strength, obesity, and depression 
scores in elderly subjects with knee pain with and without radiographic evidence of 
knee osteoarthritis. Journal of Rheumatology 2000; 27(8): 1937.  
Brosseau L, MacLeay L, Robinson V, Wells G, Tugwell P. Intensity of exercise for 
the treatment of osteoarthritis. Cochrane Database of Systematic Reviews 2003; 
(2): CD004259. 
Bulat T, Castle SC, Rutledge M, Quigley P. Clinical practice algorithms: 
Medication management to reduce fall risk in the elderly -Part 2, summary 
algorithm. Journal of the American Academy of Nurse Practitioners 2008; 20(1): 1-
4.  
Bunevicius A, Peceliuniene J, Mickuviene N, Valius L, Bunevicius R. Screening for 
depression and anxiety disorders in primary care patients. Depression and Anxiety 
2007; 24(7): 455-460.  
Burroughs H, Lovell K, Morley M, Baldwin R, Burns A, Chew-Graham C. 
‘Justifiable depression’: how primary care professionals and patients view late-life 
depression? A qualitative study. Family Practice 2006; 23(3): 369-377.  
 
282 
 
Callahan LF, Kaplan MR, Pincus T. The beck depression inventory, center for 
epidemiological studies depression scale (CESD), and general well‐being 
schedule depression subscale in rheumatoid arthritis criterion contamination of 
responses. Arthritis and Rheumatism 1991; 4(1): 3-11.  
Cameron IM, Crawford JR, Lawton K, Reid IC. Psychometric comparison of PHQ-
9 and HADS for measuring depression severity in primary care. The British 
Journal of General Practice 2008; 58(546): 32.  
Cameron O. The differential diagnosis of anxiety. Psychiatric and medical 
disorders. Psychiatric Clinics of North America 1985; 8(1): 3.  
Candelas G, Abasolo L, Leon L, Lajas C, Loza E, Revenga M, Bachiller J, Collado 
P, Richi P, Blanco M, Jover JA. Diagnostic concordance between primary care 
physicians and rheumatologists in patients with work disability related to 
musculoskeletal disorders. Rheumatology International 2011; 31(12): 1549-1554. 
Centre for Economic Performance’s Mental Health Policy Group. The depression 
report: a new deal for depression and anxiety disorders. 2006. London: Centre for 
Economic Performance, The London School of Economics and Political Science.  
Cesario S, Morin K, Santa-Donato A. Evaluating the Level of Evidence of 
Qualitative Research. Journal of Obstetric, Gynecologic, and Neonatal Nursing 
2006; 31(36): 708-714.  
Chatfield MD, Brayne CE, Matthews FE. A systematic literature review of attrition 
between waves in longitudinal studies in the elderly shows a consistent pattern of 
dropout between differing studies. Journal of Clinical Epidemiology 2005; 58(1): 
13-19. 
Ciarrochi J, Bilich L, Godsell C. Psychological flexibility as a mechanism of change 
in acceptance and commitment therapy. In: Ruth B, editor. Assessing Mindfulness 
and Acceptance: Illuminating the Processes of Change. Oakland, CA: New 
Harbinger Publications, Inc.; 2010. p. 51-75.  
Clark DB, Jones BL, Wood DS, Cornelius JR. Substance use disorder trajectory 
classes: diachronic integration of onset age, severity, and course. Addictive 
Behaviors 2006; 31(6): 995-1009.  
Clark LA, Watson D. Tripartite model of anxiety and depression: psychometric 
evidence and taxonomic implications. Journal of Abnormal Psychology 1991; 
100(3): 316.  
Clarke M. The QUORUM statement. The Lancet 2000; 355(9205):756-757.  
Cole MG. Prognosis of depression in elderly community and primary care 
populations: a systematic review and meta-analysis. American Journal of 
Psychiatry 1999; 156(8): 1182-1189. 
 
283 
 
Cole MG, Dendukuri N. Risk factors for depression among elderly community 
subjects: a systematic review and meta-analysis. American Journal of Psychiatry 
2003; 160(6): 1147-1156. 
Cook JM, Orvaschel H, Simco E, Hersen M, Joiner T. A test of the tripartite model 
of depression and anxiety in older adult psychiatric outpatients. Psychology and 
Aging 2004; 19(3): 444.  
Cook AJ, Brawer PA, Vowles KE. The fear-avoidance model of chronic pain: 
Validation and age analysis using structural equation modeling. Pain 2006; 121(3): 
195-206.  
Cooper C, Reginster JY, Chapurlat R, Christiansen C, Genant H, Bellamy N, 
Bensen W, Navarro F, Badurski J, Nasonov E, Chevalier X, Sambrook PN. 
Efficacy and safety of oral strontium ranelate for the treatment of knee 
osteoarthritis: rationale and design of randomised, double-blind, placebo-
controlled trial. Current Medical Research and Opinion 2012; 28(2): 231-239.  
Corapcioglu A, Ozer GU. Adaptation of revised Brief PHQ (Brief-PHQ-r) for 
diagnosis of depression, panic disorder and somatoform disorder in primary 
healthcare settings. International Journal of Psychiatry in Clinical Practice 2004; 
8(1): 11-18. 
Corbière M, Bonneville-Roussy A, Franche RL, Coutu MF, Choinière M, Durand 
MJ, Boulanger, A. Further Validation of the BDI-II Among People With Chronic 
Pain Originating From Musculoskeletal Disorders. Clinical Journal of Pain 2011; 
27(1): 62. 
Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. 
Antidepressant use and risk of adverse outcomes in older people: population 
based cohort study. BMJ 2011; 343: d4551.  
Coventry PA, Hays R, Dickens C, Bundy C, Garrett C, Cherrington A, Bundy C, 
Dickens C, Waheed W. Talking about depression: a qualitative study of barriers to 
managing depression in people with long term conditions in primary care. BMC 
family practice 2011; 12(1): 10.  
Craighead WE, Nemeroff CB.  The concise Corsini encyclopedia of psychology 
and behavioral science. 3rd ed. Hoboken, New Jersey: John Wiley and Sons; 
2004.  
Creamer P, Lethbridge‐Cejku M, Hochberg MC. Factors associated with functional 
impairment in symptomatic knee osteoarthritis. Rheumatology 2000; 39(5): 490-
496.  
Creamer P, Lethbridge-Cejku M, Costa P, Tobin JD, Herbst JH, Hochberg MC. 
The relationship of anxiety and depression with self-reported knee pain in the 
community: Data from the Baltimore longitudinal study of aging. Arthritis Care and 
Research 1999; 12(1): 3-7.  
284 
 
Croft P, Jordan K, Jinks C. 'Pain elsewhere' and the impact of knee pain in older 
people. Arthritis & Rheumatism 2005; 52(8): 2350-2354. 
Croghan T, Schoenbaum M, Sherbourne C, Koegel P. A framework to improve the 
quality of treatment for depression in primary care. Psychiatric Services 2006; 
57(5): 623-630. 
Croudace TJ, Jarvelin MR, Wadsworth MEJ, Jones PB. Developmental typology of 
trajectories to nighttime bladder control: epidemiologic application of longitudinal 
latent class analysis. American Journal of Epidemiology 2003; 157(9):834-842. 
Cully JA, Jimenez DE, Ledoux TA, Deswal A. Recognition and treatment of 
depression and anxiety symptoms in heart failure. Primary care companion to the 
Journal of clinical psychiatry 2009; 11(3):103-109.  
Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: 
what is known and how should it influence prescribing? CNS drugs 2006; 20(2): 
143-151.  
De Beurs E, Beekman A, Deeg D, Van Dyck R, Van Tilburg W. Predictors of 
change in anxiety symptoms of older persons: results from the Longitudinal Aging 
Study Amsterdam. Psychological Medicine 2000; 30(03): 515-527. 
De Vlieger P, Crombez G, Eccleston C. Worrying about chronic pain. An 
examination of worry and problem solving in adults who identify as chronic pain 
sufferers. Pain 2006; 120(1): 138-144.  
Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ 2004; 329(7458): 
168-169.   
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining 
heterogeneity and combining results from several studies in meta-analysis. In: 
Egger M, Davey Smith G, Altman DG, editors. Systematic Reviews in Health Care. 
Meta-analysis in Context. London: BMJ Books; 2001. p. 285-312.  
Delucchi KL, Matzger H, Weisner C. Dependent and problem drinking over 5 
years: a latent class growth analysis. Drug Alcohol Depend 2004; 74(3): 235-244. 
Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in 
adults. Cochrane Database of Systematic Reviews 2012; (9): CD007400. 
Dexter P, Brandt K. Distribution and predictors of depression symptoms in 
osteoarthritis. Journal of Rheumatology 1994; 21(2): 279.  
Dieppe P, Brandt KD. What is important in treating osteoarthritis? Whom should 
we treat and how should we treat them? Rheumatic Disease Clinics of North 
America 2003, 29: 687–716. 
 
285 
 
Dieppe PA, Lohmander LS. Pathogenesis and management of pain in 
osteoarthritis. The Lancet 2005; 365(9463): 965-973.  
Dionne CE, Dunn KM, Croft PR. Does back pain prevalence really decrease with 
increasing age? A systematic review. Age and Ageing 2006; 35(3): 229-234.  
Dowrick C, Buchan I. Twelve month outcome of depression in general practice: 
does detection or disclosure make a difference? BMJ 1995; 311(7015): 1274-
1276.  
Dowrick C, Leydon GM, McBride A, Howe A, Burgess H, Clarke P, Maisey S, 
Kendrick T. Patients’ and doctors’ views on depression severity questionnaires 
incentivised in UK quality and outcomes framework: qualitative study. BMJ 2009; 
338: b663.  
Duncan R, Hay E, Saklatvala J, Croft P. Prevalence of radiographic 
osteoarthritis—it all depends on your point of view. Rheumatology 2006; 
45(6):757-760.  
Dunlop DD, Lyons JS, Manheim LM, Song J, Chang RW. Arthritis and heart 
disease as risk factors for major depression: the role of functional limitation. 
Medical Care 2004; 42(6): 502-511.  
Dunlop DD, Semanik P, Song J, Manheim LM, Shih V, Chang RW. Risk factors for 
functional decline in older adults with arthritis. Arthritis and Rheumatism 2005; 
52(4):1274-1282. 
Dunn KM, Jordan K, Lacey RJ, Shapley M, Jinks C. Patterns of consent in 
epidemiologic research: evidence from over 25,000 responders. American Journal 
of Epidemiology 2004; 159(11):1087-1094.  
Dunn KM, Jordan K, Croft PR. Characterizing the course of low back pain: a latent 
class analysis. American Journal of Epidemiology 2006; 163(8):754-761. 
Dunn LB, Cooper BA, Neuhaus J, West C, Paul S, Aouizerat B, Abrams G, 
Edrington J, Hamolsky D, Miaskowski C. Identification of distinct depressive 
symptom trajectories in women following surgery for breast cancer. Health 
Psychology 2011; 30(6): 683–692.  
Dworkin RH, Hetzel RD, Banks SM. Toward a model of the pathogenesis of 
chronic pain. Seminars in Clinical Neuropsychiatry 1999; 4(3): 176-185. 
Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns 
RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, 
Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, 
McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, 
Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, 
Witter J. Core outcome measures for chronic pain clinical trials: IMMPACT 
recommendations. Pain 2005; 113(1-2): 9-19. 
286 
 
Dziedzic KS, Hill JC, Porcheret M, Croft PR. New Models for Primary Care Are 
Needed for Osteoarthritis. Physical Therapy 2009; 89 (12): 1371- 1378. 
Eccleston C, Crombez G. Worry and chronic pain: a misdirected problem solving 
model. Pain 2007; 132(3): 233-236.  
Egger M, Schneider M, Smith GD. Meta-analysis Spurious precision? Meta-
analysis of observational studies. BMJ 1998; 316(7125): 140-144.  
Egger M, Smith GD, O’Rourke K. Rationale, potentials, and promise of systematic 
reviews. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health 
care: Meta-analysis in context. 2nd ed. London: BMJ; 2001a. p. 3-19.  
Egger M, Smith GD, Sterne JAC. Uses and abuses of meta-analysis. Clinical 
Medicine, Journal of the Royal College of 2001b; 1(6): 478-484.  
El-Rufaie O, Absood G. Retesting the validity of the Arabic version of the Hospital 
Anxiety and Depression (HAD) scale in primary health care. Social Psychiatry and 
Psychiatric Epidemiology 1995; 30(1): 26-31. 
Expert Patients Programme Community Interest Company. Expert Patients 
Programme Courses. 2013; Available at: https://www.expertpatients.co.uk/course-
participants. Accessed 13/02/2013. 
Fava G, Tomba E, Sonino N. Clinimetrics: the science of clinical measurements. 
International Journal of Clinical Practice 2012; 66(1): 11-15.  
Fazel S, Khosla V, Doll H, Geddes J. The prevalence of mental disorders among 
the homeless in Western countries: systematic review and meta-regression 
analysis. PLoS Medicine 2008; 5(12): e225.  
Feldman BJ, Masyn KE, Conger RD. New approaches to studying problem 
behaviors: a comparison of methods for modeling longitudinal, categorical 
adolescent drinking data. Developmental Psychology 2009; 45(3): 652-676. 
Feliciano L, Areán PA. Mood Disorders: Depressive Disorders. In: Hersen M, 
Turner SM, Beidel DC, editors. Adult Psychopathology and Diagnosis. 5th ed. 
Hoboke, New Jersey: John Wiley & Sons; 2007. p. 286-316.  
Felson DT, McAlindon TE, Anderson JJ, Weissman BW, Aliabadi P, Evans S, 
Levy D, LaValley MP. Defining radiographic osteoarthritis for the whole knee. 
Osteoarthritis and Cartilage 1997; 5(4): 241-250.  
Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington 
RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole 
AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF. 
Osteoarthritis: new insights. Part 1: the disease and its risk factors. Annals of 
Internal Medicine 2000; 133(8): 635-646.  
 
287 
 
Ferreira VM, Sherman AM. Understanding associations of control beliefs, social 
relations, and well-being in older adults with osteoarthritis. International Journal of 
Aging and Human Development 2006; 62(3): 255-274.  
Figaro MK, Williams-Russo P, Allegrante JP. Expectation and outlook:The impact 
of patient preference on arthritis care among African Americans. Journal of 
Ambulatory Care Management  2005; 28(1): 41-48. 
First MB. Harmonisation of ICD–11 and DSM–V: opportunities and challenges. 
The British Journal of Psychiatry 2009; 195(5): 382-390.  
Fisher MN, Al Snih S, Ostir GV, Goodwin JS. Positive affect and disability among 
older Mexican Americans with arthritis. Arthritis & Rheumatism-Arthritis Care & 
Research 2004; 51(1): 34-39. 
Flink IK, Boersma K, MacDonald S, Linton SJ. Understanding catastrophizing from 
a misdirected problem‐solving perspective. British Journal of Health Psychology 
2011; 17(2): 408-419.  
Fransen M, McConnell S. Exercise for osteoarthritis of the knee. Cochrane 
Database of Systematic Reviews 2008; (4): CD004376. 
Fuller-Thomson E, Shaked Y. Factors associated with depression and suicidal 
ideation among individuals with arthritis or rheumatism: Findings from a 
representative community survey. Arthritis Care and Research 2009; 61(7): 944-
950.  
Furukawa TA, Guyatt GH. Sources of bias in diagnostic accuracy studies and the 
diagnostic process. Canadian Medical Association Journal 2006; 174(4): 481-482. 
García-Campayo J, Zamorano E, Ruiz MA, Pardo A, Pérez-Páramo M, López-
Gómez V, Freire O, Rejas J. Cultural adaptation into Spanish of the generalized 
anxiety disorder-7 (GAD-7) scale as a screening tool. Health and Quality of Life 
Outcomes 2010; 8(8): 1-11.  
Gerrits MMJG, Vogelzangs N, van Oppen P, van Marwijk HWJ, van der Horst H, 
Penninx BWJH. Impact of pain on the course of depressive and anxiety disorders. 
Pain 2012; 153(2): 429-36. 
Gibson C. Semi‐structured and unstructured interviewing: a comparison of 
methodologies in research with patients following discharge from an acute 
psychiatric hospital. Journal of Psychiatric and Mental Health Nursing 1998; 5(6): 
469-477.  
Gignac M, Backman CL, Davis AM, Lacaille D, Mattison CA, Montie P, Badley EM. 
Understanding social role participation: what matters to people with arthritis? 
Journal of Rheumatology 2008; 35(8): 1655-1663.  
 
288 
 
Gilbody S, House AO, Sheldon TA. Routinely administered questionnaires for 
depression and anxiety: systematic review. BMJ 2001; 322(7283): 406-409.  
Gilbody S, House A, Sheldon T. Screening and case finding instruments for 
depression. Cochrane Database Systematic Review 2005; 4: CD002792.  
Gilbody S, Sheldon T, House A. Screening and case-finding instruments for 
depression: a meta-analysis. Canadian Medical Association Journal 2008; 178(8): 
997-1003.  
Gilchrist G, Gunn J. Observational studies of depression in primary care: what do 
we know? BMC Family practice 2007; 8(1): 28.  
Glass GE. Update: spatial aspects of epidemiology: the interface with medical 
geography. Epidemiologic Reviews 2000; 22(1): 136-139.  
Glasziou P. Systematic reviews in health care: a practical guide. Cambridge: 
Cambridge University Press; 2001.  
GL Education Group. Hospital Anxiety and Depression Scale. 2012; Available at: 
http://www.gl-assessment.co.uk/products/hospital-anxiety-and-depression-scale-0 
Accessed 20/01/2012. 
Glover G, Webb M, Evison F. Improving Access to Psychological Therapies A 
review of the progress made by sites in the first roll-out year. The North East 
Public Health Observatory 2010.  
Goldberg DP, Lecrubier Y. Form and frequency of mental disorders across 
centres. In: Form TB, Sartorius N, editors. Mental Illness in General Health Care. 
An International Study. Wiley Publishers: Chichester; 1995. p. 323-334.  
Gould W. Sg124: interpreting logistic regression in all its forms. STATA Technical 
Bulletin 2000; 53: 18-29. 
Goodman JH, Tyer-Viola L. Detection, treatment, and referral of perinatal 
depression and anxiety by obstetrical providers. Journal of Women's Health 2010; 
19(3): 477-490.  
Griffin JM, Fuhrer R, Stansfel SA, Marmot M. Theimportance of low control at work 
and home on depression and anxiety: Do these effects vary by gender and social 
class? Social Science & Medicine 2002; 54: 783–798. 
Grigsby AB, Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. Prevalence of 
anxiety in adults with diabetes: A systematic review. Journal of Psychosomatic 
Research 2002 12; 53(6): 1053-1060.  
Grimes DA, Schulz KF. Uses and abuses of screening tests. The Lancet 2002; 
359(9309): 881-884. 
 
289 
 
Gruenberg AM, Goldstein RD, Pincus HA. Classification of Depression: Research 
and Diagnostic Criteria: DSM‐IV and ICD‐10. Biology of Depression 2005:1-12. In: 
Licinio J, Wong ML, editors. Biology of depression. From novel insights to 
therapeutic strategies. Weinheim, Germany: Wiley-VCH Verlag GmbH and 
Company; 2005. p. 1-12. 
Gureje O, Von Korff M, Simon GE, Gater R. Persistent pain and well-being. JAMA: 
the journal of the American Medical Association 1998; 280(2): 147-151.  
Gureje O, Ademola A, Olley BO. Depression and disability: comparisons with 
common physical conditions in the Ibadan Study of Aging. Journal of the American 
Geriatrics Society 2008; 56(11): 2033-2038. 
Hagger MS, Orbell S. A meta-analytic review of the common-sense model of 
illness representations. Psychology and Health 2003; 18(2): 141-184.  
Hampson SE, Glasgow RE, Zeiss AM. Coping with osteoarthritis by older adults. 
Arthritis and Rheumatism 1996; 9(2):133-141.  
Han C, Jo SA, Kwak JH, Pae CU, Steffens D, Jo I, Park MH. Validation of the 
Patient Health Questionnaire-9 Korean version in the elderly population: the Ansan 
Geriatric study. Comprehensive Psychiatry 2008; 49(2): 218-223.  
Hanel G, Henningsen P, Herzog W, Sauer N, Schaefert R, Szecsenyi J, Löwe B. 
Depression, anxiety, and somatoform disorders: Vague or distinct categories in 
primary care? Results from a large cross-sectional study. Journal of 
Psychosomatic Research 2009 9; 67(3): 189-197. 
Hannan MT, Felson DT, Pincus T. Analysis of the discordance between 
radiographic changes and knee pain in osteoarthritis of the knee. Journal of 
Rheumatology 2000; 27(6): 1513-1517. 
Harbord RM, Higgins JPT. Meta-regression in Stata. Stata Journal 2008; 8(4): 
493-529.  
Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study effects in meta-
analyses. Stata Journal 2009; 9(2): 197-210.  
Harris T, Cook DG, Victor C, DeWilde S, Beighton C. Onset and persistence of 
depression in older people - results from a 2-year community follow-up study. Age 
and Ageing 2006; 35(1): 25-32.  
Harris CA, D'Eon JL. Psychometric properties of the Beck Depression Inventory-
Second Edition (BDI-II) in individuals with chronic pain. Pain 2008; 137(3): 609-
622.  
Hawker G, Stewart L, French M, Cibere J, Jordan J, March L, Suarez-Almazor M. 
Understanding the pain experience in hip and knee osteoarthritis - an 
OARSI/OMERACT initiative. Osteoarthritis and Cartilage 2008; 16(4): 415-422.  
290 
 
Hayes SC, Strosahl KD, Wilson KG. Acceptance and commitment therapy: An 
experiential approach to behavior change. New York: Guilford Press; 1999.  
Haythornthwaite JA, Menefee LA, Heinberg LJ, Clark MR. Pain coping strategies 
predict perceived control over pain. Pain 1998; 77(1): 33-39.  
Hays R, Hadorn D. Responsiveness to change: an aspect of validity, not a 
separate dimension. Quality of Life Research 1992; 1(1): 73-75. 
He Y. Missing data analysis using multiple imputation. Circulation: Cardiovascular 
Quality and Outcomes 2010; 3(1): 98-105.  
He Y, Zhang M, Lin EHB, Bruffaerts R, Posada-Villa J, Angermeyer M, Levinson 
D, de Girolamo G, Uda H, Mneimneh Z, Benjet C, de Graaf R, Scott KM, Gureje 
O, Seedat S, Haro JM, Bromet EJ, Alonso J, von Korff M, Kessler RC. Mental 
disorders among persons with arthritis: results from the World Mental Health 
Surveys. Psychological Medicine 2008; 38(11): 1639. 
Henkel V, Mergl R, Coyne JC, Kohnen R, Möller HJ, Hegerl U. Screening for 
depression in primary care: Will one or two items suffice? European Archives of 
Psychiatry and Clinical Neuroscience 2004; 254(4): 215-223. 
Heuts PHTG, Vlaeyen JWS, Roelofs J, de Bie RA, Aretz K, van Weel C,  van 
Schayck OC. Pain-related fear and daily functioning in patients with osteoarthritis. 
Pain 2004; 110(1-2): 228-235.  
Hickie IB, Andrews G, Davenport TA. Measuring outcomes in patients with 
depression or anxiety: an essential part of clinical practice. Medical Journal of 
Australia 2002; 177(4): 205-207.  
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in 
meta-analyses. BMJ 2003; 327(7414): 557-560.  
Higgins JPT. Commentary: Heterogeneity in meta-analysis should be expected 
and appropriately quantified. International Journal of Epidemiology 2008; 37(5): 
1158-1160. 
Hill S, Dziedzic K, Thomas E, Baker SR, Croft P. The illness perceptions 
associated with health and behavioural outcomes in people with musculoskeletal 
hand problems: Findings from the North Staffordshire Osteoarthritis Project 
(NorStOP). Rheumatology 2007; 46(6): 944-951.  
Hipp JR, Bauer DJ. Local solutions in the estimation of growth mixture models. 
Psychological Methods 2006; 11(1): 36.  
Hippisley‐Cox J, Jumbu G. Trends in Consultation Rates in General Practice 
1995/1996 to 2007/2008: analysis of the QRESEARCH database; 2008.  
 
291 
 
Hopman-Rock M, Odding E, Hofman A, Kraaimaat FW, Bijlsma J. Differences in 
health status of older adults with pain in the hip or knee only and with additional 
mobility restricting conditions. Journal of Rheumatology 1997; 24(12): 2416. 
Huber M, Knottnerus JA, Green L, van der Horst H, Jadad AR, Kromhout D, 
Leonard B, Lorig K, Loureiro MI, van der Meer JW, Schnabel P, Smith R, van 
Weel C, Smid H. How should we define health? British Medical Journal 2011: 343: 
d4163.  
Hunsley J, Mash EJ. The role of assessment in evidence-based practice. In: 
Antony MM, Barlow DH, editors. Handbook of assessment and treatment planning 
for psychological disorders. 2nd ed. New York: The Guilford Press; 2010. p. 3-22.  
Hurley M, Walsh N, Mitchell H, Pimm T, Patel A, Williamson E, Jones R, Reeves 
B, Dieppe P. Clinical effectiveness of a rehabilitation program integrating exercise, 
self‐management, and active coping strategies for chronic knee pain: A cluster 
randomized trial. Arthritis Care and Research 2007; 57(7): 1211-1219. 
Hutton C, Vennart W. Osteoarthritis and magnetic resonance imaging: potential 
and problems. Annals of the Rheumatic 1995; 54(4): 237-243. 
Iliffe S, Haines A, Gallivan S, Booroff A, Goldenberg E, Morgan P. Assessment of 
elderly people in general practice. 1. Social circumstances and mental state. 
British Journal of General Practice 1991; 41(342): 9-12. 
Iliffe S, Kharicha K, Carmaciu C, Harari D, Swift C, Gillman G, Stuck AE. The 
relationship between pain intensity and severity and depression in older people: 
exploratory study. BMC family practice 2009; 10(1): 54.  
Jacobsen PB, Donovan KA, Swaine ZN, Watson IS. Management of anxiety and 
depression in adult cancer patients: Toward an evidence-based approach. In: 
Chang AE, Ganz PA, Hayes DF, Kinsella T, Pass HI, Schiller JH, Stone R, 
Strecher V. editors. Oncology: An evidence-based approach. New York, NY: 
Springer-Verlag; 2006. p. 1561-1588.  
Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. 
How to use an article about a diagnostic test. B. What are the results and will they 
help me in caring for my patients? The Evidence-Based Medicine Working 
Group. JAMA 1994; 271(9):703–707 
Jakobsson U, Hallberg IR. Quality of life among older adults with osteoarthritis: an 
explorative study. Journal of Gerontological Nursing 2006; 32(8): 51-60. 
Jensen MP, Keefe FJ, Lefebvre JC, Romano JM, Turner JA. One-and two-item 
measures of pain beliefs and coping strategies. Pain 2003; 104(3): 453-469.  
 
 
292 
 
Jeste DV, Blazer DG, First M. Aging-related diagnostic variations: need for 
diagnostic criteria appropriate for elderly psychiatric patients. Biological Psychiatry 
2005; 58(4): 265-271.  
Joint Formulary Committee. British National Formulary (BNF). 6th ed. London: 
BMJ Group and Pharmaceutical Press; 2011. 
Joling KJ, van Marwijk HWJ, Piek E, der Horst HE, Penninx BW, Verhaak P, van 
Hout HPJ. Do GPs' medical records demonstrate a good recognition of 
depression? A new perspective on case extraction. Journal of Affective Disorders 
2011; 133(3): 522-527. 
Jones CM, Athanasiou T. Summary receiver operating characteristic curve 
analysis techniques in the evaluation of diagnostic tests. Annals of Thoracic 
Surgery 2005; 79(1): 16-20. 
Jooste P, Yach D, Steenkamp H, Botha J, Rossouw J. Drop-out and newcomer 
bias in a community cardiovascular follow-up study. International journal of 
epidemiology 1990; 19(2): 284-289. 
Jordan KP, Thomas E, Peat G, Wilkie R, Croft P. Social risks for disabling pain in 
older people: a prospective study of individual and area characteristics. Pain 2008; 
137(3): 652-661.  
Julian LJ. Measures of anxiety: State-Trait Anxiety Inventory (STAI), Beck Anxiety 
Inventory (BAI), and Hospital Anxiety and Depression Scale-Anxiety (HADS-A). 
Arthritis Care and Research 2011; 63(S11): S467-S472.  
Jüni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical 
trials for meta-analysis. JAMA: the journal of the American Medical Association 
1999; 282(11): 1054-1060.  
Kadam UT, Croft P, McLeod J, Hutchinson M. A qualitative study of patients' views 
on anxiety and depression. British Journal of General Practice 2001; 51(466): 375.  
Kadam UT, Croft PR. Clinical comorbidity in osteoarthritis: Associations with 
physical function in older patients in family practice. Journal of Rheumatology 
2007; 34(9): 1899-1904. 
Kalichman L, Li L, Kim D, Guermazi A, Berkin V, O’Donnell CJ, Hoffmann U, Cole 
R, Hunter DJ. Facet joint osteoarthritis and low back pain in the community-based 
population. Spine 2008; 33(23): 2560. 
Kalichman L, Zhu Y, Zhang Y, Niu J, Gale D, Felson DT, Hunter DJ. The 
association between patella alignment and knee pain and function: an MRI study 
in persons with symptomatic knee osteoarthritis. Osteoarthritis and Cartilage 2007; 
15(11): 1235-1240.  
Kalin NH. The neurobiology of fear. Scientific American 1993; 268(5): 94-101.  
293 
 
Kaptein KI, de Jonge P, van den Brink RHS, Korf J. Course of depression 
symptoms after myocardial infarction and cardiac prognosis: a latent class 
analysis. Psychosomatic Medicine 2006; 68(5): 662-668.  
Karp DA. Living with depression: illness and identity turning points. Qualitative 
Health Research 1994; 4 (1): 6-30. 
Kass RE, Raftery AE. Bayes factors and model uncertainty. Journal of the 
American Statistical Association 1995; 90(430): 773-795.  
Katon W, Lin EHB, Kroenke K. The association of depression and anxiety with 
medical symptom burden in patients with chronic medical illness. General Hospital 
Psychiatry 2007; 29(2): 147-155.  
Kendell RC. The role of diagnosis in psychiatry. Oxford, England: Blackwell 
Scientific; 1975.  
Kendrick T. Depression in adults: GPs are not so bad at diagnosis. BMJ 2008; 
336(7643): 522.  
Kendrick T, Dowrick C, McBride A, Howe A, Clarke P, Maisey S, Moore M, Smith 
PW. Management of depression in UK general practice in relation to scores on 
depression severity questionnaires: analysis of medical record data. BMJ 2009; 
338: b750. 
Kendrick T, Peveler R. Guidelines for the management of depression: NICE work? 
The British Journal of Psychiatry 2010; 197(5):345-347.  
Kessler D, Bennewith O, Lewis G, Sharp D. Detection of depression and anxiety in 
primary care: follow up study. BMJ 2002; 325(7371): 1016-1017.  
Kessler D, Sharp D, Lewis G. Screening for depression in primary care. The 
British Journal of General Practice 2005; 55(518): 659-660.  
Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J. Undertaking systematic 
reviews of research on effectiveness: CRD's guidance for carrying out or 
commissioning reviews. 2nd ed. CRD Report No. 4. York: NHS Centre for 
Reviews and Dissemination; 2001.  
Kim KW, Han JW, Cho HJ, Chang CB, Park JH, Lee JJ, Lee SB, Seong SC, Kim 
TK. Association between comorbid depression and osteoarthritis symptom severity 
in patients with knee osteoarthritis. The Journal of Bone and Joint Surgery 
(American) 2011; 93(6): 556-563.  
Klapow J, Kroenke K, Horton T, Schmidt S, Spitzer R, Williams JBW. 
Psychological disorders and distress in older primary care patients: a comparison 
of older and younger samples. Psychosomatic Medicine 2002; 64(4): 635-643. 
 
294 
 
Klassen TP, Jadad AR, Moher D. Guides for reading and interpreting systematic 
reviews: I. Getting started. Archives of Pediatrics and Adolescent Medicine 1998; 
152(7): 700.  
Kline P. An easy guide to factor analysis. London: Routledge; 1994. 
Kopec JA, Rahman MM, Sayre EC, Cibere J, Flanagan WM, Aghajanian J, Anis 
AH, Jordan JM, Badley EM. Trends in physician‐diagnosed osteoarthritis 
incidence in an administrative database in British Columbia, Canada, 1996–1997 
through 2003–2004. Arthritis Care and Research 2008; 59(7): 929-934.  
Kovacs F, Noguera J, Abraira V, Royuela A, Cano A, Gil del Real MT, Zamora J, 
Gestoso M, Muriel A, Mufraggi N. The Influence of Psychological Factors on Low 
Back Pain‐Related Disability in Community Dwelling Older Persons. Pain Medicine 
2008; 9(7): 871-880.  
Kramer SE, Kapteyn TS, Kuik DJ, Deeg DJH. Association of hearing impairment 
and chronic diseases with psychosocial health status in older age. Journal of 
Aging and Health 2002; 14(1): 122-137. 
Kratz AL. Pain acceptance moderates the relation between pain and negative 
affect in female osteoarthritis and fibromyalgia patients. Annual Behavioural 
Medicine 2007; 33: 291. 
Kreuter F, Muthén B. Analyzing Criminal Trajectory Profiles: Bridging Multilevel 
and Group-based Approaches Using Growth Mixture Modeling Journal of 
Quantitative Criminology 2008; 24(1):1-31. 
Kroenke K, Spitzer RL, Williams JBW. The PHQ‐9. A validation of a brief  
depression severity measure. Journal of General Internal Medicine 2001; 16(9): 
606-613.  
Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity 
of a two-item depression screener. Medical Care 2003; 41(11): 1284.  
Kroenke K, Spitzer RL, Williams JBW, Monahan PO, Löwe B. Anxiety disorders in 
primary care: prevalence, impairment, comorbidity, and detection. Annals of 
Internal Medicine 2007; 146(5): 317-325.  
Krugh HE, Woods SR, Mahowald ML. The importance of identifying depression in 
patients with rheumatoid arthritis: evaluation of the beck depression inventory. 
JCR: Journal of Clinical Rheumatology1997; 3(5): 248.  
Krumholz HM, Butler J, Miller J, Vaccarino V, Williams CS, de Leon CFM, Seeman 
TE, Kasl SV, Berkman LF. Prognostic importance of emotional support for elderly 
patients hospitalized with heart failure. Circulation 1998; 97(10): 958-964.  
Kumar R, Indrayan A. Receiver operating characteristic (ROC) curve for medical 
researchers. Indian Pediatrics 2011; 48(4): 277-287. 
295 
 
Lacey RJ, Lewis M, Jordan K, Jinks C, Sim J. Interrater reliability of scoring of pain 
drawings in a self-report health survey. Spine 2005; 30(16): E455-8.  
Lam CLK, Pan PC, Chan AWT, Chan SY, Munro C. Can the Hospital Anxiety and 
Depression (HAD) Scale be used on Chinese elderly in general practice? Family 
Practice 1995; 12(2): 149-154. 
Lane NE, Schnitzer TJ, Birbara CA, Mokhtarani M, Shelton DL, Smith MD, Brown 
MT. Tanezumab for the treatment of pain from osteoarthritis of the knee. New 
England Journal of Medicine 2010; 363(16): 1521-1531. 
Lane NE, Brandt K, Hawker G, Peeva E, Schreyer E, Tsuji W, Hochberg MC. 
OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis 
and Cartilage / OARS, Osteoarthritis Research Society 2011; 19(5): 478-482.  
Lang AJ, Stein MB. Screening for anxiety in primary care: why bother? General 
Hospital Psychiatry 2002; 24(6): 365-366.  
Laursen B, Hoff E. Person-Centered and Variable-Centered Approaches to 
Longitudinal Data. Merrill-Palmer Quarterly: Journal of Developmental Psychology 
2006; 52: 377-389. 
Lazarus RS. Stress and emotion: A new synthesis. Springer Publishing Company; 
2006. 
LeDoux J. The emotional brain: the mistirious underpinnings of emotional life. New 
York: Simon & Schuster; 1996. 
LeDoux J. The emotional brain, fear, and the amygdala. Cellular and molecular 
neurobiology 2003; 23(4):727-738.  
Lee GK, Chan F, Berven NL. Factors affecting depression among people with 
chronic musculoskeletal pain: A structural equation model. Rehabilitation 
Psychology 2007; 52(1): 33-43.  
Lee GK, Mercurio-Riley D. Psychosocial Adjustment of People with Chronic Pain: 
A Conceptual Framework of Risk and Resistance Factors. Australian Journal of 
Rehabilitation Counselling 2009; 15(1): 40-60.  
Leeflang MMG, Deeks JJ, Gatsonis C, Bossuyt PMM. Systematic reviews of 
diagnostic test accuracy. Annals of Internal Medicine 2008; 149(12): 889-897.  
Lester H, Glasby J. Mental health policy and practice.  Basingstoke: Palgrave 
Macmillan; 2006.  
Leveille SG, Bean J, Ngo L, McMullen W, Guralnik JM. The pathway from 
musculoskeletal pain to mobility difficulty in older disabled women. Pain 2007; 
128(1-2): 69-77.  
 
296 
 
Levenson JLE. Psychiatric care for medically ill. In: Levenson JL, editor. The 
American psychiatric publishing textbook of psychometric medicine. 2nd ed. 
Washington C.C.: The American Psychiatric Publishing, Inc.; 2010. p. 241.  
Lewinnek GE, Warfield CA. Facet joint degeneration as a cause of low back pain. 
Clinical Orthopedy 1986; 213: 216–222. 
Lewis M, Jordan K, Lacey R, Jinks C, Sim J. Inter-rater reliability assessment of 
the scoring of the body pain manikin. Rheumatology 2002; 41: 52.  
Lewis DM. How should we define health? WHO definition of health remains fit for 
purpose. BMJ 2011; 343:d5357 
Li C, Friedman B, Conwell Y, Fiscella K. Validity of the Patient Health 
Questionnaire 2 (PHQ‐2) in Identifying Major Depression in Older People. Journal 
of the American Geriatrics Society 2007; 55(4): 596-602. 
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis J, Clarke M, 
Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting 
systematic reviews and meta-analyses of studies that evaluate health care 
interventions: explanation and elaboration. Journal of Clinical Epidemiology 2009; 
62(10): e1-e34.  
Licht-Strunk E, Van Der Windt DAWM, Van Marwijk HWJ, De Haan M, Beekman 
ATF. The prognosis of depression in older patients in general practice and the 
community. A systematic review. Family Practice 2007; 24(2): 168-180.  
Licht-Strunk E. The Prognosis of Late-Life Depression in General Practice. 
Amsterdam: VU University Medical Centre Amsterdam; 2008.  
Licht-Strunk E, Beekman ATF, de Haan M, van Marwijk HWJ. The prognosis of 
undetected depression in older general practice patients. A one year follow-up 
study. Journal of Affective Disorders 2009a; 114(1-3): 310-315. 
Licht-Strunk E, Van Marwijk H, Hoekstra T, Twisk J, De Haan M, Beekman A. 
Outcome of depression in later life in primary care: longitudinal cohort study with 
three years’ follow-up. BMJ 2009b; 338: a3079. 
Lin E, Katon W, Von Korff M, Tang L, Williams Jr JW, Kroenke K, Hunkeler E, 
Harpole L, Hegel M, Arean P, Hoffing M, Della Penna R, Langston C, Unützer J. 
Effect of improving depression care on pain and functional outcomes among older 
adults with arthritis. JAMA 2003; 290(18): 2428-2429.  
Lin E, Tang L, Katon W, Hegel MT, Sullivan MD, Unützer J. Arthritis pain and 
disability: response to collaborative depression care. General Hospital Psychiatry 
2006; 28(6): 482-486.  
Lipsey MW, Wilson DB. Practical meta-analysis. Thousand Oaks, CA: Sage 
Publications, Inc; 2001.  
297 
 
Loney PL, Stratford PW. The Prevalence of Low Back Pain in Adults: A 
Methodological Review of the Literature. Physical Therapy 1999; 79(4): 384-396.  
López-Ibor J, Frances A, Jones C. Dysthymic disorder: a comparison of DSM‐IV 
and ICD‐10 and issues in differential diagnosis. Acta Psychiatrica Scandinavica 
1994; 89: 12-18.  
López-Ibor JJ. The classification of stress-related disorders in ICD-10 and DSM-
IV. Psychopathology 2002; 35(2-3): 107-111. 
Lopez-Lopez A, Montorio I, Izal M, Velasco L. The role of psychological variables 
in explaining depression in older people with chronic pain. Aging and Mental 
Health 2008; 12(6): 735-745.  
Löwe B, Kroenke K, Herzog W, Gräfe K. Measuring depression outcome with a 
brief self-report instrument: sensitivity to change of the Patient Health 
Questionnaire (PHQ-9). Journal of Affective Disorders 2004a; 81(1): 61-66.  
Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression 
treatment outcomes with the patient health questionnaire-9. Medical Care 2004b; 
42(12): 1194.  
Lucassen P, Van Rijswijk E, van Weel-Baumgarten E, Dowrick C. Making fewer 
depression diagnoses: beneficial for patients? Mental Health in Family Medicine 
2008; 5(3): 161. 
Luppa M, Sikorski C, Luck T, Ehreke L, Konnopka A, Wiese B, Weyerer S, König 
HH, Riedel-Heller SG. Age-and gender-specific prevalence of depression in latest-
life-Systematic review and meta-analysis. Journal of Affective Disorders 2010; 
doi:10.1016/j.jad.2010.11.033. 
MacMillan HL, Patterson CJS, Wathen CN. Screening for depression in primary 
care: recommendation statement from the Canadian Task Force on Preventive 
Health Care. Canadian Medical Association Journal 2005; 172(1): 33-35. 
Magidson J, Vermunt J. Latent class models. In: Kaplan D, editor. The SAGE 
handbook of quantitative methodology for the social sciences. Thousand Oakes: 
Sage Publications; 2004. p. 175-198. 
Mallen C, Peat G, Croft P. Quality assessment of observational studies is not 
commonplace in systematic reviews. Journal of Clinical Epidemiology 2006a 8; 
59(8): 765-769.  
Mallen CD, Peat G, Thomas E, Wathall S, Whitehurst T, Clements C, Bailey J, 
Gray J, Croft PR. The assessment of the prognosis of musculoskeletal conditions 
in older adults presenting to general practice: a research protocol. BMC 
musculoskeletal disorders 2006b; 7(1): 84.  
 
298 
 
Mallen CD, Peat G, Thomas E, Lacey R, Croft P. Predicting poor functional 
outcome in community-dwelling older adults with knee pain: prognostic value of 
generic indicators. Annals of Rheumatic Disease 2007; 66(11): 1456-1461.  
Mallen CD, Peat G. Screening older people with musculoskeletal pain for 
depression symptoms in primary care. British Journal Of General Practice 2008 
10; 58(555):688-693.  
Mallen CD. The progress of musculoskeletal pain in older adults in general 
practice. Keele University: Arthritis Research UK Primary Care Centre; 2009.   
Maly MR, Costigan PA, Olney SJ. Self-efficacy mediates walking performance in 
older adults with knee osteoarthritis. The Journals of Gerontology Series A: 
Biological Sciences and Medical Sciences 2007; 62(10): 1142-1146.  
Marengoni A, Angleman S, Melis R, Mangialasche F, Karp A, Garmen A, Meinow 
B, Fratiglioni L. Aging with multimorbidity: A systematic review of the literature. 
Ageing Research Reviews 2011; 10(4): 430-439. 
Marshall GN, Sherbourne CD, Meredith LS, Camp P, Hays RD. The tripartite 
model of anxiety and depression: symptom structure in depressive and 
hypertensive patient groups. Journal of Personality Assessment 2003; 80(2): 139-
153.  
Martin JC. Determinants of functional health of low-income black women with 
osteoarthritis. American Journal of Preventive Medicine 1996; 12(5): 430-436. 
McAlindon T, Zhang Y, Hannan M, Naimark A, Weissman B, Castelli W, Felson D. 
Are risk factors for patellofemoral and tibiofemoral knee osteoarthritis different? 
Journal of rheumatology 1996; 23(2): 332. 
McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice. 
Fourth National Study 1991–1992. Office of Population Censuses and Surveys. 
1995; Series MB5 No.3. McCracken LM, Eccleston C. Coping or acceptance: what 
to do about chronic pain? Pain 1995; 105(1-2):197-204. 
McCracken LM, Spertus IL, Janeck AS, Sinclair D, Wetzel FT. Behavioral 
dimensions of adjustment in persons with chronic pain: pain-related anxiety and 
acceptance. Pain 1999; 80(1):283-289.  
McLachlan GJ, Peel D. Finite mixture models. New York: Wiley-Interscience; 
2000.  
McWilliams LA, Goodwin RD, Cox BJ. Depression and anxiety associated with 
three pain conditions: results from a nationally representative sample. Pain 2004; 
111(1-2):77-83.  
McWilliams LA, Clara IP, Murphy PDJ, Cox BJ, Sareen J. Associations between 
arthritis and a broad range of psychiatric disorders: Findings from a nationally 
representative sample. Journal of Pain 2008; 9(1): 37-44.  
299 
 
Meades R, Ayers S. Anxiety measures validated in perinatal populations: A 
systematic review. Journal of Affective Disorders 2010; 133(1-2): 1-15.  
Memel DS, Kirwan JR, Sharp DJ, Hehir M. General practitioners miss disability 
and anxiety as well as depression in their patients with osteoarthritis. The British 
Journal Of General Practice 2000 08; 50(457): 645-648. 
Menchetti M, Murri MB, Bertakis K, Bortolotti B, Berardi D. Recognition and 
treatment of depression in primary care: effect of patients' presentation and 
frequency of consultation. Journal of Psychosomatic Research 2009; 66(4): 335-
341. 
Mendels, J. Concepts of Depression. New York: Wiley; 1970.  
Menz H, Tiedemann A, Kwan M, Plumb K, Lord SR. Foot pain in community-
dwelling older people: an evaluation of the Manchester Foot Pain and Disability 
Index. Rheumatology 2006; 45(7): 863-867. 
Miller LR, Cano A. Comorbid chronic pain and depression: who is at risk? The 
Journal of Pain 2009; 10(6): 619-627.  
Mitchell AJ, Coyne JC. Do ultra-short screening instruments accurately detect 
depression in primary care?: A pooled analysis and meta-analysis of 22 studies. 
British Journal of General Practice 2007; 57(535): 144-151.  
Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination 
in the detection of dementia and mild cognitive impairment. Journal of Psychiatric 
Research 2009; 43(4): 411-431.  
Mitchell AJ, Vaze A, Rao S. Clinical diagnosis of depression in primary care: a 
meta-analysis. The Lancet 2009; 374(9690): 609-619.  
Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N. 
Prevalence of depression, anxiety, and adjustment disorder in oncological, 
haematological, and palliative-care settings: a meta-analysis of 94 interview-based 
studies. The Lancet Oncology 2011 2; 12(2):160-174.  
Mokkink LB, Terwee CB, Patrick DL, Alonso J, Stratford PW, Knol DL, Bouter LM, 
de Vet HC. The COSMIN study reached international consensus on taxonomy, 
terminology, and definitions of measurement properties for health-related patient-
reported outcomes. Journal of Clinical Epidemiology 2010; 63(7): 737-745.  
Montgomery S. Anxiety and Depression. London: Livingstone; 1990.  
Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, 
chronic diseases, and decrements in health: results from the World Health 
Surveys. The Lancet 2007; 370(9590): 851-858.  
 
300 
 
Munce SEP, Stewart DE. Gender differences in depression and chronic pain 
conditions in a national epidemiologic survey. Psychosomatics 2007; 48(5): 394-
399.  
Murray J, Banerjee S, Byng R, Tylee A, Bhugra D, Macdonald A. Primary care 
professionals’ perceptions of depression in older people: a qualitative study. Social 
Science and Medicine 2006; 63(5):1363-1373.  
Muthén L, Muthén B. Mplus 5.21: Statistical analysis with latent variables 
[computer software]. Los Angeles, CA: Muthén & Muthén; 2009.  
Muthén B, Muthén LK. Integrating Person-Centered and Variable-Centered 
Analyses: Growth Mixture Modeling With Latent Trajectory Classes. Alcoholism: 
Clinical and Experimental Research 2000; 24(6): 882-891.  
Muus KJ, McDonald LR, Ludtke RL, Allery AJ, Knudson A, Moulton P. Arthritis 
among American Indian and Alaska Native elders: prevalence, demographic 
patterns, and comorbidities. Journal of Native Aging and Health 2007; 2(1): 5-13.  
Myers K, Winters N. Ten-year review of rating scales. I: Overview of scale 
functioning, psychometric properties, and selection. Journal of American Academy 
of Childhood and Adolescent Psychiatry 2002; 41 (2):114-121. 
Nagin D. Group-based modeling of development. Cambridge, MA: Harvard 
University Press; 2005.  
Nagin DS, Tremblay RE. Analyzing developmental trajectories of distinct but 
related behaviors: A group-based method. Psychological Methods 2001; 6(1): 18-
34.  
Nandi A, Beard J, Galea S. Epidemiologic heterogeneity of common mood and 
anxiety disorders over the life course in the general population: a systematic 
review. BMC Psychiatry 2009; 9(1): 31. 
NCC-CC (National Collaborating Centre for Chronic Conditions). Osteoarthritis: 
national clinical guideline for care and management in adults. 2008; 90. 
NCC-MH (National Collaborating Centre for Mental Health). Post-traumatic stress 
disorder. The management of PTSD in adults and children in primary and 
secondary care. 2005; 26.  
NHS (National Health Service), IAPT (Improving Access to Psychological 
Therapies). Relieving distress, transforming lives. 2013; Available at: 
http://www.iapt.nhs.uk/. Accessed 13/12/2012. 
NHSIA (NHS Information Authority). Towards an Information Standard for 
Organising Clinical Communications. London: NHS Information Authority; 2000. 
NICE (National Institute for Health and Clinical Excellence). Depression: 
management of depression in primary and secondary care. 2004; 23. 
301 
 
NICE (National Institute for Health and Clinical Excellence). Obsessive-compulsive 
disorder: core interventions in the treatment of obsessive-compulsive disorder and 
body dysmorphic disorder. 2005; 31. 
NICE (National Institute for Health and Clinical Excellence). Management of 
anxiety (panic disorder, with or without agoraphobia, and generalised anxiety 
disorder) in adults in primary, secondary and community care. 2007; 22. 
NICE (National Institute for Health and Clinical Excellence). Osteoarthritis: the 
care and management of osteoarthritis in adults. 2008; 59. 
NICE (National Institute for Health and Clinical Excellence). Depression: The 
treatment and management of depression in adults. 2009a; 90.  
NICE (National Institute for Health and Clinical Excellence). Depression in adults 
with a chronic physical health problem: Treatment and management. 2009b; 91.  
NICE (National Institute for Health and Clinical Excellence). Chronic heart failure. 
Management of chronic heart failure in adults in primary and secondary care. 
2010; 108.  
Natvig B, Bruusgaard D, Eriksen W. Localized low back pain and low back pain as 
part of widespread musculoskeletal pain: two different disorders? A cross-
sectional population study. Journal of Rehabilitation Medicine 2001; 33(1): 21-25. 
Naylor C, Parsonage M, McDaid D, Knapp M, Fossey M, Galea A. Long-term 
conditions and mental health: the cost of co-morbidities. London: The King’s Fund 
and Centre for Mental Health; 2012.  
Nease DE, Malouin JM. Depression screening: a practical strategy. Journal of 
Family Practice 2003; 52(2):118-126. 
Nesselroade JR. Some implications of the trait state distinction for the study of 
development across the life span: The case of personality research. In: Baltes PB, 
Featherman DL, Lerner RM, editors. Life-span development and behavior 
Hillsdale, NJ: Erlbaum; 1988. p. Vol. 8, 163-189.  
Neumann I, Wegener G, Homberg J, Cohen H, Slattery D, Zohar J, Olivier JD, 
Mathé AA. Animal models of depression and anxiety: What do they tell us about 
human condition? Progress in Neuro-Psychopharmacology and Biological 
Psychiatry 2011; 35(6): 1357-1375.  
Newman MG, Zuellig AR, Kachin KE, Constantino MJ, Przeworski A, Erickson T, 
Przeworski A, Erickson T, Cashman-McGrath L. Preliminary reliability and validity 
of the generalized anxiety disorder questionnaire-IV: A revised self-report 
diagnostic measure of generalized anxiety disorder. Behavior Therapy 2002; 
33(2): 215-233.  
 
302 
 
Niti M, Ng T, Kua EH, Ho RCM, Tan CH. Depression and chronic medical illnesses 
in Asian older adults: the role of subjective health and functional status. 
International journal of Geriatric Psychiatry 2007; 22(11): 1087-1094.  
Norton S, Sacker A, Young A, Done J. Distinct psychological distress trajectories 
in rheumatoid arthritis: Findings from an inception cohort. Journal of 
Psychosomatic Research 2011; 71:5. 
Nour K, Laforest S, Gignac M, Gauvin L. Appreciating the predicament of 
housebound older adults with arthritis: portrait of a population. Canadian Journal 
on Aging 2005; 24(1): 57-69.  
Novy D, Nelson D, Berry L, Averill P. What does the Beck Depression Inventory 
measure in chronic pain? A reappraisal. Pain 1995; 61: 261-270.  
Nüesch E, Rutjes AW, Husni E, Welch V, Jüni P. Oral or transdermal opioids for 
osteoarthritis of the knee or hip. Cochrane Database of Systematic Reviews 2009; 
4: CD003115. 
Nunnally JC. Psychometric theory. 2nd ed. New York: McGraw-Hill; 1978.  
Nylund KL, Asparouhov T, Muthén BO. Deciding on the number of classes in 
latent class analysis and growth mixture modeling: A Monte Carlo simulation 
study. Structural Equation Modeling 2007; 14(4): 535-569. 
O'Brien, Robert M. "A Caution Regarding Rules of Thumb for Variance Inflation 
Factors." Quality and Quantity 2007; 41(5): 673-690. 
Office for National Statistics. National Statistics Socio-economic Classification 
2010. London: Stationary Office; 2010. 
Oladinni O. A survey of inner London general practitioners’ attitudes towards 
depression. Primary Care Psychiatry 2002; 8(3):95-98. 
Olino TM, Klein DN, Lewinsohn PM, Rohde P, Seeley JR. Latent trajectory classes 
of depressive and anxiety disorders from adolescence to adulthood: descriptions 
of classes and associations with risk factors. Comprehensive Psychiatry 2010; 
51(3): 224-235. 
O'Reilly SC, Jones A, Muir KR, Doherty M. Quadriceps weakness in knee 
osteoarthritis: the effect on pain and disability. Annals of the Rheumatic Diseases 
1998; 57(10): 588-594. 
Pai M, McCulloch M, Gorman JD, Pai N, Enanoria W, Kennedy G, Tharyan P, 
Colford JM Jr. Systematic reviews and meta-analyses: an illustrated, step-by-step 
guide. National Medical Journal of India 2004; 17(2): 86-95. 
Pallant JF, Bailey CM. Assessment of the structure of the Hospital Anxiety and 
Depression Scale in musculoskeletal patients. Health and quality of life outcomes 
2005; 3(1): 82. 
303 
 
Patsopoulos NA, Evangelou E, Ioannidis JPA. Sensitivity of between-study 
heterogeneity in meta-analysis: proposed metrics and empirical evaluation. 
International journal of epidemiology 2008; 37(5):1148-1157. 
Patten SB, Williams JVA, Wang JL. Mental disorders in a population sample with 
musculoskeletal disorders. BMC Musculoskeletal Disorders 2006; 7: 37.  
Pearson Education, Inc. Beck Depression Inventory–II (BDI–II). 2012; Available at: 
http://www.pearsonassessments.com/HAIWEB/Cultures/en-us/Productdetail.htm? 
Pid=015-8018-370. Accessed 20/01/2012. 
Peat G, Greig J, Wood L, Wilkie R, Thomas E, Croft P. Diagnostic discordance: 
we cannot agree when to call knee pain ‘osteoarthritis’. Family Practice 2005; 
22(1):96-102. 
Peat G, Thomas E, Handy J, Wood L, Dziedzic K, Myers H, Wilkie R, Duncan R, 
Hay E, Hill J, Lacey R, Croft P. The Knee Clinical Assessment Study-CAS(K). A 
prospective study of knee pain and knee osteoarthritis in the general population: 
baseline recruitment and retention at 18 months. BMC Musculoskeletal Disorders 
2006a; 7: 30. 
Peat G, Thomas E, Duncan R, Wood L, Hay E, Croft P. Clinical classification 
criteria for knee osteoarthritis: performance in the general population and primary 
care. Annals of the Rheumatic Diseases 2006b; 65(10): 1363-1367.  
Pedersen SS, Smith ORF, De Vries J, Appels A, Denollet J. Course of anxiety 
symptoms over an 18-month period in exhausted patients post percutaneous 
coronary intervention. Psychosomatic Medicine 2008; 70(3): 349-355.  
Peng VY. Latent trajectories modelling of developmental profiles of multimorbidity 
over time in primary care. Keele University: Arthritis Research UK Primary Care 
Centre; 2011.  
Penninx BWJH, Nolen WA, Lamers F, Zitman FG, Smit JH, Spinhoven P, Cuijpers 
P, Jong PJ, de Marwijk HWJ, van Meer K, van der Verhaak P. Two-year course of 
depressive and anxiety disorders: Results from the Netherlands Study of 
Depression and Anxiety (NESDA). Journal of Affective disorders 2011; 133(1-2): 
76-85. 
Pfizer, Inc. Patient Health questionnaire (PHQ) screeners. 2012; Available at: 
http://www.phqscreeners.com/overview.aspx?Screener=02_PHQ-9. Accessed 
20/01/ 2012. 
Phelan E, Williams B, Meeker K, Bonn K, Frederick J, LoGerfo J, Snowden M. A 
study of the diagnostic accuracy of the PHQ-9 in primary care elderly. BMC family 
practice 2010; 11(1): 63.  
Pignone MP, Gaynes BN, Rushton JL, Burchell CM, Orleans CT, Mulrow CD, Lohr 
KN. Screening for depression in adults: A summary of the evidence. Annals of 
Internal Medicine 2002; 136(10): 765-776. 
304 
 
Pilgrim D, Bentall R. The medicalisation of misery: A critical realist analysis of the 
concept of depression. Journal of Mental Health 1999; 8(3): 261-274.  
Pincus T, Callahan LF. Depression scales in Rheumatoid Arthritis. criterion 
contamination in interpretation of patient responses. Patient Education and 
Counseling 1993; 20:133-143. 
Pincus T, Vogel S, Field AP. A systematic review of psychological factors as 
predictors of chronicity/disability in prospective cohorts of low back pain. Spine 
2002; 27(5): E109-120.  
Pincus T, Vogel S, Burton AK, Santos R, Field AP. Fear avoidance and prognosis 
in back pain: A systematic review and synthesis of current evidence. Arthritis and 
Rheumatism 2006; 54(12): 3999-4010.  
Pinto‐Meza A, Serrano‐Blanco A, Peñarrubia MT, Blanco E, Haro JM. Assessing 
Depression in Primary Care with the PHQ‐9: Can It Be Carried Out over the 
Telephone? Journal of General Internal Medicine 2005; 20(8): 738-742. 
Polanczyk G, de Lima M, Horta B, Biederman J, Rohde L. The worldwide 
prevalence of ADHD: a systematic review and metaregression analysis. American 
Journal of Psychiatry 2007; 164(6): 942-948. 
Pollock K, Grime J. GPs’ perspectives on managing time in consultations with 
patients suffering from depression: a qualitative study. Family Practice 2003; 
20(3): 262-269. 
Polsky D, Doshi JA, Marcus S, Oslin D, Rothbard A, Thomas N, Thompson CL. 
Long-term risk for depression symptoms after a medical diagnosis. Archives of 
Internal Medicine 2005; 165(11): 1260-1266.  
Poole H, Bramwell R, Murphy P. The utility of the Beck Depression Inventory Fast 
Screen (BDI-FS) in a pain clinic population. European Journal of Pain 2009a; 
13(8): 865-869.  
Poole H, White S, Blake C, Murphy P, Bramwell R. Depression in chronic pain 
patients: Prevalence and measurement. Pain Practice 2009b; 9(3):173-180.  
Porcheret M, Hughes R, Evans D, Jordan K, Whitehurst T, Ogden H, Croft P. Data 
quality of general practice electronic health records: the impact of a program of 
assessments, feedback, and training. Journal of the American Medical Informatics 
Association 2004; 11(1): 78-86. 
Porta MS. A dictionary of epidemiology. 5th ed. New York: Oxford University 
Press, Inc; 2008.  
Prince MJ, Harwood R, Thomas A, Mann A. A prospective population-based 
cohort study of the effects of disablement and social milieu on the onset and 
maintenance of late-life depression. The Gospel Oak Project VII. Psychological 
Medicine 1998; 28(2): 337-350. 
305 
 
Rait G, Walters K, Griffin M, Buszewicz M, Petersen I, Nazareth I. Recent trends in 
the incidence of recorded depression in primary care. British Journal of Psychiatry 
2009; 195 (6): 520-524. 
RCGP (Royal College of General Practice). Weekly Returns Service Annual 
Prevalence Report 2006. Birmingham: Birmingham Research Unit; 2006. 
RCGP (Royal College of General Practice). Weekly Returns Service Annual 
Prevalence Report 2007. Birmingham: Birmingham Research Unit; 2007. 
Regier DA, Kaelber CT, Rae DS, Farmer ME, Knauper B, Kessler RC, Norquist 
GS. Limitations of diagnostic criteria and assessment instruments for mental 
disorders: implications for research and policy. Archives of General Psychiatry 
1998; 55(2): 109. 
Reilingh ML, Kuijpers T, Tanja-Harfterkamp A, van der Windt DA. Course and 
prognosis of shoulder symptoms in general practice. Rheumatology 2008; 47(5): 
724-730.  
Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining 
responsiveness and minimally important differences for patient-reported 
outcomes. Journla of Clinical Epidmiology 2008; 61 (2): 102-109. 
Rindskopf D. Trends in categorical data analyses. New, Semi-new, and Recycled 
ideas. Latent class models. In: Kaplan D, editor. The SAGE handbook of 
quantitative methodology for the social sciences. Thousand Oakes: Sage 
Publications; 2004. p. 137-149. 
Rogers, Carl May, Dianne Oliver, A. Experiencing depression, experiencing the 
depressed: the separate worlds of patients and doctors. Journal of Mental Health 
2001; 10(3): 317-333. 
Rosemann T, Wensing M, Joest K, Backenstrass M, Mahler C, Szecsenyi J. 
Problems and needs for improving primary care of osteoarthritis patients: the 
views of patients, general practitioners and practice nurses. BMC Musculoskeletal 
Disorders 2006; 7(1):48. 
Rosemann T, Backenstrass M, Joest K, Rosemann A, Szecsenyi J, Laux G. 
Predictors of depression in a sample of 1,021 primary care patients with 
osteoarthritis. Arthritis Care and Research 2007; 57(3): 415-422.  
Rosenthal R, DiMatteo MR. Meta-analysis: Recent developments in quantitative 
methods for literature reviews. Annual Review of Psychology 2001; 52(1): 59-82.  
Rosenstiel  AK , Keefe FJ.The use of coping strategies in low-back pain patients: 
relationship to patient characteristics and current adjustment. Pain 1983; 17: 33-
40. 
 
306 
 
Ross L. Screening for mental health problems and memory impairment for people 
with long term physical health conditions. North East Mental Health Development 
Unit. 2010; Available at: http://www.nemhdu.org.uk/silo/files/ltcs-screening-tool-for-
mental-health-problems--memory-loss.pdf. Accessed 28/02/ 2011. 
Roy-Byrne P, Veitengruber JP, Bystritsky A, dlund MJ, Sullivan G, Craske MG, 
Welch SS, Rose R, Stein MB. Brief intervention for anxiety in primary care 
patients. Journal of the American Board of Family Medicine 2009; 22(2):175-186. 
Roy-Byrne P, Craske MG, Sullivan G, Rose RD, Edlund MJ, Lang AJ, Bystritsky A, 
Welch SS, Chavira DA, Golinelli D, Campbell-Sills L, Sherbourne CD, Stein MB. 
Delivery of evidence-based treatment for multiple anxiety disorders in primary 
care. JAMA  2010; 303(19): 1921-1928.  
Roy-Byrne PP, Katon W, Cowley DS, Russo JE, Cohen E, Michelson E, Parrot T. 
Panic disorder in primary care: biopsychosocial differences between recognized 
and unrecognized patients. General Hospital Psychiatry 2000; 22(6): 405-411. 
Ruiz MA, Zamorano E, García-Campayo J, Pardo A, Freire O, Rejas J. Validity of 
the GAD-7 scale as an outcome measure of disability in patients with generalized 
anxiety disorders in primary care. Journal of Affective Disorders 2011; 128(3): 277-
286. 
Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in Heart 
Failure: A Meta-Analytic Review of Prevalence, Intervention Effects, and 
Associations With Clinical Outcomes. Journal of the American College of 
Cardiology 2006; 48(8):1527-1537.  
Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other 
rheumatic conditions in the ambulatory health care system in the United States, 
2001–2005. Arthritis Care and Research 2010; 62(4): 460-464. 
Sahlström A, Johnell O, Redlund-Johnell I. The natural course of arthrosis of the 
knee. Clinical Orthopaedics and Related Research 1997; 340: 152-157. 
Salaffi F, Cavalieri F, Nolli M, Ferraccioli G. Analysis of disability in knee 
osteoarthritis. Relationship with age and psychological variables but not with 
radiographic score. Journal of Rheumatology 1991; 18(10): 1581-1586. 
Sale JEM, Gignac M, Hawker G. The relationship between disease symptoms, life 
events, coping and treatment, and depression among older adults with 
osteoarthritis. Journal of Rheumatology 2008; 35(2): 335-342.  
Sarason IG, Sarason BR. Abnormal Psychology: The Problem of Maladaptive 
Behavior. 11th ed. India: Prentice Hall; 2004.  
Sartorius N, Üstün TB, Lecrubier Y, Wittchen HU. Depression comorbid with 
anxiety: Results from the WHO study on" Psychological disorders in primary health 
care." British Journal of Psychiatry. Supplement 1996; Jun (30): 38-43. 
307 
 
Schoevers R, Beekman A, Deeg D, Hooijer C, Jonker C, Van Tilburg W. The 
natural history of late-life depression: results from the Amsterdam Study of the 
Elderly (AMSTEL). Journal of Affective Disorders 2003; 76(1-3): 5-14. 
Schouten J, Valkenburg H. Classification criteria: methodological considerations 
and results from a 12 year following study in the general population. Journal of 
Rheumatology. Supplement 1995; 43: 44-45. 
Schram MT, Frijters D, van de Lisdonk EH, Ploemacher J, de Craen AJM, de Waal 
MWM, de Rooij FJ, van Heeringa J, Hofman A, Deeg DJH, Schellevis FG. Setting 
and registry characteristics affect the prevalence and nature of multimorbidity in 
the elderly. Journal of Clinical Epidemiology 2008; 61(11): 1104-1112. 
Schuurmans J, Comijs H, Beekman A, Beurs E, Deeg D, Emmelkamp P, van Dyck 
R.The outcome of anxiety disorders in older people at 6‐year follow‐up: results 
from the Longitudinal Aging Study Amsterdam. Acta Psychiatrica Scandinavica 
2005; 111(6): 420-428. 
Schwarz G. Estimating the dimension of a model. Annals of Statistics 1978; 6(2): 
461-464. 
Schwarz A. Diagnostic Test Calulator. 2002; Available at: 
http://araw.mede.uic.edu/cgi-bin/testcalc.pl?DT=0&Dt=0&dT=0&dt=0&2x2= 
Compute. Accessed 12/06/2012. 
Schwarzer AC, Aprill C, Derby R, Fortin J, Kine G, Bogduk N. Clinical features of 
patients with pain stemming from the lumbar zygapophyseal joints. Is the lumbar 
facet syndrome a clinical entity? Spine 1994; 10: 1132–1137.  
Scopaz KA, Piva SR, Wisniewski S, Fitzgerald GK. Relationships of fear, anxiety, 
and depression with physical function in patients with knee osteoarthritis. Archives 
of Physical Medicine and Rehabilitation 2009; 90(11):1866-1873. 
Scudds RJ, Robertson JM. Pain factors associated with physical disability in a 
sample of community-dwelling senior citizens. Journals Of Gerontology. Series A, 
Biological Sciences and Medical Sciences 2000 07; 55(7): M393-399.  
Seligman MEP, Walker EF, Rosenhan DL. Abnormal psychology. 4th ed. New 
York: W.W. Norton & Company, Inc; 2001.  
Shapiro S. Meta-analysis/Shmeta-analysis. American Journal of Epidemiology 
1994; 140: 771-778.  
Sharif M, Kirwan JR, Elson CJ, Granell R, Clarke S. Suggestion of nonlinear or 
phasic progression of knee osteoarthritis based on measurements of serum 
cartilage oligomeric matrix protein levels over five years. Arthritis and Rheumatism 
2004; 50(8): 2479-2488. 
 
308 
 
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta 
T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (MINI): 
the development and validation of a structured diagnostic psychiatric interview for 
DSM-IV and ICD-10. Journal of Clinical Psychiatry 1998; 59: 22-33. 
Sheskin D. Handbook of parametric and nonparametric statistical procedures. 
United States: Taylor and Francis Ltd; 2007.  
SIGN (Scottish Intercollegiate Guidelines NHS). Management of diabetes. 2010; 
116. 
Sikorski C, Luppa M, König HH, van den Bussche H, Riedel-Heller SG. Does GP 
training in depression care affect patient outcome?-A systematic review and meta-
analysis. BMC health services research 2012; 12(1):10.  
Simon GE, VonKorff M. Recognition, management, and outcomes of depression in 
primary care. Archives of Family Medicine 1995; 4(2): 99.  
Simpson A, Richards D, Gask L, Hennessy S, Escott D. Patients' experiences of 
receiving collaborative care for the treatment of depression in the UK: a qualitative 
investigation. Mental Health in Family Medicine 2008; 5(2): 95. 
Singleton R, Straits B. Approaches to Social Research. 4th ed. New York: Oxford 
University Press; 2005.  
Slade T, Andrews G. DSM-IV and ICD-10 generalized anxiety disorder: discrepant 
diagnoses and associated disability. Social Psychiatry and Psychiatric 
Epidemiology 2001; 36(1): 45-51.  
Smarr KL, Keefer AL. Measures of depression and depression symptoms: Beck 
Depression Inventory-II (BDI-II), Center for Epidemiologic Studies Depression 
Scale (CES-D), Geriatric Depression Scale (GDS), Hospital Anxiety and 
Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9). Arthritis 
Care and Research 2011; 63(11): 454-466 
Smith BH, Penny KI, Purves AM, Munro C, Wilson B, Grimshaw J, Chambers WA, 
Smith WC. The Chronic Pain Grade questionnaire: validation and reliability in 
postal research. Pain 1997; 71(2): 141-147.  
Snowden M, Steinman L, Frederick J, Wilson N. Screening for depression in older 
adults: recommended instruments and considerations for community-based 
practice. Clinical Geriatrics 2009; September: 26-32.  
Solomon DA, Keller MB, Leon AC, Mueller TI, Shea MT, Warshaw M, Maser JD, 
Coryell W, Endicott J. Recovery from major depression: a 10-year prospective 
follow-up across multiple episodes. Arch Gen Psychiatry 1997; 54(11):1001-1006.  
Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR. Methods for exploring 
heterogeneity in meta-analysis. Evaluation and The Health Professions 2001; 
24(2): 126-151. 
309 
 
Spielberger CD, Rickman RL. Assessment of State and Trait Anxiety. In: Andreoli 
V, Cassono E, G., Kielholz P, Pancher P, Racagni G, editors. Anxiety: 
Psychobiological and clinical perspectives Washington: Taylor and Francis; 1991. 
p. 69-83.  
Spies-Dorgelo MN, van der Windt DAWM, van der Horst HE, Prins APA, Stalman 
WAB. Hand and wrist problems in general practice—patient characteristics and 
factors related to symptom severity. Rheumatology 2007; 46(11): 1723-1728.  
Spitzer RL, Kroenke  K, Williams JBW. Validation and Utility of a Self-report 
Version of PRIME-MD. The PHQ Primary Care Study. JAMA 1999; 282(18): 1737-
1744. 
Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing 
generalized anxiety disorder: the GAD-7. Archives of Internal Medicine 2006; 
166(10): 1092-1097. 
Stein MB, Sherbourne CD, Craske MG, Means-Christensen A, Bystritsky A, Katon 
W, Sullivan G, Roy-Byrne PP. Quality of care for primary care patients with anxiety 
disorders. American Journal of Psychiatry 2004; 161(12): 2230-2237.  
Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. Original Paper: A 
likelihood ratio approach to meta-analysis of diagnostic studies. Journal of Medical 
Screening 2003; 10(1): 47-51.  
Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in STATA. In: Egger M, Smith 
GD, Altman DG, editor. Systematic Reviews in Health Care: Meta-analysis in 
context London: BMJ Books; 2003.  
Streiner DL. Clinimetrics vs. psychometrics: an unnecessary distinction. Journal of 
Clinical Epidemiology 2003; 56(12): 1142-1145.  
Streiner DL, Norman GR. Health measurement scales: a practical guide to their 
development and use. 4th ed. Oxford: Oxford University Press; 2008. 
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, 
Becker BJ, Sipe TA, Thacker SB. Meta-analysis of observational studies in 
epidemiology. JAMA 2000; 283(15): 2008-2012. 
Schwarzer AC, Aprill C, Derby R, Fortin J, Kine G, Bogduk N. Clinical features of 
patients with pain stemming from the lumbar zygapophyseal joints. Is the lumbar 
facet syndrome a clinical entity? Spine 1994; 10: 1132–1137.  
Summers MN, Haley WE, Reveille JD, AlarcOan GS. Radiographic assessment 
and psychologic variables as predictors of pain and functional impairment in 
osteoarthritis of the knee or hip. Arthritis and Rheumatism 1988; 31(2): 204-209.  
 
 
310 
 
Suri P, Morgenroth DC, Kwoh CK, Bean JF, Kalichman L, Hunter DJ. Low back 
pain and other musculoskeletal pain comorbidities in individuals with symptomatic 
osteoarthritis of the knee: data from the osteoarthritis initiative. Arthritis Care and 
Research 2010; 62(12): 1715-1723. 
Szoeke C, Dennerstein L, Wluka A, Guthrie J, Taffe J, Clark M, Cicuttini FM. 
Physician diagnosed arthritis, reported arthritis and radiological non-axial 
osteoarthritis. Osteoarthritis and Cartilage 2008; 16(7): 846-850.  
Tallini A. How should we define health? Health is state of physical, mental, and 
social wellbeing. BMJ 2011; 343: d5358. 
Tallon D, Chard J, Dieppe P. Exploring the priorities of patients with osteoarthritis 
of the knee. Arthritis Care and Research 2000; 13(5): 312-319.  
Tan AL, Grainger AJ, Tanner SF, Shelley DM, Pease C, Emery P, McGonagle D. 
High‐resolution magnetic resonance imaging for the assessment of hand 
osteoarthritis. Arthritis and Rheumatism 2005; 52(8): 2355-2365.  
Telford R, Hutchinson A, Jones R, Rix S, Howe A. Obstacles to effective treatment 
of depression: a general practice perspective. Family Practice 2002; 19(1): 45-52. 
Terluin B, Brouwers E, van Marwijk H, Verhaak P, van der Horst H. Detecting 
depressive and anxiety disorders in distressed patients in primary care; 
comparative diagnostic accuracy of the Four-Dimensional Symptom Questionnaire 
(4DSQ) and the Hospital Anxiety and Depression Scale (HADS). BMC family 
practice 2009; 10(1): 58.  
Terwee CB, Bot SDM, De Boer MR, van der Windt DAWM, Knol DL, Dekker J, 
Bouter LM, de Vet HCW. Quality criteria were proposed for measurement 
properties of health status questionnaires. Journal of Clinical Epidemiology 2007; 
60(1): 34-42. 
Thomas E, Peat G, Harris L, Wilkie R, Croft PR. The prevalence of pain and pain 
interference in a general population of older adults: cross-sectional findings from 
the North Staffordshire Osteoarthritis Project (NorStOP). Pain 2004; 110(1-2): 361-
368.  
Thombs BD, Taillefer SS, Hudson M, Baron M. Depression in patients with 
systemic sclerosis: A systematic review of the evidence. Arthritis Care and 
Research 2007; 57(6): 1089-1097.  
Thorstensson CA, Gooberman-Hill R, Adamson J, Williams S, Dieppe P. Help-
seeking behaviour among people living with chronic hip or knee pain in the 
community. BMC Musculoskeletal Disorders 2009; 7(10): 153-163. 
Timonen M, Liukkonen T. Management of depression in adults. BMJ 2008; 
336(7641): 435.  
 
311 
 
Titterington DM, Smith AFM, Makov UE. Statistical analysis of finite mixture 
distributions. New York: Wiley; 1985.  
Towheed T, Maxwell L, Judd M, Catton M, Hochberg MC, Wells G. 
Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews 
2006; (1): CD004257. 
Tsai PF. Predictors of distress and depression in elders with arthritic pain. Journal 
of Advanced Nursing 2005; 51(2):158-165. 
Tsuji T, Matsuyama Y, Goto M, Yimin Y, Sato K, Hasegawa Y, Ishiguro N. Knee–
spine syndrome: correlation between sacral inclination and patellofemoral joint 
pain. Journal of Orthopaedic Science 2002;7(5): 519-523. 
Tu K, Klein-Geltink J, Mitiku TF, Mihai C, Martin J. De-identification of primary care 
electronic medical records free-text data in Ontario, Canada. BMC medical 
informatics and decision making 2010; 10(1):35.  
Turk DC, Okifuji A. Detecting depression in chronic pain patients: adequacy of 
self-reports. Behaviour Research and Therapy 1994; 32(1): 9-16. 
Turner JA, Romano JM. Self-report screening measures for depression in chronic 
pain patients. Journal of Clinical Psychology 1984; 40(4):909-13. 
Tylee A, Gastpar M, Lepine J, Mendlewicz J. DEPRES II (Depression Research in 
European Society II): a patient survey of the symptoms, disability and current 
management of depression in the community. DEPRES Steering Committee. 
International Clinical Psychopharmacology 1999; 14(3): 139. 
Tylee A, Walters P. Underrecognition of anxiety and mood disorders in primary 
care: why does the problem exist and what can be done? Journal of Clinical 
Psychiatry 2007; 68: 27. 
UK National Screening Committee. Criteria for appraising the viability, 
effectiveness and appropriateness of a screening programme. 2009; Available at: 
www.screening.nhs.uk. Accessed 20/11/2010. 
U.S. Preventive Services Task Force (USPSTF). Screening for depression in 
adults: U.S. Preventive Services Task Force recommendation statement. Annals 
of Internal Medicine 2009; 151: 784-792. 
U.S. Preventive Services Task Force. Screening for Depression: rationale and 
recommendations. Annals of Internal Medicine 2002; 136(10): 760-764.  
Unützer J, Patrick DL, Diehr P, Simon G, Grembowski D, Katon W. Quality 
adjusted life years in older adults with depression symptoms and chronic medical 
disorders. International Psychogeriatrics 2000; 12(01): 15-33. 
 
312 
 
Unützer J, Katon W, Callahan CM, Williams JW, Hunkeler E, Harpole L, Hoffing M, 
Della Penna RD, Noël PH, Lin EH, Areán PA, Hegel MT, Tang L, Belin TR, Oishi 
S, Langston C.  Depression treatment in a sample of 1,801 depressed older adults 
in primary care. Journal of the American Geriatrics Society 2003; 51(4): 505-514. 
Uthman O. Prevalence and pattern of HIV-related malnutrition among women in 
sub-Saharan Africa: a meta-analysis of demographic health surveys. BMC Public 
Health 2008; 8(1): 226-233. 
van Beljouw I, Verhaak P, Cuijpers P, van Marwijk H, Penninx B. The course of 
untreated anxiety and depression, and determinants of poor one-year outcome: a 
one-year cohort study. BMC Psychiatry 2010; 10(1): 86.  
van den Brink RHS, Ormel J, Tiemens BG, Smit A, Jenner JA, van der Meer K, 
van Os TW. Predictability of the one-year course of depression and generalized 
anxiety in primary care. General Hospital Psychiatry 2002; 24(3):156-163.  
van Dijk GM, Dekker J, Veenhof C, van den Ende CHM. Course of functional 
status and pain in osteoarthritis of the hip or knee: A systematic review of the 
literature. Arthritis Care and Research 2006; 55(5): 779-785. 
Van Os J, Delespaul P. Toward a world consensus on prevention of 
schizophrenia. Dialogues in Clinical Neuroscience 2005; 7(1): 53-67.  
van Rijswijk E, van Hout H, van de Lisdonk E, Zitman F, van Weel C. Barriers in 
recognising, diagnosing and managing depressive and anxiety disorders as 
experienced by Family Physicians; a focus group study. BMC Family Practice 
2009; 10(1): 52. 
van Ryn M, Burke J. The effect of patient race and socio-economic status on 
physicians' perceptions of patients. Social Science and Medicine 2000; 50(6): 813-
828.  
Vartanian TP. Secondary data analysis. New York: Oxford University Press; 2010.  
Vermunt JK, Magidson J. Technical guide for Latent GOLD 4.0: Basic and 
advanced. Belmont Massachusetts: Statistical Innovations, Inc. 2005.  
Vermunt JK, Magidson J. Latent class cluster analysis. In: Hagenaars JA, 
McCutcheon AL, editors. Applied Latent Class Analysis. New York: Cambridge 
University Press; 2002. p. 89-106. 
Viinamäki H, Mäntyselkä P, Kumpusalo E, Halonen P, Takala J, Kauhanen J. 
Sleep disturbance is associated with mental disorder in patients with hip or knee 
osteoarthritis. European Journal of Psychiatry 2002; 16(1): 9-13.  
Vilalta-Franch J, Garre-Olmo J, López-Pousa S, Turon-Estrada A, Lozano-Gallego 
M, Hernàndez-Ferràndiz M, Pericot-Nierga I, Garre-Olmo J. Comparison of 
different clinical diagnostic criteria for depression in Alzheimer disease. American 
Journal of Geriatric Psychiatry 2006; 14(7): 589.  
313 
 
Vlaeyen JWS, Kole-Snijders AMJ, Rotteveel AM, Ruesink R, Heuts PHTG. The 
role of fear of movement/(re) injury in pain disability. Journal of Occupational 
Rehabilitation 1995; 5(4): 235-252. 
Volkers AC, Nuyen J, Verhaak PFM, Schellevis FG. The problem of diagnosing 
major depression in elderly primary care patients. Journal of Affective Disorders 
2004; 82(2): 259-263. 
Von Korff M, Ormel J, Keefe FJ, Dworkin SF. Grading the severity of chronic pain. 
Pain 1992; 50(2): 133-149.  
Vowles KE, McCracken LM. Acceptance and values-based action in chronic pain: 
a study of treatment effectiveness and process. Journal of Consulting and Clinical 
Psychology 2008; 76(3): 397-407. 
Watson D, Clark LA, Weber K, Assenheimer JS, Strauss ME, McCormick RA. 
Testing a tripartite model: II. Exploring the symptom structure of anxiety and 
depression in student, adult, and patient samples. Journal of Abnormal 
Psychology 1995; 104(1):15-25. 
Watson LC, Pignone MP. Screening accuracy for late-life depression in primary 
care: a systematic review. Journal of Family Practice 2003; 52(12): 956-964. 
Watson M, Brookes S, Faulkner A, Kirwan J. Non‐aspirin, non‐steroidal anti‐
inflammatory drugs for treating osteoarthritis of the knee. Cochrane Database of 
Systematic Reviews 2006; (1): CD000142. 
Watts S, Bhutani G, Stout I, Ducker G, Cleator P, McGarry J, Day M. Mental 
health in older adult recipients of primary care services: is depression the key 
issue? Identification, treatment and the general practitioner. International Journal 
of Geriatric Psychiatry 2002; 17(5): 427-437. 
Webb P, Bain C. Essential epidemiology: an introduction for students and health 
professionals. 2nd ed. New York: Cambridge University Press; 2011.  
Weisberg RB, Dyck I, Culpepper L, Keller MB. (2007). Psychiatric treatment in 
primary care patients with anxiety disorders: a comparison of care received from 
primary care providers and psychiatrists. American Journal of Psychiatry 2007; 
164 (2):276-82. 
Wells KB, Golding JM, Burnam MA. Affective, substance use, and anxiety 
disorders in persons with arthritis, diabetes, heart disease, high blood pressure, or 
chronic lung conditions. General Hospital Psychiatry 1989a; 11(5): 320-327. 
Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, Berry S, 
Greenfield S, Ware J. The functioning and well-being of depressed patients. JAMA 
1989b; 262(7): 914-919. 
 
314 
 
Wetherell JL, Birchler GD, Ramsdell J, Unützer J. Screening for generalized 
anxiety disorder in geriatric primary care patients. International Journal of Geriatric 
Psychiatry 2007; 22(2):115-123.  
Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. The development of 
QUADAS: a tool for the quality assessment of studies of diagnostic accuracy 
included in systematic reviews. BMC medical research methodology 2003; 3: 25. 
Whitley GG. Concept analysis of anxiety. International Journal of Nursing 
Knowledge 1992; 3(3):107-116.  
Whitley GG. Expert validation and differentiation of the nursing diagnoses anxiety 
and fear. International Journal of Nursing Terminologies and Classifications 1994; 
5(4):143-150.  
Whooley MA, Avins AL, Miranda J, Browner WS. Case-finding instruments for 
depression. Journal of General Internal Medicine 1997; 12(7): 439-445.  
Widiger TA, Sankis LM. Adult psychopathology: Issues and controversies. Annual 
Review of Psychology 2000; 51(1): 377-404. 
Widiger TA, Samuel DB. Diagnostic categories or dimensions? A question for 
DSM-V. Journal of Abnormal Psychology 2005; 114(4): 494-454. 
Widiger TA, Mullins-Sweatt S 2007. Mental disorders as discrete clinical 
conditions: Dimensional versus categorical classification. In: S.M. TURNER and 
M. HERSEN, editors, Adult psychopathology and diagnosis. 3rd ed. New York: 
Wiley, p. 3-33. 
Wilcox S, Brenes GA, Levine D, Sevick MA, Shumaker SA, Craven T. Factors 
related to sleep disturbance in older adults experiencing knee pain or knee pain 
with radiographic evidence of knee osteoarthritis. Journal of the American 
Geriatrics Society 2000; 48(10): 1241-1251. 
Wilkie R., Peat G., Thomas E., Croft P. Factors associated with restricted mobility 
outside the home in community-dwelling adults ages fifty years and older with 
knee pain: An example of use of the international classification of functioning to 
investigate participation restriction. Arthritis Care and Research 2007; 57(8): 1381-
1389. 
Wilkinson M, Barczak P. Psychiatric screening in general practice: comparison of 
the general health questionnaire and the hospital anxiety depression scale. 
Journal of the Royal College of General Practitioners 1988; 38(312): 311-313. 
Williams JW, Pignone M, Ramirez G, Perez Stellato C. Identifying depression in 
primary care: a literature synthesis of case-finding instruments. General Hospital 
Psychiatry 2002; 24(4): 225-237. 
 
315 
 
Williams DA, Farrell MJ, Cunningham J, Gracely RH, Ambrose K, Cupps T, Mohan 
N, Clauw D. Knee pain and radiographic osteoarthritis interact in the prediction of 
levels of self-reported disability. Arthritis & Rheumatism-Arthritis Care and 
Research 2004; 51(4): 558-561.  
Willis BH. Spectrum bias - why clinicians need to be cautious when applying 
diagnostic test studies. Family Practice 2008; 25(5): 390-396.  
Wilson JMG, Jungner G. The Principles and Practice of Screening for Disease. 
Geneva: WHO; 1968. 
Wilson KG, Mikail SF, D'Eon JL, Minns JE. Alternative diagnostic criteria for major 
depressive disorder in patients with chronic pain. Pain 2001;91(3):227-234.  
Wolfe F. Determinants of WOMAC function, pain and stiffness scores: evidence 
for the role of low back pain, symptom counts, fatigue and depression in 
osteoarthritis, rheumatoid arthritis and fibromyalgia. Rheumatology 1999; 38(4): 
355-361. 
Wolitzky‐Taylor KB, Castriotta N, Lenze EJ, Stanley MA, Craske MG. Anxiety 
disorders in older adults: a comprehensive review. Depress and Anxiety 2010; 
27(2): 190-211. 
Woo J, Ho SC, Lau J, Leung PC. Musculoskeletal complaints and associated 
consequences in elderly Chinese aged 70 years and over. Journal of 
Rheumatology 1994 10; 21(10):1927-1931.  
Wood F, Pill R, Prior L, Lewis G. Patients' opinions of the use of psychiatric case‐
finding questionnaires in general practice. Health Expectations 2002; 5(4): 282-
288.  
Wood L, Peat G, Thomas E, Duncan R. Knee osteoarthritis in community-dwelling 
older adults: are there characteristic patterns of pain location? Osteoarthritis and 
cartilage 2007; 15(6): 615-623. 
Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bulletin of the 
World Health Organization 2003; 81(9): 646-656. 
World Health Organization. World Health Organization (WHO). International 
Classification of Diseases: Manual of the International Statistical Classification of 
Diseases, Injuries and Causes of Death, 6th revision. Geneva: World Health 
Organization; 1948.  
World Health Organization (WHO). The ICD-10 Classification of Mental and 
Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: 
World Health Organization; 1992. 
World Health Organization (WHO). Mental Health: New Understanding, New 
Hope. Geneva: World Health Organization; 2001.  
316 
 
Yeung A, Fung F, Yu SC, Vorono S, Ly M, Wu S, Fava M. Validation of the Patient 
Health Questionnaire-9 for depression screening among Chinese Americans. 
Comprehensive Psychiatry 2008; 49(2): 211-217. 
Yohannes AM, Caton S. Management of depression in older people with 
osteoarthritis: A systematic review. Aging and Mental Health 2010; 14(6):637-651.  
Yohannes AM, Willgoss TG, Baldwin RC, Connolly MJ. Depression and anxiety in 
chronic heart failure and chronic obstructive pulmonary disease: prevalence, 
relevance, clinical implications and management principles. International Journal 
of Geriatric Psychiatry 2010; 25(12): 1209-1221. 
Zhang W, Doherty M, Leeb B, Alekseeva L, Arden N, Bijlsma J, Dincer F, Dziedzic 
K, Hauselmann HJ, Kaklamanis P, Kloppenburg M, Lohmander LS, Maheu E, 
Martin-Mola E, Pavelka K, Punzi L, Reiter S, Smolen J, Verbruggen G, Watt I. 
EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: 
report of a task force of ESCISIT. Annals of the Rheumatic Diseases  2009; 68(1): 
8-17. 
Zhang W, Doherty M, Peat G, Bierma-Zeinstra MA, Arden NK, Bresnihan B, 
Herrero-Beaumont G, Kirschner S, Leeb BF, Lohmander LS, Mazières B, Pavelka 
K, Punzi L, So AK, Tuncer T, Watt I, Bijlsma JW. EULAR evidence-based 
recommendations for the diagnosis of knee osteoarthritis. Annals of the Rheumatic 
Diseases 2010; 69(3): 483-489. 
Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clinics in Geriatric Medicine 
2010; 26(3): 355-369. 
Zigmond AS, Snaith R. The hospital anxiety and depression scale. Acta 
Psychiatrica Scandinavica 1983; 67(6): 361-370. 
 
 
 
 
 
 
 
 
 
 
 
317 
 
Appendix A:  Conference abstracts 
 
Rzewuska M, Mallen CD, Belcher J, Peat G. The prevalence of comorbid 
depressive disorders and depression symptoms in adults with osteoarthritis and/or 
joint pain: systematic review and meta-analyses. Society for Academic Primary 
Care Annual scientific Meeting, Bristol, England, 6-8 July 2011  
 
Introduction: Recent NICE guidance recommends the management of 
depressive symptoms in chronic physical conditions. As the commonest chronic 
condition managed in primary care, and linked with depression, osteoarthritis (OA) 
can be considered within these recommendations. However, with an estimated 8 
million OA sufferers in the UK, the scale of detecting and managing comorbid 
depression may be considerable. Accurate estimates of the prevalence of 
comorbid depressive disorders and depressive symptoms in people with OA are 
needed. We conducted a systematic review and meta-analyses to ascertain these 
estimates.   
Method: Electronic bibliographic databases and reference lists were searched 
from inception to November 2009. Random effects meta-analyses (for log-
transformed estimates) were conducted for observational studies in primary 
care/general populations reporting the prevalence of depressive disorders and/or 
symptoms in adults with OA/joint pain. Standardised sensitivity analyses were 
implemented to estimate pooled prevalence with a pre-specified acceptable level 
of homogeneity (I2≤ 50%). Subgroup meta-analyses and meta-regression analyses 
were conducted.   
Results: 10601 titles were identified and 746 abstracts were screened. 54 studies 
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described in 88 articles were included. There was substantial between-study 
heterogeneity in findings (sources included study design, study setting, different 
case definitions, methods of ascertainment, geographical locations, and 
populations of interest). Overall pooled prevalence estimates were obtained 
independently for depressive disorders and depressive symptoms including: major 
depression (8%, 95% CI 7.1-9.1; 25 estimates; I2=94.1%, p<0.001); dysthymia 
(2.6%, 95% CI 2-3.6; 19 estimates; I2=82.2%, p<0.001); mild-severe depressive 
symptoms (21.2%, 95% CI 17.7-25.2; 27 estimates; I2=98.2%, p<0.001); 
moderate-severe depressive symptoms (14.2%, 95% CI 9.5-20.6; 7 estimates; 
I2=97%, p<0.001). The following prevalence estimates were pooled from studies 
with the acceptable level of homogeneity: major depression 6.6% (95% CI 5.8-7.6, 
14 estimates); dysthymia 2.7% (95% CI 2.3-3.2, 18 estimates); mild-severe 
depressive symptoms 23.3% (95% CI 21.2-24.8, 8 estimates); moderate-severe 
depressive symptoms (unobtainable). Mild-severe depressive symptoms appeared 
more common in older age groups, women, and primary care patients [the pooled 
prevalence for primary care was 27.9% (95% CI 25.5-30.6); 6 estimates; I2=79%, 
p<0.001].   
Conclusions: Comorbid depressive symptoms, typically minor/subsyndromal, are 
present in one in four primary care patients with OA. Gender, age and health 
status differences support person centred detection programs. 
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Rzewuska M, Mallen CD, Peng VY, Belcher J, Peat G. A latent class growth 
analysis of anxiety symptoms in a longitudinal cohort of primary care patients with 
symptomatic osteoarthritis. Division of Health Psychology Annual Conference, 
Southampton, England, 14-15 September 2011  
 
Background: Symptomatic osteoarthritis (OA) is a painful joint disorder. Anxiety 
symptoms affect 45% of adults with OA and can deteriorate their functioning. An 
understanding of the natural course of anxiety over time in OA is required to inform 
GPs, allocate healthcare resources and improve patients’ awareness. This study 
identifies patterns in anxiety development and describes their characteristics 
among primary care patients with OA. 
Methods: Participants were older UK consecutive general practice attendees, with 
symptomatic OA. Self-complete questionnaires, containing measures of anxiety 
and depressive symptoms, age, gender, pain status, coping and social status were 
mailed within 1 week post-consultation and at 3, 6, 12 months. A Latent Class 
Growth Analysis was used to identify classes of anxiety development over time. 
Associations between baseline characteristics and class membership were 
examined.  
Results: A 4-class model emerged for 293 participants with complete anxiety 
data: normal (41.3%); persistent (29.7%); transient (19.1%) and relapsing (9.9%) 
anxiety patterns. Ineffective coping strategies, poorer pain status and limited 
physical/economic resources were associated with maladaptive anxiety 
responses. Age, gender and factors related to social interactions indicate little 
impacts on progress of anxiety in OA. Examination of risk factors is to be finalised.  
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Discussion: The identified longitudinal trajectories of anxiety support differences 
in adaptation to OA. The course of adaptation appears to be related to 
characteristics of OA as a stressor, effectiveness of coping and availability of 
fundamental resources. In practice this study clarifies which of primary care 
attendees with OA should be targeted for identification of anxiety. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
321 
 
Rzewuska M, Mallen CD, Strauss VY, Belcher J, Peat G. The Course of Comorbid 
Anxiety Symptoms in Patients Presenting to General Practice with Symptomatic 
Osteoarthritis: A Latent Class Growth Analysis. Rheumatology 2012; 51: 110.  
 
Background: Concurrent elevated anxiety symptoms are common in people with 
symptomatic OA and contribute to levels of disability. Yet it is unclear how often 
anxiety symptoms present at the time of seeking formal healthcare for OA 
represent persistent states of anxiety and what factors are associated with 
different anxiety symptom trajectories. An understanding of the natural course of 
anxiety symptoms in patients with OA is required to inform clinicians, allocate 
healthcare resources and improve patients’ awareness.   
Methods: Participants were older adults consulting general practice with 
symptomatic OA. Self-completion questionnaires, containing measures of anxiety 
and depressive symptoms, age, gender, pain status, coping and social status were 
mailed within 1 week of the consultation and at 3, 6, 12 months. A person-centred 
approach applying Latent Class Growth Analysis (LCGA) was used to identify 
clusters of anxiety symptoms, which were ascertained with cut-off score ≥8 on the 
Hospital Anxiety and Depression Scale anxiety subscale. Associations between 
baseline characteristics and cluster membership were examined using multinomial 
logistic regression (entry probability p<0.10).   
Results: A 4-cluster LCGA anxiety model was supported in 293 participants with 
complete anxiety data. Clusters were: no anxiety (41.3%), persistent (29.7%), 
unstable (19.1%) and progressive (9.9%) anxiety. Catastrophising, coping by 
increased behavioural activities, pain extent and interference with work, 
occupational class and perceived lack of instrumental support were differently 
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associated with four anxiety clusters (Table). Age, gender, other coping strategies 
and factors related to social interactions showed no significant effects on anxiety 
trajectories.   
Conclusions: Sixty percent of patients with OA have reported non-normal anxiety 
levels over 12 months. In addition, an estimated 60% of patients with symptomatic 
OA presenting to general practice with concurrent anxiety symptoms will 
experience persistent anxiety for at least 12 months. Odds ratios suggest that 
coping by catastrophising (Adj. OR=4.25, 95% CI 0.24-0.83) and pain extent (Adj. 
OR=1.09, 95% CI 1.04-1.15) are most prominent factors associated with the 
persistent anxiety trajectory. 
Table. Backward elimination multinomial logistic regression analyses of baseline 
covariates and trajectories of anxiety. 
 
 ‘Persistent’ vs.  
‘No anxiety’*  
‘Unstable’ vs.  
‘No anxiety’*  
‘Progressive’ vs.  
‘No anxiety’*  
Covariates Adj. OR (95%CI)  Adj. OR (95%CI)  Adj. OR (95%CI)  
Coping by 
catastrophising  
4.25 (1.99, 9.06)  4.04 (1.83, 8.95)  0.93 (0.28, 3.08)  
Coping by increased 
behavioural activities  
0.45 (0.24, 0.83)  0.51 (0.27, 0.97)  0.66 (0.27, 1.61)  
Lack of instrumental 
support  
5.49 (1.52, 19.81)  1.54 (0.31, 7.60)  3.35 (0.54, 20.82)  
Manual/routine 
occupational class  
1.47 (0.76, 2.81)  1.47 (0.75, 2.88)  4.00 (1.60, 9.97)  
Pain extent  
(total number of pain 
sites 0-44)  
1.09 (1.04, 1.15)  1.04 (0.98, 1.09)  1.08 (1.01, 1.15)  
Pain interference with 
work (0-10)  
1.18 (1.05, 1.33)  1.12 (0.99, 1.26)  1.29 (1.08, 1.54)  
Note:*a reference category 
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Appendix B:  Prevalence of depression and anxiety in adults with 
osteoarthritis/joint pain: a systematic review and meta-analyses 
This appendix supports analyses described in chapter two 
 
 
B.1 SEARCH STRATEGY 
Box B.1.1 Terms used to search six electronic databases.  
 
 EMBASE: 
Osteoarthritis/joint pain 
Keywords: hand, knee, ankle, foot, shoulder, elbow, wrist, hip, pain adj8 psych*, 
musculoskelet*, spondylosis, osteoarthos*, joint adj2 stiff*, joint adj2 pain, joint adj2 
diseas*, arthrit*, Osteoarthrit* 
Thesaurus: exp spondylosis, exp cartilage, exp cartilage degeneration, exp elbow, exp 
elbow disease, exp hand, hand joint, exp hip, exp hip pain, hip osteoarthritis, exp hip 
disease, exp knee, exp knee disease, knee osteoarthritis, knee pain, exp arthritis, exp 
arthralgia, exp shoulder, exp shoulder pain, exp shoulder disease, exp wrist, exp wrist 
disease, exp ankle, exp ankle pain, exp foot, exp foot disease, exp foot pain, exp joint, exp 
joint degeneration, exp joint stiffness, exp finger joint, exp interphalangeal joint, exp 
carpometacarpal joint, exp carpal joint, exp atlantoocipital joint, exp atlantoaxial joint, exp 
acromioclavicular joint, exp toe joint, exp radioulnar joint, exp sacroiliac joint, exp subtalar 
joint, exp sternocostal joint, exp sternoclavicular joint, exp tarsal joint, exp tarsometatarsal 
joint, exp temporomandibular joint, exp zygapophyseal joint, exp metacarpophalangeal 
joint, exp metatarsophalangeal joint, proximal interhalangeal joint, exp patellofemoral joint 
Depression/anxiety 
Keywords: outcome*, predictor*, anxiety*, coping, adapt*, anxious adj2 person, anxiety 
adj2 symptom*, depress* adj2 symptom*, depress*, affect adj2 symptom*, psychol* adj2 
distress, antidepressant*, emotional adj2 distress, mood, HADS, hospital and anxiety and 
depression and scale, CES-D, centre and for and epidemiologic and studies and 
depression and scale, BDI, beck and depression and inventory, GDS, geriatric and 
depression and scale, STAI, state and trait and anxiety and inventory, PHQ, patient and 
health and questionnaire 
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Box B.1.1 cont. Terms used to search six electronic databases. 
Thesaurus: exp mental disease, exp adaptation, exp coping behaviour, exp anxiety, exp 
anxiety disorder, exp beck anxiety inventory, exp hamilton anxiety scale, exp hospital 
anxiety and depression scale, exp mixed anxiety and depression, exp self-rating anxiety 
scale, exp state trait anxiety inventory, exp self-rating depression scale, exp depression, 
exp rating scale, exp center for epidemiological studies depression scale, exp depression, 
exp depression inventory, exp geriatric depression scale, exp major depression, exp 
psychological rating scale, exp mental stress, exp affect, exp emotional, exp mood 
disorder, exp lifestyle, exp mental health, exp personality test, exp clinical psychology, exp 
medical psychology, exp risk assessment, exp risk factor, exp quality of life 
Setting 
Keywords: population* adj2 survey*, primary adj2 care, general adj2 practic*, family adj2 
practic*, family adj2 medicine, general adj2 practition*, family adj2 practition*, community 
adj2 dwell*, general adj2 popul* 
Thesaurus: exp general practice, exp primary health care, exp general practitioner 
Study design 
Keywords: comorbid*, co-occurrence, prevalence*, frequency, observational adj2 stud*, 
cross-sectional adj2 stud*, prospective adj2 stud* 
Thesaurus: exp comorbidity, exp incidence, exp prevalence, exp cross-sectional study, 
exp epidemiology, exp case control study, exp cohort analysis, exp observational study, 
exp prospective study, exp sickness impact profile, exp health status, exp questionnaire, 
exp health survey 
MEDLINE: 
Osteoarthritis/joint pain 
Keywords: hand, knee, ankle, foot, shoulder, elbow, wrist, hip, musculoskelet*, 
spondylosis, osteoarthos*, joint N2 stiff*, joint N2 pain, joint N8 diseas*, arthrit*, 
osteoarthrit* 
Thesaurus: MH cartilage, MH cartilage diseases+, MH elbow, MH elbow joint, MH hand+, 
MH hand joints+, MH hip, MH hip joint, MH knee, MH knee joint+, MH osteoarthritis+, MH 
osteoarthritis spine, MH osteoarthritis hip, MH osteoarthritis knee, MH 
muskuloskuloskeletal diseases/PX, MH arthralgia+, MH shoulder, MH shoulder joint, MH 
shoulder pain, MH wrist, MH wrist joint, MH ankle, MH ankle joint, MH foot+, MH joint 
diseases+, MH pain/PX, MH spondylosis+, MH arthritis/EP/PX 
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Box B.1.1 cont. Terms used to search six electronic databases. 
 
Depression/anxiety 
Keywords: outcome*, predictor*, anxiet*, coping, adapt*, anxious N2 person, anxiety N2 
symptom*, depress* N2 symptom*, depress*, affect N2 symptom*, psychol* N2 distress, 
antidepressant*, emotional N2 distress, mood, HADS, hospital anxiety depression scale, 
CES-D, centre for epidemiologic studies depression scale, BDI, beck depression 
inventory, GDS, geriatric depression scale, STAI, state trait anxiety inventory, PHQ, 
patient health questionnaire 
Thesaurus: MH adaptation psychological+, MH anxiety+, MH anxiety disorders+, MH 
psychiatric status rating scales+, MH stress psychological+, MH affect+, MH affective 
symptoms, MH mood disorders+, MH life style+, MH mental health, MH personality 
inventory+, MH psychology clinical, MH psychology medical, MH risk assessment+, MH 
risk factors, MH quality of life 
Setting 
Keywords: population* N2 survey*, primary N2 care, general N2 practic*, family N2 
practic*, family N2 medicine, general N2 practition*, family N2 practition*, community N2 
dwell*, general N2 popul* 
Thesaurus: MH family practice, MH primary health care+, MH physicians family 
Study design 
Keywords: comorbid*, co-occurrence, prevalence*, frequency, observational N2 stud*, 
cohort N2 stud*, cross-sectional N2 stud*, prospective N2 stud* 
Thesaurus: MH comorbidity, MH prevalence, MH incidence, MH cross-sectional studies, 
MH case-control studies+, MH cohort studies+, MH epidemiologic studies+, MH follow-up 
studies, MH epidemiology+, MH epidemiologic factors+, Mh epidemiologic methods+, MH 
epidemiologic research design+, MH prospective studies, MH sickness impact profile, MH 
health status indicators+, MH health surveys+, MH health status+, MH questionnaires+ 
PSYCINFO: 
Osteoarthritis/joint pain 
Keywords: hand, knee, ankle, foot, shoulder, elbow, wrist, hip, musculoskelet*, 
spondylosis, osteoarthos*, joint N2 stiff*, joint N2 pain, joint N8 diseas*, arthrit*, osteoarth* 
Thesaurus: MH hip, MH hip joint, MH knee, MH knee joint+, MH cartilage diseases+, MH 
elbow, MH elbow joint, MH hand+, MH hand joint, MH osteoarthritis+, MH osteoarthritis 
spine, MH osteoarthritis hip, MH osteoarthritis knee, MH muskuloskletal diseases/PX, MH 
arthralgia+, MH shoulder, MH shoulder joint, MH shoulder pain, MH wrist, MH wrist joint, 
MH ankle, MH ankle joint, MH joint diseases+, MH pain/PX, MH spondylosis+, MH 
arthritis/EP/PX 
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Box B.1.1 cont. Terms used to search six electronic databases. 
 
Depression/anxiety 
Keywords: outcome*, predictor*, anxiet*, coping, adapt*, anxious N2 person, anxiety N2 
symptom*, depress* N2 symptom*, depress*, affect N2 symptom*, psychol* N2 distress, 
antidepressant*, emotional N2 distress, mood, HADS, hospital anxiety depression scale, 
CES-D, centre for epidemiologic studies depression scale, BDI, beck depression 
inventory, GDS, geriatric depression scale, STAI, state trait anxiety inventory, PHQ, 
patient health questionnaire 
Thesaurus: MH adaptation psychological+, MH anxiety+, MH anxiety disorders+, MH 
psychiatric status rating scales+, MH stress psychological+, MH affect+, MH affective 
symptoms, MH mood disorders+, MH life style+, MH mental health, MH personality 
inventory+, MH psychology clinical, MH psychology medical, MH risk assessment+, MH 
risk factors, MH quality of life 
Setting 
Keywords: population* N2 survey*, primary N2 care, general N2 practic*, family N2 
practic*, family N2 medicine, general N2 practition*, family N2 practition*, community N2 
dwell*, general N2 popul* 
Thesaurus: MH family practice, MH primary health care+, MH physicians family 
Study design 
Keywords: comorbid*, co-occurrence, prevalence*, frequency, observational N2 stud*, 
cohort N2 stud*, cross-sectional N2 stud*, prospective N2 stud* 
Thesaurus: MH comorbidity, MH prevalence, MH incidence, MH cross-sectional studies, 
MH case-control studies+, MH cohort studies+, MH epidemiologic studies+, MH follow-up 
studies, MH epidemiology+, MH epidemiologic factors+, MH epidemiologic methods+, MH 
epidemiologic research design+, MH prospective studies, MH sickness impact profile, MH 
health status indicators+, MH health surveys+, MH health status+, MH questionnaires+ 
CINAHL: 
Osteoarthritis/joint pain 
Keywords: hand, knee, ankle, foot, shoulder, elbow, wrist, hip, musculoskelet*, 
spondylosis, osteoarthos*, joint N2 stiff*, joint N2 pain, joint N8 diseas*, arthrit*, 
osteoarthrit* 
Thesaurus: MH hip, MH hip joint, MH knee, MH knee joint+, MH cartilage diseases+, MH 
elbow, MH elbow joint, MH hand+, MH foot, MH hand joint, MH osteoarthritis+, MH 
osteoarthritis spine, MH osteoarthritis hip, MH osteoarthritis knee, MH muskuloskletal 
diseases/PX, MH arthralgia+, MH shoulder, MH shoulder joint, MH shoulder pain, MH 
wrist, MH wrist joint, MH ankle, MH ankle joint, MH joint diseases+, MH pain/PX, MH 
spondylosis+, MH arthritis/EP/PX 
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Box B.1.1 cont. Terms used to search six electronic databases. 
 
Depression/anxiety 
Keywords: outcome*, predictor*, anxiet*, coping, adapt*, anxious N2 person, anxiety N2 
symptom*, depress* N2 symptom*, depress*, affect N2 symptom*, psychol* N2 distress, 
antidepressant*, emotional N2 distress, mood, HADS, hospital anxiety depression scale, 
CES-D, centre for epidemiologic studies depression scale, BDI, beck depression 
inventory, GDS, geriatric depression scale, STAI, state trait anxiety inventory, PHQ, 
patient health questionnaire 
Thesaurus: MH adaptation psychological+, MH anxiety+, MH anxiety disorders+, MH 
psychiatric status rating scales+, MH stress psychological+, MH affect+, MH affective 
symptoms, MH depression, MH depressive disorder+, MH depressive disorder major+, 
MH mood disorders+, MH life style+, MH mental health, MH personality inventory+, MH 
psychology clinical, MH psychology medical, MH risk assessment+, MH risk factors, MH 
quality of life 
Setting 
Keywords: population* N2 survey*, primary N2 care, general N2 practic*, family N2 
practic*, family N2 medicine, general N2 practition*, family N2 practition*, community N2 
dwell*, general N2 popul* 
Thesaurus: MH family practice, MH primary health care+, MH physicians family 
Study design 
Keywords: comorbid*, co-occurrence, prevalence*, frequency, observational N2 stud*, 
cohort N2 stud*, cross-sectional N2 stud*, prospective N2 stud* 
Thesaurus: MH comorbidity, MH prevalence, MH incidence, MH cross-sectional studies, 
MH case-control studies+, MH cohort studies+, MH epidemiologic studies+, MH follow-up 
studies, MH epidemiology+, MH epidemiologic factors+, MH epidemiologic methods+, MH 
epidemiologic research design+, MH prospective studies, MH sickness impact profile, MH 
health status indicators+, MH health surveys+, MH health status+, MH questionnaires+ 
ISI Web of Knowledge and CSA ILLUMINA 
(anxiet*or depress*) and (osteoarthrit*or arthrit* or joints) 
Note: Terms belonging to the same categories were linked with ‘OR’ and categories were linked with ‘AND’ 
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B.2 DETAILS OF INCLUDED STUDIES 
 
Table B.2.1 Overview of studies from which data was synthesised. S2.  
Overview of  studies from which data was synthesized  
 Methodological summary Statistical summary for cases with OA/joint pain 
Study ID  
[ID number] 
 
Country/ 
region 
Design 
(response 
rate) 
Setting Mean age 
(SD): range  
 
Grouping category (definition 
used by authors): description  
of cases ascertainment/time 
scale(anatomical site) 
Sample (% F) Mental health 
problem: 
assessment tool 
(range); cut-off 
score/severity 
Prevalence rate  
Of mental health 
problem in OA/joint 
pain and compared 
groups 
  Mean score  
 
Questionnaires/self-reported anxiety and depression ascertainment      
Allen, 2008 
[1] 
U.S.A/ 
Johnston 
county 
Prospective-
cohort  
(BL: 95%) 
General 
population 
≥45 Radiographic OA (OA): 
radiographs graded with the K+L 
criteria, 1 question on joint pain 
or stiffens/most days (knee, hip) 
With OA: 759 (67.3%) 
Without OA: 1923 
(65%) 
 
Depression: CESD-
20 (0-60);≥16/mild or 
worse 
In OA: 
13.3% 
Without OA: 
12.7% 
p>0.05 
 
Barberger-
Gateau,1992  
[2] 
France/ 
Gironde, 
Dordogn
e 
Cross-
sectional 
(BL: 68.9%) 
General 
population 
With joint 
pain: 
75: ≥65 
Symptomatic OA (joint pain): 
one question/current (all) 
Total: 2792 (60%) 
Joint pain: 1987 
Depression: CESD-
20 (0-60); ≥16/mild or 
worse 
In joint pain: 
15.8% 
 
Creamer,  
1999 [3] 
U.S.A/ 
Baltimore 
Cross-
sectional 
(BL: 88.1%) 
General 
Population 
With OA: 
64.3 (0.52):  
  40 
Radiographic OA (OA): 
radiographs graded with the K+L 
criteria, pain assessed with the 
NHANES/ever, for most days for 
at least  month 
(knee) 
OA: 374 (31.5%) Depression: AIMS-D 
(0-10); ≥4/moderate 
or worse 
 
In OA: 3.2% 
 
 In OA: 
Total: 1.25(SD 1.09) 
   F: 1.47  (SD 1.19 ) 
   M: 1.14 (SD 1.03) 
p=0.006 
   
Croft, 2005  
[4] 
UK / 
North 
Staffords
hire 
 
Cross-
sectional 
 (BL: 70%) 
Primary 
Care 
Total: 
65 (10.0): 
  50 
Symptomatic OA (joint pain): 
joint pain assessed with  a pain 
manikin and the WOMAC/ for 
more than 1 day in the last  
month (knee, elsewhere- neck, 
hand lower back, hip, foot, 
ankle) 
Total: 5364 (55%) 
No pain: 1909 (51%) 
Knee pain alone:  
457 (49%)  
Knee pain plus 1 
pain: 496 (55%)  
Knee pain plus  2 
pains: 1257(62%) 
Anxiety: HADS-A  
(0-21), above the 
highest tertile/ 
moderate or worse 
No pain:18% 
In knee pain alone: 23% 
In plus 1 pain: 32% 
In plus  2 pains: 43% 
 
Depression: HADS –
D (0-21); above the 
highest tertile/ 
moderate or worse 
No pain:16% 
In knee pain alone: 19% 
In plus 1 pain: 29% 
In plus  2 pains: 42% 
 
Dexter, 1994 
[5] 
U.S.A/ 
Indianap
olis 
Cross-
sectional 
General 
Population 
75.4 (9.45): 
50 
The ACR criteria diagnosed OA 
(OA):  the ACR criteria for OA 
(hip, knee) 
OA: 108 (88%) 
 
Depression: AIMS-D 
(0-10); ≥ 5/moderate 
or worse 
In OA: 
12% 
In OA: 
2.23 (SD 1.89) 
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Country/re
gion 
Design 
(response  
rate ) 
Setting Mean age 
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used by authors): description  
of cases ascertainment/time 
scale(anatomical site) 
Sample (%F) Mental health 
problem: 
assessment tool 
(range); cut-off 
score/severity 
Prevalence rate  
Of mental health 
problem in OA/joint 
pain and compared 
groups 
Mean score  
 
Dunlop, 
2005  
[6] 
U.S.A/ 
national 
Prospective
-cohort 
 (BL: 94%) 
General 
Population 
54 
 
Arthritis (arthritis): self-reported, 
physician-diagnosed 
arthritis/rheumatism/ lifetime or 
current (all) 
Arthritis: 
5715(64.19%) 
 
Depression: CESD-5 
(0-15) 
 
In  arthritis: 
Total: 40.3% 
 F: 44.2%  
 M: 33.3% 
 
Figaro, 
2005 
[7] 
U.S.A / 
New York 
Cross-
sectional  
(BL: 85.1%) 
General 
population 
71 ( 8): 
 50 
The ACR criteria diagnosed OA 
(OA) : OA assessed with 
screening tool consistent with 
criteria developed by Altman et 
al. (1986), pain assessed with  
the WOMAC (knee) 
OA: 94 (84%) Depression: 
2 questions on low 
mood and anhedonia 
(Whooley & Simon, 
2000); yes to one/? 
 
In OA: 
Current: 22% 
Lifetime: 14% 
 
Fisher, 
2004  
[8] 
U.S.A/Texas, 
California, 
Arizona, 
Colorado, 
New York 
Prospective
-cohort  
(BL: 83%) 
General 
Population 
72.8 (6.3): 
≥65 
Arthritis (arthritis): self-reported, 
physician-diagnosed arthritis 
/ever  (all) 
Arthritis: 1084 (70.7%) Negative affect: the 7-
item scale formulated 
from CESD (0-21): 
score ≥ 1  
 
In arthritis: 23.2% 
 
In arthritis: 
3.9 (SD 4.6) 
 
Hill, 
Dziedzic, 
Thomas 
2007a  
[9] 
UK /North 
Staffordshire 
Cross-
sectional  
(BL: 78.6%) 
Primary 
Care 
Total: 
65.4 (9.6): 
 50 
Self-reported OA (OA): 
questions on self-reported GP-
diagnosed OA (hand) 
Total: 2113 (56.1%)  
OA: 538* 
 
*data reported by 
n=535 
 
Anxiety: HADS-A 
(0-21);  
8-21- mild or worse  
 
In OA: 50% In OA: 
7.90 (SD 4.4) 
 
Depression:  
HADS-D (0-21); 
8-21- mild or worse 
In OA: 26% 
 
In OA: 
5.34 (SD 3.7) 
Jakobss
on, 2006 
[10] 
Sweden/ 
national 
Cross-
sectional  
(BL: 49%) 
General 
Population 
With OA: 83.8 
(5.8) 
Reference 
group: 
82.7 (5.6 ): 
≥75 
Self-reported OA (OA): 
self-reported OA / past 3 
months 
(all) 
 
OA: 168  (66.1%) 
Reference group: 246 
(58.9%) 
Depressed mood: 
Altman, 1999 
No, not at all 
Yes, little 
Yes, rather much 
Yes, very much 
 
In OA (in reference 
group): 
No, not at all 63.7 % 
(66.3%) 
Yes, little 23.8% 
(18.7%) 
Yes, rather much  
4.8 % (5.7%) 
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(SD): range  
 
Grouping category (definition 
used by authors): description  
of cases ascertainment/time 
scale(anatomical site) 
Sample (%F) Mental health 
problem: 
assessment tool 
(range); cut-off 
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Of mental health 
problem in OA/joint 
pain and compared 
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Mean score  
 
Kramer, 
2002 
[11] 
Netherlands/
Amsterdam 
Prospective-
cohort 
 (BL: 62.3%) 
General 
Population 
68(7.9): 
 55 
Self-reported OA (OA): self-
reported, GP diagnosed OA (all) 
Total: 3017 (51.5%) 
With OA: 
1005*(66.9%) 
Without OA: 2081  
*Depression data for 
n=995 
Depression: CESD 20 
(0-60);  
≥ 16/ mild or worse 
≥23/moderate or 
worse 
 
In OA: 
Mild or worse: 
  Total: 19.2% 
   F: 21.6% 
   M: 14.4% 
Moderate or worse: 
  Total: 7.4% 
In OA: 
 Total: 9.6 (SD 8.2) 
 M: 8.1 (SD 7.5) 
 F: 10.3  (SD  8.4) 
Leveille, 
2007 
[12] 
U.S.A/ 
East 
Baltimore 
Prospective-
cohort 
(BL : 78% ) 
General 
Population 
 
 65 Symptomatic OA (joint pain): 
self-reported joint pain scored 
on a 0-10 NRS, the WOMAC/ 
on most days for at least 1 
month in the previous year 
(knee, hip, foot) 
Total: 1002  
Analysed: 460  
Joint pain: 136  
 
Anxiety: HSCL-4; 
positive response to 
at least 2 items; 
prevalent 
In no pain: 12.5% 
In joint pain:  19.1% 
In other pain: 19% 
In widespread pain: 28.4 
Trend p=0.005 
 
Depression: GDS-30; 
 14/ mild or worse 
 
In no pain: 5.2% 
In joint pain: 9.6% 
In other pain: 12% 
In widespread pain: 
18.2% 
Trend p=0.007 
 
Mallen, 
2008  
[13] 
UK / 
North 
Staffordshire 
Prospective-
cohort 
(BL crude: 
77.2%) 
Primary 
Care 
Analysed: 
63.1 (10.6): 
 50 
Symptomatic OA (joint pain): 
medical record of 
musculoskeletal pain identified 
through the EMIS template 
recorded by GP;  pain intensity 
assed on a 0-10 NRS (all) 
Total: 502 (60%) 
Analysed with joint 
pain: 
 428 (59.6%)  
Anxiety: HADS-A 
 (0-21); 0-7- no 
≥8 mild or worse, 
≥11 mild or worse  
In joint pain: 
No 53.5% 
Mild or worse: 44.4% 
Moderate or worse: 
21.3% 
In joint pain:7.31  
(SD 4.04) 
 
Depression: HADS-D 
(0-21);0-7-no 
8-21-mild 
11-14-moderate 
15-21-severe 
In joint pain: 
No 63.8% 
Mild: 21.7% 
Moderate: 11.4% 
Severe:  1.9% 
In joint pain:6.1 (SD 
3.8) 
 
2 questions on low 
mood and anhedonia, 
yes to one  
GP (self-administered) 
Yes: 18.2% (50.9%) 
No: 69.4% (48.1%) 
Unclear: 12.4% (0.9%) 
 
 
331 
 
Table B.2.1 cont. Overview of studies from which data was synthesised. 
 
 Methodological summary Statistical summary for cases with OA/joint pain 
Study ID  
[ID 
number] 
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pain and compared 
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Mean score  
 
Memel, 
2000  
[14] 
UK/Bristol Cross-
sectional  
(BL: 91%) 
Primary 
Care 
71: 42 Medical records defined OA 
(OA): the practices’ 
computerized appointment 
systems, medical records and 
diagnoses verified in the paper 
records  (knee, hip) 
Eligible: 200  
Analysed with OA: 
182 (65%) 
Anxiety: HADS-A 
(0-21); 
0-7- no  
8-10- mild 
11-21- moderate or 
worse 
 
In OA: 
Self-completed: 
  No: 53.6% 
  Mild: 22% 
  ≥ Moderate: 24.4% 
GP-assessed: 
   No:  63.7 % 
   Mild: 24.4 % 
   ≥ Moderate:  11.9 % 
 
Depression: HADS-D-
7 (0-21); 
0-7- no  
8-10- mild 
11-21- moderate or 
worse 
 
In OA: 
Self-completed 
No: 70.8%,Mild:  20.8% 
≥ Moderate:  8.3% 
GP-assessed 
No:  71.4%,Mild:  22.6% 
≥ Moderate:  6.0% 
 
Muus, 
2007  
(15) 
U.S.A/ 
national 
  
Cross-
sectional   
 
General 
Population 
 55 Arthritis (arthritis): self-reported 
doctor-diagnosed arthritis (all) 
Total: 8305  
Arthritis: 3613 (50.2%) 
Depression: 
self-reported doctor-
diagnosed 
In arthritis : 
18.8% 
 
Niti, 2007 
(16) 
China/ 
Singapor
e 
Cross-
sectional  
(BL: 78.5%) 
General 
Population 
 55 Arthritis (arthritis): self-
reported, doctor-diagnosed 
arthritis (all) 
Total: 2611 (63.1%), 
Arthritis: 432  
Depression: GDS-15 
(0-15);  5/mild or 
worse 
In arthritis: 
16.7% 
 
 
Nour, 
2005 
(17) 
 
 
Canada/ 
Montreal 
Cross-
sectional 
General 
Population 
Total: 
76.9 (10.5)  
OA: 
79.39(8.25): ≥ 
50 
 
Medical records defined OA 
(OA): medical records on OA 
(provided by care managers), 
confirmed by patients, the 
WOMAC, a 100-mm long VAS 
for pain intensity (all) 
Total: 125 (91.2%) 
OA: 81  
Depression:  
CES-D-20 (0-60), 
0-15- no 
16-22- mild 
23-29-moderate  
30-60- severe 
 
In OA: 
  No: 46.1% 
  Mild: 17.1% 
  Moderate: 17.1% 
  Severe: 19.7% 
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problem: 
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Of mental health 
problem in OA/joint 
pain and compared 
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Mean score  
 
O’Reilly, 
1998  
[18] 
UK/ 
Nottingha
m 
Nested case-
control 
(BL: 63.3%) 
General 
Population 
Joint pain: 
61.3 (10.4)  
No pain: 
60.8 (11.0): 
 40 
Radiographic OA (OA): 2 
questions on joint pain, the 
WOMAC, radiographs/ever on 
most days for at least a month 
and  within the last year (knee) 
Total: 600 (64%) 
OA: 300^  
Without  pain: 300~ 
^- anxiety data for 
n=296; 
depression data for 
n=297  
~ anxiety data for 
n=298;  
depression data for 
n=299  
Anxiety: HADS-A  
(0-21); ≥8/mild or 
worse 
 
In OA: * 
  Total: 39% 
  M: 30 %, F: 45%  
In without OA:* 
  Total:  24.12% 
   M: 18%, F: 28%  
In OA: 
7.1(95% CI 6.6 - 7.6) 
In without OA: 
5.4 (95% CI 5.1- 5.8) 
p<0.005 
Depression: HADS-D 
(0-21);  8/mild or 
worse 
 
In OA*: 
  Total: 19% 
  M: 18%,  F: 20%  
In without OA:* 
  Total: 5.9% 
   M: 4%, F: 7% 
 *read from the graph 
 
In OA: 
4.9 (95% CI 4.6- 5.3) 
In without OA: 
2.9 (95%CI 2.6- 3.1) 
p<0.005 
 
Peat, 
2006a  
[19] 
UK/ North 
Staffordsh
ire 
 
Prospective-
cohort 
(BL:  69.7% 
FUP 1: 87.7%  
FUP 2: 42.2%  
FUP 3: 96.8%) 
 
Primary 
Care 
65 (10 ): 
 50 
Symptomatic OA (Joint pain): 
the Health Survey 
Questionnaire, and the 
WOMAC  and digital 
photographs at FUP (knee) 
 
1. BL: 6108 (56%) 
2. Reported knee pain 
in last 12 months:  
3106 (59%)* 
3. Consented to further 
contact: 2226 (57%) 
4. FUP 1 Respondents 
to regional pains 
survey: 1949 (57%)  
5. FUP 2 Attended 
research clinic: 819 
(54%) 
6. FUP 3 (18 months): 
776 (54%) 
*meta- analysed 
 
Anxiety: HADS-A 
 (0-21), 
0-7-no 
8-10-mild 
11-21- moderate or 
worse 
 
No: 
1 -62%,2 -55%,  
3-56%, 4 -57%, 
5-62%,6 -63% 
Mild: 
1-25%,2-28%,    
3-28%,4-28%,  
5-27%,6 -27% 
Moderate or worse: 
1-13%,2-17%,  
3-16%,4-15%, 
5-11%,6-11% 
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problem: 
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Of mental health 
problem in OA/joint 
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Mean score  
 
Peat, 
2006a  
[19] 
UK/ North 
Staffordsh
ire 
 
Prospective-
cohort 
(BL:  69.7% 
FUP 1: 87.7%  
FUP 2: 42.2%  
FUP 3: 96.8%) 
 
Primary 
Care 
65 (10 ): 
 50 
Symptomatic OA (Joint pain): 
the Health Survey 
Questionnaire, and the WOMAC  
and digital photographs at FUP 
(knee) 
 
1. BL: 6108 (56%) 
2. Reported knee pain 
in last 12 months:  
3106 (59%)* 
3. Consented to 
further contact: 2226 
(57%) 
4. FUP 1 
Respondents to 
regional pains survey: 
1949 (57%)  
5. FUP 2 Attended 
research clinic: 819 
(54%) 
6. FUP 3 (18 months): 
776 (54%) 
*meta- analysed 
 
 
Depression: HADS-D 
(0-21), 
0-7-no 
8-10-mild 
11-21- moderate or 
worse 
 
 
 
 
 
 
 
 
  
No 
1-78%, 2-73%,  
3-75%, 4-77%,  
5-83%, 6-83% 
Mild 
1-16%, 2-20%,  
3-18%,4-17%, 
 5-13%, 6-12% 
Moderate or worse 
1-6%, 2-7% 
3-6%,4-6% 
5-4%,6- 5% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Polsky, 
2005 
[20] 
U.S.A/ 
national 
Prospective-
cohort 
 
General 
Population 
OA: 
55.9 (3.2 ): 
≥ 51 
Arthritis (arthritis): self-reported 
doctor-diagnosed arthritis/ 
rheumatism (all) 
Total: 8387 (51.8%) 
Arthritis: 1754 (51%) 
Depression: CESD-8 
(0-24);  5 
 
 
 
In arthritis: 4.4% 
 
 
 
 
In arthritis: 
3.3 (SD 2.5) 
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Design 
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problem: 
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Prevalence rate  
Of mental health 
problem in OA/joint 
pain and compared 
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Roseman
n, 2007  
[21] 
German/ 
75 
general 
practices 
Cross-
sectional 
(BL: 81.68%) 
Primary 
care 
Total: 
66.1(15.1):   
 18 
The ACR criteria defined OA 
(OA):  the ACR criteria and 
radiographs graded with the 
K+L (hip, knee) 
Total: 1021 (66%) 
Analysed with OA: 
1012 
Depression: PHQ-9 
(0-27); 
1-4- no  
5-9- mild 
10-14-moderate * 
15-19-moderately 
severe  
20-27-severe  
*a recommended 
threshold for any 
clinically relevant 
symptoms, so 
equivalent of mild or 
worse in other scales 
In OA: 
No: 
  Total: 32.9% 
   M: 29.1%, F: 34.9% 
Mild 
  Total: 38.6% 
  M: 39.8%,  F: 38% 
Moderate 
  Total: 9.1%  
   M: 11.3%,  F: 7.9% 
Mod.-Severe:  
   Total: 14.9%  
   M: 15.1%, F: 14.8% 
Severe:  
  Total: 4.4%  
  M: 4.7% F: 4.3% 
Gender diff.: 
   No p=0.11 
   Mild p=0.06 
   Moderate p<0.05 
   Mod. severe  p=0.23 
   Severe p=0.34 
In OA: 
Total: 15.7(SD 4.7) 
F: 15.33 (SD 4.8) 
M: 15.95 (SD 4.6) 
Sale, 2008 
[22] 
Canada/ 
Ontario 
Prospective-
cohort 
 (BL: 72%) 
General 
Population 
75.1 (7.8): 
  61 
Symptomatic OA (joint pain): 
difficulty in mobility in the past 
3m; joint pain/ stiffness/ 
swelling; a pain manikin, 
WOMAC /lasting 6 weeks ≥ in 
the past 3 months (knee, hip) 
OA at BL: 1227 
(75.6%) 
 
Depression: CESD-
20 (0-60); ≥ 16/mild 
or worse 
 
In joint pain: 
21.3% 
In joint pain: 
9.4 (SD 8.0) 
Schram, 
2008 
[23] 
Netherlan
ds/ Leiden 
Cross-
sectional 
 (BL: 85%) 
General 
Population 
≥ 85 Arthritis (arthritis): arthritis 
identified via GP interviews, 
medical and pharmacy records 
(all) 
Total: 599 (67%) 
Joint problems: 171  
Depression: GDS-
15(0-15); 
  4/borderline 
normal and mild 
In arthritis: 25.7% In arthritis: 
2.5 (SD 2.5) 
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Of mental health 
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Scudds, 
2000 
[24]  
Canada/ 
Ontario 
Cross-
sectional 
 (BL: 70.7%) 
General 
population 
Musculoskel
etal pain 
75.8 (5.83): 
 65 
Symptomatic OA (joint pain): 
self-reported pain in joint, 
muscles or bones, a pain 
manikin/ the past 2 weeks (all) 
Total: 884  
Musculoskeletal pain : 
644 (63.2%) 
Depression: CESD-
20 (0-60);  ≥ 16/mild 
or worse 
 
In musculoskeletal pain: 
   Total: 25.4% 
    F: 26.5% 
    M: 23.6%  
 
Szoeke, 
2008  
[25] 
Australia/ 
Melbourn
e 
Prospective-
cohort  
(BL: 71%) 
General 
Population 
59.9 (2.5):  
 45 
Arthritis (arthritis): self-perceived 
OA and manikin (all) 
Total: 224 (100%) 
Self-perceived 
arthritis: 118* 
 
*depression data 
reported for 89 
Depression: CESD-
10(0-30) 
 
In  self-perceived 
arthritis : 17%* 
 
 
*calculated by the 
authors of the review 
In  self-perceived 
arthritis : 
7.08  (SD 4.3) 
Without  self-
perceived arthritis : 
5.7 (SD 3.5)  
Wilcox, 
2000  
[26] 
U.S.A/ 
Winston-
Salem 
Prospective 
cohort 
(BL: 54.9%) 
 
Primary 
Care 
BL: 71.76 
(4.95): 
 65 
 
The ACR criteria defined OA 
(OA): self-reported joint pain, 
radiographs, the ACR Criteria 
(knee) 
Total OA: 463 
Analysed with OA: 
429* (52.4%) 
* avaialble for n=424 
Depression: CESD-
20 (0-60); ≥ 16/mild 
or worse 
In OA: 
17.9% 
In OA: 
9.59 (SD 7.39) 
Wilkie, 
2007 
[27] 
UK/North 
Staffordsh
ire 
Cross-
sectional 
(Stage 1: 
71.3%,  
Stage 2: 
88.8%) 
Primary 
Care 
65.3 (9.7): 
 50 
Symptomatic OA (joint pain): 
joint pain assessed with the 
WOMAC (knee) 
 
Joint pain: 2252 (58%) Anxiety: HADS-A 
(0-21),  
0-7-no, 8-10- mild 
11-21-moderate or 
worse 
In joint pain: 
  No: 53.9% 
  Mild: 24.9% 
  ≥ Moderate: 21.3% 
 
Depression: HADS-D 
(0-21), 0-7-no, 8-10- 
mild ,11-21-moderate 
or worse 
In joint pain: 
  No: 75.4% 
  Mild: 15.1% 
  ≥ Moderate:9.5% 
 
Woo, 
1994 
[28] 
China/ 
Hong-
Kong 
Cross-
sectional 
 (BL: 60%) 
General 
Population 
70 Symptomatic OA (joint pain): 
self-reported joint pain / the past 
12 months (knee: 65.44%, back-
thoracic region- 46.23%, 
ankle/foot-31.30%, shoulder-
33.45%, wrist/finger/ neck-
17.5%, elbow-17.67% 
back- lumpar region-20.15%) 
 
Total: 2023 (51.1%) 
Pain at various sites: 
1166 (60.63%) 
Pain limiting activities: 
600 (67.67%) 
Depression: GDS-15 
(0-15);  8/mild or 
worse 
 
In with pain limiting 
activities group: 39.8%* 
 
 
*calculated by the 
authors of the review 
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Dunlop, 
2004 
[29] 
U.S.A/ 
national 
Prospective-
cohort  
(BL: 94%) 
General 
populati
on 
54 Arthritis (arthritis): self-reported, 
physician diagnosed arthritis or 
rheumatism/  lifetime /current (all) 
Total at BL: 7825 
(52%) 
Arthritis : 3912  
Major  depression: 
WMH WHO-CIDI-SF 
(DSM-III-R),12 months 
In arthritis: 10.88% 
Gureje, 
2008  
[30] 
Nigeria/ 
Yoruba 
speaking 
area 
Cross-sectional 
(BL: 74.2%) 
General 
Populati
on 
65 Arthritis (arthritis): arthritis 
identified with  a checklist of 
chronic physical and pain 
conditions (all) 
Total: 2152  
Arthritis: 1488 
(56.6%) 
Major depression: WMH 
WHO-CIDI-III  
(DSM-IV),12 months 
In arthritis: 7.9% (95% CI 6.6-9.4) 
 
He, 2008  
[31] 
Internatio
nal/ 17 
countries 
in 
America, 
Europe, 
the 
Middle 
East, 
Asia, the 
South 
Pacific 
Cross-sectional: 
(BL weighted 
average: 71%  
Range: 46%-88% 
) 
General 
populati
on 
 
Colombia: 
36.6  
Mexico: 35  
U.S.A: 45  
Japan: 51  
Beijing: 40  
Shanghai: 
42.9 New 
Zealand: 46 
Belgium: 
46.9 France: 
46.3 
Germany 
48.2 Italy: 
47.7 
Netherlands: 
45 Spain: 45 
Ukraine: 46 
Lebanon: 40 
Nigeria: 35.8 
Israel: 44.4 
South 
Africa:37.1/
18 
Arthritis (arthritis): 2 questions 
adapted from the US Health 
Interview Survey (NCHS, 1994):  
1. Have you experienced arthritis 
or rheumatism in the prior 12 
months  
2. Have you ever had arthritis and 
rheumatism/ period or lifetime (all) 
Total: 85088  
Analysed: 42697  
(Range 47.5%- 
53.6%) 
With arthritis: 7842, 
including: 
Colombia: 184  
Mexico: 229  
U.S.A: 1588  
Japan: 117  
Beijing, PRC: 111  
Shanghai, PRC: 
114  
New Zealand: 1474  
Belgium: 227  
France: 432 
Germany: 151 Italy: 
510 Netherlands: 
134 Spain: 617 
Ukraine: 479 
Lebanon: 57 
Nigeria: 469  
Israel : 496 
South Africa: 453 
 
Anxiety disorders: 
A. Generalized anxiety 
disorder 
B. Panic disorder and/or 
agoraphobia  
C. Social phobia 
D. PTSD 
Depressive disorders:  
E. Major depression 
F. Dysthymia: WMH 
WHO - CIDI 
(DSM-IV),12 months 
 
In  arthritis: Colombia: A. 1%   B. 3.2% C. 
3.7% D. 0.6% E. 9.3% F. 1.6% Mexico: A. 
1.4% B. 2.9% C. 5.3% D. 0.3% E.10.2% F. 
2% U.S.A:  A. 5.9% B. 5.0% C.7.5% D. 5.2% 
E. 9.3 % F.3.6%  Japan: A. 2.5% B. 0.9% C. 
0%  D. 0.1% E. 2.2 % F. 0.1%      Beijing:  A. 
2.3% B. 0.3% C. 0% D. 0% E. 3.9 % F. 1.1% 
Shanghai: A. 3.6% B. 0% C. 0% D. 0.8% E. 
5.7 % F. 0.3% New Zealand: A. 3.9 % B. 
2.6% C. 4.7% D. 4 % E. 6.2 % F. 2.4%  
Belgium: A. 1.4% B. 2.2% C. 2.2% D. 1.2% E. 
4.7% F. 2.1%  France: A. 3.2% B. 1.6% C. 
2.2% D. 3.1% E. 5.9% F. 2.7%  Germany: A. 
0.2% B. 0.6% C.0.4% D. 0.6% E.3.8% F. 
2.2%  Italy: A. 0.8% B. 1.5% C. 1.2% D. 1% 
E. 5.1 % F. 2.1% Netherlands: A. 1.3% B. 
1.7% C. 2.2% D. 3.1% E. 5% F. 1.6% Spain: 
A. 2%   B. 1.7% C. 1% D. 0.9% E. 6.8 % F. 
3.2% Ukraine: A. 6%  B. 4% C. 3.2% D. 4.5% 
E. 19.2 % F. 10.6% Lebanon: A. 0.2% B. 
0.4% C. 0% D. 0.7% E. 1.4 % F. 1.1%  
Nigeria: A. 0.2% B. 1.1% C. 0.2% D. 0% E. 
2.2 % F. 0.6% Israel : A. 4.5% B. 2.9% C.- D. 
1.1% E. 10.5 % F. 3.9% South Africa: A. 3.5% 
B. 8.5% C. 3.8% D. 0.5% E. 7.6 % F. 0% 
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Table B.2.1 cont. Overview of studies from which data was synthesised. 
 
 Methodological summary Statistical summary for cases with OA/joint pain 
Study ID  
[ID 
number] 
 
Country/ 
region 
Design 
(response rate) 
Setting Mean age 
(SD): range  
 
Grouping category (definition 
used by authors): description  of 
cases ascertainment/time 
scale(anatomical site) 
Sample (%F) Mental health problem: 
assessment tool 
(reference standard), 
time frame 
Prevalence rate of mental health problem 
in OA/ joint pain and compared groups 
(Continuous from previous page)     
Kadam, 
2004  
[32] 
England 
and 
Wales/ 
national 
Nested case-
control 
Primary 
Care 
≥ 50 Medical records defined OA 
(OA):codes used in patients records 
(all) 
Total: 23155 
(65.5%) 
OA: 11375 
Without OA: 
11780  
Depressive disorder: 
computerized patients 
records (code E2B) 
In OA: 2.8% 
In without OA group: 1.9% 
OR 1.45(95% CI 1.15,1.82) 
McWilliam
s, 2008  
[33] 
U.S.A/ 
national 
Cross-sectional 
(BL: 81%) 
General 
Populati
on 
18 Arthritis (arthritis): self-reported 
physician-diagnosed arthritis/  the 
last 12 months (all) 
 
Total: 43093  
Joint problems: 
7876 (63.5%) 
Panic with  and without 
agoraphobia, 
social and simple 
phobia, GAD,MD, 
Dysthymia: AUDADIS 
(DSM-IV),12 months 
 
In joint problems: 
    Major depression:  9.8% 
    Dysthymia: 3.0% 
    Panic with agoraphobia: 0.8% 
    Panic disorder: 2.6% 
    Social phobia: 3.6% 
    Simple phobia: 9.4% 
    Generalized anxiety disorder: 3.5% 
Moussavi, 
2007  
[34] 
Internatio
nal/ 60 
countries 
Cross-sectional  
(BL: 63%-99%) 
General 
Populati
on 
18 Arthritis (arthritis): self-reported, 
doctor-diagnosed or being treated 
for arthritis/ the last 12 months (all) 
Total: 254404  
Arthritis: 10431  
Depressive episode: 
WHO-CIDI-III (DSM-IV), 
12 months 
In arthritis: 
    10.7% (95% CI 9.1- 12.3) 
 
Fuller-
Thompso, 
2007  
[35] 
Canada/ 
national 
Cross-sectional 
(BL: 83.7%) 
 
General 
Populati
on 
20 Arthritis (arthritis): self-reported, 
health-professional diagnosed 
arthritis/rheumatism, excluding 
fibromyalgia/ lasted or are expected 
to last ≥6 months(all) 
Total: 130880  
Arthritis: 23405 
(65.5%) 
Major depression: 
WHO-CIDI-SF(DSM-III-
R),12 months 
In arthritis:  
Total: 9.9%, F: 10.8%, M: 8.2% 
Patten, 
2006  
[36] 
Canada/ 
national 
Cross-sectional 
(BL: 77%) 
General 
Populati
on 
 15 (but 
group with 
arthritis was 
25+) 
Arthritis (arthritis): self-reported , 
doctor diagnosed presence of 
arthritis or rheumatism, excluding 
fibromyalgia/ ≥6 months (all) 
Total: 36984 
Joint problems: 
8245  
Panic disorder, social 
phobia, major 
depression: CCHS 1.2 
interview based on 
WMH WHO-CIDI 
(DSM-IV), 12 months 
In joint problems: 
    Panic disorder: 3.0% (95% CI 2.5-3.6) 
    Social phobia: 2.9% (95% CI 2.4-3.4) 
    Major depression: 5 % (95% CI 4.3-5.7) 
Wells, 
1989a  
[37] 
U.S.A/ LA 
ECA site 
Cross-sectional 
(BL: 68%) 
General 
Populati
on 
Total: 39.5 Arthritis (arthritis): indicated on a 
scale if  is ever/ currently under a 
medical care for arthritis/current and 
lifetime (all) 
Total: 2554 
(50.4%) 
Lifetime (current) 
arthritis: 518 (417)  
Anxiety Disorders: 
NIMH-DIS, recent and 
lifetime (DSM-III) 
In lifetime arthritis: Lifetime 20 % (SE 2.5) 
Recent 9.1 % (SE 1.8) 
With current arthritis: Lifetime 20.7% (SE 3.3) 
Recent 11.9 % (SE 2.6) 
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B.3 QUALITY ASSESSMENT 
Table B.3.1 Summary of quality assessment of 127 quality assessed articles. 
Authors A B C D E F G H I J K L M N O Scores 
Included studies:                
 Allen et al. (2008) + + - - + + + + + + + + + + + 13 
Barberger-Gateau et al. (1992) + + - ? - + + - - + + + + + - 9 
Creamer et al. (1999) + + - - + ? + - + + + + + + + 11 
Croft, Jordan, Jinks (2005) + + - - + ? + + - + + + + + + 11 
Dexter & Brandt (1994) + + - - + + + ? ? + + + + + + 11 
Dunlop et al. (2004) + + - - - ? - - - + ? + + + - 6 
Dunlop et al. (2005) + + - - - ? - + - + ? + + + - 7 
Figaro et al.(2005) + + - + - - + + + + + + + + + 12 
Fisher et al.(2004) + + - - - + + + - - - + + + + 9 
Fuller-Thompson & Shaked (2009) + + - - - ? - + - + + + + + + 10 
Gureje et al. (2008) + + - - - + + + + + + + + ? - 10 
Hill, Dziedzic, Thomas et al. (2007) + + + + + + + + + + + + + + + 15 
He et al. (2008) + + - - - + + + - + - + + + + 10 
Jakobsson & Hallberg (2006) + + - - - - - - + + + - + + + 8 
Kadam et al. (2004) + + - + + + + N/A N/A + + - + + + 13 
Kramer et al. (2002) + + - ? - + + - + + + + + + ? 10 
Leveille et al. (2007) + + - + + + + + - + + + + + + 13 
Mallen & Peat (2008) + + + + ? + - + - + + + + + - 11 
McWilliams et al. (2008) + + - ? ? + + + - + + + + ? - 9 
Memel et al. (2000) + + + + + + + + - + + + + + + 14 
Moussavi et al. (2007) + + - - ? + + ? - + ? + + + - 8 
Muus et al. (2007) + + - - - + + ? - + + - - + + 8 
Niti et al.(2007) + + - + - + + + + + ? + + + + 12 
Nour et al. (2005) + + - + + + + ? - + + + + + + 12 
O’Reilly et al. (1998) + + - + + + + - - + + + + + - 11 
Patten et al. (2006) - ? - + - + + + - + + + + ? - 8 
Peat, Thomas, Handy et al. (2006a) + + + ? + + - + + + + + + + + 13 
Polsky et al. (2005) + + - ? ? + + + - - + + + + + 10 
Rosemann, Backenstrass, Joest et al. (2007a) + - - + + + ? + + + + + + + + 12 
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Table B.3.1 Summary of quality assessment of 127 quality assessed articles. 
Authors A B C D E F G H I J K L M N O Scores 
Sale et al. (2008) + + - - + + - + + + ? + + + + 11 
Schram et al. (2008) - ? - - - + - + + + + + + ? + 8 
Scudds & Robertson (2000) + + - - + + + + - + + + + + + 12 
Szoeke et al. (2008) + + - - + + ? + - + + + - + - 9 
Wells et al. (1989a) + + + - - + + - - + + + + + + 11 
Wilcox et al. (2000) + + - + + + + - ? + + + + + + 12 
Wilkie et al. (2007) + + + + + + - + - + + + + + + 13 
Woo et al. (1994) + + - - - + + - - + + + + + + 10 
Excluded multiple articles:                
 Allen et al. (2009) + + - - + + + + + + + + + + + 13 
Elliot, Kraus, Fang et al. (2007) + + - + + + + + + + + + + + + 14 
Jinks, Jordan, Blagojevic, Croft (2008) + + - ? + + - + + + + + + + + 12 
Jinks, Jordan, Croft (2002) + + ? - + + - + - + + + + + + 11 
Jordan et al. (2006) + + - ? + + - + - + + + + + + 11 
Lee et al. (2007) + + ? - - + + + - + + + + + + 11 
Mallen et al. (2007) + + + + + + - - - + + + + + + 12 
Munce & Stewart (2007) + + ? + - + ? + - + + + + + + 11 
Peat & Thomas (2009) + + + - + + - + + + + + + + - 12 
Peat, Thomas, Croft (2006c) + + + + + + - - + + + + + + - 12 
Rosemann, Kuehlein, Laux, Szecsnyi (2007) + + - + + + ? + + + + + + + + 13 
Rosemann, Wensing, Szecsnyi, Grol (2009)  + + - + + + ? + + + + + + + + 13 
Rosemann, Laux, Szecsnyi, Grol (2008) + + - + + + ? + + + + + + + + 13 
Rosemann, Gensichen, Sauer et al. (2007) + + - - + + ? + + + + + + + + 12 
Rosemann, Grol, Herman et al. (2008) + + - - + + ? + + + + + + + + 12 
Rosemann, Joos, Koerner et al. (2006) + + - + + + - + + + + + + + - 12 
Rosemann, Kuehlein, Laux, Szecsnyi (2008) ? + - + + + ? + + + + + + + + 12 
Rosemann, Laux, Kuehlein (2007) ? + - + + + ? + + + + + + + + 12 
Rosemann, Laux, Szecsnyi et al. (2008)  ? + - + + + ? + + + + + + + + 12 
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Table B.3.1 cont. Summary of quality assessment of 127 quality assessed articles. 
Authors A B C D E F G H I J K L M N O Scores 
Rosemann, Joos, Szecsnyi et al. (2007) + + - + + + ? + + + + + + + + 13 
Scott et al. (2009) + + - - - + - + - + - + + - - 7 
Sherman (2003) + + - + + + + + + + + + + + + 14 
Szoeke et al.(2005) + + - - - + - + - + ? + + + + 9 
Thomas, Dunn, Mallen, Peat (2008) + + + + + + - - - + + + + + + 12 
Thomas, Peat, Mallen et al. (2008) + + + + + + - - - + + + + + + 12 
Verweij et al. (2009) + + - + + + + - + + + + + + + 13 
Wells et al. (1988) + + + - - + + - - + + + + + + 11 
Wood et al. (2007) + + + + + + - - + + + + + + + 13 
Mixed anxiety and depression:                 
Alonso et al. (2004) + + + - - + - - - + - + + + + 9 
Antonopoulou et al. (2009) + + + + ? + + + - + ? + + + - 11 
Bot, Van Der Waal, Van Der Windt et al. (2005) + + - + + + + ? - + + ? + + + 11 
Bot, Van Der Waal, Terwee et al. (2005)  + + - + + + + + - + + + + + + 13 
Boutron et al. (2008) + + - + + + + + - + + + + + + 13 
Busija et al. (2007) + + - ? - + + - + + + + + + + 11 
Cimmino et al. (2005) + + - - +  + + + + + + - - + + 11 
Fernandez-Lopez et al. (2008) + + + - + + + + + + + + + + - 13 
Hill, Parsons, Taylor, Leach (1999) + + - + - + + + ? + + + - + + 11 
Hill, Gill, Taylor et al. (2007) ? + ? - - + + - - + + + + + + 9 
Hughes et al. (1994) ? + - - + ? + ? + + ? ? + + + 8 
Jinks, Jordan, Croft (2007) + + - ? + + - + + + + + + + - 11 
Jones et al. (2008) + + - + ? ? ? ? - + + + + - + 8 
Jordan et al. (2008) + + + + + + - + + + + + + + + 14 
Kaplan et al. (2003) ? + - - - + + + - + ? ? + + + 8 
Lima et al. (2009) + + + - - + + ? - + + + + + + 11 
Machado et al. (2006) + + - - ? + + ? - - - + + + + 8 
Mitchell et al. (2006) ? + - + + + + - - + + + + + - 10 
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Table B.3.1 cont. Summary of quality assessment of 127 quality assessed articles. 
Authors A B C D E F G H I J K L M N O Scores 
Palmer et al. (2006)  + + - ? + + + - + + + + + + - 11 
Peat, Thomas, Handy, Croft (2004) + + + + + + + + + + + + + + + 15 
Rannou et al. (2007) + + - + + + - ? - - + + + + - 9 
Strine et al. (2004) + + - + ? + + ? - + + - + + + 10 
Tangtrakulwanich et al.(2006) + + - - + + + ? - + + + + + + 11 
Van der Waal, Terwee, van der Windt et al. (2005) + + - + + + - + - + + + + + + 12 
Van der Waal, Bot, Terwee et al. (2005) + + - + + + - ? + + + + + + + 12 
Van der Waal, Bot, Terwee et al. (2006) + + + + + + - ? - + + + + + + 12 
Van der Windt, Kuijpers, Jellema et al . (2007) + + - + ? + - ? - + + + + + + 10 
Wang et al. (2008) + + - - + + - + ? - + + + + + 10 
Central tendency only:                 
Appelt et al .(2007) + - - - + - + + - + + + + + + 10 
Badcock et al. (2002) + + - - + + + + + + + + + ? - 11 
Baker (2003) + + - - ? + + + - + ? + + + + 10 
Brandt, Heilman et al. (2000) + - - + + + + - - + + + + + + 11 
Ferreira & Sherman (2006) ? ? - - - ? - ? - + + + - + + 7 
Gignac et al. (2008) + + - + - ? + + + + + - + + + 11 
Hampson et al. (1996) + + - + + + + + + + + + + + + 14 
Hopman-Rock  et al. (1997) + + - ? ? + + + ? + + ? + - + 9 
Kalichman et al. (2007) + + - - + ? + ? - + + + + + - 9 
Maly, Costigan, Olney (2007) + + - + + - - ? - + ? + + + - 8 
Martin (1996) + + - + + - - ? - + ? + + + + 9 
Menz et al. (2006) + + - + + + + - - + ? + - + - 9 
Reilingh et al. (2008) + + - + + + - ? - + + + + + + 11 
Spies-Dorgelo et al. (2007) + + - + + + - + + + + + - + + 12 
Tsai (2005) + + - ? - + ? ? - + ? + + + + 8 
Viinamaki et al. (2002) + + - ? ? + + ? - + + + + + + 10 
Williams et al. (2004) + + - + + + ? ? - + + + + + - 10 
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Table B.3.1 cont. Summary of quality assessment of 127 quality assessed articles. 
Authors A B C D E F G H I J K L M N O Scores 
Excluded multiple articles with central tendency only:         
Ang et al. (2002) + + - - + - - + - + ? + + + + 9 
Kuijpers et al. (2006) + + - + + + - ? - + + + - + + 10 
Ferreira & Sherman (2007) + + - - - ? - + + + + + - + + 9 
Maly, Costigan, Olney (2006) + + - ? + + - ? - + + + + + + 10 
Maly, Costigan, Olney (2006) + + - + + - - ? - + - + + + + 9 
Maly, Costigan, Olney (2005) + + - - + - - ? - + - + + + + 8 
Definition of OA illegible:                 
McWilliams et al. (2004) + + - - - ? + - - + - + + + - 7 
Required details unobtainable:                 
Blay et al. (2007) ? + - -  ? ? + - - + ? + - + + 6 
Chang-Quan et al. (2008) ? + - - - ? - ? - + ? + - + - 4 
Chou & Chi (2002) + + - - - + - - + + + +  - + + 9 
Davis et al. (1992) + + - - + + - + ? + + ? - ? - 7 
Fautrel et al. (2002) + + - - - + ? ? - + + + - + + 8 
Hawker et al. (2008) + ? - + + + - ? - + + - - + + 8 
McCauley et al. (2008) + + - + - ? + + + + + + - + + 11 
Ormel et al. (1997) + + - ? - + + - - +  - + - + + 8 
Ormel et al. (1998) ? + - ? - + + - - + - + - + - 6 
Wu et al. (2004) + ? - - - ? - ? - + + + - ? + 5 
Note: -  no, +- yes, ?- unclear; Bibliography contains only included studies. 
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B.4 OVERALL META-ANALYSES (STATA OUTPUTS) 
 
Table B.4.1 Meta-analysis of log-transformed prevalence rates of ‘moderate or worse’ 
depression symptoms. 
 
 
 
Table B.4.2 Meta-analysis of log-transformed prevalence rates of ‘mild or worse’ depression 
symptoms. 
 
 
 
 
 
 
  Test of ES=1 : z=   7.87 p = 0.000
  Estimate of between-study variance Tau-squared =  0.4770
  I-squared (variation in ES attributable to heterogeneity) =  97.7%
  Heterogeneity chi-squared = 387.40 (d.f. = 9) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.171       0.110     0.266        100.00
---------------------+---------------------------------------------------
10                   |  0.105       0.092     0.120         10.43
9                    |  0.239       0.207     0.276         10.41
8                    |  0.075       0.066     0.086         10.43
7                    |  0.582       0.391     0.866          9.69
6                    |  0.091       0.054     0.152          9.19
5                    |  0.156       0.120     0.203         10.15
4                    |  0.079       0.062     0.099         10.24
3                    |  0.136       0.077     0.240          8.97
2                    |  0.235       0.189     0.291         10.27
1                    |  0.550       0.437     0.693         10.23
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
  Test of ES=1 : z=  12.62 p = 0.000
  Estimate of between-study variance Tau-squared =  0.1379
  I-squared (variation in ES attributable to heterogeneity) =  95.1%
  Heterogeneity chi-squared = 344.89 (d.f. = 17) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.312       0.260     0.374        100.00
---------------------+---------------------------------------------------
18                   |  0.661       0.561     0.779          5.88
17                   |  0.326       0.296     0.359          6.08
16                   |  0.218       0.170     0.279          5.54
15                   |  0.340       0.285     0.407          5.83
14                   |  0.346       0.245     0.487          5.06
13                   |  0.271       0.236     0.310          5.97
12                   |  0.397       0.346     0.455          5.97
11                   |  0.370       0.342     0.400          6.11
10                   |  0.235       0.176     0.313          5.34
9                    |  1.174       0.758     1.817          4.54
8                    |  0.200       0.156     0.258          5.52
7                    |  0.412       0.300     0.568          5.18
6                    |  0.550       0.452     0.671          5.75
5                    |  0.106       0.060     0.188          3.83
4                    |  0.238       0.203     0.278          5.91
3                    |  0.351       0.290     0.426          5.78
2                    |  0.188       0.166     0.212          6.01
1                    |  0.153       0.124     0.189          5.71
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
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Table B.4.3  Meta-analysis of log-transformed prevalent rates of ‘moderate or worse’ anxiety 
symptoms. 
 
 
 
 
 
Table B.4.4 Meta-analysis of log-transformed prevalent rates of ‘mild or worse’ anxiety 
symptoms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Test of ES=1 : z=  15.03 p = 0.000
  Estimate of between-study variance Tau-squared =  0.0299
  I-squared (variation in ES attributable to heterogeneity) =  83.3%
  Heterogeneity chi-squared =  23.91 (d.f. = 4) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.262       0.220     0.312        100.00
---------------------+---------------------------------------------------
5                    |  0.271       0.245     0.299         24.40
4                    |  0.323       0.230     0.453         13.30
3                    |  0.264       0.213     0.328         18.82
2                    |  0.299       0.240     0.371         18.79
1                    |  0.205       0.187     0.225         24.68
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
  Test of ES=1 : z=   4.43 p = 0.000
  Estimate of between-study variance Tau-squared =  0.0045
  I-squared (variation in ES attributable to heterogeneity) =  50.6%
  Heterogeneity chi-squared =  10.12 (d.f. = 5) p = 0.072
---------------------+---------------------------------------------------
D+L pooled ES        |  0.833       0.768     0.903        100.00
---------------------+---------------------------------------------------
6                    |  0.852       0.784     0.925         27.21
5                    |  0.818       0.762     0.878         29.50
4                    |  0.639       0.507     0.806          9.21
3                    |  0.852       0.636     1.140          6.41
2                    |  0.808       0.677     0.966         13.42
1                    |  1.000       0.844     1.185         14.25
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
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Table B.4.5 Meta-analysis of log-transformed prevalent rates of major depression.  
 
 
 
Table B.4.6 Meta-analysis of log-transformed prevalent rates of dysthymia. 
 
 
 
 
  Test of ES=1 : z=  30.49 p = 0.000
  Estimate of between-study variance Tau-squared =  0.1079
  I-squared (variation in ES attributable to heterogeneity) =  93.6%
  Heterogeneity chi-squared = 342.54 (d.f. = 22) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.079       0.067     0.093        100.00
---------------------+---------------------------------------------------
23                   |  0.109       0.101     0.117          6.33
22                   |  0.103       0.087     0.121          6.00
21                   |  0.122       0.110     0.135          6.26
20                   |  0.238       0.189     0.298          5.70
19                   |  0.073       0.053     0.100          5.18
18                   |  0.082       0.058     0.116          4.97
17                   |  0.060       0.027     0.133          2.55
16                   |  0.022       0.012     0.042          3.34
15                   |  0.086       0.071     0.104          5.91
14                   |  0.066       0.053     0.082          5.79
13                   |  0.053       0.024     0.114          2.61
12                   |  0.114       0.074     0.174          4.45
11                   |  0.014       0.002     0.129          0.50
10                   |  0.022       0.007     0.077          1.37
9                    |  0.054       0.036     0.080          4.66
8                    |  0.117       0.088     0.156          5.35
7                    |  0.040       0.017     0.091          2.39
6                    |  0.063       0.042     0.094          4.63
5                    |  0.103       0.062     0.169          4.02
4                    |  0.053       0.048     0.058          6.27
3                    |  0.110       0.105     0.115          6.39
2                    |  0.049       0.027     0.091          3.35
1                    |  0.041       0.016     0.106          1.99
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
  Test of ES=1 : z=  22.38 p = 0.000
  Estimate of between-study variance Tau-squared =  0.2653
  I-squared (variation in ES attributable to heterogeneity) =  82.2%
  Heterogeneity chi-squared = 100.98 (d.f. = 18) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.027       0.020     0.037        100.00
---------------------+---------------------------------------------------
19                   |  0.031       0.027     0.035          9.64
18                   |  0.037       0.029     0.049          9.17
17                   |  0.119       0.089     0.159          9.05
16                   |  0.033       0.021     0.052          8.18
15                   |  0.000       0.000     0.999          0.12
14                   |  0.003       0.000     0.086          0.81
13                   |  0.006       0.002     0.019          4.17
12                   |  0.025       0.018     0.034          8.83
11                   |  0.016       0.004     0.063          3.52
10                   |  0.022       0.009     0.054          5.53
9                    |  0.011       0.001     0.134          1.38
8                    |  0.001       0.000     0.309          0.29
7                    |  0.021       0.012     0.039          7.21
6                    |  0.041       0.026     0.064          8.15
5                    |  0.022       0.008     0.067          4.54
4                    |  0.028       0.016     0.050          7.35
3                    |  0.017       0.005     0.052          4.30
2                    |  0.021       0.009     0.053          5.42
1                    |  0.011       0.002     0.066          2.34
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
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Table B.4.7 Meta-analysis of log-transformed prevalence rates of GAD. 
 
 
Table B.4.8 Meta-analysis of log-transformed prevalence rates of social phobia. 
 
 
 
 
  Test of ES=1 : z=  27.40 p = 0.000
  Estimate of between-study variance Tau-squared =  0.1422
  I-squared (variation in ES attributable to heterogeneity) =  74.3%
  Heterogeneity chi-squared =  69.91 (d.f. = 18) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.031       0.024     0.039        100.00
---------------------+---------------------------------------------------
19                   |  0.036       0.032     0.041         11.07
18                   |  0.063       0.051     0.077         10.53
17                   |  0.064       0.044     0.094          9.04
16                   |  0.020       0.011     0.035          7.11
15                   |  0.037       0.022     0.060          7.81
14                   |  0.036       0.013     0.099          4.03
13                   |  0.002       0.000     0.015          1.39
12                   |  0.040       0.031     0.052         10.07
11                   |  0.015       0.004     0.061          2.48
10                   |  0.013       0.004     0.041          3.37
9                    |  0.002       0.000     0.824          0.16
8                    |  0.026       0.008     0.083          3.34
7                    |  0.008       0.003     0.021          4.08
6                    |  0.046       0.030     0.071          8.52
5                    |  0.002       0.000     0.071          0.47
4                    |  0.033       0.020     0.057          7.48
3                    |  0.010       0.002     0.043          2.34
2                    |  0.013       0.004     0.042          3.36
1                    |  0.028       0.009     0.087          3.33
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
  Test of ES=1 : z=  25.01 p = 0.000
  Estimate of between-study variance Tau-squared =  0.1767
  I-squared (variation in ES attributable to heterogeneity) =  84.9%
  Heterogeneity chi-squared = 118.84 (d.f. = 18) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.031       0.024     0.041        100.00
---------------------+---------------------------------------------------
19                   |  0.037       0.033     0.042         10.64
18                   |  0.081       0.067     0.098         10.33
17                   |  0.033       0.020     0.055          7.86
16                   |  0.010       0.005     0.022          5.64
15                   |  0.040       0.024     0.064          8.09
14                   |  0.000       0.000   9390.202         0.02
13                   |  0.002       0.000     0.015          1.54
12                   |  0.049       0.039     0.063         10.00
11                   |  0.022       0.007     0.071          3.67
10                   |  0.056       0.031     0.100          7.28
9                    |  0.000       0.000    1.9e+07         0.01
8                    |  0.000       0.000   7409.655         0.02
7                    |  0.012       0.005     0.027          5.61
6                    |  0.004       0.000     0.050          1.04
5                    |  0.022       0.012     0.043          6.75
4                    |  0.038       0.018     0.083          5.83
3                    |  0.030       0.026     0.034         10.60
2                    |  0.022       0.009     0.055          5.03
1                    |  0.000       0.000    1.2e+04         0.02
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
. metan  ln se, eform random
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Table B.4.9 Meta-analysis of log-transformed prevalence rates of panic with agoraphobia. 
 
 
 
Table B.4.10 Meta-analysis of log-transformed prevalence rates of PTSD. 
 
 
 
  Test of ES=1 : z=  16.36 p = 0.000
  Estimate of between-study variance Tau-squared =  0.7258
  I-squared (variation in ES attributable to heterogeneity) =  91.0%
  Heterogeneity chi-squared = 199.35 (d.f. = 18) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.022       0.014     0.035        100.00
---------------------+---------------------------------------------------
19                   |  0.008       0.006     0.010          7.37
18                   |  0.053       0.042     0.066          7.40
17                   |  0.042       0.026     0.066          7.01
16                   |  0.017       0.009     0.032          6.65
15                   |  0.093       0.067     0.129          7.25
14                   |  0.000       0.000   9390.202         0.06
13                   |  0.011       0.005     0.026          5.93
12                   |  0.027       0.019     0.037          7.27
11                   |  0.017       0.005     0.064          4.66
10                   |  0.030       0.014     0.065          6.21
9                    |  0.004       0.000     0.245          1.07
8                    |  0.009       0.001     0.062          3.25
7                    |  0.015       0.007     0.031          6.37
6                    |  0.030       0.018     0.050          6.86
5                    |  0.006       0.001     0.048          2.98
4                    |  0.016       0.008     0.034          6.27
3                    |  0.033       0.015     0.075          6.07
2                    |  0.022       0.009     0.055          5.88
1                    |  0.003       0.000     0.090          1.46
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
  Test of ES=1 : z=  18.88 p = 0.000
  Estimate of between-study variance Tau-squared =  0.3773
  I-squared (variation in ES attributable to heterogeneity) =  76.5%
  Heterogeneity chi-squared =  72.25 (d.f. = 17) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.018       0.012     0.027        100.00
---------------------+---------------------------------------------------
18                   |  0.055       0.044     0.069         11.57
17                   |  0.048       0.031     0.074         10.62
16                   |  0.010       0.004     0.022          8.26
15                   |  0.004       0.001     0.018          5.12
14                   |  0.008       0.001     0.063          3.01
13                   |  0.000       0.000     0.853          0.21
12                   |  0.042       0.032     0.054         11.42
11                   |  0.031       0.011     0.083          7.11
10                   |  0.003       0.000     0.032          2.52
9                    |  0.007       0.000     0.159          1.55
8                    |  0.001       0.000     0.309          0.51
7                    |  0.010       0.004     0.024          7.79
6                    |  0.010       0.004     0.025          7.79
5                    |  0.006       0.001     0.048          3.03
4                    |  0.031       0.018     0.054          9.88
3                    |  0.005       0.001     0.039          3.25
2                    |  0.013       0.004     0.042          6.31
1                    |  0.000       0.000    1.2e+04         0.05
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
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Table B.4.11 Meta-analysis of log-transformed prevalence rates of panic disorder. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Test of ES=1 : z=  48.22 p = 0.000
  Estimate of between-study variance Tau-squared =  0.0107
  I-squared (variation in ES attributable to heterogeneity) =  98.8%
  Heterogeneity chi-squared =  82.60 (d.f. = 1) p = 0.000
---------------------+---------------------------------------------------
D+L pooled ES        |  0.029       0.025     0.033        100.00
---------------------+---------------------------------------------------
2                    |  0.027       0.026     0.027         50.02
1                    |  0.031       0.030     0.032         49.98
---------------------+---------------------------------------------------
           Study     |     ES    [95% Conf. Interval]     % Weight
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B.5 PUBLICATION BIAS ANALYSES (STATA OUTPUTS) 
 
Table B.5.1 Results of publication bias analyses of questionnaire assessed prevalence rates. 
STATA output Construct 
 
‘Moderate or 
worse’ 
depression 
symptoms 
 
‘Mild or worse 
depression’ 
symptoms 
 
 
‘Moderate or 
worse’ anxiety 
symptoms 
 
‘Mild or worse 
anxiety’ 
symptoms 
 
 
                                                                              
        bias     4.563562   5.075614     0.90   0.395    -7.140824    16.26795
       slope    -2.350264   .5210055    -4.51   0.002    -3.551705   -1.148823
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  10                                Root MSE      =   6.632
                                                                              
        bias    -.8662851   2.470181    -0.35   0.730    -6.102834    4.370264
       slope    -1.077688   .2026203    -5.32   0.000    -1.507224   -.6481519
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  18                                Root MSE      =   4.625
                                                                              
        bias     3.064652   2.334053     1.31   0.281    -4.363346    10.49265
       slope    -1.610284    .164093    -9.81   0.002    -2.132501   -1.088067
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  5                                 Root MSE      =    2.25
                                                                              
        bias    -.2693585   1.374855    -0.20   0.854    -4.086568    3.547851
       slope    -.1676395   .0816767    -2.05   0.109    -.3944103    .0591313
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  6                                 Root MSE      =   1.583
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Table B.5.2 Results of publication bias analyses of clinical interview assessed prevalence rates. 
STATA output Construct 
 
Major 
depression 
 
Dysthymia 
 
GAD 
 
Social 
phobia 
 
Panic with 
agoraphobia 
 
PTSD 
                                                                              
        bias    -1.979141   1.040259    -1.90   0.071    -4.142478    .1841952
       slope    -2.201553   .0769298   -28.62   0.000    -2.361537   -2.041568
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  23                                Root MSE      =    3.73
                                                                              
        bias    -1.096108   .7364898    -1.49   0.155    -2.649966    .4577493
       slope    -3.207467   .1518885   -21.12   0.000    -3.527924    -2.88701
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  19                                Root MSE      =   2.292
                                                                              
        bias    -1.441039   .5454236    -2.64   0.017    -2.591782   -.2902956
       slope    -3.038313   .1037814   -29.28   0.000    -3.257273   -2.819354
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  19                                Root MSE      =   1.707
                                                                              
        bias    -1.017197   .7596155    -1.34   0.198    -2.619846    .5854513
       slope    -3.145241    .119896   -26.23   0.000      -3.3982   -2.892283
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  19                                Root MSE      =   2.515
                                                                              
        bias    -1.067535   1.261041    -0.85   0.409      -3.7281    1.593029
       slope    -3.374512   .3203648   -10.53   0.000    -4.050423   -2.698601
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  19                                Root MSE      =   3.354
effect estimate against its standard error
                                                                              
        bias    -2.313868   .3904681    -5.93   0.000    -3.141623   -1.486112
       slope    -2.786855   .1178428   -23.65   0.000    -3.036671    -2.53704
                                                                              
     Std_Eff        Coef.   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                              
Number of studies =  18                                Root MSE      =   1.189
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B.6 SENSITIVITY ANALYSES 
 
Table B.6.1 Summary of results for the non-standardised (I) and the sequential algorithm 
method (II). 
 
Construct/
method of 
omitting 
Number of 
pooled 
estimates  
Pooled 
prevalence 
(95%CI) 
I
2 
(95%CI) Omitted studies  
(I
2 
after omitting) 
Major 
depression 
23 7.3  (6.3,8.5) 93.6 
(91.6,95.1) 
 
I.   I
2 
≤75% 17  7.0  
(6.0,8.0) 
61.3 
(34.4,77.2) 
Patten,2006 (87.0) 
Ukraine*(82.4 ) Fuller-Thomson, 
2007 (82.1) 
Nigeria* (78.3), McWilliams, 
2008 (78.0),  Dunlop,2004 
(61.3),  Israel* (57.1), U.S.A* 
(39.5) 
     I
2 
≤50% 15 6.5  
(6.7,7.5) 
39.5 
(0.0,67.2) 
II.   I
2 
≤75% 19 8.3  
(7.5, 9.1) 
73.9 
(59.0,83.4) 
Patten, 2006 (87.0), Ukraine* 
(82.4), Nigeria* (78.6), New 
Zealand* (73.9), Italy* (70.3), 
Dunlop,2004 ( 68.3), Fuller- 
Thomson, 2007 (65.4), 
McWilliams, 2008 ( 54.5), 
U.S.A* (49.8) 
 
      I
2 
≤50% 14 7.0  
(6.0,8.3) 
49.8 
(7.2,72.9) 
Dysthymia 19 2.6  
(2.0, 3.6) 
82.2 
(73.2,88.1) 
 
I. I
2 
≤75% - - - Nigeria* (81.6), McWilliams, 
2008 (81.3), U.S.A*(82.4), Israel 
*(83.6) Ukraine* (0.0) 
   I
2 
≤50% 14 2.3  
(2.0,2.9) 
0.0 
(0.0,29.3) 
II. I
2 
≤75% - - - Ukraine* (23.9) 
    I
2 
≤50% 18 2.7  
(2.3, 3.2) 
29.3 
(0.0,60.0) 
 
‘Moderate or 
worse’ 
depression 
symptoms 
10 14.6  
(9.9, 21.0) 
97.7 
(96.8,98.3) 
 
 
I.   I
2 
≤75% 4 16.6 
(13.6,20.1) 
72.5 
(22.2,90.3) 
Nour, 2005 (97.6), Creamer, 
1999 (96.4), Peat, 2006a (95.0), 
Kramer, 2002(94.1), Memel, 
2000 (95.0), Wilkie, 2007 (72.5), 
Rosemann, 2007(71.8), Croft, 
2005 (0.0) 
     I
2 
≤50% 2 13.2 
(10.7,16.2) 
0.0 
(0.0,0.0) 
 
II. I
2 
≤75% 4 16.6 
(13.6,20.1) 
72.5 
(22.2,90.3) 
Creamer, 1999 (96.8), Peat, 
2006a (95.7), Wilkie, 2007 
(94.7), Kramer, 2002 (89.0), 
Nour, 2005 (81.4),  
Memel, 2000 (72.5), Mallen, 
2008 (44.2) 
 
    I
2 
≤50% 3 18.4 
(15.8,21.3) 
44.2 
(0.0,83.3) 
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Table B.6.1 cont. Summary of results for the non-standardised (I) and the sequential 
algorithm method (II). 
 
Construct/
method of 
omitting 
Number of 
pooled 
estimates  
Pooled 
prevalence 
(95%CI) 
I
2 
(95%CI) Omitted studies  
(I
2 
after omitting) 
Mild or 
worse 
depression 
symptoms 
18 23.8 
 (20.6,27.2) 
95.1 
(93.4,96.3) 
 
I.    I
2 
≤75% 9 25.1 
(23.3,27.1) 
71.9 
(44.6,85.7) 
Nour, 2005 (94.8), Woo, 1994 
(93.4), Leveille, 2007 (93.5), 
Allen,2008 (92.4), Barberger-
Gateau, 1992 (87.9), Mallen, 
2008(84.8), Niti, 2007(82.9), 
Wilcox, 2000 (81.1), Kramer, 
2002 (71.9), O’Reilley,1998 
(67.6), Memel, 2000 (70.7), 
Rosemann, 2007 (68.4), Peat, 
2006a (46.3) 
     I
2 
≤50% 5 24.2 
(22.4,26.1) 
46.3 
(0.0,80.3) 
II. I
2 
≤75% 7 22.8 
(20.7,25.1) 
74.8 
(51.2,87.0) 
Woo, 1994 (93.9), Barberger-
Gateau, 1992 (92.4), Allen, 2008 
(90.4), Nour, 2005 (88.6), 
Mallen, 2008 (86.2), Peat, 
2006a (84.3), Rosemann, 2007 
(81.1), Niti, 2007(76.9), Leveille, 
2007 (74.8), Kramer, 2002 
(68.7), Wilcox, 2000 (57.9), 
Sale, 2008 (36.7) 
 
    I
2 
≤50% 6 24.9  
(23.0, 26.8) 
36.7 
(0.0,74.8) 
GAD 19 3.0  
(2.5,3.9) 
74.3 
(59.6,83.6) 
 
I.    I
2 
≤75% 18 4.1  
(3.2,4.6) 
74.1 
(58.9,83.7) 
McWilliams, 2008 (74.1), Italy* 
(70.4), Ukraine* (69.9), New 
Zealand* (71.8), Nigeria* (68.0), 
U.S.A* (29.7) 
      I
2 
≤50% 13 2.6 
(2.0, 3.5) 
29.7 
(0.0,63.6) 
II.   I
2 
≤75% 18 2.8 
 (2.2,3.6) 
63.7 
(39.9,78.1) 
 
U.S.A* (63.7), Ukraine* (56.8), 
Italy* (46.9)       I
2 
≤50% 16 2.9  
(2.3,3.6) 
46.9 
(4.9,70.3) 
Social 
phobia  
19 3.0 
 (2.3,3.9) 
84.9 
(77.6,89.7) 
 
I.    I
2 
≤75% - - - Spain* (84.2), McWilliams, 2008 
(85.0), Italy*(84.6), New 
Zealand* (85.3), Nigeria* (85.0), 
Mexico*  (86.0), U.S.A* (0.0) 
      I
2 
≤50% 12 2.9 
(2.6,3.3) 
0.0 
(0.0,46.3) 
II.   I
2 
≤75% 18 3.0 
(2.4,3.7) 
65.7 
(43.5,79.1) 
 
U.S.A*  (65.7), Spain (60.1), 
New Zealand* (52.2), Nigeria* 
(41.8) 
      I
2
 ≤50% 15 3.1 
(2.6,3.8) 
41.8 
(0.0,68.4) 
Panic with 
agoraphobia 
19 2.2 (1.4,3.4) 91.0 
(87.4,93.5) 
 
I.  I
2 
≤75% 17 2.2 
(1.7,3.0) 
66.7 
(44.7,80.0)  
McWilliams,2008  (79.4), South 
Africa* (66.7), U.S.A* (23.1) 
    I
2 
≤50% 16 2.2 
(1.8,2.7) 
23.1 
(0.0,57.7) 
II. I
2 
≤75% 17 2.2 
(1.7,3.0) 
66.7 
(44.7,80.0)   
McWilliams, 2008 (79.4), South 
Africa* (66.7), U.S.A* (23.1) 
     I
2
 ≤50% 16 2.2 
(1.8,2.7) 
23.1 
(0.0,57.7) 
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Table B.6.1 cont. Summary of results for the non-standardised (I) and the sequential 
algorithm method (II). 
 
Construct/
method of 
omitting 
Number of 
pooled 
estimates  
Pooled 
prevalence 
(95%CI) 
I
2 
(95%CI) Omitted studies  
(I
2 
after omitting) 
PTSD 18 1.8  
(1.2,2.6) 
76.5 
(63.0,85.0) 
 
I.   I
2 
≤75% 16 1.3  
(0.0,2.2) 
63.4 
(37.3, 78.6) 
New Zealand* (77.6), U.S.A* 
(63.4), Ukraine* (32.4) 
     I
2 
≤50% 15 1.2  
(0.0,1.8) 
32.4 
(0.0,63.6) 
II.  I
2 
≤75% 17 1.5 
(0.0,2.0) 
70.2 
(51.2,81.6) 
U.S.A* (70.2), New Zealand* 
(63.4),Ukraine* (32.4) 
      I
2 
≤50% 15 1.2 
(0.0,1.8) 
32.4 
(0.0, 63.6) 
‘Moderate or 
worse’ 
anxiety 
symptoms 
5 20.8 
(18.0,23.8) 
83.3 
(62.0,92.6) 
 
I. and II.     
    I
2 
≤75% - -   
Peat, 2006a (0.0)      I
2 
≤50% 4 21.6 
(20.3,23.1) 
0.0 
(0.0,71.8) 
‘Mild or 
worse’ 
anxiety 
symptoms 
6 45.4 
 (43.4,47.5) 
50.6 (0.0,80.4)  
I.  I
2 
≤75% 5 45.5  
(43.2,47.9) 
60.0 
(0.0,85.0) 
Mallen, 2008 (60.0), O’Reilley, 
1998 (35.2) 
     I
2 
≤50% 4 46.1 
(44.4, 47.9) 
35.2 
(0.0,77.4) 
II.  I
2 
≤75% - - - O’Reilley, 1998 (17.8) 
     I
2 
≤50% 5 45.9 
 (44.4,47.3) 
17.8 
(0.0,82.9) 
Note: Omitted studies are reported in an order of dropping with I
2
 after removing the study presented in 
brackets; *- study by He (2008). 
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Appendix C: Self-report measures for depression and anxiety 
symptom screening and assessment in osteoarthritis: a narrative 
review of selected measurement properties 
This appendix supports selected analyses described in chapter three 
 
 
C.1    METHODS OF QUANTIFYING CONCURRENT VALIDITY OF SELF-
REPORT MEASURES  
 
        Quantifying concurrent validity is based on a fourfold (two-by-two) table 
summarising a binary outcome (see Table C.1.1). The table allows estimating 
numbers of: (a) Individuals with the disease detected by the test (true positives) (b) 
Individuals without the disease with a positive test (false positives) (c) Individuals 
with the disease with a negative test (false negatives) and (d) Individuals without 
the disease with a negative test (true negatives) (Porta, 2008). 
 
Table C.1.1 2x2 diagnostic accuracy table  
 
 Disease  
Present Absent 
Test Positive True positive (a) False positives 
(b) 
a+b 
Negative False negatives (c) True negatives 
(d) 
c+d 
 a+c b+d a+b+c+d 
 
Source: Porta et al., 2008 
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Table C.1.2 Methods of quantifying concurrent validity of self-report measures  
 
Concept Definition Equation Interpretation Comments 
Accuracy A measure of the ability to correctly 
classify cases and non-cases 
   
       
 
 
Frequency  Affected by prevalence 
A diagnosis for rare conditions may result 
in high sensitivity and specificity, but low 
accuracy 
 
Diagnostic odds 
ratio (DOR) 
A global index of diagnostic 
accuracy, defined as the ratio of odds 
of positive test in subjects with the 
targeted disorder to the odds in 
subjects with the targeted disorder 
     (a/c)/(b/d) Unclear Rule-in and -out accuracy cannot be 
interpreted 
Likewise sensitivity and specificity, is 
unaffected by the prevalence, but is 
responsive to characteristic of the disease 
(e.g. severity and comorbidities) 
Likelihood ratios: “The probability that a given test 
result would occur in a person with 
the target disorder divided by the 
probability that the same result would 
occur in a person without that 
disorder.” 
(Porta, p.145, 2008)
 
 Classification of magnitude of 
change in disease likelihood:   
LR+ or LR- 
>10.0 or <0.10  - large change 
5-10 or 0.10-0.2- moderate change 
2-5 or 0.2-0.5  - small change 
1-2 or 0.5-1.0  - negligible change 
(Ahrens & Pigeot, 2005)
 
Allows for predicting probability of 
abnormality from the test and is 
prevalence independent 
(Deeks & Altman, 2004)
 
Likelihood ratio for 
positive test results 
(LR+) 
The likelihood of a positive test in 
patients with the targeted disorder 
versus without the targeted disorder 
((sensitivity)/(1
-specificty))  
 Unaffected by prevalence, but affected by 
the spectrum of the disease, unless 
adapting for prior probabilities through 
Bayes theorem 
Likelihood ratio for 
negative test 
results (LR-)  
 
    
 
The likelihood of a negative test in 
patients with the targeted disorder 
versus without the targeted disorder 
((1-sensitivity)/ 
(specificity))  
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Table C.1.2 cont. Methods of quantifying concurrent validity of self-report measures.  
 
Concept Definition Equation Interpretation Comments 
Predictive values:     
Positive predictive 
value (PPV) 
The probability of having the disease 
in a person who has a disease (a 
true positive). Also known as 
predictive value of a positive test. 
 
   
 Used in combination with sensitivity 
and specificity to estimate rule-in 
and out accuracies  
Predict particular test result from normality 
and abnormality, but are prevalence 
dependent 
(Deeks & Altman, 2004)
 
Negative predictive 
value (NPV) 
The probability of not having the 
disease in a person who does not 
has a disease (a true negative). Also 
known as predictive value of a 
negative test. 
 
   
  Increases with the increase of the 
prevalence  of the disease 
Sensitivity and 
specificity:  
   Describe how normality and abnormality 
predict particular test result 
(Deeks & Altman, 
2004)
 
Sensitivity (Sn.) “The probability that a diseased 
person (case) in the population 
tested will be identified as diseased 
by the test (syn: true positive 
probability). Sensitivity is thus the 
probability of correctly diagnosing a 
case or the probability that any given 
case will be identified by the test 
(syn: true-positive rate).” 
(Porta, p.227, 
2008)
 
 
   
 Exemplar interpretations: 
- An optimal balance between Sn. 
and Sp. 
- A two-stage diagnostic process- 
maximum Sn. plus sp. ≥75% for 
rule-out accuracy 
(Lowe et al., 2004a)
 
Independent of prevalence 
Likely to decrease with a cut-off point 
Likely decrease when subclinical 
symptoms are assessed 
Is likely to be higher in secondary care 
than primary care and community 
samples 
Specificity (Sp.) “The probability that a person without 
the disease (non-case) will be 
correctly identified as non-diseased 
by the test. It is thus the probability of 
correctly identifying a non-diseased 
person with a test (syn: true-negative 
probability).” 
( Porta, p.227, 2008) 
 
 
   
  Independent of prevalence 
Likely to increase with a cut-off point 
Is likely to be higher in community and 
primary care samples than secondary 
care patients (due to higher number of 
comorbidities) 
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Table C.1.2 cont. Methods of quantifying concurrent validity of self-report measures.  
 
Concept Definition Equation Interpretation Comments 
Receiver 
Operating 
Characteristic 
curve (ROC) 
The area under ROC curve (AUC) is 
a global index for measuring the 
diagnostic performance of the test.  
A relationship 
between 
sensitivity and 
1-specificty 
(false positives 
probability) 
(Kumar & Indrayan, 
2011)
 
Range from 0.5 (chance) to 1.0 
(perfect diagnostic accuracy) 
Cut-off point with the highest AUC 
is considered optimal. Exemplar 
interpretation for a summary ROC 
(Jones & Athanasious, 2005)
: 
0.97 - 1.0 -   excellent  
0.93 - 0.96 - very good   
0.75 - 0.92-  good 
0.50 - 0.74-  reasonable but with 
deficiencies  
Inference on screening and case-finding 
abilities is disenabled 
More useful to compare discriminating 
ability between two tests with quantifiable 
statistical difference 
The clinical utility 
index (UI) 
“A measure of the clinical value of a 
diagnostic test taking into accounts 
both the accuracy of the test and its 
occurrence”. 
(Mitchell, p. 413, 2009)
 
Two aspects are measures rule-in 
accuracy (case-finding ability) and 
rule-out accuracy (screening ability). 
Case-finding 
ability: 
UI+= Sn x 
PPV  
Screening 
ability: 
UI-= Sp x NPV 
(can be 
weighted) 
Landis & Koch (1977,
 
cited in 
Mitchell, 2009):
 
0.93 -  1.0-   near perfect value  
0.81 -  0.92- excellent value 
0.61 -  0.80- good value 
0.41 -  0.60- fair value 
0.21 -  0.40- slight value 
0.0   -  0.20-  minimal value 
As involves predictive values can be 
affected by prevalence 
As to, PPV increases and NPV decrease 
with prevalence and UI+ and UI- change 
accordingly 
When possible weighting should be 
executed 
Youden’s index A global index of diagnostic 
performance. 
((sensitivity + 
specificity) -1) 
(Kumar & Indrayan, 
2011)
 
0 (poor) to 1 (perfect) 
No agreed cut-off point, the highest 
Youden’s index suggests the best 
cut-off point. 
Affected by the factors affecting sensitivity 
and specificity (a spectrum of disease) 
A balance between sensitivity and 
specificity is ignored 
Note: a- true positives; b- false positives; c- false negatives; d- true negatives.  
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C.2   SEARCH STRATEGY 
 
Box C.2.1 Terms used to search EMBASE, MEDLINE, PsycInfo, CINHAL, CSA 
ILLUMINA and ISI Web of Knowledge. 
 
EMBASE and EBSCO Health databases (MEDLINE, PsycInfo, CINHAL) 
Text-word searched in all text 
Data synthesis/ recommendations: 
Review* OR systematic and review OR summary OR recommend* 
Depression/anxiety: 
depress* OR Anxiet* OR depressive symptom* OR depressed person OR depress* and symptom* 
OR anxious person OR anxiety symptom* OR  affect and symptom* OR psychol* and distress OR 
HAD* OR hospital anxiety depression scale OR BDI OR beck a depression inventory OR PHQ OR 
patient and health and questionnaire OR GAD OR generalized anxiety disorder scale  
Primary care: 
primary and care OR general and practic* OR family and practic* OR family and medicine OR 
general and practition* OR family and practition*  
Psychometric/diagnostic utility: 
clinical utility OR psychometric* OR diagnos* OR validity OR reliability OR accuracy OR sensitivity 
OR specificity OR predictive value OR ROC OR screening OR false positive OR false negative OR 
logistic regression OR likelihood ratio OR accuracy OR attitude* OR belief OR perception OR 
clinical utility OR barrier* 
Musculoskeletal complaints: 
Joint diseases OR arthrit* OR musculoskeletal OR hand OR knee OR ankle OR foot OR shoulder 
OR elbow OR wrist OR hip OR pain and psych* OR musculoskelet* OR spondylosis OR 
osteoarthos* OR joint and stiff* OR joint and pain OR joint and diseas* OR osteoarthrit*)  
Older adults: 
Old* OR elderly OR age* OR geriat* OR adult* 
Thesaurus/Mesh-terms 
Depression/anxiety: 
Depression OR Depressive disorder OR depressive disorder, major OR mental disease OR mixed 
anxiety and depression OR major depression, OR mood disorder OR mental health OR beck 
anxiety inventory OR hospital anxiety and depression scale  
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Box C.2.1 cont. Terms used to search EMBASE, MEDLINE, PsycInfo, 
CINHAL, CSA ILLUMINA and ISI Web of Knowledge. 
 
Musculoskeletal complaints: 
arthritis OR cartilage OR elbow OR elbow joint OR hand OR hand joint OR hip OR hip joint OR 
knee OR knee joint OR arthralgia OR shoulder OR shoulder join OR shoulder pain OR wrist OR 
wrist joint OR ankle OR ankle joint OR foot OR spondylosis OR cartilage degeneration OR elbow 
disease OR hip pain OR hip osteoarthritis OR hip disease OR knee disease OR knee osteoarthritis 
OR knee pain OR shoulder disease OR wrist disease OR ankle pain OR foot disease OR foot pain 
OR joint OR joint degeneration OR joint stiffness OR finger joint OR interphalangeal joint, exp 
carpometacarpal joint OR carpal joint OR atlantoocipital joint OR atlantoaxial joint OR 
acromioclavicular joint OR toe joint OR radioulnar joint OR sacroiliac joint OR subtalar joint OR 
sternocostal joint OR sternoclavicular joint OR tarsal joint OR tarsometatarsal joint OR 
temporomandibular joint OR zygapophyseal joint OR metacarpophalangeal joint OR 
metatarsophalangeal joint OR proximal interhalangeal joint OR patellofemoral joint OR cartilage 
diseases OR osteoarthritis OR osteoarthritis spine OR osteoarthritis hip OR osteoarthritis knee OR 
musculoskeletal diseases OR joint diseases OR pain/PX 
Primary care: 
general practice OR primary health care OR general practitioner  OR family practice OR primary 
health care OR physicians family 
Diagnostic/psychometric utility: 
Sensitivity and specificity OR diagnosis OR predictive value of tests OR ROC Curve OR mass 
screening OR reproducibility of results OR false positive reactions OR false negative reactions OR 
logistic models OR psychometrics OR questionnaires OR rating scale OR depression inventory OR 
self-rating depression scale 
CSA ILLUMINA and ISI Web of Knowledge 
(depress*) AND (primary and care OR general and practice OR general and popul*) AND (diagnos* 
OR psychometric OR accuracy) AND (musculosk* OR pain OR osteoarthr* OR arthritis*) AND 
(perception OR attitude OR belief OR clinical and utility)  
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C.3   COPIES OF THE FULL VERISONS OF THE REVIEWD DEPRESSION 
MEASURES  
BDI-21  
361 
 
cont. BDI-21  
 
Source: http://www.ibogaine.desk.nl/graphics/3639b1c_23.pdf
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PHQ-9  
 
 
Source: www.iapt.nhs.uk/silo/files/phq9-and-gad7.doc 
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HADS  
 
                                  Note: A- anxiety items; D- depression items.
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GAD-7  
 
 
Source: http://www.antiagingvancouver.com/pdfs/anxiety-depression-
questionnaire.pdf
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C.4   DATA USED FOR ESTIMATING LIKELIHOOD RATIOS 
 
Table C.4.1 Overview of data extracted to calculate likelihood ratios for BDI-II, PHQ-9 and -2, HADS-D. 
 
Study ID Questionnaire N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Arroll, 2003  
 
PHQ-2 
 
476  
 
Major depression  
(6.1%) 
Yes to 1 or 2 97.0 (83.0,99.0) 67.0 (62.0,72.0) 
Yes to 1st 86.0  (69.0,95.0) 72.0 (67.0,76.0) 
Yes to 2nd 83.0  (66.0,92.0) 79.0 (74.0,82.0) 
Arroll, 2010 
 
PHQ-2  
PHQ-9 
 
2,642  Major depression (6.2%) PHQ-2:   
1 96.0 60.0 
2 86.0 78.0 
3 61.0 92.0 
4 40.0 96.0 
PHQ-9:   
8 82.0 85.0 
10 74.0 91.0 
12 61.0 94.0 
15 45.0 97.0 
Depression 
algorithm 
45.0 97.0 
Axford, 2010 
 
HADS-D 
HADS 
54  Depression disorder 
(27.7%) 
HADS-D:   
8^ 53.0 (27.0,79.0)  85.0 (69.0,94.0)  
HADS:   
16^ 55.0 (32.0, 76.0) 88.0 (71.0, 96.0) 
Beck, 1997 BDI-7 56 Major depression (22%) 6A 83.0 95.0 
Bunevicius, 
2007  
HADS-D 
 
503  Major depressive episode 
(22%) 
  
6R 80.0 69.0 
Corapcioglu, 
2004 
PHQ-9 1387 (A) Major + minor depressive 
disorder (19.3%) 
(B) Major depression (6.6%) 
Algorithm 
(A) 
(B) 
 
76.0 
71.4 
 
85.3 
91.9 
El-Rufaie, 
1995 
HADS-D 
 
217  Depression (24%) 7B 
 
66.0 97.0 
366 
 
Table C.4.1 cont. Overview of data extracted to calculate likelihood ratios for BDI-II, PHQ-9 and -2, HADS-D. 
 
Study ID Questionnaire N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
Harter, 2001 HADS 
 
206  Major depression, dysthymia 
(11%) 
 
  
16M 78.3 70.6 
Kroenke, 
2003 
 
PHQ-2 580 
 
Major depression (7%) 
Any depressive disorder 
(18.3%) 
Major depression:  
1 97.6 59.2 
2 92.7 73.7 
3N 82.9 90.0 
4 73.2 93.3 
5 53.7 96.8 
6 26.8 99.4 
   
 
 Any depressive disorder :       
1 90.6 65.4 
2 82.1 80.4 
3 62.3 95.4 
4 50.9 97.9 
5 31.1 98.7 
6 12.3 99.8 
Lam, 1995 HADS-D 100  Depressive disorders (9%)  
 
6*  78.0 91.0 
Li, 2007  PHQ-2 8205  Major depression in past 12 
months (3.7%) 
Yes to 1 and 2 77.0 (72.6,82.9) 86.0(85.4,87.2) 
Yes to 1 92.0 (88.6,95.8) 79.0 (77.5,79.6) 
Yes to 2 85.0 (80.2,89.8) 85.0 (83.7,85.5) 
Yes to 1 or 2Y 100 77.0 (75.8,78.0) 
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Table C.4.1 cont. Overview of data extracted to calculate likelihood ratios for BDI-II, PHQ-9 and -2, HADS-D. 
 
Study ID Questionnaire N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
Phelan, 2010 PHQ-9 
 
71  Major depression (12%) 
Major and minor depression 
(25%) 
 
 
 
Major depression:  
8     88.0  (56.0,98.0) 75.0  (71.0,77.0) 
9B 88.0  (56.0,98.0) 80.0  (76.0,82.0) 
10^ 63.0  (33.0,85.0) 82.0  (78.0,85.0) 
11 63.0  (33.0,85.0) 84.0  (80.0,87.0) 
12 63.0  (33.0,85.0) 84.0  (80.0,87.0) 
Major and minor depression:  
6 77.0  (56.0,90.0) 69.0  (63.0,74.0) 
7 77.0  (56.0,90.0) 77.0  (70.0,81.0) 
8B 77.0  (57.0,89.0) 83.0  (76.0,87.0) 
9 71.0  (51.0,85.0) 87.0  (80.0,91.0) 
10 59.0  (40.0,74.0) 89.0  (82.0,93.0) 
Phelan, 2010 PHQ-2 
 
71 
 
Major depression (12%) 
Major and minor depression 
(25%) 
Major depression:  
1 88.0  (55.0,98.0) 61.0  (56.0,62.0) 
2B 75.0  (43.0,93.0) 67.0  (63.0,70.0) 
   3^ 63.0  (33.0,85.0) 85.0  (81.0,88.0) 
   4 38.0  (15.0,62.0) 93.0  (91.0,97.0) 
   5 38.0  (16.0,48.0) 98.0  (96.0,100) 
   Major and minor depression:  
1 82.0  (62.0,94.0) 67.0  (61.0,71.0) 
 2 71.0  (50.0,86.0) 73.0  (66.0,78.0) 
  3 53.0  (35.0,67.0) 90.0  (85.0,95.0) 
   4 35.0  (21.0,40.0) 98.0  (94.0,100) 
   5 18.0  (7.0, 22.0) 98.0  (95.0,100) 
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Table C.4.1 cont. Overview of data extracted to calculate likelihood ratios for BDI-II, PHQ-9 and -2, HADS-D. 
 
Study ID Questionnaire N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
Poole, 2009b  
 
BDI-II 36  Any depression (72%) 
 
14.5 100 60.0 
16.0 100 70.0 
17.5 89.0 90.0 
18.5 96.0 80.0 
20.0 92.0 80.0 
22.0* 89.0 90.0 
23.5 85.0 100 
24.5 73.0 100 
Terluin, 2009  
 
HADS-D 
 
295  Any depressive disorder (49%) 
Moderate or severe depressive 
disorder (26%) 
 
Any depressive disorder:  
 8 93.0 39.0 
 9 88.0 49.0 
11B 75.0 67.0 
14 40.0 88.0 
Moderate or severe depressive 
disorder: 
 
8 
10 
11 
96.0 
87.0 
81.0 
30.0 
48.0 
56.0 
12B 64.0 65.0 
15 39.0 85.0 
Watts, 2002 HADS-D 115 Sub-clinical psychiatric 
(33.9%) 
8^ 24.0 89.0 
Whooley, 
1997 
 
BDI-II 
 
536  Major depression (18.1%) 
 
BDI-II: 10^ 89.0 (81.0,95.0) 64.0 (59.0,68.0) 
PHQ-2:   
Yes to 1 or 2:   
     All  96.0 (90.0,99.0) 57.0 (53.0,62.0) 
     By age:   
        18 to 35   100 (59.0,100) 59.0 (43.0,74.0) 
        35-64 95.0 (88.0,99.0) 52.0 (46.0,58.0) 
        65+ 100 (54.0,100) 69.0 (60.0,77.0) 
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Table C.4.1 cont. Overview of data extracted to calculate likelihood ratios for BDI-II, PHQ-9 and -2, HADS-D. 
 
Study ID Questionnaire 
 
N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
Wilkinson & 
Barczak, 
1988 
 
HADS-D 
 
100 
 
Depressive disorders (23%)    
 8* 90.0 86.0 
Yeung, 2008 
 
PHQ-9 
 
184  
 
Major depression (20%) 15^ 81.0 40.00 
Note: Methods of ascertainment of optimal cut-off point, if such is specified: ^ - reported by authors as previously recommended; * - Area Under the Curve; A - 
balance between sensitivity, specificity, negative and positive predictive values; B - balance between sensitivity and specificity; M - minimised false positive and 
false negatives; N - sensitivity, specificity, positive predictive value, positive likelihood ratio, Area Under the Curve; Y - the Youden index. 
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Table C.4.2 Overview of data extracted to calculate likelihood ratios for HADS-A, GAD-7 and -2. 
 
Authors Questionnaire N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
Axford, 2010 
 
HADS-A 
HADS 
 
54  Anxiety disorders 
(31.48%) 
HADS-A: 8^ 88.0 (64.0,99.0) 81.0 (65.0,92.0)  
HADS: 16^ 55.0 (32.0,76.0) 88.0 (71.0,96.0) 
Bunevicius 2007 
 
HADS-A 
 
503  
 
Anxiety disorders (27%) 
Social phobia (4%) 
Panic disorder (3%) 
GAD (25%) 
 
Anxiety disorders:     
9* 77.0 75.0 
Social phobia: 
9* 
 
95.0 
 
63.0 
Panic 
disorder: 
11* 
 
100 
 
77.0 
GAD 
9* 
 
76.0 
 
73.0 
El-Rufaie & 
Absood,1995 
HADS-A  
 
217  Anxiety (18.4%) 9B 
 
66.0 
 
93.0 
 
Garcia-Campayo, 
2010 
 
GAD-7  
 
212 
 
GAD (50%) GAD-7: 
8 
9 
10^ 
11 
12 
13 
14 
 
93.4 
91.5 
86.8 
79.2 
74.5 
67.9 
62.3 
 
85.8 
90.6 
93.4 
95.3 
96.2 
97.2 
100 
Harter, 2001 HADS 206  Anxiety disorders (15%) 
 
17M 75.0 72.2 
Lam, 1995 HADS-A 100  Anxiety (6%) 
 
3* 67.0 83.0 
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Table C.4.2 cont. Overview of data extracted to calculate likelihood ratios for HADS-A, GAD-7 and -2. 
 
Authors Questionnaire N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
Spitzer, 2006 
 
GAD-7 
GAD-2  
 
965 
 
GAD (7.6%) 
Panic disorder (6.8%) 
 
GAD:   
GAD-7  
5 
6 
7 
8      
9     
10^  
15  
97.0 (90.0,100) 
95.0 (87.0,98.0) 
95.0 (87.0,98.0) 
92.0 (83.0,97.0) 
90.0 (81.0,96.0) 
89.0 (80.0,95.0) 
48.0  
57.0 (53.0,60.0) 
65.0 (61.0,67.0) 
70.0 (67.0,73.0) 
76.0 (73.0,79.0) 
79.0 (76.0,82.0) 
82.0 (80.0,85.0)  
95.0  
GAD-2:   
2            
3K 
 
95.0 (87.0,98.0) 
86.0 (76.0,93.0) 
 
64.0 (61.0,67.0) 
83.0 (80.0,85.0) 
     Panic disorder:  
GAD-7: 
5 
6 
7 
8 
9         
10 
94.0 (85.0,98.0) 
88.0(78.0,95.0) 
83.0(72.0,91.0) 
82.0 (70.0,90.0) 
79.0 (67.0,88.0) 
74.0 (62.0,84.0) 
56.0 (53.0,59.0) 
64.0  (60.0,67.0) 
69.0  (66.0,72.0) 
75.0  (72.0,78.0) 
78.0  (75.0,80.0) 
81.0  (78.0,83.0) 
GAD-2:   
2 
3 
 
91.0  (81.0,97.0) 
76.0  (64.0,85.0) 
 
63.0  (60.0,66.0) 
81.0  (79.0,84.0) 
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Table C.4.2 cont. Overview of data extracted to calculate likelihood ratios for HADS-A, GAD-7 and -2. 
 
Authors Questionnaire N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
Spitzer, 2006 
 
GAD-7 
GAD-2  
 
965 
 
Social phobia (6.2%) 
PTSD (8.6%) 
 
Social phobia:  
GAD-7:   
5 
6 
7      
8 
9 
10 
 
88.0  (85.0,98.0) 
87.0  (75.0,94.0) 
85.0  (73.0,92.0) 
78.0  (66.0,88.0) 
77.0  (64.0,87.0) 
72.0  (59.0,83.0) 
 
55.0  (52.0,59.0) 
63.0 (60.0,66.0) 
69.0  (66.0,72.0) 
74 .0 (71.0,77.0) 
77.0  (74.0,80.0) 
80.0  (77.0,83.0) 
GAD-2:    
2 
3 
 
85.0  (73.0,93.0) 
70.0  (57.0,81.0) 
 
62.0  (59.0,65.0) 
81.0  (78.0,83.0) 
    PTSD:     
1. GAD-7:     
2. 5          
3. 6 
7             
8              
9         
10 
 
90.0  (82.0,96.0) 
86.0  (76.0,92.0) 
78.0  (68.0,87.0) 
76.0  (65.0,85.0) 
74.0  (63.0,83.0) 
66.0  (55.0,76.0) 
 
57.0  (53.0,60.0) 
64.0  (61.0,68.0) 
70.0  (66.0,73.0) 
75.0  (72.0,78.0) 
78.0  (75.0,81.0) 
81.0  (78.0,84.0) 
GAD-2: 
2           
3 
 
86.0  (76.0,92.0) 
59.0  (48.0,70.0) 
 
64.0  (60.0,67.0) 
81.0  (78.0,84.0) 
 
 
 
 
 
 
373 
 
Table C.4.2 cont. Overview of data extracted to calculate likelihood ratios for HADS-A, GAD-7 and -2. 
 
Authors Questionnaire N  Diagnosis (%) Cut of point  Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
 
Spitzer, 2006 
 
GAD-7 
GAD-2  
 
965 
 
Any anxiety disorder 
(19.5%) 
Any anxiety disorder: 
4. GAD-7:      
5. 5 
6      
7 
8 
9 
10 
90.0  (85.0,94.0) 
85.0  (79.0,90.0) 
80.0  (74.0,86.0) 
77.0  (70.0,82.0) 
73.0  (66.0,80.0) 
68.0  (60.0,74.0) 
63.0  (60.0,66.0) 
71.0  (68.0,74.0) 
76.0 (73.0,79.0) 
82.0  (80.0,85.0) 
85.0  (83.0,81.0) 
88.0  (85.0,90.0) 
GAD-2:     
2 
3S 
 
86.0  (80.0,90.0) 
65.0  (57.0,71.0) 
 
70.0  (67.0,74.0) 
88.0  (85.0,90.0) 
Terluin, 2009 
 
HADS-A 
 
295  
 
Any anxiety disorders 
(34%) 
Panic disorder, 
agoraphobia and social 
phobia (19%) 
 
Any anxiety disorders:  
8 
10 
11 
13B 
16 
98.0 
91.0 
84.0 
65.0 
32.0 
27.0 
43.0 
51.0 
70.0 
89.0 
Panic disorder, agoraphobia and social phobia:  
8 
11 
13B 
16 
100 
86.0 
68.0 
41.0 
23.0 
45.0 
65.0 
87.0 
Watts, 2002 
 
HADS-A 
  
115 
 
Sub-clinical psychiatric 
diagnosis (33.9%) 
 8^ 
 
57.0 
 
71.0 
 
Wetherell, 2007 HADS-A 37 GAD (47.1%) 8^ 96.7 66.0 
Note: Methods of ascertainment of optimal cut-off point, if such is specified: ^ - reported by authors as previously recommended; * - Area Under the Curve; 
B - balance between sensitivity and specificity; K - sensitivity, specificity, LR+; M - minimalised false positive and false negatives; S - optimal for screening. 
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Appendix D: The course of anxiety and depression symptoms in 
older patients presenting to general practice with musculoskeletal 
pain  
Part 2: A latent class growth analysis 
 
This appendix supports selected analyses described in chapter five  
 
D.1     DISTRIBUTION OF SCORES FOR CONTINUOUS BASELINE 
COVARIATES ASSESSED FOR ASSOCCIATIONS WITH CLUSTER 
MEMBERSHIP 
 
Figure D.1.1 Distribution of the number of pain sites variable in 443 consenters for 
follow-up. 
 
 
 
  
 
 
 
375 
 
Figure D.1.2 Distribution of the pain interference with daily activities variable in 443 
consenters for follow-up. 
 
 
Figure D.1.3 Distribution of the pain interference with work variable in 443 
consenters for follow-up. 
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Figure D.1.4 Distribution of the interference with social activities variable in 443 
consenters for follow-up. 
 
 
D.2    EXEMPLES OF PATTERNS OF HADS SCORES OVER TIME 
                    
                           Figure D.2.1 Exemplar for the pattern  ‘1111’*. 
 
 
                              Note: *1- HADS score ≥ 8. 
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                        Figure D.2.2  Exemplar of the pattern ‘0000’*.  
 
 
                           Note:*0- HADS score 0-7. 
                   
 
                       Figure D.2.3 Exemplar of the pattern ‘1000’*.   
 
 
                            Note: *1- HADS score ≥ 8; 0- HADS score 0-7. 
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                        Figure D.3.4 Exemplar of the pattern ‘0010’*.  
 
 
                          Note: *1- HADS score ≥ 8, 0- HADS score 0-7. 
 
 
                         Figure D.3.5 Exemplar of the pattern ‘1101’*.  
 
 
                            Note: *1- HADS score ≥ 8, 0- HADS score 0-7. 
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D.3    INDIVIDUAL DEPRESSION PATTERNS IN 2 CLUSTERS NESTED IN THE 
2-CLUSTER LCGA DEPRESSION MODEL 
  
   Figure D.3.1 Individual HADS-D scores over time for 232 individuals in the no  
   depression symptom trajectory.  
 
 
 
 
  Figure D.3.2 Individual HADS-D score for 66 individuals in the persistent 
  depression symptom trajectory. 
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D.4  THE 4-CLUSTER LCGA ANXIETY MODEL FOR 293 PARTICIPANTS   
WITH COMPLETE HADS-A DATA 
 
Figure D.4.1 Cluster 1: 4-cluster LCGA anxiety model for complete binary 
anxiety data (n=121). 
 
 
Figure D.4.2 Cluster 2: 3-cluster LCGA anxiety model for complete binary 
anxiety data (n=87). 
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Figure D.4.3 Cluster 3: 3-cluster LCGA anxiety model for complete binary 
anxiety data (n=56). 
 
 
Figure D.4.4 Cluster 4: 3-cluster LCGA anxiety model for complete binary 
anxiety data (n=29). 
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D.5    INDIVIDUAL ANXIETY PATTERNS IN 3 CLUSTERS NESTED IN THE 3-
CLUSTER LCGA ANXIETY MODEL 
 
Figure D.5.1 Individual HADS-anxiety scores over time for 119 individuals with the 
no anxiety symptom trajectory. 
 
 
 
 
Figure D.5.2 Individual HADS-anxiety scores over time for 86 individuals in the 
transient anxiety symptom trajectory. 
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Figure D.5.3 Individual HADS-A scores over time for 88 individuals in the persistent 
anxiety symptom trajectory. 
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Appendix E: The course of anxiety and depression symptoms in 
older patients presenting to general practice with musculoskeletal 
pain  
Part 3: Factors associated with the course of anxiety and 
depression symptoms 
This appendix supports selected analyses described in chapter six 
 
 
E.1     RESULTS OF THE MULTICOLLINEARITY TEST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table E.1.1 Results of VIF test for multicollinearity. 
 
Variable VIF 1/VIF 
Pain interference with daily activities 5.19 0.19 
Pain interference with work 3.83 0.26 
Pain interference with social activities 3.70 0.27 
Lack of partner 2.83 0.35 
Living alone 2.79 0.36 
Often using coping self-statements 1.48 0.68 
Age 70+ 1.37 0.73 
Age 60-69 1.32 0.76 
Lack of emotional support 1.31 0.76 
Often using increased behavioural activities 1.30 0.77 
Often ignoring sensations 1.25 0.80 
Often catastrophising 1.25 0.80 
Pain extent 1.19 0.84 
Lack of instrumental support 1.12 0.89 
Gender 1.08 0.93 
Manual/routine work 1.06 0.94 
Mean VIF 2.05  
Note: 1/VIF- tolerance; VIF-variance inflation factor   
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E.2     SATURATED REGRESSION ANALYSES 
Table E.2.1 Saturated logistic regression analysis for the 2-cluster 
LCGA depression model. 
 
No depression symptoms^ vs. 
Persistent depression symptoms 
Odds 
Ratio 
P 95% CI 
 
Age 60-69  1.60 0.269 0.70 3.69 
Age 70+  3.63 0.002 1.61 8.17 
Gender  0.97 0.938 0.50 1.90 
Number of pain sites (0-44) 1.07 0.001 1.03 1.12 
Interference with daily activities (0-10) 0.81 0.144 0.61 1.07 
Interference with social activities (0-10) 1.38 0.006 1.10 1.73 
Interference with work (0-10) 1.16 0.183 0.93 1.44 
Catastrophising  1.76 0.127 0.85 3.64 
Ignoring pain sensations  1.15 0.736 0.51 2.56 
Coping self-statements  0.85 0.686 0.39 1.86 
Increased behavioural activities  0.56 0.122 0.27 1.17 
Lack of partner  1.12 0.851 0.33 3.80 
Living alone  1.39 0.627 0.37 5.28 
No emotional support  3.89 0.190 0.51 29.73 
No instrumental support  2.37 0.161 0.71 7.70 
Manual/routine work 0.86 0.673 0.43 1.74 
Note: ^- reference group. 
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Table E.2.2 Saturated multinomial logistic regression analysis for the 
3-cluster LCGA anxiety model. 
 
No anxiety symptoms^ vs. OR                     P 95% CI 
Persistent anxiety symptoms     
Age 60-69  0.48         0.054 0.23 1.01 
Age 70+  0.70       0.388 0.31 1.57 
Gender  1.20        0.578 0.63 2.31 
Number of pain sites (0-44) 1.10        0.000 1.05 1.16 
Interference with daily activities (0-10) 1.22        0.147 0.93 1.58 
Interference with social activities (0-10) 0.92          0.426 0.75 1.13 
Interference with work (0-10) 1.09 0.394 0.89 1.34 
Catastrophising  3.58 0.002 1.57 8.13 
Ignoring pain sensations  1.29 0.530 0.59 2.81 
Coping self-statements  0.96 0.926 0.45 2.05 
Increased behavioural activities  0.39 0.011 0.19 0.80 
Lack of partner  1.75 0.395 0.48 6.37 
Living alone  0.68 0.600 0.16 2.84 
No emotional support  1.93 0.628 0.14 27.38 
No instrumental support  5.74 0.023 1.27 15.99 
Manual/routine work 1.33 0.428 0.66 2.66 
Transient  anxiety symptoms        
Age 60-69  1.26 0.527 0.62 2.57 
Age 70+  1.58 0.256 0.72 3.47 
Gender  1.22 0.524 0.66 2.28 
Number of pain sites (0-44) 1.06 0.019 1.01 1.12 
Interference with daily activities (0-10) 1.20 0.154 0.93 1.55 
Interference with social activities (0-10) 0.92 0.429 0.76 1.12 
Interference with work (0-10) 1.10 0.327 0.91 1.34 
Catastrophising  2.77 0.013 1.23 6.20 
Ignoring pain sensations  1.22 0.599 0.58 2.57 
Coping self-statements  1.38 0.387 0.67 2.82 
Increased behavioural activities  0.44 0.020 0.22 0.88 
Lack of partner  1.59 0.450 0.48 5.30 
Living alone  0.66 0.544 0.17 2.54 
No emotional support  1.34 0.838 0.08 21.67 
No instrumental support  2.60 0.235 0.54 7.54 
Manual/routine work 2.38 0.008 1.26 4.52 
Note: ^- reference group; OR- odds ratio. 
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E.3     THE 2-CLUSTER LCGA DEPRESSION MODEL BASED ON 368 
PARTICIPANTS WITH AT LEAST THREE HADS SCORES AVAILABLE        
 
 
 
 
Figure E.3.1 2-cluster LCGA depression model: no depression symptom trajectory 
(n=272). 
 
 
                 Note: Frequencies exclude missing data. 
 
 
 
Table E.3.1 Average assignment probabilities based on maximum 
posterior probability for 2 clusters LCGA depression model (n=368). 
 
Assigned 
cluster 
n % Average posterior probabilities for 
each cluster 
1 2 
1 272 73.9 .9877 .0123 
2 96 26.1 .0690 .9310 
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Figure E.3.2 2-cluster LCGA depression model: persistent depression symptom 
trajectory (n=96). 
 
 
             Note: Frequencies exclude missing data. 
 
E.4     THE 3-CLUSTER LCGA ANXIETY MODEL BASED ON 368    
PARTICIPANTS WITH AT LEAST THREE HADS SCORES AVAILABLE        
 
Table E.4.1 Average assignment probabilities based on maximum posterior 
probability for 3 clusters LCGA anxiety model (n= 368). 
 
Assigned 
cluster 
n % Average posterior probabilities for each 
cluster 
1 2 3 
1 139 37.8 .8756 .0001 .1243 
2 123 33.4 .0001 .8869 .1130 
3 106 28.8 .0853 .0942 .8205 
Note: Cluster 1- no anxiety symptoms, Cluster 2- ‘transient anxiety symptoms’, Cluster 3- ’persistent anxiety 
symptoms’. 
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Figure E.4.1 3-cluster LCGA anxiety model: no anxiety symptom trajectory (n=139). 
 
 
                      Note: Frequencies exclude missing data. 
 
 
Figure E.4.2 3-cluster LCGA anxiety model: transient anxiety symptom trajectory 
(n=72).  
 
 
                            Note: Frequencies exclude missing data. 
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Figure E.4.3 3-cluster LCGA anxiety model: persistent anxiety symptom trajectory 
(n=118). 
 
 
                     Note: Frequencies exclude missing data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
391 
 
Appendix F:  Documented detection of depression and anxiety in 
older adults consulting with musculoskeletal pain: analyses of 
medical record data 
This appendix consists of Read terms and codes used in chapter seven 
 
 
F.1    LIST OF SEARCH TERMS 
 
Table F.1.1 Read term list for depression. 
Read code   Read terms 
Depression diagnosis/problem codes 
1BT..                    Depressed mood/ Low mood/Depression 
E11z2                Masked depression 
Eu32z                 [X]Depression NOS 
E2B1.                Chronic depression 
212S.                Depression resolved 
2257.                   O/E - depressed 
E135.                Agitated depression 
1B1U.               Depression symptoms/ Symptoms of depression 
E112.               Single major depressive episode/ Major depression 
                        Mild major depression/ Moderate major depression 
E113.                Recurrent major depressive episode 
Eu32.               [X]Depressive episode 
Eu341                       [X]Depressive personality disorder 
E2B..                     Depressive disorder NEC 
1B17.                C/O - feeling depressed/depressed 
E290z                     Brief depressive reaction NOS  
Eu32z                     [X]Depressive disorder NOS 
Eu412                     [X]Mild anxiety depression 
E291.                     Prolonged depressive reaction 
E130.                     Reactive depressive psychosis 
Eu33.                        [X]Seasonal depressive disorder 
Eu33.                   [X]Recurrent depressive disorder 
E113.                 Endogenous depression - recurrent 
Eu32z                [X]Depressive episode, unspecified 
E112.                Endogenous depression first episode 
Eu3y1                        [X]Recurrent brief depressive episodes 
Eu31.                     [X]Bipolar affective disorder 
9HA0.                 On depression register 
9HA1.                   Removed from depression register 
6891.                      Depression screen 
388K.                  Geriatric depression scale 
ZV790                      [V]Screening for depression 
388P.                 HAD scale: depression score 
388g.                     Beck depression inventory second edition score 
388Z.                     Depression anxiety stress scales depression score 
6896.                     Depression screening using questions 
388f.                    Pt Health Questionnaire score  
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Table F.1.1 cont. Read term list for depression. 
Read code Read terms 
Interventions: Antidepressants  
da... 
da1..  
da2..  
da3..  
da4.. 
da5.. 
da6.. 
da7.. 
da8.. 
da9..  
daA..  
daB..  
daC..  
daD..  
OTHER ANTIDEPRESSANT DRUGS:  
FLUPENTIXOL [ANTIDEPRESSANT]  
TRYPTOPHAN 
FLUVOXAMINE MALEATE 
FLUOXETINE HYDROCHLORIDE 
SERTRALINE HYDROCHLORIDE 
PAROXETINE HYDROCHLORIDE (SEROXAT) 
VENLAFAXINE 
NEFAZODONE 
CITALOPRAM 
REBOXETINE 
MIRTAZAPINE  
ESCITALOPRAM 
AGOMELATINE 
d7...                         
d71..                        
d72..                         
d73..                        
d74..                         
d75..                        
d76..                        
d77..                        
d78..                         
TRICYCLIC ANTIDEPRESSANTS:  
AMITRIPTYLINE HYDROCHLORIDE 
[ANTIDEPRESSANT] 
*BUTRIPTYLINE  
CLOMIPRAMINE HYDROCHLORIDE 
DESIPRAMINE HYDROCHLORIDE  
DOSULEPIN HYDROCHLORIDE  
DOXEPIN  
IMIPRAMINE HYDROCHLORIDE [ANTIDEPRESSANT] 
IPRINDOLE 
d79..                        LOFEPRAMINE 
d7a..                        MAPROTILINE HYDROCHLORIDE 
d7b..                        
d7c..     
d7d..                                        
MIANSERIN HYDROCHLORIDE 
NORTRIPTYLINE 
PROTRIPTYLINE HYDROCHLORIDE 
d7e..                    
d7f..                          
d7g..                        
d7h..                                            
TRAZODONE HYDROCHLORIDE 
TRIMIPRAMINE 
VILOXAZINE HYDROCHLORIDE 
AMOXAPINE 
d8...                         
d81..                        
d82..                        
d83..                        
d84..                        
d85..                             
MONOAMINE-OXIDASE INHIBITORS:  
PHENELZINE  
*IPRONIAZID 
ISOCARBOXAZID  
TRANYLCYPROMINE 
MOCLOBEMIDE 
d9...                   
d911.                       
d912.                    
d913.                    
d914.                    
d915.                       
d916.                       
d917.                    
COMPOUND ANTIDEPRESSANT DRUGS:  
*LIMBITROL 5 capsules 
*LIMBITROL 10 capsules 
*MOTIPRESS tablets x28CP 
*MOTIVAL tablets 
*PARSTELIN tablets 
TRIPTAFEN tablets 
TRIPTAFEN-M tablets 
d6...                    
d61..                        
d62..                        
LITHIUM SALTS:  
LITHIUM CARBONATE  
LITHIUM CITRATE 
Note: *- discontinued  
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Table F.1.2 Read term list for anxiety. 
 
Read codes Read terms 
Anxiety diagnosis/problem codes 
1B13.                                       Anxious /Anxiety-symptoms/ Anxiousness/ Feeling anxious 
          Level of anxiety/ Anxiety and fear/ Nervously anxious / 
Acknowledging anxiety/Anxiety about treatment/ Adjustment 
reaction with anxious mood 
E200.  
E2000  
E2001  
E2002  
E2003                                   
E2004   
E2005  
E200z 
Anxiety states: 
Anxiety state unspecified  
Panic disorder  
Generalised anxiety disorder  
Anxiety with depression  
Chronic anxiety  
Recurrent anxiety  
Anxiety state NOS 
E202.  Phobic anxiety: 
E2020  
E2021  
E2022  
E2023  
Phobia unspecified  
Agoraphobia with panic attacks  
Agoraphobia without mention of panic attacks  
Social phobia, fear of eating in public 
E2024  
E2025  
E2026  
E2027  
E2028 
E2029  
E202A  
E202B  
E202C  
E202D  
E202z  
Social phobia, fear of public speaking  
Social phobia, fear of public washing  
Acrophobia 
Animal phobia   
Claustrophobia 
Fear of crowds  
Fear of flying  
Cancer phobia 
Dental phobia  
Fear of death  
Phobic disorder NOS 
Eu515 [X]Dream anxiety disorder 
Eu41.  
Eu410  
Eu411  
Eu412  
Eu413  
Eu41y  
Eu41z  
[X]Other anxiety disorders:  
[X]Panic disorder [episodic paroxysmal anxiety] 
[X]Generalized anxiety disorder 
[X]Mixed anxiety and depressive disorder 
[X]Other mixed anxiety disorders 
[X]Other specified anxiety disorders 
[X]Anxiety disorder, unspecified 
Eu40.  
Eu400  
Eu401 
Eu402 
Eu403 
Eu40y 
Eu40z  
[X]Phobic anxiety disorders 
[X]Agoraphobia  
[X]Social phobias  
[X]Specific (isolated) phobias  
[X]Needle phobia  
[X]Other phobic anxiety disorders 
[X]Phobic anxiety disorder, unspecified 
Eu054                                  [X]Organic anxiety disorder 
Eu411  [X]Generalized anxiety disorder 
Eu341   [X]Persistent anxiety depression 
Eu606  [X]Anxious [avoidant] personality disorder 
388b.                                      Depression anxiety stress scales anxiety score 
388N.                                    HAD scale: anxiety score 
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Table F.1.2 cont. Read term list for anxiety. 
Read code Read terms 
Interventions: Anxiolytic medication 
d2...  
d21..  
d22..  
d23..  
d24..  
d25.. 
d26..  
d27..  
d28..  
d29..  
d2a..  
d2b.. 
d2c.. 
d2d..  
d2e..  
d2f..  
d2g.. 
ANXIOLYTICS: 
DIAZEPAM [ANXIOLYTIC] 
ALPRAZOLAM 
BROMAZEPAM  
CHLORDIAZEPOXIDE  
CHLORMEZANONE  
CLOBAZAM  
CLORAZEPATE DIPOTASSIUM  
HYDROXYZINE HCL [ANXIOLYTIC]  
*KETAZOLAM  
LORAZEPAM [ANXIOLYTIC]  
*MEDAZEPAM  
MEPROBAMATE  
OXAZEPAM 
*PRAZEPAM  
BUSPIRONE HYDROCHLORIDE  
FLUMAZENIL  
gde.. DULOXETINE (SNRIs) 
bd1.. PROPRANOLOL HYDROCHLORIDE 
Note: *- discontinued 
 
 
 
Table F.1.3 Read term list for specialist mental health care (inteventions). 
 
Read codes Read terms 
8G94.                                    Anxiety management training 
8BK0.                  Depression management programme 
8HHq.                Referral for guided self-help for depression 
8CAa.               Patient given advice about management of depression 
8CQ..                Mental health crisis plan/Agreement of mental health crisis 
plan/ Completion of mental health crisis plan/Mental health 
crisis plan discussed with service user/ Mental health care 
programme approach crisis plan 
8Cd..                Further patient given advice 
8CX..                Common mental health conditions stepped care model (Care 
Services Improvement Partnership 2006) 
8H75.                
8H78.                  
8H7A.           
8H7B.                
8H7J.               
8H7T.                
8G...                
                                
                                               
8HlB.         
8HHp.                                              
Refer to social worker 
Refer to counsellor 
Refer to mental health worker 
Refer to community psych. nurse 
Refer to occupational therap. 
Refer to psychologist 
Psychotherapy/sociotherapy/ Seen by psychiatric nurse/ 
Community-based occupational therapy service/ Seen by 
community occupational therapy – service 
Urgent referral to psychiatrist  
Referral for guided self-help for anxiety 
8H49. 
8HlK.   
Psychiatric referral 
Referral for cognitive behavioural therapy 
8A2..                 Psychiatric monitoring 
8H34.                 Psychiatric day care 
8HK9.                    Psychiatric D.V. requested 
665..                 Psychiatric disorder monitoring 
8H23.                 Admit psychiatric emergency 
8HVO.                Private referral to psychiatrist 
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F.2     DISTRIBUTION OF THE NUMEBER OF ALL CONSULTATIONS IN 143 
PARTICIPANTS ELIGIBLE FOR ANALYSES OF DETECTION 
 
Figure F.2.1 Distribution of the number of consultations in 143 participants eligible 
for analyses of detection. 
 
 
